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Abstract 
Understanding the behaviour of T cells in context of tumour responses is crucial for 
designing adoptive immunotherapy strategies. The aim of the study is to characterise 
tumour-specific T cells, including conventional and regulatory T cells (Tregs), in 
tumour-bearing mice after adoptive transfer.  Male-specific minor histocompatibility 
antigen HY was used as the tumour-associated antigen, expressed by MB49 murine 
bladder carcinoma and recognised by TCR transgenic CD4 (Marilyn) and CD8 
(Matahari) T cells.  Unlike male skin grafts, MB49 tumours express a panel of 
immune-suppressive molecules including PD-L1, FAS-L, TGF-, IL-10 and IDO 
which contribute to the formation of a tolerogenic microenvironment.  As a result, 
HY-specific CD8 T cells reject syngeneic male skin grafts but not MB49 tumours.  
In response to MB49 tumours, HY-specific Tregs underwent expansion.  A fraction 
of proliferating Tregs also lost FoxP3 and became ex-Tregs, which upregulated 
IFN, and downregulated a panel of Treg-specific genes.  In addition, it was 
observed that preferential ex-Treg differentiation took place in an IL-6-enriched 
microenvironment, such as in the mesenteric lymph nodes.  The antigen-specific 
CD8 response to MB49 is insufficient for rejection.  Retroviral modification of 
MB49 to express hIL-2 allows for induction of effective antigen-specific CD8 
responses, providing a potent whole cell in vivo vaccine strategy for exploring factors 
mediating immune evasion.  Finally, the role of anti-HY TCR transgenic T cells in 
GvHD is assessed.  Lymphopenic male recipients lose weight after adoptive transfer 
of CD4 but not CD8 T cells. With radiation preconditioning, full-blown GvHD 
ensues, raising questions about this combination for clinical therapy. 
 
This study advances knowledge of antigen-specific T effector and Treg responses to 
HY in a range of environments, including MB49 tumours, male skin grafts and 
GvHD.  It highlights the importance of understanding not only induction of effector 
responses, but potentially harmful side-effects of adoptive cell transfer.   
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Chapter 1:  Introduction 
 
1.1:  The Immune System 
 The higher vertebrate immune system is possibly the most highly evolved 
system known to biology.  Immune systems and cells undergo constant selective 
pressures from the environment and pathogen interactions, driving genetic diversity.  
Over vast time periods this has lead to a plethora of cellular and molecular networks 
designed to protect against all forms of threat to the survival of an organism (Du 
Pasquier 1992).  The oldest branch of the immune system, known as the innate 
system, is universal to the animal domain and has evolved to protect the host against 
early phases of infection.  The innate system is comprised of both soluble mediators 
such as cytokines and chemokines as well as cellular components that include 
phagocytitic cells, natural killer cells and some antigen-presenting cells (APC) 
(Azuma 2006).   This system relies primarily on a restricted number of germ line-
encoded receptors such as the Toll-like receptors designed to recognise infectious 
agents based on pathogen associated molecular patterns (PAMPS) (Fraser, Koziel et 
al. 1998).   This system allows the organism to respond effectively to a wide range of 
infections and natural damage and is often sufficient in protecting short-lived 
organisms (Medzhitov and Janeway 1997).   
 Although the innate system is able to mount potent early stage responses, it is 
not able to recognise the plethora of disease causing agents, nor is it able to retain 
„memory‟ of these events.  A low reproduction rate coupled with a long life span and 
high energy usage in vertebrates has lead to the evolution of an adaptive immune 
system.  The adaptive immune system has evolved to enable directed responses 
against „non-self‟ or infectious/malignant „self‟ by modulating the components of the 
innate system and by activating antigen-specific T and B lymphocytes (Janeway 
2005).  The ability to specifically tailor an immune response, such as by the 
production of target-specific antibodies, underlies the adaptive system and its ability 
to provide lifelong protection for the host.   
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1.2:  Major Histocompatibility Complex (MHC) 
A vital component of the adaptive immune system is antigen presentation 
through MHC molecules.  The MHC was discovered by Gorer and Snell in the early 
1950s as a locus responsible for the rejection of transplantable tumours and tissues 
(Gorer 1948).  Subsequent studies revealed two classes of MHC genes encoding 
glycoproteins involved in antigen presentation; MHC class I glycoproteins are 
expressed on almost all nucleated cells and can present antigen to CD8 T cells, MHC 
class II glycoproteins are expressed on APCs and present antigen to CD4 T cells 
(Potts and Wakeland 1990).  MHC class I and class II genes encode structurally 
distinct but homologous proteins with the common feature of a cleft running across 
the membrane distal surface where a vast variety of small peptides are bound.  MHC 
genes are co-dominantly expressed in each individual and are some of the most 
polymorphic genes known.  The human MHC complex (HLA) spans 3.6 megabases 
and encodes 140 genes (MHC sequencing consortium1999).  The DNA encoding 
HLA Class I and II genes has a diversity of around 5-10% between individuals.   
  The MHC class I pathway of antigen presentation is present in almost all 
cells and processes mainly intracellular proteins for presentation on the surface; 
MHC class I is often referred to as the cell‟s „window‟.  MHC I proteins are 
assembled in the endoplasmic reticulum (ER) where the polymorphic MHC I heavy 
chain , encoded by the MHC complex, associates with the non-polymorphic 2 
microglobulin, forming a heterodimer.  Peptides that are generated in the cell, mainly 
through proteasome mediated degradation, are translocated into the ER by the 
transporter associated with antigen processing (TAP1/2) proteins.  TAP forms a 
complex with MHC I and several other proteins to optimise loading of stably bound 
peptides.  Once a peptide has bound MHC and assumes the correct conformation, it 
is released from the loading complex and moves from the ER to be transported to cell 
surface where the loaded peptide is presented (Cresswell 2005).  CD8 T cells can 
recognise non-self peptide-MHC I complexes through their specific T cell receptor 
(TCR) and, if previously primed, can respond; for example by killing the cell through 
release of cytotoxic granules (Garcia and Adams 2005).  
Professional APCs can also present peptides using the MHC II molecules.  
This pathway primarily processes proteins derived from extracellular sources through 
phagocytosis, endocytosis and pinocytosis and subsequent digestion in endosomes 
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and lysosomes.  Like MHC I molecules, MHC II is also a heterodimer which initially 
assembles in the ER and presents peptides on the cell surface.  However, MHC II is 
formed by the  and  chains, each composed of two domains.  Polymorphism is 
mainly present in the class II beta chain  (Nakagawa and Rudensky 1999).  CD4 T 
cells recognise non-self peptide-MHC II complexes through their specific TCRs.  If 
sufficient secondary signals are present T cells are activated to mediate a variety of 
effector functions appropriate to the response, including cytokine production and 
priming of other cell types such as CD8 T cells and B cells (Garcia and Adams 
2005). 
   
 
1.3:  T cell subsets 
 
1.3.1:  T cell Development  
 T cells are an essential component of the adaptive immune system.  T cell 
lineage progenitors (TLP) migrate from the bone marrow and enter the thymus where 
they progress into the inner cortex and interact with resident cortical epithelial cells 
(Bhandoola, Sambandam et al. 2003).  Notch signalling commits TLPs to the T cell 
lineage where they become double negative thymocytes that do not yet express CD4 
or CD8 (Harman, Jenkinson et al. 2003) but do express a pre-TCR (Shortman, 
Vremec et al. 1991).  Ligand independent signalling through the pre-TCR ensures 
survival and directs proliferation and differentiation to the double positive (DP) 
CD4
+
 CD8
+ 
stage when the mature TCR heterodimer is expressed (von Boehmer, 
Aifantis et al. 2003).  The vast diversity of the TCR repertoire is generated by 
assembly of each chain via rearrangement of multiple variable (V), diversity (D,  
only) and joining (J) gene segments.  Recombination is mediated by several enzymes 
including the Recombination Activating Genes 1 and 2 (Rag1/2) nucleases 
(Fugmann, Lee et al. 2000).  Rag creates double stranded breaks at sites containing 
recombination signal sequences that flank the gene segments.  Once rejoined and 
translated this produces a TCR with unique CDR3 loop structures which generally 
engage with the peptide component of the peptide-MHC complex (Bodmer, Marsh et 
al. 1991; Bassing, Swat et al. 2002). 
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 At the DP stage, the mature TCR interacts with complexes on cortical thymic 
epithelial cells as well as thymic B cells and dendritic cells (DCs).  If interaction 
occurs with sufficient affinity to MHC-I, cells are directed into CD8 single positive 
(SP) lineage.  If the TCR favourably reacts with MHC-II, cells are directed into the 
CD4 SP lineage.  At the DP stage, thymocytes recognising self peptide with a high 
affinity are deleted by negative selection, preventing autoreactive T cells from 
entering the periphery, known as central tolerance (Davey, Schober et al. 1998).  DP 
cells then migrate to the medulla where terminally differentiated medullary thymic 
epithelial cells (MTEC) present a variety of tissue specific gene products under the 
control of the autoimmune regulator gene (AIRE).  This facilitates presentation of 
peptides from a large proportion of extra-thymic self on MHC-I and II broadening 
the extent of thymic central tolerance (Kyewski and Klein 2006).   However, it is this 
tolerance mechanism which acts to prevent autoimmunity that allows for the evasion 
and persistence of many tumours.  Many tumour-associated antigens (TAAs) are 
derived from self proteins expressed in the thymic medulla; as a consequence, T cells 
that are highly reactive to TAAs are also deleted (see chapter 3) (Overwijk 2005). 
DP thymocytes that successfully audition for positive selection mature into 
SP CD4 (TCR-specific to MHC-II) or SP CD8 (MHC-I) thymocytes and migrate to 
the periphery as naive T cells (CD62 high; CD44 low).  TCRs are highly variable 
and the T cell compartment has a potential repertoire of  up to 10
12
 structurally 
distinct TCRs (Davis and Bjorkman 1988), however the human TCR repertoire in 
adults is estimated to comprise 10
7 
structually distinct forms (Arstila, Casrouge et al. 
1999).   It is this process of selection that allows  T cells, as a population, to 
monitor and regulate other cells within the host.  Having specific binding features for 
a given peptide bound to MHC allows for recognition of a huge number of peptides 
never before encountered by the immune system.  These features allow an individual 
organism to respond to a wide range of structurally distinct pathogens.  
Polymorphism at the MHC locus also enhances immune defences across the 
population as a whole by ensuring wide variation in the T cell response to a broad 
array of epitopes (Lawlor, Zemmour et al. 1990).   
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1.3.2:  CD4
+
 T cells 
 CD4 T cells can recognise peptide MHC-II complexes expressed by APCs, 
known as signal 1.  If other congruent signals (signal 2) are provided, such as 
positive co-stimulation, commonly through CD28 (Harding, McArthur et al. 1992) 
(see co-stimulation below), CD4 T cells can activate and clonally expand.   If signal 
1 is provided in the absence of signal 2, T cells fail to become fully activated and can 
become anergic or adapted.  Adaptation is a state of functional unresposniveness to 
antigen induced by chronic exposure, this is not a sate of anergy (Choi and Schwartz 
2007).  This is a common outcome associated with anti-tumour responses (Walunas, 
Bakker et al. 1996).     
 Activated CD4 T cells can also develop cytotoxic effector function (Williams 
and Engelhard 1996), however their primary role is to maintain and regulate B cells, 
NK cells and CD8 T cells (Janssen, Lemmens et al. 2003).  CD4 cells can activate, 
modulate and maintain other immune cells by the secretion of cytokines such as IL-2 
(Antony, Paulos et al. 2006).  Once antigen is cleared from the host, a small 
proportion of CD4 cells become persistent memory cells capable of activation and 
clonal expansion at a dramatically accelerated rate upon re-encounter of antigen.  
The precise function of CD4 T cells depends on the manner in which they are 
activated by APCs, with multiple lineage options being available at the naïve stage 
including Th1, Th2, Th17 and Treg (see later sections). 
 
1.3.3:  CD8
+
 T cells 
 CD8 T cells, also known as cytotoxic T lymphocytes (CTLs), are the other 
major subset of T cells.  CD8 T cells can recognise peptide MHC I complexes which 
are expressed by most nucleated cells.  CD8 T cell priming, however, requires 
engagement of specific peptide MHC I complexes presented by activated dendritic 
cells (signal 1).  Again, if secondary congruent signals are present, such as positive 
co-stimulation (signal 2), then the CD8 T cell will clonally expand, while incomplete 
activation signals induce anergy or adaptation (Choi and Schwartz 2007). 
 Following binding of the specific peptide-MHC-I complex to which they 
have been primed, activated CD8 T cells upregulate perforin, granzyme B and FAS-
L all of which can be used to induce the death of target cells (Cao, Cai et al. 2007).  
In addition, activated CD8 T cells secrete cytokines such as IFN- or IL-4 (Sad, 
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Marcotte et al. 1995) capable of modulating the local environment and recruiting and 
activating other cell types in an immune response, and like their CD4 counterparts, 
CD8 T cell responses can be defined as Tc1, Tc2 or Tc17 (see later sections).  
Cytotoxicity is a common mechanism by which CD8 T cells kill tumour cells 
(Hinrichs, Gattinoni et al. 2006).  CD8 cell function is modulated by the 
microenvironment in which they are activated: IL-2 (Yron, Wood et al. 1980), IL-7 
(Schluns, Kieper et al. 2000) and IL-15 (Schluns, Williams et al. 2002) are all known 
to enhance CD8 T cell activation and proliferation.  Following the primary immune 
response, the antigen-specific CD8 T cell population contracts, and like CD4 T cells, 
a small proportion of high affinity CD8 T cells remain as memory cells capable of 
rapid proliferation in response to secondary antigen exposure (Harty and Badovinac 
2008). 
 
1.3.4:  CD4
+
 FoxP3
+
 Regulatory T cells 
A subset of CD4
+
 T cells (~5-10%) are known as regulatory T cells (Tregs); 
they express the transcription factor Forkhead box P3 (FoxP3) (Fontenot, Rasmussen 
et al. 2005) and often the surface IL-2 receptor chain (CD25) (Sakaguchi, 
Sakaguchi et al. 1995).  Tregs are primarily suppressive to T cell responses through 
the release of suppressive cytokines such as IL-10 and TGF- (Sakaguchi, Ono et al. 
2006), as well as directly causing T cell death and anergy through perforin-dependent 
cytotoxicity and through negative co-inhibitory molecules (see later sections).  Tregs 
can be classified as natural or induced/adapted (Bluestone and Abbas 2003).   
Natural Tregs (nTreg) develop and mature in the thymus where TCR and self 
peptide-MHC interaction falls into an avidity range between positive and negative 
selection.  This is thought to produce peripheral regulatory T cells specific for 
particular self-antigens (Fontenot, Gavin et al. 2003), capable of controlling self-
reactive T cells that have escaped central tolerance, as shown through studies using 
CD25 depletion (Kohm, McMahon et al. 2006) and verified using FoxP3
DTR 
mice 
(see later) (Kim, Rasmussen et al. 2007).  Induced or adaptive Tregs (i/aTregs) form 
in the periphery by conversion from conventional CD4 T cells in conditions of 
suboptimal antigen presentation, however, they can be specific for mutated self-
antigens as well as foreign antigens.  iTregs often develop under conditions of poor 
activation caused by low levels of antigen presented by immature APCs, generally 
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coupled with negative co-stimulation through CTLA-4 (Horwitz, Zheng et al. 2008) 
(see co-stimulation), such conversion as is seen with many low dose antigens that 
induce suboptimal APC activation  (Kretschmer, Apostolou et al. 2005).  The process 
of expanding nTregs and reprogramming of conventional CD4 T cells into iTregs is a 
common immunoevasive mechanism associated with tumour microenvironments 
(Curiel 2007).  
 
1.3.5:  Th1, Th2 and Th17 T cell responses 
 The environment in which T cells are activated is critical in determining the 
type of T cell response to be induced.  The type of T helper (Th) response induced is 
dependent on the manner in which antigen is presented in combination with co-
stimulation and cytokine signals from APCs.  Th1 responses are often generated in 
response to viruses, bacteria and intracellular pathogens.  A Th1 response by CD4 T 
cells is characterised by the production of IL-2, INF and TNF leading to activation 
and induction of IFN, TNF and by induction of cytotoxic granules in CD8 T cells, 
along with the activation of macrophages, NK cells and B cells.  IFN induces the 
production of IL-12 by DCs and macrophages which in turn induces further IFN 
production by Th1 cells in a positive feedback loop (Mosmann and Sad 1996).  It has 
been suggested that the most effective anti-tumour responses are driven by the Th1 
lineage (Surman, Dudley et al. 2000).   
 Th2 responses are generated against multi-cellular pathogens with the 
primary function of activating B cells.  Activated Th2 cells produce IL-4, 5, 6, 10 
and 13, inducing maturation of B cells and the production of antibodies in a humoral 
response (Mosmann and Sad 1996).  In general, Th2 responses are associated with a 
poor tumour prognosis (Hung, Hayashi et al. 1998). 
 Recently, an additional Th subset has been characterised in which activated 
CD4 T cells were identified as secreting IL-17 (Yao, Fanslow et al. 1995).  This has 
therefore become known as a Th17 response.  Th17 cells are often found in 
proinflammatory environments similar to those that produce Th1 responses. Th17 
cells are induced in environments where TCR stimulation occurs in the presence of 
TGF- and IL-6 (Kryczek, Wei et al. 2007; Bettelli, Korn et al. 2008).  Th17 cells 
secrete IL-17 and IL-22 capable of producing a wide range of responses from 
surrounding tissues due to the broad expression of IL-17 and IL-22 receptors (Korn, 
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Bettelli et al. 2009).  The inflammatory environment within tumours often contains 
high levels of TGF- and IL-6, giving the potential for favourable induction of a 
Th17 response.  The prognosis associated with Th17 anti-tumour responses is mixed, 
with several conflicting reports in the literature (Hinrichs, Kaiser et al. 2009; Wang, 
Yi et al. 2009).  The precise role of Th17 and its relation to Th1 and Th2 responses 
remains to be fully elucidated, particularly in response to tumours.  CD8 T cells 
primed under conditions of Th1, 2 or 17 also have distinct cytokine profiles.  These 
are known as Tc1 (IFN, TNF producing), Tc2 (IL-4, IL-10 producing) and Tc17 
(IL-17, IL-22 producing) cells. 
 
1.3.6:  T cells and Co-stimulation 
 Naive T cells require two signals to become fully activated, the first, which 
defines specificity, is TCR engagement with peptide-MHC and the second is through 
the ligation co-stimulatory molecules and their ligands expressed on mature APCs 
(Janeway 2005).  Proinflammatory environments, for example following engagement 
of PAMPS by pathogen recognition receptors, can upregulate positive co-stimulatory 
molecules.  The nature of the activation signals received by the APC often defines 
the type of co-stimulation molecules that are upregulated and the consequent immune 
response (Wang and Chen 2004), see table 1.  Toll like receptors (TLR) on APCs 
detect PAMPS, for example TLR4 detects lipopolysaccharide (LPS).  Binding of 
TLR4 for example induces high levels of CD80/86, IL-12 and IL-18 expression by 
APCs resulting in stong Th1 priming of T cells(Iwasaki and Medzhitov 2004).  
 The most characterised co-stimulatory and co-inhibitory molecules 
expressed by T cells are members of the CD28 Imuunoglobulin superfamily.   CD28 
binds B7.1 (CD80) and B7.2 (CD86), part of the B7 Immunoglobulin superfamily, 
expressed on APCs, thus inducing a positive signal to T cells (Lanier, O'Fallon et al. 
1995).  When combined with antigen stimulation this signal allows T cells to be 
activated with a Th1 phenotype, to proliferate and survive.  CTLA-4 is a co-
inhibitory molecule on T cells and Tregs that can also bind CD80/86, an antagonist 
of CD28 (Greenwald, Boussiotis et al. 2001).  There are other co-stimulatory 
molecule pairs, such as Glucocorticoid Induced Tumour necrosis factor Receptor 
family-related gene (GITR (L)), Inducible Co-stimulatory Ligand (ICOS (L)), CD40 
(L), 4-1BB (L) and Ox40 (L), which are generally believed to act to further expand 
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or maintain survival of already activated T cells. The effects of these molecules are 
summarised in Table 1.   Another family of death receptor molecules, in the CD28 
and B7 Immunoglobulin superfamily, can act as co-inhibitory molecules, namely 
Programmed Death Receptor-1 (PD-1) expressed on activated T cells and its ligand 
PD-L1 and PD-L2 expressed on APCs (Butte, Keir et al. 2007).  The PD-1 pathway 
is commonly used by tumours to induce programmed cell death or exhaustion in 
tumour-specific T cells and is a common mechanism of immune evasion (Blank, 
Gajewski et al. 2005). 
Table 1: Co-stimulatory molecules and Ligands   
  
Receptor/Ligand  
(T cell) 
Cognate 
Receptor/Ligand  
Effect on T cell Reference. 
(Expressed by) 
CD28  (CD4; 
CD8) 
CD80/86 (Bc;DC;Tc) Activation; 
Proliferation; 
 (Lanier, O'Fallon et al. 
1995)
 
Cytokine secretion 
CTLA-4 (CD4; 
CD8; Treg) 
CD80/86 Inhibition;  
Tolerance 
 (Rudd, Taylor et al. 
2009)
 
(Bc;DC;Tc) Th1 
ICOS (act CD4; 
act CD8; Treg) 
ICOS-L Increased IL-10.  
Th2 
 (Hutloff, Dittrich et al. 
1999)
 
(Bc;DC) 
GITR (Treg; act 
CD4; act CD8) 
GITR-L (Bc; DC; Mθ) Th1 or Th2  (Kwon, Yu et al. 1999) 
CD40L (CD4) CD40 (Bc; Mθ) Th2  (Banchereau, Bazan et 
al. 1994)
 
4-1-BB (CD8 
more than CD4) 
4-1-BBL (Bc; DC; 
Mθ) 
Increased CD4/8 
proliferation. Th1 or 
Th2. 
 (Watts 2005)
 
OX-40 (mainly 
CD4; some CD8) 
OX-40L (Bc; DC; act 
Tc) 
Th2, but sustains 
Th1 proliferation and 
survival 
 (Watts and 
DeBenedette 1999)
 
PD-1 (act CD4; 
act CD8) 
PD-L1/PD-L2 (Bc; 
DC; Mθ; Tc) 
Negative regulation 
of PD-1 expressing 
cell 
 (Probst, McCoy et al. 
2005; Butte, Keir et al. 
2007)
 
Bc - B cell, Tc - T cell, DC - dendritic cell, Mθ - macrophage, act - activated 
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1.4:  Antigen-presenting Cells (APCs) 
 MHC Class II is constitutively expressed by a set of cell types collectively 
known as professional antigen-presenting cells, which includes dendritic cells, 
macrophages and B cells.  The principle function of APCs is to capture antigens from 
the environment by endocytosis, phagocytosis and pinocytosis.  Complex antigens 
are processed and some of the resulting peptides are presented on the APC surface in 
the context of MHC-II where specific CD4 T cells are capable of recognising and 
becoming activated in response (Boniface, Reich et al. 1999).   
 
1.4.1:  Dendritic Cells 
 DCs derive from progenitor cells in the bone marrow and were originally 
discovered by Paul Langerhans, the term dendritic cells coined by Steinman and 
Cohn in 1973 (Steinman and Cohn 1973).  DCs have a dishevelled membrane 
morphology with a high degree of motility that provides a large surface area, 
allowing efficient uptake and presentation of antigen.  DCs are broadly classified as 
either lymphoid, CD11c
+ CD8α+ DEC205+ CD11b-, myeloid (mDC) CD11c+ CD8α- 
DEC205
+ 
CD11b
+
 or plasmacytoid (pDC) as mDC with CD123
+
 (IL-3R) as a 
marker (Shortman and Liu 2002).  Although similar to other DCs, pDCs look more 
like plasma cells and generally produce IFN- and IL-6 upon maturation while 
lymphoid and mDCs broadly produce IL-1, IL-10, IL-12 and TNF (Cella, Sallusto 
et al. 1997).   
DCs circulate through lymph nodes, spleen and peripheral tissues.  Upon 
antigen encounter and activation in the periphery, they migrate to secondary 
lymphoid organs where they present peptide antigen to T cells by via MHC-I and II 
molecules along with co-stimulatory signals as discussed earlier inducing activation 
of naïve T cells.  DCs will induce different T cell responses depending on the 
secondary signals recieved during maturation.  For example DCs express a range of 
toll-like receptors (TLRs) capable of interacting with a wide range of microbial 
PAMPs such as LPS and CpG that can induce the DC to produce high levels of IL-12 
and CD80/86 inducing a strong Th1 response by T cells (Macatonia, Hosken et al. 
1995).       
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1.4.2:  Macrophages and Monocytes 
 Macrophages are produced by the differentiation of monocytes deriving from 
granulocyte/monocyte progenitor cells in the bone marrow.  These progenitors 
develop into pro-monocytes and migrate to the blood stream where they become 
monocytes and eventually into peripheral tissues where they mature into 
macrophages.  Macrophages are phagocytic cells that express a range of receptors 
that allows them to phagocytose dying or dead cells, microorganisms and cell debris.  
Macrophages are able to present antigenic peptides to T cells by MHC I and II 
molecules, along with co-stimulatory signals and cytokines to enable activation 
(Aderem and Underhill 1999).  As with DCs, the environment in which the 
macrophage scavenges antigen is critical to the type of responses to be induced in T 
cells. 
 
1.4.3:  B cells 
 B cells differentiate from lymphoid stem cells to progenitor B cells within the 
bone marrow where they proliferate and further differentiate into precursor B cells.  
Formation of immature B cells is then dependent on the rearrangement of the DNA 
encoding immunoglobulin, driven by the RAG genes and IL-7.  In a highly similar 
mechanism to T cell development, immunoglobulin chains are rearranged and 
expressed on the cell surface as a B cell receptor (BCR), each with a unique structure 
and range of specificity.  Self-reactive B cells are deleted in the bone marrow while 
non-self reactive cells are released into the periphery as naive B cells (Janeway 
2005).   
B cells are activated upon engagement of the BCR by cognate antigen, 
inducing the upregulation of peptide-MHC II for presentation to CD4 T cells.  B cells 
can cross-talk with T cells through co-stimulation of CD40 (B cell) engaging CD40L 
(T cell).  This leads to the activation and proliferation of B cells and the generation of 
plasma cells that ultimately secrete high levels of antibody, the isotype of which 
depends on the cytokine environment (Banchereau, Bazan et al. 1994).  B cells 
therefore can act as APCs for CD4 T cells, although prior activation by DCs is often 
required (Parker 1993).  B cells are considered as poor APCs, mainly due to poor co-
stimulation, although B cells can be highly effective at endocytosing antigen through 
their surface BCR for representation at the surface in the context of MHC-II 
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molecules.  In addition, the large B cell number in the periphery of lymphoreplete 
hosts can often equilibrate this effect (Janeway, Ron et al. 1987).   
 
 
1.5:  Cytokines and Chemokines 
 Cytokines are small cell-signalling molecules extensively produced and used 
by lymphocytes and glial cells.  They are immunomodulating agents with similar 
properties to many hormones.  Cytokines are often sub-classified as lymphokines, 
interleukins and chemokines based on their source, mode of action and target.  Most 
cytokines are soluble or membrane-bound and all have a corresponding receptor that 
when bound by the cytokine can convey a signal to the target cell.  These signals 
induce a variety of responses, such as specific upregulation or downregulation of 
gene expression, structural and morphological changes, differentiation, activation 
and even inhibition.  The effects of a cytokine on a given target cell depend on the 
context in which it is delivered and cytokines often act synergistically.  Cytokine 
genes and families are often highly homologous, with many cytokines evolving 
through gene duplications, for example IL-2 and IL-21 are believed to have diverged 
recently in terms of evolution (Hinrichs, Spolski et al. 2008).  The highly 
homologous nature of cytokines and their receptors also means they tend to work in 
pathways and feedback loops (Casciari, Sato et al. 1996), for example CD4 T cell 
activation can result in the production of IL-2, IL-2 is required for activated CD4, 
CD8 T cell and Treg survival (Janeway 2005).  Common cytokines associated with 
immune responses to tumours are described below and in table 2. 
Table 2: Common cytokine effector functions 
Cytokine Source Effect on T 
cells 
Effect on APCs Other effects 
IL-2 Th1 CD4 
and some 
CD8  
Growth T cells, 
Growth and 
survival of 
Tregs 
- activation of NK cells 
IL-4 Th2, mast 
cells 
Growth, 
survival, 
inhibits IFNg 
Inhibits 
macrophage 
activation 
IgE isotype switching 
IL-6 Macrophage, 
DC, Th2, 
endothelium 
- Inhibition of IDO 
synthesis by pDC 
B cell proliferation, synthesis 
of acute phase proteins 
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IL-10 Th2, 
macrophage 
Growth Inhibition of IL-12 inhibition of 
proinflammatory cytokines 
IL-12 Macrophage, 
DC, B cells 
CD4 Th1 
differentiation, 
IFN synthesis, 
CTL activation 
- NK cell activation, inhibition 
of IL-4 
IL-17A CD4 Th17, 
some CD8 
Th17 
development 
Macrophage 
activation 
Neutrophil activation, 
secretion of IL-6 and IL-8 in 
fibroblasts, epithelial cells 
and keratinocytes 
GM-CSF T, B cells, 
NK cells, 
endothelial, 
macrophage 
- Monocyte 
differentiation, DC 
maturation and 
survival 
granulocyte and 
mononuclear cell growth and 
survival 
IFN Th1 CTL, 
NK, some 
CD4 
Th1 
development, 
activation 
Maturation of 
macrophage, DC 
IgG isotype switching 
TNF Macrophage, 
DC, Th1 
Th1 Activation, Nitric 
Oxide (NO) 
production by 
macrophages 
synthesis of acute phase 
proteins, endothelial 
activation, increased vascular 
permeability, fever,  
adhesion molecules 
TGF- Treg, T 
cells, 
monocytes 
Treg growth, 
survival, CD4 T 
cell conversion, 
inhibits CTL 
Inhibits maturation suppression of inflammation, 
increased fibrosis 
 
 
1.5.1:  Interleukin-2 (IL-2) 
 IL-2 was the first mitogenic factor described for lymphocytes (Kasakura and 
Lowenstein 1965) and is discussed in detail in chapter 6.  IL-2 is a proinflammatory 
cytokine produced by CD4 and CD8 T cells upon TCR engagement and activation 
when it acts in an autocrine fashion to induce proliferation, differentiation and 
cytotoxic functions (Villarino, Tato et al. 2007).  The IL-2 receptor alpha (CD25), 
one of several IL-2 receptors, is transiently expressed on both CD4 and CD8 T cells 
following activation and is ubiquitously expressed on nTregs.  IL-2 is required for 
the effective priming of typical Th1 T cell response, however, nTregs can sequester 
excess IL-2 from the local microenvironment in a co-evolved system to limit 
autoimmunity.  In fact IL-2 knockout mice have lymphoproliferative disorder and 
autoimmunity rather than immunodeficiency (Sadlack, Lohler et al. 1995).  
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1.5.2:  IL-10 
 IL-10 is often classed as an anti-inflammatory cytokine commonly secreted 
by monocytes, mast cells, Tregs and Th2-cells.  IL-10 can modulate T cell responses 
either directly or indirectly through APCs (Sharma, Stolina et al. 1999) and is often 
termed an immune regulator.  IL-10 acts mainly by inhibiting cellular Th1 responses 
through downregulation of MHC II (de Waal Malefyt, Haanen et al. 1991) and 
positive co-stimulatory molecules CD80/86 on APCs (Ding and Shevach 1992). 
Additionally, acting on the JAK-STAT signalling pathway and blocking NF-B, IL-
10 inhibits the production of proinflammatory cytokines such as IL-12 by APCs and 
IL-2 by CD4 T cells limiting T cell activation (de Waal Malefyt, Yssel et al. 1993).  
Like IL-2, IL-10 has a dual role in the controlling development and function of T 
regulatory type 1 (Tr1) cells, an independent Treg population that does not express 
FoxP3 (Vieira, Christensen et al. 2004) but can inhibit T cell responses.  
 
1.5.3:  IL-12 
 IL-12 is a heterodimer produced by DCs, macrophages and B cells in 
response to antigen stimulation.  IL-12 is another proinflammatory cytokine that can 
direct T cells towards a Th1 phenotype, inducing proliferation and expression of 
other Th1 cytokines, such as INF and TNF, while inhibiting IL-4-mediated 
suppression.  IL-12 is required for the effective induction of cytotoxic responses in 
CD8 T cells and NK cells, which is enhanced by co-exposure to IL-2 (Wang, Frank 
et al. 2000). 
 
1.5.4:  IL-17A 
 IL-17A is a proinflammatory member of the IL-17 cytokine family first 
described in 1993 (Rouvier, Luciani et al. 1993).  IL-17A has been shown to promote 
cytotoxicity in T cells, angiogenesis and has been implicated as a mediator of 
rheumatoid arthritis (Korn, Bettelli et al. 2009).  It is primarily produced by CD4 T 
cells and some CD8 T cells, while the five receptors of IL-17 are broadly expressed 
by most cell lineages.  IL-17 receptor signalling can induce the secretion of IL-6 and 
IL-8 in fibroblasts, epithelial cells and keratinocytes (Yao, Fanslow et al. 1995).  IL-
17, IL-22 co-producing T cells are often described as differentiated Th17 cells 
(Bettelli, Korn et al. 2008).  
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1.5.5:  Interferon Gamma (IFN) 
 IFN is a soluble homodimer and the only known member of the type II 
interferon family (Gray and Goeddel 1982).  It is a signature cytokine produced by 
Th1 activated CD8 T cells and NK cells and induces the upregulation of MHC I and 
II in many cell types (Morris and Tomkins 1989).  It has also been shown to increase 
lysosome activity and active inducible nitric oxide synthase in macrophages 
(Schroder, Hertzog et al. 2004).  IFN promotes anti-microbial and anti-tumour 
responses in macrophages through the JAK-STAT pathway by activating NF-B. 
Inhibition of this cytokine using blocking antibodies in vivo can abrogate anti-viral 
and anti-tumour responses (Spitalny and Havell 1984).  IFN is also implicated in 
immunoglobulin production and isotope class switching in B cells (Schroder, 
Hertzog et al. 2004). 
 
1.5.6:  Tumour Necrosis Factor alpha (TNF) 
 TNF was discovered in the late 1960s as a macrophage product able to 
mediate apoptosis in mouse fibrosarcoma L-929 cells (Carswell, Old et al. 1975).  It 
is a proinflammatory cytokine of the TNF family and is associated with the acute 
phase reaction along with IL-1, INF and .  The acute phase reaction is a response 
to local inflammation and injury and is discussed in detail in Chapter 7 (Hattori, 
Hirano et al. 1998).  While TNF receptor 1 (TNFR1) is broadly expressed on most 
cells, TNFR2 is mainly restricted to immune cells.  TNF can mediate a Th1 
phenotype by the induction of NF-B MAP kinase pathways, leading to production 
of other proinflammatory factors (Wajant, Pfizenmaier et al. 2003).  TNFR1 contains 
a death domain that triggers apoptosis in a caspase-dependent manner, using the 
same intracellular pathways as FAS (Gaur and Aggarwal 2003).  
 
1.5.7:  Transforming Growth Factor Beta (TGF-) 
 TGF- is soluble cytokine that exists in at least three isoforms (1-3) and is 
expressed to some degree by most cells, specifically by T cells and monocytes, and is 
an important mediator of immune suppression.  TGF- can induce apoptosis, inhibit 
proliferation, control inflammatory responses (Li, Sanjabi et al. 2006) and prevent 
the action of CD8-mediated cytotoxic responses (Fukuyama, Ichiki et al. 2007). 
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TGF-1 signals through TGF-RII and propagates apoptotic signals through the 
Smad pathway (Wahl and Chen 2005).  TGF- is powerfully suppressive to T cells 
and can induce the conversion of conventional CD4 cells to FoxP3
+
 iTregs (Chen, 
Jin et al. 2003; Coe, Addey et al. 2010).  TGF- is often expressed to a high level by 
tumours and induced by certain pathogens such as mycobacterium tuberculosis 
(Reed 1999). 
 
1.5.8:  Chemokines 
 Chemokines are a family of small cytokines (8-10 kDa) named for their 
ability to induce chemotaxis in motile target cells such as T cells and APCs.  
Chemokines have a definitive 3D shape conferred by four conserved cysteine 
residues but can function in a variety of ways with some members being 
proinflammatory, others largely suppressive and many involved in homeostasis 
(Fernandez and Lolis 2002).  Chemokines can induce migration of resting and 
activated lymphocytes and leukocytes to sites of inflammation or injury.  Due to the 
large numbers of chemokines, receptors and modes of action, specific chemokines 
are addressed when necessary in this study.  A few notable chemokine receptors 
include CCLR5 and CXCR3 expressed on Th1 activated T cells.  These bind the 
CXCL9, 10 and 11 chemokines which are primarily involved in the migration of T 
cells from secondary lymphoid organs to sites of inflamation (Smit, Verdijk et al. 
2003).   Other chemokine receptors, such as CCR3 and CCR4, are highly expressed 
on Th2-cells and bind CCL7 and CCL5 (RANTES) which are commonly expressed 
by many tumours (Luboshits, Shina et al. 1999). 
 
1.6:  Tumour biology and tumour: T cell interactions  
 Tumours arise principally through genetic abnormalities deriving from innate 
genetic instabilities, carcinogens and environmental factors including radiation. 
Progressive accumulation of mutations that enhance survival can ultimately lead to 
tumour development. Such enhancing mutations can allow cancers to provide their 
own growth signals, become resistant to inhibitory signals, avoid cell death, induce 
angiogenesis and in some cases metastasise (Hanahan and Weinberg 2011).  These 
mutations can also allow cancers to evade immune elimination, a process termed 
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immunoevasion.  Cancers that are able to evade the immune system often thrive and 
eventually come to represent the majority of cells within a tumour by immuno-
selection (Zitvogel, Tesniere et al. 2006).  Immunoevasion is not a necessary 
component for tumour development but it is certainly common to most cancers to 
some degree and enhances their development (Dunn, Old et al. 2004). 
 Tumours have several mechanisms associated with their ability to evade 
immune responses; these have been touched on earlier in this section.  Briefly, 
tumour cells can reduce expression of MHC and co-stimulatory molecules, 
preventing immune recognition.  Tumours are known to actively suppress APC 
function, preventing their maturation and upregulation of co-stimulatory molecules.  
Tumours themselves can make suppressive factors to modulate the 
microenvironment and even induce immune cells to produce inhibitory factors.  In 
addition, tumours can express surface molecules such as FasL and PD-L1 that can 
actively induce apoptosis of infiltrating lymphocytes.  Finally, tumours can 
downregulate the TCR of infiltrating T cells limiting their ability to recognise the 
tumour (Dunn, Old et al. 2004; Zitvogel, Tesniere et al. 2006). 
 Immune responses to solid tumours are mostly mediated by T cells and NK 
cells (Perez-Diez and Marincola 2002).  Tumour development is also favoured by 
hijacking natural mechanisms of immune regulation including Tregs.  As the primary 
function of Tregs is to prevent autoimmune responses to self-antigens they also 
mediate suppression of responses to common tumour-associated antigens (TAAs).  
TAAs are generally over expressed or altered self antigens.  These factors are 
discussed in more detail here. 
 
1.6.1:  Immunoevasion and Immunomodulation 
 Defects in antigen processing and presentation confer an advantage for 
tumour development due to reduced T cell recognition.  The classical MHC I 
pathway presents intracellular peptides on the cell surface, loss of MHC I or its 
related accessory proteins can confer a protective advantage to tumours.  Human 
colorectal and ovarian carcinomas have been shown to downregulate 2-
microglobulin and the TAP heterodimer, reducing surface MHC I (Atkins, 
Breuckmann et al. 2004; Vitale, Pelusi et al. 2005).   Coupled with these defects in 
antigen presentation, tumours are generally poor stimulators of T cells, due to the 
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limited level of co-stimulatory molecules on their surfaces.  This is evident in the 
effective immunity stimulated by CD80 transfected melanoma cells, which can lead 
to subsequent rejection of untransfected melanoma cells (Townsend, Su et al. 1994). 
 Tumours can downregulate co-stimulatory molecules such as CD80 on their 
surfaces; however this is a double-edged sword as they can express abundant levels 
of T cell co-inhibitory molecules.  The interaction between PD-L1 expressed on 
APCs and PD-1 on activated T cells is essential for peripheral CD8 T cell tolerance 
(Ansari, Salama et al. 2003), through inhibition of T cell proliferation, cytotoxic 
function and induction of apoptosis (Butte, Keir et al. 2007).  Many tumours 
upregulate PD-L1 as a mechanism to induce apoptosis in tumour-specific activated T 
cells expressing PD-1 (Blank, Gajewski et al. 2005), as described on human 
colorectal, lung, ovarian carcinomas and melanomas (Dong, Strome et al. 2002).   
CTLA-4 (CD152) can also be induced on human T cells, B cells and APCs; ligation 
of this molecule can inhibit T cell responses (Sica, Choi et al. 2003).  Many tumours 
also express CTLA-4 which can be increased by IL-6 and IL-10 and decreased in 
environments of GMCSF and IL-4.  Kryczek et al. has shown CTLA-4 expression on 
human ovarian carcinoma infiltrating macrophages is associated with an increase in 
Treg infiltration and a poor prognosis.  This is also correlated with CTLA-4 
expression on the tumour itself (Kryczek, Wei et al. 2007).  Further dynamics of 
tumours and co-stimulation are discussed in chapter 3. 
 Tumour environments also often contain immunosuppressive factors secreted 
by the tumour or induced from APCs and T cells.  Indoleamine-2,3-dioxygenase 
(IDO) is an enzyme that catabolises tryptophan in the kynurenine pathway and IDO-
induced depletion of tryptophan can cause reduced T cell proliferation and render 
DCs tolerogneic to tumour-specific T cells (Grohmann, Fallarino et al. 2003).  
Tumours can induce IDO expression by DCs in the tumour-draining lymph node 
(dLN) (Belladonna, Puccetti et al. 2007).  Tumours can also directly secrete 
suppressive factors that include prostoglandins, gangliosides, GMCSF, IL-6, IL-10, 
TGF-and VEGF into the local microenvironment (Ghiringhelli, Puig et al. 2005). 
IL-10 and TGF- are two of the best characterised suppressive cytokines found in the 
tumour microenvironment (see sections 1.5.2 and .6).  Further details of tumour-
related cytokines are discussed in chapter 3.  Briefly, IL-10 modulates T cell 
responses directly or through APCs and controls the development of Tr1 (non-FoxP3 
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expressing Tregs) (Sharma, Stolina et al. 1999).  TGF is directly secreted by many 
tumour lines in vitro and in vivo (Fukuyama, Ichiki et al. 2007) and can convert 
conventional CD4 T cells to FoxP3
+
 Tregs (Chen, Jin et al. 2003) and inhibit tumour-
specific CD8 T cells (see chapter 3).  Tumours are therefore capable of modulating 
naturally occurring immunosuppressive mechanisms at both the cellular and 
molecular level in order to enhance their survival.  Better understanding of these 
mechanisms allows for rational design of new cancer immunotherapies. 
 
 1.6.2:  T cells and cancer 
 Tumour resident T cells, specific for TAAs, are found in most tumours, such 
as human melanomas (Mortarini, Piris et al. 2003) and colorectal cancers (Wagner, 
Koch et al. 2008).  As discussed in section 1.3, T cells can mediate cytotoxic 
responses against tumour cells when sufficiently primed (Perez-Diez, Joncker et al. 
2007).  Despite this, many tumours are not controlled by these T cells, partly due to 
the immunomodulatory mechanisms discussed above.  Tumour-specific T cells are 
also often subject to TCR downregulation (Abad, Wrzensinski et al. 2008).  This 
effect can be caused by factors contained in the microenvironment and is a 
characteristic signature of T cell exhaustion/anergy induced by the tumour rather 
than tolerance to the TAA (Melchionda, McKirdy et al. 2004).  T cells are therefore 
capable of activating and proliferating in response to TAA but cannot mediate 
effective anti-tumoural responses as a result of incomplete activating signals and 
inhibitory factors.  
Other factors that inhibit anti-tumour cytotoxicity include an inability for 
large numbers of T cells to access solid tumour environments.  Many progressive 
tumours also have poor tumour cell to T cell ratios of over 10,000:1.  Lower ratios of 
T cell to tumour cells are associated with a worse prognosis (Yu, Lee et al. 2003).  
Established tumour environments are also highly hypoxic and induce T cell apoptosis 
through inhibition of CCR7 (Sun, Zhang et al. 2010).  T cells must overcome a vast 
range of inhibitory mechanisms in order to induce successful tumour regression.  
Therefore, pro-effector modulation of tumour-specific T cells remains a challenging 
target for cancer immunotherapy. 
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1.6.3:  Tregs and cancer 
Tregs can have a major role in preventing sufficient immune responses to 
tumours by direct suppression of the immune response (Curiel 2007).  
As discussed above, established tumours are rarely rejected by their hosts despite the 
presence of detectable anti-tumour T cell responses.  One major reason for this 
failure is the presence of tumour-specific regulatory T cells.  Tregs play a key role in 
suppressing anti-tumour responses as many TAAs are aberrantly expressed normal 
self-peptides (Wang, Huang et al. 2004).  nTregs develop in the thymus where they 
are thought to recognise self-peptides with moderate affinity (see section 1.3.3) and 
have the potential to recognise these ligands expressed in the tumour environment.  
In vivo use of anti-CD25 mAb to deplete nTregs can lead to improved anti-tumour 
immunity and inhibition of tumour growth (Shimizu, Yamazaki et al. 1999; Turk, 
Guevara-Patino et al. 2004).  Tumour-specific Tregs are found at elevated levels in 
the peripheral blood and tumour samples of patients with invasive breast or 
pancreatic cancer, with higher numbers of Treg and enhanced Treg function  
associated with poor prognosis (Liyanage, Moore et al. 2002).  Tumour infiltrating 
Tregs are also able to inhibit the effector functions of CD4 Th cells (Chaput, 
Darrasse-Jeze et al. 2007) and CD8 CTLs (Chen, Pittet et al. 2005).  Tregs can also 
be induced (see section 1.3.3) in tumour microenvironments, leading to direct 
suppression of anti-tumour T cell responses (Zhou and Levitsky 2007).   
Tregs require activation via their TCR in order to suppress anti-tumour 
responses; tumours themselves can often induce this activation, via direct and 
indirect antigen presentation.  Activated Tregs can also be maintained by several 
factors produced directly by the tumour in vivo, such as TGF- (Yang, Nurieva et al. 
2008).  The molecular mechanism of Treg-induced immune modulation remains to 
be fully defined.  However, the expression of TGF- (Daley, Ma et al. 2007), the 
production of adenosine and the catabolism of tryptophan, have all been shown to 
play a role (Mellor and Munn 2004).  IDO is an immuno-regulatory enzyme which 
catalyses the first rate-limiting step of tryptophan catabolism.  IDO is expressed by 
plasmacytoid DCs (pDCs) that produce IDO in a GCN-2 kinase-dependent fashion 
that can activate Tregs in the draining lymph node of tumour-bearing mice (Munn, 
Sharma et al. 2004; Munn and Mellor 2007).  This regulation check-point can be 
suppressed by IL-6 which can then induce Tregs to become proinflammatory 
Th17/Th1-like cells (Sharma, Hou et al. 2009), a process called Treg reprogramming.  
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1.7:  Cancer Immunotherapy 
 The strongest risk factor for cancer is age (Coleman and Tsongalis 2009) and 
with greater life expectancy it is an increasing burden on society.  In 2008, 12.7 
million cases of cancer were recorded resulting in 7.6 million deaths, the most 
common forms being lung (1.3M), stomach (0.8M) and colorectal cancer (0.64M) 
(Jemal, Bray et al. 2011).   
  Cancers are caused largely by chemical/radiation exposure, diet, physical 
trauma and hormones although ~5% arise from genetic susceptibility.  Many 
common cancers are carcinomas of epithelial origin, such as prostate, breast, lung, 
pancreas and colon.  Other cancer groups include sarcomas, lymphomas, germ-cell 
tumours and blastomas (Jemal, Bray et al. 2011).  Whatever the cause and type, 
cancers are characterised by their failure to regulate tissue growth.  Genetic 
predisposition and spontaneous genetic contributions often involve genes 
(oncogenes) that regulate growth and differentiation (Croce 2008).  Overexpressed 
gene products (often oncognes) provide markers for distinguishing tumours as 
different from normal tissue and are so termed tumour-associated antigens (TAAs).  
 In recent decades, many TAAs have been identified in murine and human 
tumours.  TAAs are antigens derived from aberrantly expressed non-mutated 
proteins, aberrantly expressed intronic sequences, alternative reading frames of 
normal genes and cancer-specific mutated proteins (Rosenberg 1999).  While TAAs 
are not tumour-specific, they provide a target for immunotherapy as their limited 
distribution makes targeted therapies more specific than chemo/radiotherapy.  The 
identification of TAAs and TAA-specific T cells for a range of tumours has allowed 
development of immunotherapies which have shown promise in several melanoma 
trials (Abad, Wrzensinski et al. 2008).  Tumour-specific antigens are soley expressed 
on the tumour and are therefore rare in naturally arising tumours, although these can 
be common in virally induced tumours (Coulie, Hanagiri et al. 2001). 
 
1.7.1:  Cancer immunotherapeutic strategies 
 There are four general strategies for cancer immunotherapy.  1) Monoclonal 
antibodies (mAb) to directly target tumour cells or modulate the immune system.  2) 
Vaccination including tumour-specific peptides, peptide loaded DCs and/or novel 
adjuvants designed to activate endogenous DCs and T cells.  3) Direct genetic 
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modification of tumours using gene therapy.  4) Adoptive transfer of TAA-specific 
lymphocytes.  This last approach, from now on called adoptive immunotherapy, has 
yielded encouraging clinical responses in melanoma patients (Dudley and Rosenberg 
2003).  This strategy will be discussed in the next section.   
 
1.7.1.1:  Monoclonal antibody therapy 
  mAb therapy is utilised in two ways.  Firstly, immuno-targeting therapy that 
directs mAbs to TAAs and other factors associated with tumour growth can lead to 
antibody-mediated immunity.  An example of this class of mAbs includes 
Alemtuzumab, a humanised antibody against CD52 that induces the destruction of 
leukaemia by antibody mediated immunity (Hale, Hoang et al. 1983).  mAbs, such as 
Mylotag™ have also been engineered to carry toxins sufficient to directly kill target 
cells (Reichert and Valge-Archer 2007).   
Secondly, immuno-modulating mAbs binding to receptors, cytokines and 
chemokines that naturally regulate anti-tumour immune responses.  For example, 
these mAbs can block inhibitory pathways such as PD-1/L1/L2 or, conversely, 
activate stimulatory pathways for APCs and T cells.  Clinically relevant antibodies 
include anti-CTLA4 (Ipilimumab™), constitutively expressed on Tregs.  In vivo 
blockade using this antibody has led to successful therapy in prostate cancer (Small, 
Tchekmedyian et al. 2007).  GITR is highly expressed on activated T cells.  Ligation 
of GITR using the DTA-1 mAb (Shimizu, Yamazaki et al. 2002) is sufficient to 
cause upregulation of proinflammatory factors.  DTA-1 has been shown to eliminate 
large established tumours (Turk, Guevara-Patino et al. 2004). 
While several clinical mAb approaches are now in use, they are of limited 
value.  Most mAb therapies target single pathways or cells types, which can limit 
their efficacy and effectiveness for many cancers.  In addition, it can often be 
difficult to ensure mAbs can enter into the tumour mass due to tumour-induced 
exclusion (e.g metastatic pressure).  The use of mAbs in conjunction with other 
therapeutic approaches may be a more promising approach in the future. 
 
1.7.1.2:  Vaccination therapy 
 Cancer vaccines fall into two general categories: those that target immunity to 
TAAs, such as use of peptide loaded DCs, and those that modulate enhanced immune 
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responses to TAAs, such as novel adjuvants.  Due to the nature of cancer it is 
difficult to vaccinate pre-emptively unless the cancer is associated with specific 
infectious diseases, e.g. cervical cancer rates and liver cancer rates are reduced by 
vaccination against HPV and Hepatitis B respectively (Doren 2010).  Cancer vaccine 
designs must therefore aim to generate or enhance immune responses to already 
established tumours.   
Cancers of a particular lineage develop from the same cell type and can 
involve mutations to a limited set of genes and gene families, for example human 
melanomas often express the antigen MART1MelanA, against which T cell clones 
have been expanded for use in clinical immunotherapy (Yee, Thompson et al. 2002).  
Such TAA prediction allows for identification of potentially useful vaccines.  
Clinically relevant vaccines such as Provenge™ are used in the treatment of 
advanced prostate cancer.  This vaccine uses APCs activated using the prostatic acid 
phosphatise (PAP) - a prostate cancer antigen linked to granulocyte-macrophage 
colony-stimulating factor (GM-CSF), an immune cell activator which is currently 
undergoing clinical trials (Cheever and Higano 2011).   Other approaches such as the 
use of synthetic peptides are currently also being developed with varying levels of 
success (Perez-Diez, Martinez-Crespo et al. 1996). 
The other major vaccine approach is designed to enhance the immune 
responses to tumours using novel adjuvants.  As discussed in previous sections 
tumours can be highly immunoevasive and can escape control by either preventing 
antigen recognition or by creating a suppressive microenvironment (Melchionda, 
McKirdy et al. 2004; Kim, Emi et al. 2006).  Adjuvants against cancers have been 
known for many decades.  For example, it was noted in 1975 that serum from BCG 
inoculated mice can induce necrosis in transplanted tumours (Carswell, Old et al. 
1975).   Currently many new therapeutic approaches are being investigated, 
particularity using immuno-modulatory cytokines such as IL-2, GMCSF and others 
(Elias, Zapas et al. 2005).  However, in a clinical setting only BCG, aluminium based 
salts and squalene-oil-water emulsifications are approved for use.  Cancer vaccines, 
such as anti-cancer mAbs, are currently of limited use and often insufficient when 
used on their own.  Only two therapeutic vaccines of this sort are currently at phase 
II or above at this present time. 
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1.7.1.3:  Genetic modification and gene therapy 
Genetic modification of tumours is a novel approach to directly alter tumour 
cells and the tumour-related factors released into the microenvironment.  For 
established tumours, in vivo delivery of genes can be achieved through local injection 
of viral vectors containing the gene into the tumour itself or to specific immune cells 
(Dummer, Hassel et al. 2004; Dummer, Rochlitz et al. 2008).  Many vectors are now 
available for in vivo or ex vivo modification of the immune system, including 
lentivirus (Poeschla, Wong-Staal et al. 1998), adenovirus (Bramson, Hitt et al. 1996), 
retrovirus (Miller, Miller et al. 1993), herpes simplex virus (Rees, McArdle et al. 
2002), vaccinia (Carroll, Overwijk et al. 1998), and fowlpox  (Kim, Cormier et al. 
1998).  Transduction of the IL-2 gene into rat gliosarcoma 9L cells in vivo, in 
combination with treatment with an irradiated 9L cell vaccine, was sufficient to 
induce tumour rejection (Iwadate, Yamaura et al. 2001).  Other studies using TNF 
transduced B16 melanoma tumours in vivo have also resulted in reduced tumour 
growth and increased infiltration of CD4 and CD8 T cells (Kianmanesh, Hackett et 
al. 2001).  Clinical trials using canarypox viral vectors to express cytokines in murine 
prostate cancer has shown positive results, inhibiting tumour growth (Griffith, 
Kawakita et al. 2001). OncoVEX GM-CSF is currently in a phase III trial using 
modified herepes simplex engineered to selectively replicate in melanoma tissue and 
express GM-CSF to enhance the anti-tumour response.  This has shown a very high 
degree of efficacy in Phase II trials.  
Ex vivo genetic modification of tumour cells for use as a whole cell vaccine is 
a recent approach to provide exposue to TAAs under pro-immune conditions.   This 
is a promising approach that avoids the logistical problems faced in trying to direct 
vectors specifically to tumour cells as well as ethical issues associated with gene 
therapy (Ettinghausen and Rosenberg 1995).   The use of a genetically modified 
tumour as a whole cell vaccine is discussed in more detail chapter 6. 
 
 
1.8:  T cell Adoptive Immunotherapy 
 Adoptive immunotherapy for the treatment of cancer was first utilised in mice 
in the late 1950s and 60s, where it was demonstrated that transfer of leukocytes, 
before tumour inoculation, could lead to rejection (Mitchison 1955).  It was later 
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found that leukocytes from immunised mice transferred to tumour-bearing mice 
could also lead to tumour regression (Borberg, Oettgen et al. 1972).  Shortly after 
these observations, IL-2 was discovered to be an important cytokine in the 
maintenance and proliferation of T cells, allowing generation of large numbers of T 
cells in vitro (Robb, Munck et al. 1981).  Subsequently, IL-2 was used to expand 
tumour infiltrating lymphocytes for use in adoptive transfer to reduce tumour burden 
(Rosenberg and Lotze 1986). 
 Special note must be made of Rosenberg and colleagues in applying the 
system of ex vivo expansion of melanoma-specific T cells for adoptive 
immunotherapy.  Initially lymphocytes were harvested from surgically removed 
melanomas and expanded in vitro for adoptive transfer back to the patient, combined 
with high doses of IL-2.  This produced promising results with some patients 
entering into complete remission, however many experienced significant „cytokine 
storm‟ side effects associated with high doses of IL-2, causing this approach to be 
dropped or modulated by others (Rosenberg, Mule et al. 1985; Rosenberg 1988).  
This has been furthered by Dudley and colleagues who have demonstrated that 
lymphocyte depletion using cyclophosphamide and other drugs prior to adoptive cell 
transfer significantly improved the anti-tumour response (Dudley, Wunderlich et al. 
2005).  Following the early success of adoptive immunotherapy utilising polyclonal 
tumour responses, more recent trials have focused on transfering tumour-specific 
lymphocytes.  The most recent clinical adoptive therapy strategies have been utilised 
against melanomas using well defined melanoma TAAs such as Melan-A/Mart-1 
(Dudley and Rosenberg 2003).  Recently however, identification of many other 
TAAs in association with other cancers has increased the clinical relevance of 
adoptive immunotherapy.  Table 3 highlights some of the most recent adoptive 
immunotherapy trails.     
Table 3: Clinical trials using adoptive T cell transfer 
Date Cell Type Treatment 
regimen 
Tumour Responses Reference 
1988 In vitro 
expanded 
Tumour 
infiltrating 
Lymphocytes 
(TIL) 
High IL-2 (7.2 
x10
5
 IU/Kg) 
Melanoma 11/15 
Objective 
response (OR) 
 (Rosenberg, 
Packard et al. 
1988) 
1994 In vitro 
expanded TIL 
Cyclo. High IL-
2 TIL and IL-2 
in two week 
Melanoma 24/86 Partial 
response (PR) 
(Rosenberg, 
Yang et al. 
1994)  
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cycles 5/86 Complete 
response (CR) 
1990 In vitro 
expanded TIL 
High IL-2. TIL 
and IL-2 in two 
week cycles 
Melanoma   (Rosenberg, 
Anderson et 
al. 1993)  
2002 In vitro 
expanded Mart-
1 or gp-100 T 
cells from 
Peripheral blood 
mononuclear 
cells (PBMC) 
Increasing 
doses of IL-2 
s.c. 
Melanoma 5/10 Stable 
disease (SD) 
(Yee, 
Thompson et 
al. 2002)  
1/10 Major 
response (MR) 
2/10 Minor 
response 
(MiR) 
2002 In vitro 
expanded TIL 
Cyclo and Flur 
for 7 days, cell 
transfer.  High 
IL-2.  
Melanoma 6/13 OR (Dudley, 
Wunderlich et 
al. 2002)  (7.8 x 10
10
 cells 
i.v.) 
4/13 MR 
2005 In vitro 
expanded TIL 
Cyclo (2d) then 
Flur (5d) 
transfer then 
high IL-2 
Melanoma 15/35 PR  (Dudley, 
Wunderlich et 
al. 2005) 
3/35 CR 
2006 PBMC 
transduced with 
Mart-1 specific 
TCR.  
Cyclo (2d) then 
Flur (5d) 
transfer then 
high IL-2 and 
Mart-1 vaccine 
Melanoma 2/17 PR 
1/17 MR 
(Morgan, 
Dudley et al. 
2010)  
 
2008 In vitro 
expanded NY-
ESO-1 specific 
CD4 from PBL 
N/A Melanoma 1/1 CR (Hunder, 
Wallen et al. 
2008)  
2008 Genetically 
modified T cells 
expressing 
CD20 specific 
chimeric 
receptor 
Varied 
cytoreductive 
therapy before 
cell transfer 
then 14 days 
low IL-2 (5 x 
10
5
 IU/m
2
) 
Non 
Hodgekins 
Lymphoma / 
Mantel cell 
lymphoma 
2/7 CR  (Till, Jensen 
et al. 2008) 
4/7 SD 
1/7 PR 
2010 PBMC 
transduced with 
CD19 chimeric 
antigen 
receptor, 66% 
CD8, 34% CD4. 
Cyclo, 2 days 
and Flur for 5 
days. Then cell 
transfer 
followed by 
high IL-2 i.v. 
every 8hrs 
Folliculoar 
lymphoma 
1/1 PR (Kochenderfer, 
Wilson et al. 
2010)  
 
 
1.8.1:  Adoptive immunotherapy using TCR transgenic T cells 
 Initial approaches to obtain tumour antigen-specific T cells were to 
selectively expand TILs using cytokines such as IL-2 in the hope of expanding 
tumour-specific lymphocytes (Rosenberg and Lotze 1986).  Later identification of 
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specific TAAs has allowed for selective expansion, isolation and purification of 
tumour-specific T cells prior to adoptive transfer, as is the case with many melanoma 
trails (Dudley and Rosenberg 2003).  Despite this, the resultant T cell responses in 
vivo are often limited by tumour-induced immunosuppressive networks, combined 
with the relatively low affinity of TCR/TAA interactions due to most TAAs being 
self-peptides.  These factors can induce tolerance, adaptation and anergy in tumour-
specific T cells, representing a major challenge for adoptive immunotherapy (Lohr, 
Knoechel et al. 2005).  A more recent strategy is to genetically modify T cells, 
usually CD8 T cells, to counteract tumour-mediated suppression (Kershaw, Hsu et al. 
2001). 
 The use of TCR transgenic mouse models has provided much insight in this 
area of research (Johnson, Morgan et al. 2009).  Abad et al. used Pmel1 specific TCR 
transgenic CD8 T cells that recognise the gp100 B16 melanoma antigen in the 
context of H2D
b
 (Overwijk, Theoret et al. 2003).  Adoptive transfer of Pmel1 
specific CD8 T cells caused tumour regression in a dose-dependent manner.  This 
response was inhibited when Pmel1 T cells were co-transferred with unmodified 
lymphocytes (Abad, Wrzensinski et al. 2008).  Similar results are also seen by 
DeWitte et al., who showed OT-1 TCR transgenic CD8 T cells, which recognise the 
OVA antigen expressed by the B16-OVA cell line (Johnson, Morgan et al. 2009), 
can mediate tumour rejection.  When transferred with unmodified lymphocytes, this 
response can also be inhibited.  Conversely, irradiation before OT-1 transfer was 
found to increase the anti-tumour response (de Witte, Jorritsma et al. 2008), 
supporting initial observations by Dudley using immunosuppressive drugs (Dudley, 
Wunderlich et al. 2005). 
 Similar observations have also been reported in spontaneous tumour models.  
De Witte used transgenic adenocarcinoma of mouse prostate (TRAMP) mice in 
which transforming SV40 large T antigen is expressed under control of the probasin 
promoter resulting in the development of prostatic intraepithelial neoplasia between 
8-12 weeks of age.  T cells that are isolated and transduced with a TCR specific for 
an epitope of SV40 are able to induce tumour regression on adoptive transfer to 
tumour-bearing TRAMP mice; when combined with an SV40IV recombinant virus 
vaccine at week 10, long-term remission was achieved (de Witte, Bendle et al. 2008).   
Similar observations have been reported using T cell adoptive transfer 
coupled with radiation pre-conditioning (Cao, Daniel et al. 2002).  Irradiation is 
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beneficial to adoptively transferred T cells by increasing antigen shedding by 
tumours, and by creating „space‟ for expansion, increasing cytokine availability by 
depletion of other T cells and by the removal of Tregs (Gattinoni, Powell et al. 
2006).  Together, these results indicate that genetic modification of T cells with TCR 
gene therapy can be sufficient to induce regression and this response is enhanced by 
radiotherapy, lymphopenia and vaccination.  However, as an unwanted side effect, T 
cell responses specific for TAAs can have the potential to cause GvHD in irradiated 
hosts (see chapter 7) (Kaplan, Anderson et al. 2004). 
 
1.8.2:  Adoptive immunotherapy using CD8 T cells  
Adoptive transfer of CD8 CTLs has been used extensively in mouse tumour 
models.  As discussed above, TCR transgenic CD8 T cells can induce anti-tumour 
responses in vivo leading to tumour rejection (Abad, Wrzensinski et al. 2008).   A 
plethora of new CTL targets and improved cell culture protocols have lead to a 
succession of clinical trails in humans, particularly in melanoma treatment (Yee 
2010).   Efficacy of these treatments however rarely exceeds 50% (Yee, Thompson et 
al. 2002) and the high costs associated with generating large numbers of CTL clones 
make widespread treatments impossible at this time.  Approaches that produce lower 
numbers of CTLs with a more robust anti-tumour response are promising for future 
therapies.  This can be achieved by in vitro conditioning and genetic modification. 
Driving T cell differentiation in vitro prior to adoptive cell transfer is an 
approach to increase the efficacy of in vivo anti-tumour responses.  Adoptive transfer 
studies using CD8 T cells have revealed that optimal anti-tumour function is 
dependent on their differentiation state.  Effector memory (TEM) CD8 T cells have up 
to 100 fold less effective anti-tumour activity than central memory (TCM) CD8 T 
cells (Wang, Huang et al. 2004).  This is because TEM have reduced expression of 
lymphoid homing molecules (CCR7
-
) and co-stimulatory molecules (CD28) 
(Klebanoff, Gattinoni et al. 2006), and lose their ability to produce IL-2 and TNF 
and to respond to homeostatic cytokines, resulting in decreased survival and 
exhaustion in vivo (Zhou, Ou et al. 2004).  
IL-15 drives T cells to a TCM phenotype while IL-21 promotes a CD45RO
+
 
CD28
hi
 stable phenotype that retains ability to produce IL-2 after antigen exposure 
(Hinrichs, Borman et al. 2009).  Driving towards a TCM phenotype is a promising 
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strategy to maintain effective anti-tumour immunity; however this is likely to require 
supplementary modification to overcome tumour immune evasion (Klebanoff, 
Gattinoni et al. 2006).  IL-21 is the most recently identified member of the common 
gamma chain receptor cytokine family and has been used in clinical trials for treating 
cancer patients.  In vivo, IL-21 is more potent than IL-15 at maintaining tumour-
specific CD8 T cells and eliminating tumours (Moroz, Eppolito et al. 2004).  In vitro 
activation of tumour-specific CD8 T cells with antigen plus IL-21 induces a less 
differentiated population that can make IL-2 following antigenic re-stimulation, 
representing potential helper independent CD8 T cells (Li, Bleakley et al. 2005).  
Interestingly, IL-21 primed Pmel1 specific T cells display a distinct gene expression 
profile in comparison with IL-15 conditioned cells (Zeng, Spolski et al. 2005).   It is 
therefore very important to consider the activation conditions and phenotype of CD8 
T cells before adoptive transfer. 
 
1.8.3:  Adoptive immunotherapy using CD4 T cells 
 CD4 T cells are critical for the anti-tumour response in a variety of murine 
models, largely based on their ability to produce IL-2 (Antony, Paulos et al. 2006) 
and IFN (Hung, Hayashi et al. 1998).  CD4 cells have been shown to reject tumours 
alone or in combination with additional treatments, and can be more efficient at 
rejecting tumours that CD8 T cells (Perez-Diez, Joncker et al. 2007).  Mumberg et al. 
also demonstrated that CD4 T cells were able to clear MHC-II
-/-
 tumours in vivo by a 
mechanism that was dependent on the indirect effects of IFN (Mumberg, Monach et 
al. 1999).  Despite this, most basic and clinical studies have focused on adoptive 
transfer of CD8 T cells alone, or those co-transferred with CD4 T cells (Antony, 
Piccirillo et al. 2005) (Cohen, Peng et al. 2000).  
 As for CD8 T cells, the differentiation status of CD4 T cells is important for 
their in vivo behaviour following adoptive transfer.  CD4 T cells can be differentiated 
into Th1, Th2 or Th17 cells in vitro.  Th17 cells produce IL-17A, IL-6 and GM-CSF, 
capable of activating other innate immune cells such as neutrophils, leading to local 
inflammation (Korn, Bettelli et al. 2009).  Several groups have shown Th17 cells can 
be more effective at tumour eradication than Th1 cells (Muranski, Boni et al. 2008).  
This observation is relevant to recent findings describing antigen-driven loss of 
FoxP3 by Tregs and their subsequent differentiation towards Th1 or Th17 like 
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phenotypes in tumour-draining lymoh nodes (Sharma, Hou et al. 2009) (see chapter 
5). 
 It is clear that a large variety of factors influence the anti-tumour activity of 
adoptively transferred T cells. These factors must be considered in the design of 
future adoptive T cell therapies.  Despite many clinical trials, novel protocols, along 
with reports of donor T cell persistence (Rosenberg 1988; Kochenderfer, Wilson et 
al. 2010), and infiltration into the tumour mass (Yee, Thompson et al. 2002), the 
potential of adoptive immunotherapy has yet to be realised.   
 
 
 
1.9:  Project Aims 
The key aim of this project is increase our understanding of the in vivo fate of 
adoptively transferred HY-specific CD4 and CD8 T cells in response to HY antigens 
in various models including tolerance induction and immunotherapy: 
Specific questions to be addressed are: 
1.  Why do endogenous T cell responses fail to control tumours?  
2.  What are the processes that underlie the distinct responses of CD4 and 
CD8 T cells to male skin grafts, and male-derived tumour cells? 
3.  What is the role of antigen-driven FoxP3 downregulation in antigen-
specific anti-tumour responses? 
4. Why do polyclonal and antigen-specific CD8 T cells eliminate tumour cells 
expressing IL-2 but not wild type tumour cells? 
5.  Why do male antigen-specific CD4 but not CD8 T cells induce GvHD in 
radiation conditioned lymphopenic male mice? 
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Chapter 2: Materials and Methods 
 
The materials and methods used in this project are described in this chapter. 
Buffers and chemical reagents are described first, followed by protocols. Experiment 
specific detail is described in Results.  
 
2.1:  Media and Reagents 
Table 4: List of Reagents 
Medium Use Composition 
Phosphate 
Buffered 
Saline (PBS) 
Resuspending of 
cells/reagents for 
in vivo use 
Made from tablets (Oxoid, Hampshire, UK) in 
distilled water. NaCl, 137mmol/L; KCl, 
2.7mmol/L; Na2HPO4, 8mmol/L; KH2HPO4, 
2mmol/L. pH 7.3. 
MACS buffer Washing of single 
cell suspensions 
before 
MACS/FACS 
sorting 
PBS, 2mM EDTA, 1% FCS 
RBC lysis 
buffer 
(Qiagen, 
Hilden, 
Germany).  
Depletion of red 
blood cells before 
counting/FACS 
Unspecified concentrations of NaCl, EDTA 
and Sodium Bicarbonate 
Complete 
medium 
Maintenance of 
hybridomas / 
tumour cell lines / 
in vitro cultures 
RPMI 1640 Medium (Invitrogen), 
supplemented with 10% foetal calf serum 
(FCS; Autogen Bioclear, Calne, UK), 10mM 
HEPES (N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid) (Invitrogen), 100 IU/ml 
penicillin (Invitrogen), 100μg/ml Streptomycin 
(Invitrogen), 2mM L-glutamine (Invitrogen) 
and 2x10
5 M β2-Mercaptoethanol. 
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Complete 
medium 2  
Maintainance of 
phoenix cell line 
IMDM (Iscove‟s Modified Dulbecco‟s 
Medium) supplemented as with RPMI 1640 
Blood Buffer Collection of 
blood 
PBS, 100U/ml Heparin, 2mM EDTA 
Ammonium 
Sulphate 
Solution 
Purification of 
Antibodies from 
hybridomas 
culture supernatant  
4.1M (NH4)2SO4 in dH2O 
Freezing 
Medium 
Storing cells in 
liquid nitrogen 
8ml FCS, 2ml DMSO (20%) (1ml freezing 
medium + 1ml cell suspension)  
Ingredients of complete culture medium (Invitrogen, Paisley, UK) except for FCS 
(Autogen Bioclear, Calne, UK).   
 
 
2.2:  Animals 
Mice used in this project were housed under specific pathogen-free 
conditions at the Central Biological Services Unit in Hammersmith Campus, 
Imperial College London.  Animals were used in accordance with the Home Office 
guidelines as defined in the project licence and Animal Procedures Act 1986.  All 
mice were on a C57BL/6 background.  
Table 5: Mouse strains used in this project 
Strain Phenotype Reference 
C57BL/6 Wild type, Thy1.2
+
 (Russell, Neufeld et al. 
1951; Hoag 1963) 
C57BL/6 
Thy1.1
+
 
Wild type, Thy1.1
+
 (Russell, Neufeld et al. 
1951) 
Rag2
-/-
 Deficient in B cells and T cells No TCR 
rearrangement due to a lack of Rag 
Enzyme. 
(Shinkai, Rathbun et 
al. 1992) 
Marilyn TCR transgenic for HY-A
b
Dby (Valujskikh, Lantz et 
al. 2002) 
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Marilyn 
dnTGFRII 
Double transgenic Marilyn TCR and 
dominant negative TGF receptor type II 
(Gorelik and Flavell 
2001) 
Matahari TCR transgenic for HY-D
b
Uty (Lantz, Grandjean et 
al. 2000) 
FoxP3-GFP FoxP3
+ 
T cells co-express GFP which 
can be detected by FACS 
(Wang, Kissenpfennig 
et al. 2008)  
FoxP3-GFP 
Marilyn  
TCR transgenic for HY-A
b
Dby with 
FoxP3
+ 
T cells co-express GFP 
(Chai, Coe et al. 2008) 
FoxP3-GFP-
DTR  
FoxP3
+ 
T cells co-express GFP and 
Diphtheria Toxin receptor 
(Kim, Rasmussen et 
al. 2007) 
FoxP3-GFP-
DTR Marilyn 
TCR transgenic for HY-A
b
Dby
 
with 
FoxP3
+ 
T cells co-express GFP and 
Diphtheria Toxin receptor 
(Developed by Chai, 
JG. Unpublished) 
IL-10 KO Defect of IL-10 production  (Kuhn, Lohler et al. 
1993) 
IL-17A KO Defect of IL-17A production (Nakae, Komiyama et 
al. 2002) 
 
C57BL/6 wild type mice (H2
b+
,Thy1.2
+
) were originally produced in 1921 by 
Clarence Little and have since been maintained as an inbred strain.  B6 have a high 
leukocyte count (Russell, Neufeld et al. 1951); a low frequency of tumour 
development (Hoag 1963), and a skew towards a Th1-like phenotype (Hsieh, 
Macatonia et al. 1995).  The phenotype of B6 mice makes them useful for studying 
the cellular and molecular mechanisms of tumour development.  B6 were purchased 
from Harlan Laboratories (Bicester, UK).  
Rag deficient mice (Rag2
-/-
) have an inactivated recombination activating 
gene 2 required for TCR and BCR rearrangement and without which B cells and T 
cells do not develop.  B6 Rag2
-/-
 mice were originally produced by Frederick Alt et 
al. (Columbia University, NY) (Shinkai, Rathbun et al. 1992).  Marilyn and Matahari 
mice on a B6 background were kindly provided by Dr Oliver Lantz (Curie Institute, 
Paris).  Marilyn mice express a HY-specific V6+ TCR which directs development 
of CD4
+
 T cells recognising the Dby (NAGFNSNRANSSRSS) peptide presented by 
the MHC class II molecule H2-A
b
 (Valujskikh, Lantz et al. 2002).  Marilyn mice 
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were provided on a Thy1.2
+
 Rag2
-/-
 background, these were then crossed with B6 
Thy1.1
+
 male mice to produce Thy1.1
+
 and/or Thy1.2
+
 Marilyn mice on a Rag2
-/-
 or 
Rag2
+/-
 background.  Matahari mice express a HY-specific V8.3+ TCR which 
directs development of CD8
+
 T cells recognising the Uty (WMHHNMDLI) peptide 
presented by the MHC class I molecule H2-D
b
 (Lantz, Grandjean et al. 2000). 
Matahari mice were provided on a Rag1
-/- 
Thy1.2
+
 background and crossed with B6 
Thy1.1
+
 male mice to produce Thy1.1
+
 and or Thy1.2
+
 Matahari mice on a Rag2
-/-
 or 
Rag2
+/-
 background.   
FoxP3-GFP knock in mice on a Thy1.2
+
 B6 background were kindly 
provided by Dr B. Malissen (Centre d‟Immunologie de Marseille-Luminy, Marseille, 
France) (Wang, Kissenpfennig et al. 2008).  These mice were also bred with Rag2
-/- 
Marilyn mice to give Rag2
+/-
 F1 females that are TCR transgenic for HY-A
b
-Dby 
with FoxP3
+ 
T cells co-expressing GFP.  FoxP3-GFP Marilyn mice produce double 
transgenic HY-specific Tregs that can be purified by FACS cell sorting. Those 
purified from the thymus represent nTregs whilst those purified from spleen (SP) and 
lymph node (LN) includes both nTreg and iTreg.  
FoxP3-GFP-DTR knock in mice on a Thy1.2
+
 B6 background were kindly 
provided by Prof Daniel Altmann (Imperial College London) (with the permission of 
Prof Rudensky) (Kim, Rasmussen et al. 2007).  These mice have a double fusion 
protein linked to FoxP3 that induces FoxP3
+ 
cells to express DTR on their surface in 
addition to GFP.  These cells were purified as above and selectively deleted by 
administration of Diphtheria Toxin (DT) in vivo (i.p) or in vitro.  By mating FoxP3-
GFP-DTR male mice with Rag2
-/-
 Marilyn females we were able to produce Rag2
+/-
 
F1 females that are TCR transgenic for HY-A
b
-Dby with FoxP3
+ 
T cells co-
expressing GFP and DTR.  FoxP3-GFP Marilyn mice produce triple transgenic Tregs 
that can be purified by FACS cell sorting and selectively deleted using DT.  
IL-10 knockout (IL-10 KO) mice do not produce IL-10 and were generated 
on a C57BL/6 background using gene targeting, by Ralf Kuhn et al. (University of 
Cologne) (Kuhn, Lohler et al. 1993). IL-10 KO mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME).   IL-17A knockout mice (IL-17A KO) mice 
do not produce IL-17A and were generated, on a C57BL/6 background by Susumu 
Nakae et al. (Institute of Medical Science, Tokyo) (Nakae, Komiyama et al. 2002).  
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2.3:  Peptides 
The HY-A
b
-Dby peptide, NAGFNSNRANSSRSS (Scott, Addey et al. 2000), 
and the HY-D
b
-Uty peptide, WMHHNMDLI (Simpson, Scott et al. 1997), were 
synthesised by the central research resource unit at the Clinical Sciences Centre 
(Hammersmith Hospital, London) using 9-fluorenylmethyloxycarbonyl-protected 
amino acids and (2-(1-H-benzotriazol-2-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU)) activation chemistry.  
 
 
2.4:  Cell purification 
 
2.4.1:  Purification of Lymphocytes using MACS 
Lymphocytes were purified from single cell suspensions of pooled LN and 
SP or from in vitro cultures.  Suspensions were passed through a 70m nylon cell 
strainer (Becton Dickinson, Oxford UK), using the base of a 1ml syringe plunger to 
force through cell suspensions.  Cells were then purified using MACS® cell 
purification kits (Miltenyi Biotec, Surrey, UK).  Firstly, cells were labelled with 
small chemically inert magnetic beads with a specific mAb antibody on their surface 
(MACS beads) (4
o
C 15minutes 100-200l volume).  Cells were washed and re-
suspended in ~2ml MACS buffer (PBS, 2mM EDTA, 1% FCS) and then passed 3 times 
through magnetic columns mounted on a powerful magnet.  MS (medium) or LS 
(large) MACS separation columns were used initially in this study followed by 
AutoMACS® cell separation machine at later stages.  Columns were washed by 
passing through a further 2ml of MACS buffer.  Columns are then removed from the 
magnetic source and cells are forced out of the column using MACS buffer (~5-
10ml) and the provided plunger.  Cells were then washed using MACS buffer and 
pelleted by centrifugation (1800rpm 5mins). 
 
2.4.2:  Purification of Marilyn and Matahari conventional T cells 
 Matahari or Marilyn cells were purified from LN and SP cell suspensions or 
from in vitro culture.  30l of anti-CD4 (Marilyn T cells) or anti-CD8 (Matahari T 
cells) MACS beads were added to cell suspensions and stained as described 
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previously.  Samples were then purified using an MS or LS MACS separation 
columns or AutoMACS®.  Following separation, cells were re-suspended in an 
appropriate volume of either PBS or complete culture medium for in vivo injection 
(i.v.) or cell culture.   
Matahari and Marilyn T cells particularly from Rag
+/-
 mice have CD8 or CD4 
compartments that can contain T cells not expressing a surface transgenic TCR.  In 
some experiments it was therefore important that cells were further purified using 
FACS sorting.  For Matahari, cells are stained using 1-5l of anti-V8.3PE or FITC 
and anti-CD8
PE/cy5 
or 
APC
 (4
o
C 15minutes 100-200l volume) and sorted by the 
Medical Research Council (MRC) cell sorting facility (Hammermith Hospital, 
London) using cell sorters such as Becton Dickinson FACS Aria®.  This gave cell 
preparations of >99% purity. These cells were then re-suspended in an appropriate 
volume of PBS or complete culture medium for in vivo injection (i.v.) or in vitro cell 
culture. 
 For Marilyn, cells were stained using 1-5l of anti-V6PE or FITC and anti-
CD4
PE/cy5 
or 
APC
 (4
o
C 15minutes 100-200l volume) and sorted as described 
previously. 
 
2.4.3:  Purification of Tregs from B6 and Marilyn mice 
 Marilyn CD4
+
 CD25
+
 Tregs were purified from spleen and pooled LN of 
Rag
+/-
 mice which produce ~5% Tregs (containing both nTreg and iTreg) in the CD4 
T cell compartment.  To purify nTregs alone, cell suspensions were made from 
thymus, and CD8
+
 and CD4
+
CD8
+
 thymocytes were removed using anti-CD8 
microbeads.   Cells were isolated and suspended as described previously before 
staining using 5l of anti-CD25PE antibody (e-Bioscience) (4oC 15minutes 100-
200l volume).  Cells were then washed (MACS buffer) and stained using 20l anti-
PE MACS beads (4
o
C 15minutes 100-200l volume).  Cells were washed again and 
separated using columns or AutoMACS® as described previously.  The negative 
fraction was used to generate a CD25 depleted conventional CD4 T cell fraction.  
This was then further purified by staining using CD4 beads as described previously.  
CD25
+
 fractions were used as a pre-enriched suspension of Tregs.  For further 
purification, cells were stained using 1-5l of anti-V6FITC, CD25PE anti-CD4PE/cy5 
or 
APC
 (4
o
C 15minutes 100-200l volume) and sorted by FACS as described 
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previously.  To obtain a purified fraction of WT B6 Tregs, the same procedure was 
used as described above except cells were stained using anti-TCRFITC instead of 
V6.  It is of note that not all CD4+ CD25+ cells are regulatory T cells.   
 
2.4.4:  Purification of green Treg cells from single or double transgenic mice. 
 To obtain reliable Tregs populations, FoxP3-GFP knock in mice were used as 
the FoxP3 transcription factor expression is required for the development of Tregs 
which can be sorted based on GFP expression (Williams and Rudensky 2007).  For 
FoxP3-GFP knock in Marilyn double transgenic mice, cells were isolated and 
suspended as described previously.  CD25-expressing cells were first enriched by 
MACS prior to staining with anti-V6FITC, anti-CD25PE and anti-CD4APC and FACS 
sorted for triple positive population CD4
+
 V6+ and GFP+ (or GFP- for conventional 
population) with >99% purity.  For FoxP3-GFP knock in B6 mice the same 
procedure was followed except cells are stained using TCRFITC instead of V6FITC. 
For the isolation of GFP
+
 nTregs, the initial cell suspension was thymocytes, which 
were subjected to CD8 depletion to removal of both CD8
+
 and CD4
+
CD8
+
 
thymocytes.    
 
2.4.5:  Purification of antigen-presenting cells (APCs) 
 Due to peripheral lymphoid organ architecture, SP and LN must be 
additionally digested prior to APC purification.  SP and LN were initially diced using 
a size 22 scalpel.  The resulting tissue was added to a 50ml Falcon tube and digested 
by the addition of 2 mg/ml Collagenase XI and 10 μg/ml DNase in 1ml PBS with 2% 
FCS.  This was incubated by shaking at 37
o
C for 30 minutes.  100μl 0.1M EDTA 
was added for the final 5 minutes to terminate the reactions.  The tissue was then 
strained into a cell suspension as described previously.  APCs were then further 
isolated by the addition of MACS beads; anti-CD11c for dendritic cells, anti-CD11b 
for macrophages and anti-B220 for B cells (4
o
C 15minutes 100-200l volume) and 
MACS purification as described previously.  These cells were then used for further 
cell culture. 
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2.5:  Proliferation Assays 
 
2.5.1:  T cell proliferation assays with peptide and cytokine 
 Cell suspensions were made as described previously.  Either whole SP and 
LN cells were plated in 200l volume complete media +/- HY peptide +/- cytokine 
(37
o
C 5%CO2).  When purified T cells were used as responders, APC populations 
were also included.  48-72 hours later 0.5μlCi/well of tritiated thymidine (New 
England Nuclear) was added and cells were cultured for a further 8-24 hours.  Plates 
were then harvested onto a filter mat and analysed using a Wallac Trilux 1450 
Microbeta liquid scintillation and luminescence counter (PerkinElmer, Beaconsfield, 
UK).  
 
2.5.2:  Activation of HY-specific T cells with Male SP cells in vitro, 
 Cell suspensions were made as described previously.  Either whole SP and 
LN or purified T cells (either CFSE labelled or not) were plated out in 1ml complete 
media +/- cytokine.  Male SP cells were also re-suspended at 5 x 10
6
cells/ml and 
added to 1ml of responders in a 24 well plate and cultured for 5-7 days (37
o
C 
5%CO2).  Cells were then harvested and analysed for in vitro phenotype, cytokine 
production and expansion or harvested for adoptive cell transfer. 
 
2.5.3:  Carboxyfluorescein Succinimidyl Ester (CFSE) dilution assay   
 T cell proliferation can be measured by dilution of CFSE.  T cells were 
isolated ex-vivo or directly from culture as described previously.  Following 
purification using MACS and or FACS cell sorting, cells were washed three times 
using PBS and re-suspended in 1ml PBS. CFSE (Molecular Probes, Cambridge, UK) 
was added to the cell suspension with a final concentration of 1M and incubated for 
10 minutes RT in the dark.  Following incubation, cells were washed in MACS 
buffer before being re-suspended in either PBS for injection (i.v.) or complete 
medium for in vitro culture.  Following in vitro culture or in vivo experiment T cells 
were isolated from SP and LN as described previously and stained for surface 
markers using conjugated antibodies (see next section).  CFSE dilution was 
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measured as a readout of T cell proliferation analysed using FACS™ Calibur 
(Becton Dickinson). 
 
2.6:  Flow Cytometry Analysis 
 
2.6.1:  Surface staining for Flow Cytometry 
 A wide variety of cell types were prepared for Flow cytometric analysis.  Ex-
vivo cells were harvested and washed and, if necessary, depleted of red blood cells 
using 2ml of red blood cells lysis buffer (Qiagen) and incubated (15 mins at RT).  
When staining APCs, LN and or SP may also be digested using collagenase and 
DNAase as described previously.  All types of cells (ex vivo and in vitro) were then 
centrifuged (1800rpm 5mins) and washed (PBS) before centrifuging once more.  
Cells were incubated with conjugated antibodies (eBioscience, Hatfield, UK or R&D 
Systems, Abingdon, UK) and incubated (4
o
C 15 minutes 100-200l volume of PBS) 
in the dark.  Antibody concentrations were variable and defined on the basis of 
previous data although generally 1l of antibody is added per million target cells.  
Cells were washed once more analysed using a FACS™ Calibur (Becton Dickinson).  
When staining for tetramer, cells were treated as above but were stained with 
tetramer conjugated with PE and incubated for 15 minutes at 37
o
C in 100-200l 
complete medium followed by further surface staining of CD8 as described 
previously. 
  
 2.6.2:  Intracellular staining for Flow Cytometry 
 Intracellular staining was used to detect protein targets that are not expressed 
on the cell surface, such as cytokines.  If intracellular staining was required, cells 
harvested either from in vitro cultures or isolated ex vivo must be stimulated in vitro 
with 0.05μg/ml PMA and 0.25μg/ml Ionomycin.  After 2 hours, 1.0μg/ml Brefeldin 
(BD Biosciences, Oxford, UK) was added for a further 2 hours.  Following in vitro 
stimulation, live cells were harvested, re-suspended (~2ml complete media) and 
isolated by layering the cell suspension onto Ficoll (GE heathcare) and centrifuging 
for 20 minutes 400g at room temperature (RT).  Live cells form a layer above the 
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Ficoll which can be pipetted off.  Cells were then washed once in PBS.  Cells were 
then washed once in PBS, then prepared and stained for surface molecules as 
described previously.  Cells were then washed and fixed by removing all PBS and re-
suspending cells in 300l of Fix-Perm (e-Bioscience) and incubated for 30 minutes 
in the dark at RT.  Then washed once in 1ml Perm buffer (e-Bioscience) and 
incubated with an appropriate volume of conjugated antibody (4
o
C 15 minutes 100-
200l volume of Perm buffer).  Cells were washed once more in Perm buffer and 
finally in PBS before analysis using a FACS™ Calibur (Becton Dickinson). 
 
 
2.7:  Antibodies 
 Some monoclonal antibodies (mAbs) were purified from hybridoma culture 
supernatant.  Hybridomas were grown in rotating (0.02rpm) 1 litre roller bottles in 
500ml complete medium at 37
o
C for 10 days.  Following incubation cells were 
removed by centrifugation (1800rpm 10 mins), supernatant was removed and 
carefully mixed with saturated ammonium sulphate solution (VWR, Lutterworth, 
UK) at a 1:1 ratio and left overnight 4
o
C with a magnetic stirrer.  A precipitate was 
formed which was pelleted by centrifugation (2000g for 30 minutes) and re-
suspended in 10ml PBS.  The resultant suspension was aliquoted into dialysis tubing 
and sealed at both ends before floating in 4 litres PBS with magnetic stirirng 
overnight at 4
o
C, PBS was replaced once and left for a further overnight dialysis.  
The purified antibody was then isolated from dialysis tubing by first centrifuging 
(1800rpm 10 mins) to remove any remaining cells or particulates.  The supernatant 
was then sterilised (0.2 m) before being aliquoted for use in vivo.   
mAbs were typically used as 200l i.p. or further purified using a protein AG 
column (ThermoFisherScientific, UK).  To purify further 10ml of supernatant was 
concentrated using a Centricon YM-10 centrifugal filter (Millipore, Southampton, 
UK).  Antibodies were then purified from a 2ml concentrated supernatant using a 
protein A/G spin kit (ThermoFisherScientific), concentration was measured with a 
BCA
TM
 Protein Assay Kit (ThermoFisherScientific).  A table of mAbs used in this 
project is listed below. 
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Table 6: List of Hybridomas 
Antibody/Hybridoma Brief Description Reference 
DTA-1 Rat anti-mouse GITR, IgG2a (Shimizu, Yamazaki et 
al. 2002) 
PC61 Anti-CD25 (depleting) (Lowenthal, Corthesy et 
al. 1985) 
GL113 Anti-Galactosidase, control mAb (Savelkoul, Seymour et 
al. 1991) 
YTS169.4 Anti-CD4 (depleting) (Benjamin, Cobbold et 
al. 1986) 
YTS191 Anti-CD8 (depleting) (Cobbold, Jayasuriya et 
al. 1984) 
R46A/2 Anti-IFNγ (neutralising)      (Li, Sanjabi et al. 2006) 
 
2.8:  Microscopy and Imaging 
 
2.8.1:  Deconvolution microscopy 
 Tumour cells transduced with the GFP fluorescent transgene were imaged 
using a Deconvolution microcope Zeiss LSM-510 (Faculty for imaging by light 
microscopy, Hammersmith Hospital, Imperial College London).  Cells were 
suspended at 10
3 
cells/ml and 100l was mounted on a slide (unfixed).  Cells were 
then imaged using standard white light (brightfield), followed by imaging using a 
TRITC laser which excites cells at a frequency of 475nm.  Cells containing the GFP 
transgene will emit light at a wavelength of 510nm which was imaged.  The 
fluorescent image was overlaid onto the brightfield image to give a final image 
where genetically modified tumour cells were visible as green.  
 
2.8.2:  Ex vivo images 
 Photographic images were used in several experiments to reveal tumour 
structure and lymphoid organ architecture and size.  A FugiFilm 5 mega pixel 
63 
 
camera was used in close-up mode fixed to a tripod.  All photographs were taken at 
the same distance with similar lighting conditions.  Photographs of tumours were 
taken in situ; photographs of lymphoid organs were taken on petri-dishes. 
 
2.9:  Skin Grafting  
 I am indebted to Dr David Coe and Dr Jian-Guo Chai for surgical grafting of 
tail skin onto the lateral thorax as described by Billingham and Medawar 
(Billingham, Krohn et al. 1951). 
 Tail skin from the donor was cut into sections (1cm
2
).  Recipients were 
anaesthetised using Isoflurane (Halocarbon Products Corp) until surgical anaesthesia 
was reached when 0.26μg of Metacam (Boehringer Ingelheim GmbH) was injected 
(s.c.).  Mice were then immobilised giving access to the surgical site which was 
shaved and washed with 70% ethanol and Opsite spray dressing administered.  A 
1cm
2
 section of skin was removed from the right flank creating a graft bed.  Any 
blood was removed and the donor skin was placed in the graft bed.  Grafts were then 
covered in Vaseline (VWR)-soaked muslin and a plaster was wrapped around the 
thorax and graft.  Mice were placed in a warming chamber at 32
o
C to allow the 
plaster to dry and the mice to recover.  Animals were inspected daily, plasters were 
removed after 10 days and grafts were then scored every other day 
 
2.10:  Tumour and T cell lines 
 
2.10.1:  MB49 
 The MB49 tumour cell line was derived from a 7,12 
Dimethylbenz(a)anthracene (DMBA) induced bladder carcinoma arising in a male 
B6 mouse (Summerhayes and Franks 1979).  Aliquots of MB49 were stored in liquid 
nitrogen. MB49 cells were rapidly thawed, washed with complete medium and 
cultured for 5-7 days.  Once MB49 cells had grown to an optimal density, non-
adherent cells were washed away with PBS and the remaining adherent cells were 
removed from the flask after 10 minutes incubation at RT with 2ml trypsin solution 
(Invitrogen), washed with PBS/2% FCS and centrifuged (1800rpm 5 minutes).  Cells 
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were then plated out for continued culture (2 x 10
5
 cells/25cm
3
) or re-suspended at an 
appropriate concentration in 0.2-0.3ml PBS for in vivo injection.  Cells were injected 
sub-cutaneously (s.c.) using a 0.5ml insulin syringe into the right-hand side dorsal 
lateral flank of the animal (unless stated otherwise).  Mice were shaved in the area of 
injection and anesthetised using Isoflurane (Halocarbon Products Corp).  The area of 
the tumour (mm
2
) ((length (mm) X width (mm)) was then measured at regular 
intervals (3-4 times per week) using a digital calliper (Fisher Scientific).  The 
humane end-point of this procedure was reached when any dimension reaches 14mm 
or if a tumour became ulcerated.  
 
2.10.2:  B16F10 and B16F10/HY 
 B16F10 (Fidler 1973) cell lines were maintained and used as for MB49 
described previously.  B16F10/HY cell line was developed within our lab by Dr 
Caroline Addey by transduction of HY-Dby transgene (pcDNA3.1/Zeo-Dby).  Cells 
transduced with the HY transgene were selected in vitro using Zeocin (1mg/ml) 
(Invirtogen).  Resistant colonies were selected after 2-3 weeks and tested for Dby 
expression by RT-PCR (Coe, Addey et al. 2010).  These cells were also maintained 
as an in vitro culture as for B16F10 and MB49.  
 
2.10.3:  CTLL-2 
 CTLL-2 is an IL-2 dependent cytotoxic T cell line originally derived from 
C57BL/6 mice immunized with allogeneic (DBA/2, H2
d
) Friend leukemia cells 
(Weston, Geczy et al. 1998).  Cells were plated out in complete medium and 
recombinant human (rh) IL-2 at 10IU/ml at 1 x 10
5
 in a 25cm
3
 culture flask and split 
every 3 days or used at appropriate concentrations for thymidine proliferation assays. 
 
 
2.11:  Polymerase chain reaction (PCR) 
 
2.11.1:  Standard PCR 
 Standard PCR was used in this project to amplify genes of interest used for 
retroviral transduction of T cells and tumour lines.  Much of this work was 
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performed by Dr Caroline Addey and Dr Istvan Bartok using the protocol outlined 
below: 
2.5ul   10x buffer 
1ul   DNA template 
1ul   Forward primer 
1ul   Reverse Primer 
0.5ul   dNTPs (10mM) 
0.7ul   MgSO4 (50mM) 
0.1ul   Taq polymerase 
18.2ul               dH2O 
 
Denaturation 
95
 o
C   5 minutes 
 
PCR (30 cycles) 
95
 o
C   30 seconds 
(55 to 62
 o
C)
 o
C 30 seconds 
72
 o
C   30 seconds 
 
Final extension 
72
 o
C   7 minutes 
Standard PCR was used to add EcoR1 and Bgl II restriction enzyme sites to all 
products to facilitate cloning into the MIGR1 retroviral vector. 
 
2.11.2:  Reverse transcription PCR (RT-PCR) 
 I am again grateful to Dr Caroline Addey for her assistance in performing 
many of the RT-PCR techniques in this thesis.  To assess expression of HY genes by  
tumour cells (MB49 and B16F10/HY), RNA was extracted from in vitro cultures or 
ex vivo excised tumour samples and male C57BL/6 SP cells by phenol-chloroform 
extraction using Trizol (Invitogen) according to the manufacturer‟s instructions.  
RNA was then quantified using a spectrophotometer (NaNoDrop® Technologies, 
USA) (Thermo Scientfic) prior to conversion into complementary DNA (cDNA) 
using BRL Superscript Reverse Transcriptase (Invitrogen) according to 
manufacturer‟s instructions.  cDNA was then used as template in the PCR protocol 
outlined below, PCR products were then analysed on a 1% agarose gel 
electrophoresis containing Safeview (Invitrogen).    
2.5ul   10x buffer 
2ul   cDNA template 
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1ul   0.4 M Forward primer 
1ul   0.4 M Reverse Primer 
0.5ul   dNTPs 0.4 mM 
0.7ul   MgSO4 50mM) 
1.0ul   Taq polymerase 
18.2ul               dH2O 
 
Denaturation 
95
 o
C   5 minutes 
 
PCR (30 cycles) 
95
 o
C   60 seconds 
52.5
o
C   60 seconds 
72
 o
C   60 seconds 
 
Final extension 
72
 o
C   7 minutes 
 
Dby: Forward: CAGCAAGAGGTCTAGACA. Reverse: 
TCCTCTGTTGTGGCTACT 
 
Smcy: Forward: TGAGACATAAGAAGCCCC. Reverse: 
GGCTTAATCCTTGAACTC 
 
Uty: Forward: ACTTCGCCATATCCTCCT. Reverse: GTGCTTTCTGTCTCCTTC 
 
2.11.3:  StellARray® quantitative PCR (qPCR) 
 A commercial StellARray® was used for the analysis of a gene expression 
for a wider range of immune related genes.  RNA was extracted from sorted cells 
using an RNAqueous 4PCR kit (Applied Biosystems, Warrington, U.K.) including a 
DNase I digestion step.  cDNA was made from 300ng RNA using a High-Capacity 
cDNA Reverse Transcription kit (Applied Biosystems), which facilitates quantitative 
conversion of mRNA to cDNA.   
For T Regulatory and MB49 gene expression analyses, 383 StellARray qPCR 
array plates (Lonza Sales AG, Basel, Switzerland) were used, with each plate 
containing 96 immune gene primer pairs.  Power Sybr green master mix (Applied 
Biosystems) was mixed with cDNA and water following the manufacturer‟s 
instructions and 10 l was added per well representing 1.5 ng cDNA.  Plates were 
run on a 7900HT Real-Time PCR system (Applied Biosystems), under standard PCR 
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cycling conditions (50°C 2 min, 95°C 10 min followed by 40 cycles of 95°C for 15 
sec and 60°C for 1 min).  The resulting cycle threshold (Ct) data were analyzed using 
a modification of Global Pattern Recognition algorithm, GPR 2.0 (Lonza), 
comparing three replicates of control cDNA with test cDNA.  When there was no 
difference between the Ct values of both groups, the genes were considered as 
“normalizers”. Each gene was compared with every normalizer in succession and the 
DCt was calculated (DCT Gene = CT Gene - CT Normalizer).  The DCt for each 
group were then compared by a two tailed unpaired Student t test.  Results were 
expressed as fold change, and those changes with a p value <0.05 were considered 
significant. 
 
2.11.4:  Taqman® RT-PCR 
 For the analysis of specific gene expression in a small set of samples, 
Taqman® RT-PCR assays were performed.  10 l reactions were set up in 384 well 
plates, using Taqman MGB (minor groove binder) gene expression assays from 
Applied Biosystems.  Target gene Taqman MGB probes were FAM dye labelled, 
whereas the 18S endogenous control probe was VIC dye labelled. 
1-10ng 1st strand cDNA (in 4.5 l H2O) 
0.5 l 20x Taqman gene expression assay mix (primers and probe) 
5 l 2x Taqman master mix (Applied Biosystems) 
Plates were run on a 7900 HT Real Time PCR System (Applied Biosystems), 
under standard cycling conditions (95
o
C 10 min, followed by 40 cycles of 95
o
C for 
15 sec and 60
o
C for 1 min).  The resulting Ct data was analysed by the comparative 
Ct method 2
-Ct
, using RQ Manager 1.2 software (Applied Biosystems).  
 
2.12:  DNA amplification 
 To obtain sufficient DNA for retroviral transductions, E.Coli containing the 
plasmid of interest was plated out from glycerol stocks onto ampicillin LB agar 
plates.  These colonies were then grown up in 100ml LB containing ampicillin at 
37
o
C overnight with shaking.  A QIAGEN Maxiprep kit was then used to purify 
plasmid DNA from the bacterial culture according to the manufacturer‟s instructions. 
DNA concentrations were determined using a NANODROP spectrophotometer 
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(NaNoDrop Technologies, USA). Typically, around 250-500 ug of DNA was 
isolated using this procedure.  
 
2.13:  Transfection of Phoenix cell line using lipofectamine™ 2000 
 The Phoenix retroviral packaging cell line (Kinsella and Nolan 1996), was 
maintained by passaging every 2-3 days.  This was done by removing adherent cells 
from a 75cm
3
 flask by digesting with 2ml trypsin (Invitrogen) for 3-5minutes. Cells 
were then suspended in HBSS (Hank‟s Balanced Salt Solution) medium containing 
10% FCS and penicillin/streptomycin and centrifuged (1800rpm 5 minutes) and re-
suspended in 20ml IMDM (Iscove‟s Modified Dulbecco‟s Medium) containing L-
Glutamine/25mM HEPES (Invitrogen), 10% FCS and penicillin/streptomycin.  Cells 
were plated at 2 x 10
6
 cells per 75cm
2
 flask in 50ml IMDM and maintained at 37
o
C 
in 5% CO2.  For plasmid transfections, 2 x 10
5
 Phoenix cells were plated at in 2 
ml/per well of IMDM in a 6 well plate and grown overnight (37
o
C, 5%CO2).   
4 hours prior to transfection, media was discarded and 7.5ml of fresh IMDM 
added.  Phoenix cells were transfected with appropriate DNA using a 
lipofectamine™ 2000 kit following the manufacturer‟s instructions (Invitogen). In 
summary two solutions were made for each transfection.  Tube A contained l 
Optimem with 3g vector of interest and 1g PCLE helper vector; tube B contains 
250l Optimem and 2l liopfectimine™ 2000 (incubate 5 minutes RT).  Tubes A 
and B were then mixed and incubated for 20 minutes at RT.  The mix was slowly 
added to the Phoenix cells on the 6 well plate and left overnight (37
o
C, 5%CO2).  
Media was then discarded and the cells washed twice with HBSS, 5ml of fresh 
IMDM media (without penstrep) was then added and the cells left overnight (37
o
C, 
5%CO2).  Viral supernatant was harvested (~5ml), centrifuged (1800rpm 5 minutes) 
and either used immediately or frozen in liquid nitrogen. As an indication of 
transfection efficiency and virus production, Phoenix cells were harvested and GFP 
expression determined by FACS.  For larger scale transductions up to 30ml of virus 
was produced using cell culture Petri dishes (Becton Dickinson).  For the 
transduction of T cells virus was usually concentrated by high speed centrifugation 
(13500rpm 90 minutes), 90% supernatant was removed and virus re-suspended at 
10x concentration. 
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2.14:  Retroviral transduction of tumour cells  
 MB49 cells were plated out at 2x10
5
 cells/well in a 24 well plate 48 hours 
prior to transduction.  Conditioned media was removed and stored and cells were 
washed once with PBS.  1ml viral supernatant was added to each well and the plate 
was centrifuged at (2000 rpm for 120 minutes at RT).  The 1 ml of conditioned 
media was removed before the spin infection was re-added and cells were left to 
grow for 48 hours (37
o
C, 5%CO2).  Cells were harvested and washed with PBS.  
Cells were then analysed by FACs to measure transduction efficiency against an 
untransduced control.  MIGR1 retroviral vectors containing GFP or a rat Thy-1 
reporter genes (either empty or containing gene of interest) (kindly supplied by 
Douglas Fearon) were purified using an endofree MaxiPrep kit (Invitrogen). The 
resulting virus containing MIGR1 with the respective reporter and gene of interest 
was used to transduce MB49 cells.  MB49 cells were left to grow for 48 hours before 
FACS sorting to select for GFP
+
 or RatThy-1
+
 (using anti Rat-Thy-1
FITC
) 
populations.   
 
 
2.15:  Retroviral transduction of T cells  
Whole lymph nodes and spleen suspensions of the relevant animal were 
plated out in a 24 well plate at 2ml/well (5 x 10
6
 cells/well) in complete medium. 
Peptides were used as antigen to induce an appropriate T cell activation.  HY-D
b
-
UTY peptide at a concentration of 0.1-1nM was used to specifically activate 
Matahari CD8 T cells and HY-A
b
-Dby peptide was used at a concentration of 10-100 
nM to activate Marilyn CD4 T cells.  Cells were left to grow for 48 hours at (37
o
C, 
5%CO2).   
Cells were harvested, washed in complete media and layered onto Ficoll (GE 
heathcare), centrifuged (400g, 20 minutes).  Live cells harvested and washed in PBS.  
Cells were then depleted of lymphocytes not required for retroviral transduction.  For 
transduction of Matahari CD8 T cells, B cells and CD4 T cells were removed using 
B220 and CD4 dynabeads.  For Marilyn CD4 T cell transductions, B cells and CD8 
cells were removed (CD8 and B220 dynabeads).  In brief, cells were re-suspended in 
2ml PBS, 30ul anti-B220 and 10ul anti-CD4- or anti-CD8-dynabeads were added.  
Cells were incubated at 4
o
C under a low speed centifugation (10 rpm) for 20 minutes.  
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Cells attached to dynabeads were attracted to the tube wall in a mageneic field and 
the negatively selected target population collected.  Cells were then centrifuged 
(1800rpm 5 mins) and plated out in 24 well plates (1-5 x 10
5
/well).  1ml of relevant 
concentrated virus supernatant was added, viral spin infection and was then 
conducted as described for MB49 above.  Following spin infection, 1ml of 
conditioned media (S/N stored following primary culture) was added back to each 
well with 50IU/ml rhIL-2 to aid expansion.  Cells were then FACS sorted or used 
directly for i.v. injection.  
 
 
2.16:  Adoptive cell transfer 
 Relevant cell populations were injected into mice i.v. in 0.2ml PBS using a 
0.5ml insulin syringe.  Briefly, mice were placed in a 37
o
C warming chamber for 10 
minutes to induce vasodilation.  The mouse was restricted in a tail holder and 
injections were made into the either the ventral or dorsal tail vein.  Pressure was 
applied to the injection site to prevent bleeding and loss of adoptively transferred 
cells.  
 
 
2.17:  Analysis of adoptively transferred donor cell populations 
 The representation of donor populations in various tissues including tumour 
dLN, ndLN, SP and tumour, control peripheral inguinal LN (pLN), mLN, kidney, 
liver, heart and lungs were analysed.  Organs were harvested and excess fat tissue 
removed.  Where necessary, organs were sliced and digested as described in section 
2.6.  Cells were then forced through a 70m cell strainer to create a cell suspension.  
Cells to be analysed using FACS were treated with RBC lysis buffer (Qiagen) (RT 
10 minutes) and washed with PBS before staining as described in section 2.6.  Cells 
to be used for further cell culture were washed in culture medium and purified using 
MACS or FACS cell sorting where required.  Cells to be used for secondary adoptive 
cell transfer were purified as described in section 2.5 and injected i.v. 
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2.18:  Animal phenotyping 
 In order to ensure correct donor and recipient mice were used for each 
experiment, mice bred internally were phenotyped between 4-8 weeks of age.  Mice 
were placed in a 37
o
C warming chamber for 10 minutes and restricted in a tail 
holder, 1-2 drops of blood were taken using a 25g needle to puncture the tail vein and 
collected in an eppendroff tube containing 0.3 ml blood buffer.  Red blood cells were 
then lysed as described previously.  Cells were washed in PBS and stained as 
described in section 2.6.  Mice were phenotyped for surface expressed proteins 
including Thy1.1, Thy1.2, CD4, CD8, V6 (Marilyn), V8.3 (Matahari), GFP, B220, 
CD44 and CD62L.   
 
 
2.19:  Irradiation of cells and mice 
 In certain assays, cells were exposed to gamma radiation from a caesium 
source to prevent proliferation that may interfere with the responder population (e.g. 
assays using male SP see section 2.5.2).  30Gy (3000Rads) was used to induce DNA 
damage preventing replication but not killing the cells.  For certain reagents and 
materials used in vivo or for sterile in vitro cultures, irradiation was also used for 
sterilisation at 30Gy. Animals were irradiated in order to induce lymphopenia at a 
rate between 5-9Gy.  For the purposes of our experiments a sub-lethal dose of 5Gy 
was used.  Mice were then adoptively transferred with donor T cells for therapy or 
induction of GvHD. 
 
 
2.20:  Generation of bone marrow dendritic cells (BMDCs) 
 For vaccination purposes, male B6 BMDCs were generated by culturing bone 
marrow cells with GM-CSF (Inaba, Inaba et al. 1992).  Bone marrow was harvested 
by the epiphyses of the femur, tibia and fibula and flushing the marrow using a 22g 
needle, 1ml syringe and PBS.  The resultant suspension was forced through a 70m 
cell strainer and washed once in PBS.  Cells were re-suspended in complete media 
with 10% GMCSF
*
 and 4g/ml Gentamycin (to prevent microbial infection) 
(Invitrogen) and plated out at 1 x 10
5
/ml in 10 ml in a 25cm
3
 cell culture flask.  72 
72 
 
hours later the media was replaced.  On day 6, cells were harvested, and replated as 
above.  On day 7, lipopolysaccaride (LPS) was added at 10ng/ml in order to induce 
DC maturation.  On day 8, cells were harvested and centrifuged with Ficoll (400g 20 
minutes) to separate live cells.  Cells were counted and used for injection at 1 x 10
6
 
i.v. or i.p.in 0.2ml PBS. 
* GM-CSF was produced from the murine encoded gene cloned into the mammalian 
expression vector BCMGSNeo and transfected into the X63-Ag8 plasmacytoma cell 
line.  Cells were selected in media further supplemented with G148 (1 mg/ml). When 
ready for supernatant harvesting, cells were washed twice and cultured for a further 
2-3 days in media lacking antibiotics. Supernatant was harvested and stored at -20°C. 
 
 
2.21:  Enzyme-linked immunosorbent assay (ELISA) 
 A mouse anti-TNF sandwich ELISA (Biolegend LEGEND MAX™) was 
used in the analysis of murine blood serum samples.  Blood samples were incubated 
at 4
o
C overnight, pelleted (3000rpm 5 mins) and serum pipetted off and stored at -
80
o
C.  ELISA was conducted as per the protocol provided, briefly: serum was 
serially diluted from 1/10 to 1/10000 and standards serially diluted from 1000pg/ml 
to 15.6pg/ml.   Plates were washed four times in >300l wash buffer and diluted 
samples and standards added to the plate (in 50l) and incubated (2hrs, RT, shaking).  
Plates were washed (x4) and 100l mouse TNF detection antibody added and 
incubated (1hr, RT, shaking).  Plates were washed (x4) and 100l Avidin-HRP 
solution added and incubated (30 min, RT, shaking).   Plates were washed (x5) and 
100l substrate solution added and incubated (15mins RT, in the dark).   100l stop 
solution was added/well and absorbance at 450-570nm was read within 30 minutes 
(SpectramaxM2, Molecular Devices).  
 
2.22:  Quantification and statistics 
 All statistics were carried out using non-parametric tests.  Error is presented 
as ± standard error mean where possible, or as ± standard deviation.  All P values 
were generated using paired and unpaired two sample students T test or two-tailed 
non-parametric Mann-Whitney U-test. 
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Chapter 3: Characterisation of the phenotype for the MB49 
tumour  
 
3.1:  Introduction 
 
3.1.1:  Recognition of tumour-associated antigens (TAA) 
Most tumours express tumour-associated antigens (TAAs).  In addition to 
tumour cells, TAAs can be expressed on some non-malignant tissues.  Tumour 
antigens can be derived from cancer-specific mutated genes, abnormally expressed 
intronic sequences, viral genes or from non-mutated genes that are expressed in a 
tumour-specific pattern.  Antigens restricted solely to tumour cells are known as 
tumour-specific antigens (TSAs) (Wortzel, Philipps et al. 1983).  Antigen-presenting 
cells (APCs) particularly dendritic cells (DCs) can cross present TAAs to T cells 
(Shurin 1996).  As the majority of TAAs derive from host DNA, most of these 
antigenic components will be expressed in the thymic epithelium or by thymic DCs 
during primary T cell selection, leading to the deletion of high avidity self-reactive T 
cells.   T cells in the periphery that are responsive to TAAs therefore have a low to 
moderate avidity, resulting in a poor proliferation and effector function in response to 
TAAs (Overwijk 2005).   
In addition, tumours have several mechanisms by which they evade host 
responses to TAAs.  Factors released by tumours can act on the host immune system 
to downregulate T cell receptor (TCR) expression on T cells thereby preventing 
activation of these T cells in response to TAAs (Takahashi, Kono et al. 2001).  
Conversely, tumour cells often have defects in antigen processing and presentation.  
This mechanism is selective as those tumour cells that are less immunogenic will 
survive and proliferate (Zitvogel, Tesniere et al. 2006).  Tumour cells can down 
regulate MHC I and II directly by deletion, or indirectly by deletion of chaperone and 
accessory molecules.  For example, many human primary cervical carcinomas show 
strong downregulation of MHC Class I and TAP, with a potent upregulation of MHC 
Class II (Cromme, van Bommel et al. 1994).  
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3.1.2:  Tumours, APCs and co-stimulation  
Tumours can modulate host APCs by downregulating expression of co-
stimulatory molecules while upregulating inhibitory molecules (Zitvogel, Tesniere et 
al. 2006).  Many cancers can downregulate positive T cell co-stimulatory molecules 
that initiate immune responses and can upregulate T cell inhibitory molecules to 
remain immunoevasive.  Tumours also commonly release or express factors which 
allow escape from immune system, for example tumours often express high levels of 
apoptotic promoting molecules such as Fas ligand (FasL) that can induce apoptosis 
in T cells by binding to the Fas molecule (Bennett, O'Connell et al. 2001).  
Programmed Death Ligand 1 (PD-L1) is expressed on APCs and is able to bind the 
PD-1 receptor on T cells, transducing an inhibitory signal preventing T cell 
proliferation and cytokine production that can ultimately lead to anergy or cell death 
(Fife and Bluestone 2008).  This mechanism is used physiologically to remove auto 
reactive T cells in the periphery that have escaped central tolerance (Probst, McCoy 
et al. 2005).  PD-L1 is therefore upregulated by many tumour cell lines with the 
effect of abrogating effector T cell function through binding to the PD-1 receptor on 
T cells and inducing cell death (Blank, Gajewski et al. 2005; Okazaki and Honjo 
2007).  Research has shown that tumours that express high levels of PD-L1 are 
associated with decreased survival, decreased CD8 T cells in the tissue and a high 
level of T cell anergy (Willimsky and Blankenstein 2005).  Studies using antibody 
blockade of PD-1 and PD-L1 have shown increased tumour responsiveness with 
improved survival (Iwai, Ishida et al. 2002; Iwai, Terawaki et al. 2005).   
Commonly DCs upregulate B7-1 (CD80) and B7-2 (CD86) molecules in 
response to danger signals (Lanier, O'Fallon et al. 1995) these factors are required for 
primary T cell activation.  Once activated, CD8 T cells become effector cells and 
produce perforin and Granzyme B, on encounter with antigen in the periphery they 
are activated by ligation of the T cell receptor and co-stimulatory molecules (e.g. on 
the tumour).  In murine trials, transduction of melanoma with B7-1 is sufficient to 
stimulate rejection; consequently it is common for tumours to downregulate positive 
co-stimulatory molecules (Townsend, Su et al. 1994).  Once activated, effector T 
cells can remain reactive or differentiate into memory T cells for an effective 
secondary response in the correct environment of IL-2 and other proinflammatory 
cytokines (Antony, Piccirillo et al. 2005).  
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3.1.3:  Tumour-related cytokines and immunomodulatory factors 
Tumour microenvironments can augment the cytokine milieu, making it 
difficult to achieve an effective and sustained T cell response.  Tumour cells can 
direct the host immune system to release factors that abrogate responses to the 
cancer.  For example the indoleamine-2,3-dioxygenase (IDO) enzyme can be 
induced in DCs.  IDO is the first enzyme of tryptophan catabolism in the kynurenine 
pathway and IDO induced depletion of tryptophan can cause reduced T cell 
proliferation and render DCs tolerogneic to the TAA specific T cells (Grohmann, 
Fallarino et al. 2003).  Tumours can also induce or secrete immunosuppressive 
factors such as prostoglandins, gangliosides, GMCSF, IL-6, IL-10, TGF-and 
VEGF.  IL-10 and TGF- are particularly well characterised immunosuppressive 
cytokines in the tumour microenvironment (Ghiringhelli, Puig et al. 2005).  TGF-is 
associated with the induction or activation of Tregs from naïve CD4 T cells, with 
upregulation of the transcription factor FoxP3 (Chen, Pittet et al. 2005; Coe, Addey 
et al. 2010).  In the tumour microenvironment a high level of TGF-
CD8 T cell activation, leading to anergy (Fukuyama, Ichiki et al. 2007).  IL-10 has a 
similar effect by modulating host APCs, crucially, IL-10 is important in the 
production of non-FoxP3 producing Tr1 Tregs (Vieira, Christensen et al. 2004). 
Collectively, cancers can produce or induce a wide range of growth and 
immune-inhibitory factors to modulate their environment to an immunosuppressive 
milieu.  By investigating and understanding these modulation mechanisms it is 
possible to design new cancer immunotherapy strategies that focus not just on the 
killing of the tumour but also on modulating the local tumour environment to 
maintain T cell activity. 
 
3.1.4:  MB49/HY as a model TAA for antigen-specific T cell responses 
 Minor histocompatibility (H) antigens are self peptides derived from 
polymorphic genes that are presented to T cells in the context MHC class I and II 
molecules (Scott, Ehrmann et al. 1995).  Like minor H antigens, tumour antigens are 
exclusively self proteins (except for virally induced tumours) that share 
commonalities with minor H antigens in their molecular composition and 
immunogenic properties.  Both tumour antigens and minor H antigens consist of a 
limited set of MHC-binding peptide epitopes.  The proteins from which they are 
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derived are often expressed at low levels (Spierings, Wieles et al. 2004; Spierings 
2008) giving a low cell surface density of peptide-MHC complexes that is generally 
insufficient to trigger optimal T cell activation.  As T cell responses to minor H and 
tumour antigens are guided by the same rules, the response to minor H antigens has 
been regarded as an excellent surrogate to study tumour immunity.  One of the best 
characterised minor H antigens is the male-specific HY transplantation antigen 
which has been identified at molecular level (Scott, Ehrmann et al. 1995; Simpson, 
Scott et al. 1997).   
In C57BL/6 H2
b+
 male mice, HY T cell epitopes are derived from 3 genes 
located on the Y chromosome: two H2D
b
 restricted peptides are encoded by the Smcy 
and Uty genes, while one H2A
b
 restricted epitope derives from the Dby gene 
(Greenfield, Scott et al. 1996; Scott, Addey et al. 2000).  One of the key reagents in 
this project are the TCR transgenic Marilyn and Matahari mouse strains that have 
been backcrossed to Rag1
-/-
 and Rag2
-/-
 mice respectively, thus preventing 
rearrangements of their endogenous TCR genes (Lantz, Grandjean et al. 2000).  
These TCR transgenic mice produce monoclonal T cells recognising the H2D
b
 
restricted Uty peptide (WMHHNMDLI) for Matahari CD8
+ 
T cells and the H2A
b
 
restricted Dby peptide (NAGFNSNRANSSRSS) for Marilyn CD4
+ 
T cells 
(Valujskikh, Lantz et al. 2002; Valujskikh, Baldwin et al. 2010).  This makes them 
attractive T cell populations for adoptive transfer in the treatment of male B6 derived 
tumours such as murine bladder carcinoma 49 (MB49).  Matahari mice harbour 
functional HY-specific CD8 T cells that can induce rejection of male skin grafts 
although they fail to control HY-expressing tumours in vivo (Perez-Diez, Joncker et 
al. 2007), suggesting that Matahari T cell function is inhibited directly in this system 
by the tumour. 
The other component of this system is MB49, a chemically induced murine 
bladder carcinoma cell line generated by administration of the DMBA (7,12-
Dimethylbenz(a)anthracene) carcinogen to male mice.  A mouse that became tumour 
positive was used to establish a stable in vitro tumour cell line that expresses all three 
HY genes naturally (Summerhayes and Franks 1979) (Loskog, Ninalga et al. 2005).  
MB49 cells also express H2D
b 
 molecules that present Uty peptide to CD8 T cells 
and H2A
b 
that presents Dby peptide to CD4 T cells, although the MB49 cell line is 
MHC class II negative in vitro, H2A
b
 is upregulated in vivo or upon IFN treatment.    
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The use of HY system for the study of anti-tumour T cell responses has 
several unique features which provide advantages to existing model systems (Chen, 
Pittet et al. 2005; Yang and Baltimore 2005).  MB49 cells express HY peptides at a 
physiological level relevant to the expression levels of naturally occurring TAAs 
(Perez-Diez, Joncker et al. 2007), therefore it is likely that the HY system mirrors the 
in vivo T cell response to true tumour antigens.  Other models rely on transduced 
antigen such as cOVA (Yang and Baltimore 2005) or viral antigens such as gp100 
(Abad, Wrzensinski et al. 2008) that are often over expressed in a non-physiological 
manner.  While MB49 has also been shown to express other male TAA such as 
prostate cancer stem cell antigen (PSCA) and transmembrane epithelial antigen of 
the prostate (STEAP) (Loskog, Ninalga et al. 2005), the primary response to the 
tumour by female C57BL/6 mice is against the HY minor antigens. This has been 
demonstrated previously as male mice fail to control MB49 at doses females do, 
suggesting that HY responses make a significant contribute to anti-MB49 immunity 
in female mice (Melchionda, McKirdy et al. 2004). 
 
3.1.5:  MB49 tumour growth and wildtype T cell responses 
 The growth of MB49 tumour in vivo has been well characterised in C57BL/6 
female mice.  Models have included use of intravenous (i.v.), and subcutaneous (s.c.) 
injection.  Inoculation of MB49 cells i.v. induces a metastatic tumour that is difficult 
to quantify and often leads to rapid morbidity and mortality (Weiss, Wong et al. 
1987; Loskog, Ninalga et al. 2005).  Inoculation of MB49 cells s.c. to female mice at 
doses between 0.7-1 million cells produces an progressive solid tumour that can be 
measured externally with little morbidity to the animal (Loskog, Ninalga et al. 2005).  
This result also demonstrates the immunogenicity of the tumour is insufficient to 
induce rejection at high doses of MB49.  Other studies have shown that lower does 
(0.1 million MB49 cells) female mice can reject the tumour but not at higher doses 
(0.6 million cells) (Melchionda, McKirdy et al. 2004).  In addition, T cells isolated 
from female mice with large MB49 tumours, adoptively transferred to athymic mice, 
are capable of rejecting male skin grafts, indicating that tumour-bearing mice 
generate a functional immune response to the HY antigen (Melchionda, McKirdy et 
al. 2004). 
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3.1.6:  MB49 Characterisation and phenotype 
 Tumour cell lines often change their expression profiles following tumour 
formation by the mechanisms discussed earlier (e.g immuno-editing of MHC or 
TAAs).  It is important therefore to understand the natural molecular and cellular 
phenotype of the MB49 tumour in vivo in order to evaluate the effects of 
therapeutics, such as the HY-specific T cell adoptive cell transfer discussed later.  
Little published data exists regarding the phenotype of this tumour cell line, for 
example MHC expression levels, cytokine production and surface marker expression.  
It is therefore my aim in this section to give an overview of the MB49 phenotype 
both in vivo and in vitro to provide a base line to evaluate tumour responses in later 
sections. 
 
 
 
3.2:  Results 
 
3.2.1:  MB49 cell line expresses all 3 HY genes (encoding HY-specific T cell 
epitopes in the context of MHC I and II) 
 The MB49 cell line has been maintained in vitro for nearly two decades.  
Prolonged culture has the potential to cause down regulation or even loss of HY gene 
expression.  To test this possibility RNA was extracted from MB49 cells or from 
freshly isolated female B6 splenocytes, as a negative control.  Following this DNA 
was amplified by RT-PCR using primers specific for Uty, Smcy, Dby and HPRT 
genes.  All 3 HY genes are expressed by the MB49 cell line but not by female 
splenocytes (Fig. 3.1a) demonstrating MB49 cells constitutively express HY genes, 
which is consistent with other reports (Halak, Maguire et al. 1999; Perez-Diez, 
Joncker et al. 2007). 
 Many tumours downregulate Class I and Class II MHC molecules and co-
stimulatory molecules as a mechanism of immune escape, particularly in vivo where 
the tumours are under greater selection pressures, termed immune-editing (Zitvogel, 
Tesniere et al. 2006).  Long term cultured MB49 cells and ex vivo fresh MB49 
tumour cells (from a WT B6 female mouse) were analysed for surface expression of 
MHC class I (D
b
 and K
b
) and MHC class II (A
b
) (Fig. 3.1b) as well as co-stimulatory 
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molecules (CD40, CD80 and CD86) (Fig. 3.1c).  Both in vitro and ex vivo MB49 
cells express MHC I although there is a clear upregulation of class II and 
downregulation of class I in vivo.  Freshly isolated ex vivo MB49 tumour cells 
expressed significant levels of CD40, CD80 and CD86, in comparison with the in 
vitro cell line that had a much lower level of expression (Fig. 3.1c).  These data show 
that MB49 cells expresses all 3 HY genes and both MHC I and II, also upregulating 
positive co-stimulatory molecules in vivo, indicating that MB49 tumour is potentially 
immunogenic. 
 
Figure 3.1. MB49 cells express HY genes, MHC and co-stimulatory molecules 
a. Expression of HY genes by cultured MB49 cells. RNA was isolated from cultured 
MB49 cells and female B6 splenocytes and was amplified by RT- PCR using primers 
specific for Uty, Smcy, Dby and HPRT genes. PCR products were analysed on a 1% 
Agarose gel.  
b and c. Analysis of expression of MHC (b) and co-stimulatory molecules (c) by 
fresh ex vivo and cultured in vitro MB49 cells. In vitro or ex-vivo MB49 cells were 
stained with PE or FITC conjugated antibodies (green line) or isotype control mAb 
80 
 
(red line) and analysed by FACS for the expression of MHC Class I (D
b
 and K
b
), 
Class II (A
b
) (b), co-stimulatory molecules (CD40, CD80 and CD86) (c).  
 
 
3.2.2:  MB49 tumour expresses an array of immunological markers 
 Tumour identity in the context of the immune system can be defined by two 
broad categories, immunological and non-immunological.  Non-immunological 
tumours tend to evade the immune system by downregulation of immunological 
molecules and often grow slowly in non-inflammatory environments.  In contrast, 
immunological tumours are visible to the immune system and so often exist in more 
inflammatory environments.  These tumours therefore escape control by other 
methods such as having a very fast growth rate and through the expression of co-
inhibitory molecules and other suppressive factors such as cytokines (Zitvogel, 
Tesniere et al. 2006).   
MB49 cells were tested for a range of immunological markers to define their 
immunogenicity.  An in vitro culture was set up with MB49 cells either in media 
alone or in media containing IFN for 4 days.  Cultures were then harvested and 
stained for a range of surface markers (Fig. 3.2a).  IFN treated cultures were 
designed to resemble a similar affect to an in vivo Th1 immune response, IFN 
secretion is associated with a Th1 viral immune response and consistent with a Th1 
biased C57BL/6 T cell mouse line.  MHC class II A
b
, MHC class I D
b 
and K
b
, co-
stimulatory molecules CD80, CD86, CD40 and co-inhibitory molecules PD-L1 and 
PD-L2 were upregulated by IFN, B7H4 was reduced and GITR-L was unchanged. 
These data indicate the MB49 phenotype can change dramatically dependent on the 
cytokine microenvironment.   
In a separate experiment MB49 cells were cultured for 4 days in medium 
alone and tested for various phenotypic markers ranging from cell surface adhesion 
molecules, chemokine receptors, cancer stem cell markers and TNF family ligands 
and receptors (Fig. 3.2b).  The expression of MHC, positive and negative co-
stimulatory molecules by MB49 cells was described previously.  Importantly MB49 
cells also showed expression of the TNF family molecule FAS-L (~11%), which can 
serve as an altered mechanism to mediate apoptosis other than the PD-1 pathway.  
MB49 also expresses lymphocyte adhesion molecules CD44 and CD62L as well as 
CD49b which binds collagen and associates with CD29 on leukocytes.  MB49 
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universally expresses stem cell antigen-1 (Sca-1 99.8%), a molecule that is 
downregulated when haematopoietic stem cells (HSC) differentiate into myeloid 
progenitors (Bradfute, Graubert et al. 2005; Zitvogel, Tesniere et al. 2006).  
Interestingly MB49 has some expression of CD48 (~8%), this molecule is a putative 
ligand of CD244 involved in the regulation of NK cells, believed to be the major 
cytotoxic killer of tumour cells (Perez-Diez, Joncker et al. 2007).  Finally MB49 
cells express the chemokine receptor CCR9, but no other chemokine receptors tested 
for were expressed in vitro.  This result confirms MB49 is highly immunogenic and 
visible to the immune system but able to employ various inhibitory molecules to 
mediate escape.  MB49 can also be defined by the expression of other molecules 
such as CD49b and sca-1. 
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Figure 3.2. MB49 is immunogenic 
a. MB49 cells were plated out at 5 x 10
5
 cells/well for 5 days in the presence of IFN 
(10ng/ml) or in media alone.  Cells were harvested and aliquoted in equal amounts 
for surface staining using a range of PE- and FITC- conjugated mAbs and analysed 
using FACS.  MB49 cells were gated as a single population and results displayed as 
histograms.  Media alone (filled green histograms) and INF cultured (open red 
histograms) were compared for expression of A
b
, D
b
, CD40, CD80, CD86, B7H4, 
GITR-L, PD-L1 and PDL2 along with FITC and PE isotope controls.  
b. MB49 cells were plated out as above for 4 days in media alone.  PE isotype 
control (red histograms) cultured MB49 (blue histograms) were compared for 
expression of a range of surface expressed molecules.  
 
 
 
3.2.3:  MB49 tumour maintains immunogenicity in vivo 
 The analysis shown in Fig. 3.1b and c was conducted using cells from MB49 
tumour tissue, which contain MB49 tumour cells and tumour-infiltrated 
lymphocytes.  Next, CD45 was used as a marker to distinguish host lymphocytes 
from MB49 cells.  CD45 is a lymphocyte common antigen (Arendt and Ostergaard 
1995) and is not expressed by MB49 cells which are of epithelial origin 
(Summerhayes and Franks 1979).  MB49 tumours were isolated ex vivo and CD45-
negative fractions were analysed for various molecules described previously (MHC I, 
CD86, GITR, PD-L1/2) with the addition of chemokine receptors (CXCR3 and 4, 
CCR5,7 and 9), which are of interest in determining recruitment of lymphocytes. 
 Ex vivo MB49 tumour cells clearly expressed MHC class I molecules D
b
 and 
K
b
, and co-inhibitory molecules PD-L1 and PD-L2, they also expressed a low level 
of GITR but not 4-1BB.  CD80 expression by gated MB49 was low, thus previous a 
high CD80 profile was likely to due to the contribution by tumour-infiltrating 
lymohocytes.  Among five chemokine receptors tested, MB49 expressed CCR9 but 
not other markers CXCR3 and 4 and CCR5 and 7.  
83 
 
 
Figure 3.3. Phenotype of MB49 tumour cells ex vivo  
MB49 cells (5x10
5
) were injected (s.c) to 2 WT B6 female mice.  20 days later, two 
MB49 tumours were isolated and digested with collagenase before staining with anti-
CD45
FITC
 and PE-conjugated antibodies against respective cell surface markers or 
PE-conjugated isotype control mAb. CD45-negative and intermediated cells were 
gated and analysed for cell surface marker expression. Isotype control from tumour 1 
(red line) and from tumour 2 (green line), PE-conjugated stained from tumour 1 
(Blue line) and from tumour 2 (brown line).  Inserted numbers in each histogram 
represent mean fluorescence intensity (MFI). 
 
 
3.2.4:  Cytokine and chemokine gene expression changes in the in vitro cell line 
and in vivo tumour 
 In order to quantify cytokine and chemokine gene expression changes 
between the in vitro cell line and the in vivo tumour, the two populations were 
compared by qPCR using a 383 StellARray
TM
.   StellARay
TM
 is a collection of PCR 
assays designed in this case to measure immunological cytokines and chemokines.  
MB49 tumour cells ex vivo (as described in Fig. 3.1) as well as in vitro cultured 
MB49 tumour cells were subjected to RNA extraction using an RNAqueous 4PCR 
kit and cDNA conversion.  Both populations were analysed for the expression of a 
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range of 96 selected cytokine, chemokine and their receptor genes and significant 
changes are shown as fold change from a „normaliser‟ 18sRNA control gene (Fig. 
3.4).  Fig. 3.4a shows 21 genes were significantly upregulated by MB49 tumour ex 
vivo, in comparison to MB49 cell line. The one gene downregulated by MB49 
tumour ex vivo was IL13 (Fig. 3.4a).  28 genes were highly expressed by both the cell 
line and the tumour (Fig. 3.4b).  It is of note that several molecules tested in surface 
phenotyping (Fig. 3.2 and 3.3) were not included on StellARray
TM
 such as Sca-1, 
MHC and many co-stimulatory and adhesion markers.  
 
Figure 3.4. Comparison of cytokine and chemokine expression profiles between 
MB49 tumour and cell line 
Ex vivo MB49 cells were harvested at day 17 from B6 tumour-bearing female mice 
(inoculated (s.c) with 5 x 10
5
/mouse).  MB49 cell line was also harvested from 
culture and both populations were subjected to RNA extraction and cDNA 
conversion before running qPCR array assay using 383 StellARray
TM
 plates, which 
assays 96 murine chemokine and cytokine genes.   
a. 21 genes were significantly upregulated following tumour formation.   
b. Genes highly expressed by both cell line and tumour.  
85 
 
3.2.5:  Male and female B6 mice show a disparity in the anti-MB49 response 
 MB49 is immunogenic and expresses all 3 HY genes and can present these T 
cell epitopes in the context of MHC I and II with sufficient co-stimulation.  To 
evaluate the immune response to these HY antigens, MB49 was injected (s.c.) to 
male and female WT B6 mice at a range of doses and percentage survival was 
measured (Fig. 3.5 a-d).  Tumour size is measured daily and mice were culled and 
recorded as dead when they reach humane end point (any dimension of tumour 
reaches 14mm) as stipulated by our project licence and defined by the animal 
procedures act 1986.  At all concentrations of MB49 tested, there was a statistically 
significant protective effect in female B6 mice.  This effect was able to ensure 
survival at lower concentrations (1 x 10
4
 and 3 x 10
4
) (Fig. 3.5a and b) where 60 and 
80% of females survived compared with 0 and 20% males respectively.  At higher 
concentrations (1 x 10
5
 and 6 x 10
5
) (Fig. 3.5c and d) all mice were culled but again a 
clear protective effect is seen in female mice which survived ~ 10 days longer.  
 To further evaluate the HY response to MB49, male and female B6 mice 
were immunised with HY and other TAAs antigens by s.c. injection with a high dose 
of irradiated (30Gy) MB49 cells (9 x 10
5
).   21 days later mice were re-challenged 
with a high dose of MB49 (5 x 10
5
).  All female mice rejected the MB49 tumour 
with 100% survival, only 60% of male mice were able to mount an effective anti-
tumour response (Fig. 3.5e) this was statistically significant.  Male mice are able to 
mount effective tumour responses to TAAs other than HY although this is 
insufficient to provide the same protection as seen in the female response to HY 
antigen. 
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Figure 3.5. Male vs female disparity in the in vivo anti-tumour response  
a-d. Male and female B6 mice were injected (s.c.) with 1x10
4
 (a), 3x10
4
 (b), 1x10
5
 
(c) and 6x10
5
 (d) MB49 cells.  Tumour growth was measured over 70 days (a and b) 
or 40 days (c and d) and data were presented as % survival in a Kaplan-Meyer plot, 
with p value calculated by using students T-Test.  Tumour area was measured daily 
until a humane end point was reached (any dimension >14mm) at which time mice 
were culled and recorded as dead.  
e. Male and female B6 mice were injected (s.c.) with 9x10
5
 irradiated MB49 cells.  
21 days later the mice were challenged (s.c.) with 5x10
5
 MB49 cells at the same 
injection site.  Tumour growth and survival of mice were measured as above. 
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3.2.6:  The kinetics of MB49 tumour growth in female B6 mice 
 The growth profile of MB49 has previously been characterised at high doses 
of 7x10
5
 and 1x10
6
 that produced a progressive solid tumour in female B6 mice 
(Loskog, Ninalga et al. 2005).  In order to establish an MB49 dose that would be 
appropriate for therapeutic interventions, groups of female B6 mice were challenged 
with titrated doses of MB49 cells (1x10
5
, 3x10
5
or 6x10
5
) injected (s.c.) to the right 
lateral flank.  Tumours become visible at around 2mm in 3-5 days after inoculation, 
tumours are then measured daily as described previously, until humane end point is 
reached. 
At lower doses of 1 x 10
5
 cells (Fig. 3.6a), MB49 grew in all mice, with 
>60% of mice reaching humane endpoint by day 36.  At moderate doses of 3 x 10
5
 
cells (Fig. 3.6b) 80% of mice developed tumours which grew bigger and faster.  With 
high doses of MB49 6 x 10
5
 cells (Fig. 3.6c) 100% of mice developed tumours to 
humane endpoint with some mice being culled due to ulceration, an effect only seen 
at higher dose tumour inoculations.  These results are typical of tumour growth of 
MB49 in our lab; to obtain reliable tumour growth in all recipients, the dose of 
MB49 cells has been carefully selected as 5 x 10
5
 cells (s.c.) to WT B6 mice and 1 x 
10
5
 cells for Rag
-/-
 B6 mice, based on data from several representative experiments 
from this lab and others (Perez-Diez, Joncker et al. 2007).  Fig. 3.6d shows a typical 
MB49 tumour image (isolated at day 21 from a female mouse inoculated (s.c.) with 5 
x 10
5
 MB49 cells).  MB49 forms a solid progressive tumour (top left) with high 
angiogenesis (top right), metastatic pressure and blood volume shown by cutting the 
tumour with a scalpel (bottom). 
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Figure 3.6. MB49 tumour growth profile in C57BL/6 WT female mice 
a. MB49 cells were injected at 1 x 10
5
 cells s.c. to the right flank of B6 female mice 
(n=8) tumour growth was measured on consecutive days using digital callipers and 
tumour area calculated (length x width (mm
2
)). 
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b. MB49 cells were injected at 3 x 10
5
 cells s.c. to the right flank of B6 female mice 
(n=10) tumour growth was measured as above. 
c. MB49 cells were injected at 6 x 10
5
 cells s.c. to the right flank of B6 female mice 
(n=8) tumour growth was measured as above. 
d. MB49 cells were injected at 5 x 10
5
 cells s.c. to the right flank of B6 female mice.  
Tumours were imaged on day 21.  Tumours were also cut using a 22 grade scalpel 
(bottom image). 
 
 
3.2.7:  CD11c
+
 cells from tumour-draining lymph node are able to stimulate 
HY-specific CD4 T cells in vitro  
 In principle, to induce an anti-tumour response sufficient to cause regression, 
tumour derived antigens must be persistent in the tumour-draining lymph node 
(dLN).  These antigens are presented by APCs to prime adaptive responses, however 
little is known regarding the relative contribution of B cells, macrophages and DCs 
in this response to these tumour cells.  To test the priming abilities of these APC 
subsets, 3 groups of B6 female mice (n=2/group) were inoculated with 5 x 10
5
 MB49 
cells on day -24, -17 or -10 along with a group of naive female B6 mice not given 
tumour cells that were culled on day 0 as HY-negative controls.  CD11c
+
 DCs were 
purified from the tumour dLN using MACS and co-cultured with MACS-enriched 
Marilyn CD4
 
T cells as responders (see chapter 4).  Resting Marilyn CD4 T cells 
were purified from a Rag
-/-
 Marilyn transgenic female and plated out with APC in a 
tritiated thymidine proliferation assay (Fig. 3.7a).  Marilyn CD4 T cells did not 
proliferate in response to CD11c
+ 
DCs from naive female pLN (peripheral LN) due 
to lack of HY antigens, but showed a significant level of proliferation in response to 
DCs from the dLN of MB49-bearing females, with a peak response induced by 
CD11c
+
 cells from mice challenged on day -17.  These results indicate that CD11c
+
 
cells from tumour dLN display HY peptide/MHC complexes.  
 In order to compare the magnitude of this response to that seen with B cells 
and macrophages, individual APC populations were sorted from female mice 
challenged with MB49 on day -17.  B cells (B220
+
), macrophages (CD11b
+
) or DCs 
(CD11c
+
) were plated out with Marilyn responders in a tritiated thymidine 
proliferation assay (Fig. 3.7b).  Marilyn T cells cultured with DCs showed the most 
potent proliferative response compared to macrophages and B cells, indicating that 
they are the most effective APC in priming CD4 T cells in vitro.   
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Figure 3.7. CD11c
+
 cells from tumour dLN of MB49-bearing B6 female mice are 
capable of stimulating resting HY-specific CD4 T cells in vitro 
a. 3 groups of female B6 mice (n=2/group) were inoculated with MB49 (s.c) at 5 x 
10
5
 on day -24, -17 and -10.  On day 0 tumour dLN as well as pLN from a tumour 
free naive B6 female were harvested and CD11c
+
 cells were purified using MACS.  
CD4
+
 T cells were purified from SP + LN from a Rag
-/-
 Marilyn female mouse by 
MACS.  DCs were plated at 1 x 10
5
 cells and Marilyn at 4 x 10
5
 in a 96U bottom 
plates.  Tritiated thymidine (0.5 μCi/well) was added on day 3 and proliferation was 
evaluated 24 hours later as counts per minute (CPM).   
a. CD11c
+ 
DCs (white bar), CD11b
+
 macrophages (grey bar) and B220
+
 B cells 
(black bar) were isolated and MACS enriched from tumour dLN of B6 female mice 
inoculated with MB49 cells 17 days earlier.  Cells were plated with MACS purified 
Marilyn responders for a tritiated thymidine proliferation assay as described in „a‟.  
(** = p value <0.01) Error is represented as ± standard error mean.  
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3.2.8:  Endogenous T cell responses to MB49 tumours in vivo 
In general terms CD8 T cells and NK cells are the major cytotoxic effectors 
in tumour killing, although optimal CD8 T cell activation requires CD4 help 
(Antony, Piccirillo et al. 2005).  In order to characterise the antigen-specific anti-
tumour response it is important to derive the kinetics of the endogenous T cell 
response, antigen-specific tumour responses will be discussed in a separate chapter in 
this thesis.  To evaluate the endogenous T cell response an in vivo T cell depletion 
strategy was designed whereby female B6 mice were depleted of CD4 T cells, CD8 
or both using a single injection (i.p.) of 1mg of depleting monoclonal antibody (YTS 
191 (CD8) (Cobbold, Jayasuriya et al. 1984), YTS 169 (CD4) (Benjamin, 
Cobbold et al. 1986)).  72 hours after depletion mice were inoculated s.c. with a sub-
optimal dose of MB49 cells (see Fig. 3.5, 2 x 10
4
).  It is anticipated that tumours 
should not develop in the majority of WT B6 female mice following this suboptimal 
dose inoculation.  
 Depletion of the CD4 or CD8 endogenous T cell compartment results in more 
rapid tumour growth (Fig. 3.8a) coupled with reduced survival (Fig. 3.8b) when 
compared to control mice that receive no treatment (Fig. 3.8).  Interestingly there is 
no significant difference in mean survival time (MST) between CD4- (MST 34 days) 
and CD8-depleted mice (MST 33.8 days), indicating that both subsets are important 
for tumour rejection.  Depletion of both the CD4 and CD8 T cell compartment 
resulted in a synergistic effect and MST was reduced to 29.3 days (Fig. 3.8b).  
Therefore these data show that both CD4 and CD8 T cells are required for 
controlling tumour development in WT B6 female mice inoculated with a suboptimal 
dose of MB49 cells.   
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Figure 3.8. Impact of in vivo T cell depletion mediated by mAb treatment on 
tumour growth 
a. 4 groups of B6 female mice were inoculated with 2 x 10
4
 MB49 cells (s.c.).  3 
days earlier, one group were treated with an CD4 mAb (YTS 191) (n=7 open 
circles), one group with an CD8 mAb (YTS 169) (n=7 open diamonds), one group 
treated with both (n=6 open triangles) (all doses 1mg i.p.) and one group received no 
treatment (open squares).  Tumour growth was measured as in Fig. 3.5. (* P value 
<0.0001).  
b. MB49 tumour progression was also represented as % survival of mice as 
described in Fig. 3.5. Error is represented as ± standard error mean. 
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3.2.9:  Endogenous regulatory T cell responses to MB49 
 The inhibitory role of regulatory T cells (Tregs) has been highlighted in many 
tumour systems (Curiel 2007).  Studies using Treg depletion have demonstrated 
promising results in enhancing tumour rejection (Shimizu, Yamazaki et al. 1999; Ko, 
Yamazaki et al. 2005).  The role of tumour antigen-specific Tregs will be addressed 
later in this study, however, polyclonal Treg depletion using mAb PC61 (CD25) 
has shown promise in promoting tumour rejection (Onizuka, Tawara et al. 1999).  To 
see if this is the case in the MB49 tumour model, WT female B6 mice were depleted 
of CD4
+
 or CD25
+
 T cells 3 days prior to inoculation with a sub-optimal dose of 
MB49 (2 x 10
4
 (s.c)) (Fig. 3.9).  Untreated mice rejected tumours quickly as in the 
previous experiment.  Mice depleted of CD4 T cells showed a more rapid tumour 
development with a reduced MST than mice depleted of CD25
+
 cells (34 days vs 
37.3 days) (Fig. 3.9b).  This is at odds with predictions of published results where 
CD25
+
 depletion was shown to decrease tumour growth and increase survival 
compared to controls. It is likely in this model that other CD25
+
 effector T cells may 
also be deleted.  Despite this CD25 depletion induces increased survival and 
decreased tumour growth compared to CD4 depletion. 
 This result is supported by published results from our lab (Coe, Begom et al. 
2010).  In this study it was shown that removal of Tregs using DTA-1 anti-GITR 
mAb therapy can induce MB49 tumour regression in WT B6 females (5 x 10
5
 
optimal dose) while administration of PC61 is insufficient to prevent tumour growth.  
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Figure 3.9. Impact of in vivo CD4
+
 CD25
+ 
depletion on tumour growth 
a. 3 groups of B6 female mice were inoculated with 2 x 10
4
 MB49 (s.c.).  3 days 
previously, one group were treated with an CD4 mAb (YTS 191) (n=7 open 
circles), one group with an CD25 mAb (PC61) (n=7 open diamonds) (all doses 1mg 
i.p.) and one group received no treatment (n=6 open squares).  Tumour growth was 
measured as in Fig. 3.5. (* P value <0.001). 
b. MB49 tumour progression was also represented as % survival of mice as 
described in Fig. 3.5. Error is represented as ± standard error mean. 
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3.2.10:  Local vs systemic endogenous T cell responses against MB49 tumour in 
vivo 
 T cells are required for the rejection of MB49 tumours and CD4 and CD8 
endogenous populations synergise in their anti-tumour response (Fig. 3.8).  To 
further quantify the endogenous tumour response, tumour dLN and ndLN (non-
draining LN) were harvested from WT B6 female mice bearing MB49 tumours at 
different stages of progression (day -21, day -13 or day -7).  pLN (peripheral LN) 
from a naive B6 female was used as a control.  Lymph node samples were analysed 
for the proportion of lymphocytes, CD4, CD8 and Treg cells (CD4
+
FoxP3
+
) (Fig. 
3.10e).  Fig. 3.10 represents the mean absolute cell numbers in naive pLN (control), 
tumour dLN and ndLN for lymphocytes (Fig. 3.10a), CD8 T cells (3.10b), 
conventional CD4 T cells (3.10c) and Tregs (3.10d).     
 The absolute number of lymphocytes was significantly higher in the dLN 
compared to ndLN and naive pLN (control) at all time points tested.  The number of 
lymphocytes in mice inoculated with MB49 cells on day -7 was on average three 
times higher in the dLN compared to ndLN, indicative of a local antigen dependent 
anti-tumour response (Fig. 3.10a).  Although the number of CD4, CD8 and Tregs in 
the dLN tended to be higher than that in the naive pLN control and ndLN (Fig. 
3.10b-d), the difference was not significant.  
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Figure 3.10. Representation of T cell subsets in tumour dLN from MB49-
bearing B6 females 
3 groups of B6 female mice were inoculated with 5 x 10
5
 MB49 (s.c.) on day -21 
(black bars), day -13 (grey bars) and day -7 (white bars) (n=2/group).  On day 0 mice 
were culled dLN and ndLN was harvested or pLN from a naive B6 female control.  
Cells were counted and stained with anti-CD4
FITC
 and anti-TCR
PE
 for CD4
+
 T cells, 
anti-CD8
PerCP
 and anti-TCR
PE
 for CD8 T cells, and anti-CD4
PE
 and anti-FoxP3
FITC
 
for Treg cells. Cells were analysed by FACS and gated for relevant populations.  
Absolute cell numbers were calculated (proportion of cell population x total cell 
number). 
a. Absolute number of lymphocytes in naive pLN, tumour dLN and ndLN. (* P value 
<0.05). 
b. Mean absolute number of CD8 T cells. 
c. Mean absolute number of conventional CD4 T cells. 
d. Mean absolute number of Tregs (CD4
+
 FoxP3
+
 T cells). 
e. Representative FACS plots of gating strategy for CD4 and CD8 (top) and Tregs 
(bottom).  Error is expressed as ± standard error mean. 
 
 
 
3.2.11:  Development of positive HY tetramer responses in MB49-bearing mice 
upon HY re-challenge 
 As MB49 tumours naturally express HY antigens and can induce HY-specific 
responses (Loskog, Ninalga et al. 2005; Perez-Diez, Joncker et al. 2007), it is of 
interest to measure anti-tumour CD8 T responses during the course of tumour 
progression.  Female B6 mice were challenged with an optimal dose of MB49 (5 x 
10
5
 (s.c)) and tail bled on day 17 after tumour challenge when tumours were 
approximately 25mm
2
 in size.  To measure the frequency of HY-specific CD8 T cells 
in circulation, the peripheral blood lymphocytes (PBL) were stained using a HY-
specific tetramer (Millrain, Chandler et al. 2001) (D
b
-UTY-PE) along with CD8 (Fig. 
3.11a).  No detectable levels of tetramer
+ 
CD8
+
 T cells were found in any of the mice 
tested (2 representative FACS plots shown), indicating that systemic HY-specific 
CD8 cell activation did not occur during the course of the primary response to the 
tumour. 
 In a second experiment mice that had previously rejected an MB49 tumour by 
day 35 were subjected to MB49 re-challenge at a high dose (1 x 10
6
).  Mice were 
again tail bled 7 days later and PBL stained as above (Fig. 3.11b).  Tetramer
+
 CD8
+
 
cells were detected in peripheral blood of all mice indicating that systemic HY-
specific CD8 T cell responses are induced during the course of a secondary memory 
response.  To further confirm these results another group of mice that had rejected 
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MB49 tumours by day 35 were boosted with an injection of male spleen cells in 
suspension (i.v), 7 days later mice were tail bled and tested for the presence of 
tetramer
+
CD8
+
 T cells.  This generated a very strong tetramer response in all mice 
tested (Fig. 3.11c) indicating a potent secondary response to HY antigens presented 
by male spleen cells and this response was markedly greater than that to MB49 re-
challenge.  The significantly greater tetramer positive response seen in mice boosted 
with male spleen is likely due to the non-immunoevasive environment under which 
HY is recognised.  
 
Figure 3.11. Measurement of the frequency of HY-specific CD8 T cells in 
response to primary and secondary tumour challenge by tetramer staining 
a. B6 female mice were inoculated with 5 x 10
5
 MB49 cells (s.c.) (n=4).  17 days 
later when tumour area was ~25mm
2
 mice were tail bled.  Red blood cells were lysed 
and the peripheral blood lymphocytes were stained with D
b
-UTY
PE
 and then stained 
with anti-CD8
PerCP
.  Cells were analysed by FACS, 2 representative FACS plots 
shown. 
b. 3 B6 female mice that had previously rejected MB49 tumours were subjected to 
secondary tumour re-challenge by injection (s.c.) of 1 x 10
6
 MB49 cells.  Mice were 
bled on day 7 and stained as above, 2 representative FACS plots shown. 
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c. 3 B6 female mice that had previously rejected MB49 tumours were boosted with 
B6 male SP cells (i.v.) with 10x10
6
 cells. Mice were bled on day 7 and stained as 
above, 2 representative FACS plots shown. 
 
 
3.2.12:  MB49 tumours are infiltrated and tumour cells killed in vivo  
 Evasive tumours can often grow by preventing host lymphocytes and 
leukocytes entering the tumour, thereby inhibiting tumour killing (Yu, Lee et al. 
2003).  Tumour-specific T cells that do infiltrate the tumour can be exposed to 
factors such as death ligands (e.g. PD-L1, FAS-L) that can potentially induce 
apoptosis in lymphocytes such as T cells.  To test the cytotoxic activity within MB49 
tumours, B6 female mice were injected with an optimal dose of MB49 (5 x 10
5
) on 
both the left and right lateral flanks.  Once the tumours were established into a large 
progressive solid state tumour >8mm in diameter (Fig. 3.12b) mice were culled and 
tumour tissues were analysed by Propidium Iodide (PI) staining (Fig. 3.12).  PI is an 
intercalating agent that binds non-specifically to DNA and RNA, PI increases 
fluorescence 30 fold in the red spectrum (PE channel) upon DNA binding.  This 
allows cell viability to be measured as PI can is not membrane permeable and 
therefore will only stain dead or dying cells (Lecoeur 2002). 
 Large tumours (Fig. 3.12b) and dLN cells were harvested and stained for 
CD45 and PI.  CD45
-
 cells were classified as MB49 and CD45
+
 as lymphocytes.  A 
large proportion of MB49 tumour cells stain PI
+
 and are therefore actively 
undergoing cell death even in tumours that have escaped immune control (Fig. 
3.12b).  This is also true for lymphocyte cell death within the tumour (Fig. 3.12b) but 
not for lymphocytes in the local dLN where only a small fraction are dead or dying 
(Fig. 3.12a).  When this was quantified from 24 individual tumours (12 mice) this 
showed a large proportion of tumour cells are dead or dying within the tumour with 
an average ratio of dead to live cells of 0.36:1.  This was also true of lymphocyte 
compartment within the tumour which had an average ratio of 0.46:1 (Fig. 3.12c). 
This effect was not as profound in the local dLN where the average ratio was 0.04:1.  
These data indicate MB49 tumours are sites of active cell death of both tumour cells 
and host lymphocytes even in tumours that have escaped immune control. 
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Figure 3.12. Both MB49 cells and lymphocytes stain PI
+
 in large progressive 
tumours 
B6 female mice were inoculated with 5 x 10
5
 MB49 (s.c.) to the left and right flanks 
(n=12).  18 days later when tumour area was >60mm
2
 mice were culled and tumour 
tissue and dLN excised and stained for CD45
FITC
 and with PI. 
a. Representative FACS plot of dLN stained as above. 
b. Representative FACS plot of MB49 tumour stained as above. 
c. Representative image of a large progressive tumour analysed in this experiment. 
d. Ratio of live to dead cells in the tumour for MB49 gate and lymphocyte gate and 
for lymphocyte gate in the dLN (n=24 tumours and 24 dLN in 12 individual mice).  
Error is expressed as ± standard error mean. (* p value <0.05). 
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3.2.13:  MB49 can express IL-10, TGF- and IL-17 cytokine genes  
 Solid tumours often produce immunosuppressive and immunoevasive factors 
in the local microenvironment (Zitvogel, Tesniere et al. 2006).  Tumours can induce 
lymphocyte cell death by direct binding through death receptors such as PD-1 and 
FAS as seen earlier, or by inducing an immunosuppressive environment driving 
Tregs and myeloid derived suppressor cells to negatively augment the anti-tumour 
response.  Several studies including studies in this and other labs have linked the 
production of IL-10 and TGF- in the local tumour microenvironment to poor 
tumour prognosis driven by Treg activation (Fukuyama, Ichiki et al. 2007; Coe, 
Addey et al. 2010; Coe, Begom et al. 2010).  MB49 cells were isolated from B6 
tumour-bearing females (WT B6, IL-10KO and IL-17KO) as described in Fig. 3.4 
and compared with the MB49 in vitro cell line for expression of  TGF- (Fig. 3.13a), 
IL-10 (Fig. 3.13b) and IL-17 (Fig. 3.13c) using an RT-PCR Taqman® assay.  
18sRNA was used as the normaliser gene results are expresses as relative 
quantification (RQ) to this gene.   
MB49 expresses TGF- in both the cell line and the in vivo tumour, 
indicating the tumour is naturally immunomodulatory, presumably by inducing Treg 
activation and expansion (Fig. 3.13a).  MB49 cell line however does not express high 
levels of IL-10, but upregulates IL-10 expression after forming tumours (Fig. 3.13b).  
Moreover IL-10 is upregulated further by inoculation of MB49 cells in IL-10 KO 
mice, indicating IL-10 is secreted in even higher amounts by the tumour cells if it is 
lacking exogenously in the in vivo setting.  IL-17 production by MB49 in vivo 
displays a similar kinetic to IL-10.  In IL-17 KO mice tumours express much higher 
levels of IL-17 again potentially compensating for lack of exogenous cytokine.  
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Figure 3.13. Comparison of cytokine gene expression profiles between various 
MB49 tumours and cell line 
Ex vivo MB49 cells were harvested from a B6 tumour-bearing female (5 x 10
5
 day 
17) from either WT, IL-10KO or IL-17KO mice.  MB49 cell line was also harvested 
and both populations were subjected to RNA extraction and cDNA conversion before 
running RT-PCR Taqman® assay in triplicate.  Control represents expression of 
18SRNA gene.  Error is expressed as ± standard error mean (* P value <0.01, ** 
0.0134). 
a. TGF- gene expression changes between cell line and tumour. 
b. IL-10 gene expression changes between cell line, tumour from WT and IL-10KO. 
c. IL-17 gene expression changes between tumour from WT and IL-17KO mice. 
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3.2.14:  MB49 produces Indoleamine 2,3-dioxygenase (IDO) in vivo   
IDO is involved in the activation and maintenance of Tregs.  Due to the 
potent immunosuppressive effect of IDO (see section 1.6.3) produced by 
plasmacytoid DCs (pDC) in tumour dLN, it is of interest to evaluate the ability of the 
MB49 tumour itself to produce IDO.  Ex vivo MB49 tumours express high levels of 
IDO, significantly higher than the cell line (Fig. 3.14a).  IDO was also significantly 
higher in the dLN compared to ndLN in agreement with published data (Sharma, 
Hou et al. 2009).   
In addition to tryptophan consumption, other essential amino acids have been 
identified that may be rate limiting to effector T cell activation and proliferation 
(Cobbold, Adams et al. 2009).  One enzyme branched chain amino acid transaminase 
(Bcat1) has been shown to be upregulated in proinflammatory conditions of allogenic 
skin graft from lymphopenic CBA male to lymphopenic female mice while the 
enzyme histidine decarboxylase (Hdc) was shown to only be upregulated with both 
skin graft and Treg adoptive transfer (Cobbold, Adams et al. 2009).  Bcat1 enzyme 
catalyzes the reversible transamination of branched-chain alpha keto acids to 
branched chain L amino acids essential for cell growth while Hdc metabolises 
histidine.  MB49 tumours were also tested for the expression of Hdc (Fig. 3.14b) and 
Bcat1 (Fig. 3.14c), compared with the cell line.  Both genes were upregulated in the 
tumour compared to the cell line, with Hdc demonstrating a significant change.  
These data in combination indicates essential amino acids in the local tumour 
microenvironment are consumed which may abrogate the T cell response and 
promote the activation of Tregs. 
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Figure 3.14. Upregulation of IDO, Hdc and Bcat1 by MB49 tumours  
Ex vivo MB49 cells were harvested from a WT B6 tumour-bearing female (5 x 10
5
 
day 17), MB49 cell line was also harvested and both populations were subjected to 
RNA extraction and cDNA conversion before running RT-PCR Taqman® assay in 
triplicate.  Error is expressed as ± standard error mean (* P value <0.005, ** 0.03) 
a. IDO gene expression changes between cell line and tumour. 
b. Hdc gene expression changes between cell line and tumour. 
c. Bcat1 gene expression changes between cell line and tumour. 
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3.3:  Discussion 
 To create a transplantable tumour model for adoptive cancer immunotherapy 
it was necessary to characterise the MB49 tumour model both in terms of kinetics 
and phenotype.  Later in this study I will evaluate tumour antigen-specific responses 
by T effector cells and Tregs in an adoptive cell transfer model.  Prior to conducting 
these later studies MB49 cells were characterised to give a fundamental phenotype 
around which future therapies could be designed.  MB49 is a carcinoma cell line that 
expresses HY genes, derived from a B6 male mouse (Fig. 3.1), expression being 
verified by RT-PCR.  MB49 expresses all 3 HY antigens (Fig. 3.1a) as well as the 
MHC restriction molecules H2D
b
, H2K
b
 (MHC-I) and H2A
b
 (MHC-II), and co-
stimulatory molecules (Fig. 3.1b and c).  MB49 is therefore a good model for 
measuring responses to HY minor antigen as the tumour is able to present these 
physiological antigens in an immunological manner.    
 The ability to maintain MB49 as a stable in vitro cell line allows for 
consistent replicate experiments to be conducted.  MB49 tumours however show 
significant changes in surface marker expression profile compared to the in vitro cell 
line (Fig. 3.1b and c).  Experiments in which MB49 cells were cultured in the 
presence of IFNa Th1 cytokine known to be highly upregulated during anti-tumour 
responses (Fig. 3.2) (Nishikawa, Kato et al. 2005), and others in which CD45 
negative MB49 tumour cells were isolated ex vivo (Fig. 3.3) (Arendt and Ostergaard 
1995), showed high levels of MHC-I and II expression as well as positive co-
stimulatory molecules, indicating the tumour has immunogenic features.  MB49 cells 
also expressed PD-L1 and PD-L2 (Fig. 3.2a and 3.3) and expressed Fas-L (Fig. 3.2b) 
indicating that it has the potential ability to directly bind PD-1 and Fas on activated T 
cells as a mechanism of immune evasion.  Interestingly a series of other rather 
unexpected molecules emerged as surface markers, including leukocyte adhesion 
molecules CD44, CD49b and CD62L. The function of these molecules on MB49 
tumours is not fully understood, but they may be involved in mediating tumour cell 
adhesion and extra cellular matrix modification (Sillanpaa, Anttila et al. 2003).  The 
stem cell marker Sca-1 was also upregulated by MB49 cell line, a molecule often 
identified as an oncogene in many tumours (Bradfute, Graubert et al. 2005).  Finally 
the chemokine CCR9 was shown to be expressed in MB49 tumour cells ex vivo.  
CCR9 is involved in gut homing and is often expressed in prostate and colon cancers 
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(Koizumi, Hojo et al. 2007), so perhaps expression by MB49 is unsurprising, as it 
originated as a bladder carcinoma (Fig. 3.2b and 3.3).   
MB49 tumour cells from WT B6 female mice and the in vitro MB49 cell line 
were subjected to RNA extraction and conversion to cDNA (Fig. 3.4).  They were 
compared for the expression of a range of cytokine, chemokine and receptor genes, 
significant and relevant gene expression by the MB49 tumour and cell line are shown 
in the table below.  
Table 7: MB49 gene expression changes 
Gene upregulated in vivo Immunological relevance Reference 
IL-1 
Proinflammatory mediator expressed 
mainly by activated macrophages 
(Fukuyama, 
Ichiki et al. 
2007)  
CCL3, 4 and 5 
CC chemokines recruit lymphocytes 
in many cancer systems.  CCL3 
(MIP1) and 4 (MIP1) shown to 
recruit CTLs, CCL5 (RANTES) 
shown to recruit Tregs 
(Luboshits, 
Shina et al. 
1999)  
CXCR3 and CXCL9 
Activation marker of T cells, 
expressed highly on pDCs and binds 
CCL9 
(Smit, 
Verdijk et 
al. 2003)  
IL-3RA 
Cell surface marker of pDCs and 
immature myeloid DCs 
(Iwasaki and 
Medzhitov 
2004)  
KIT 
Proto-oncogene implicated in the 
sequestration of myeloid derived 
suppressor cells by binding stem cell 
factor. MDSCs can promote 
tolerance and Treg recruitment. 
(Bradfute, 
Graubert et 
al. 2005)  
Gene downregulated in 
vivo 
    
IL-13RA 
Originally believed to be redundant 
to IL-4, new studies have shown this 
factor can induce potent anti-tumour 
responses 
(Kioi, 
Shimamura 
et al. 2009)  
Genes expressed in cell 
line and in vivo 
    
TGF-, IL10 and IL-4 
Th2 Immunosuppressive cytokines 
associated with suppression of 
effector T cells and survival and 
expansion of Tregs 
(O'Farrell, 
Liu et al. 
1998; Coe, 
Addey et al. 
2010)  
 
Taken together with surface phenotyping data, this demonstrates MB49 
tumours are immunogenic but crucially have the potential to expresses suppressive 
107 
 
factors on the cell surface or into the local tumour microenvironment, with potential 
to directly and indirectly abrogate tumour-specific T cell responses. 
 As MB49 is immunogenic in vivo and expresses HY minor antigens, the 
disparity in the response between male and female B6 mice is not surprising 
(Loskog, Ninalga et al. 2005).  Female B6 mice are able to mount antigen-specific T 
cell responses to HY antigens in vivo whereas males are tolerant (Scott, Ehrmann et 
al. 1995), initially demonstrated through skin grafting experiments (Eichwald and 
Silmser 1955).  MB49 cells were injected in a range of doses (1 x 10
4
- 6 x 10
5
) to 
WT B6 female and male mice (Fig. 3.5).  At all doses a protective effect was seen for 
female mice with a significantly increased survival time.  B6 females were in fact 
able to reject MB49 tumours at low doses whereas males could not, demonstrating 
the effect of the HY response could be immuno-dominant over TAA expressed by 
the tumour (Fig. 3.5a-d).  Female B6 mice that received irradiated MB49 cells were 
able to reject a high dose of MB49 cells while only 60% of males were able to do so 
(Fig. 3.5e).  MB49 tumours expresses several TAAs, such as prostate cancer stem 
cell antigen (PSCA), and therefore male mice do make an immune response to these 
TAA (Loskog, Ninalga et al. 2005).  However this response is insufficient to protect 
at low doses of MB49 challenge or a high dose of MB49 re-challenge.  HY is the 
major surrogate TAA and responses to this minor H antigen show a clear difference 
between male and female mice.  
 Female B6 mice were challenged with a range of MB49 doses and tumour 
growth measured to define an optimal dose for tumour formation in >90% of mice 
(Fig. 3.6).  An optimal dose of between 3-6 x 10
5
 MB49 cells to WT B6 female mice 
is able to induce a progressively growing solid tumour reaching approximately 
64mm
2
 by day 14 (Fig. 3.6b and c).  Therefore from this point MB49 cells will be 
used at a dose of 5 x 10
5
 to WT B6 female mice to produce rapidly growing solid 
tumours (Fig. 3.6d) for the evaluation of various therapeutic experiments. 
 Having established the phenotype of MB49 in vivo and its growth kinetics, it 
was necessary to assess the various aspects of the endogenous immune response to 
MB49.  DCs (CD11c
+
) in the local draining lymph node of MB49-bearing female 
mice were purified and co-cultured with Marilyn CD4 responder cells (Fig. 3.7a).  
Marilyn CD4 T cells are TCR transgenic and recognise H2A
b
-Dby expressed by 
MB49 (Chen, Demir et al. 2003) (see chapter 4).  Marilyn T cells responded to all 
APCs from tumour dLN (day -24, -17 or -10) with the highest response to DCs from 
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the draining lymph node of 17 day old tumours (Fig. 3.7b).  Marilyn T cells showed 
the greatest proliferative response to DCs.  MB49 is the only source of HY antigen in 
this system and therefore must be processed and presented in the local draining 
lymph node, and the most effective presentation is achieved by DCs.   
 T cell responses to MB49 are required to control the tumour (Perez-Diez, 
Joncker et al. 2007).  B6 female mice were therefore depleted of CD4, CD8 T cells 
or both and subsequently challenged a sub-optimal dose of MB49 cells (Fig. 3.8) and 
in a separate experiment mice were depleted of CD4
+
 or CD25
+
 cells prior to tumour 
challenge (Fig. 3.9).  Tumours grew quicker in mice depleted of CD4, CD8 or both 
but were controlled in mice that received no treatment, who showed 100% survival 
(Fig. 3.8).  Tumour growth was further increased and mean survival time decreased 
in mice that were depleted of both CD4 and CD8 T cells, indicating that there is a 
synergistic effect between the two compartments (Fig. 3.8).  Interestingly when 
CD25
+
 cells were depleted this also had a negative impact on survival with faster 
tumour growth although these effects were not as profound those produced by CD4 
depletion (Fig. 3.9).  This result may be accounted for by the expression of CD25 not 
just on Tregs but also on anti-tumour effector cells.  Subsequent studies by 
colleagues have revealed that more selective Treg depletion using other mAbs such 
as DTA-1 (anti-GITR mAb) in MB49-bearing B6 females can induce increased 
tumour survival (Coe, Begom et al. 2010). 
 Comparing lymphocyte numbers from the draining lymph node of tumour-
bearing mice (day -21, 13 and -7) to non-draining lymph node or peripheral lymph 
node from a naive B6 shows draining lymph node has significantly higher absolute 
numbers of lymphocytes at all time points tested  (Fig. 3.10a) with absolute numbers 
of CD8, CD4 and Tregs on average higher than non-draining lymph node or control 
peripheral lymph node (Fig. 3.10b-d).  These results, combined with T cell depletion 
data and APC assays, indicate that MB49 induces a local antigen-driven T cell 
response.  In support of this, HY tetramer data also shows that MB49 tumours can 
induce antigen-specific CD8 cells upon re-challenge (Fig. 3.11).  MB49 induces a 
poor systemic T cell response upon primary challenge and consequently no tetramer 
positive cells are detected in peripheral blood samples (Fig. 3.11a).  When female 
mice are re-challenged with a high dose of MB49 cells, tetramer positive CD8 T cells 
are detected (Fig. 3.11b).  This demonstrates MB49 induced priming to HY is 
sufficient to induce a HY antigen-specific secondary response.  This was confirmed 
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by vaccinating mice that had rejected MB49 following boosting with male spleen 
cells that induced a potent tetramer positive response 7 days later (Fig. 3.11c). The 
response to male spleen cells propagates systemically and does not elicit the 
immunoevasive responses that may be the reason for lower levels of MB49 tetramer
+
 
response. 
 As many tumours evade the immune system by excluding immune effector 
components, MB49 tumours were excised for ex vivo analysis by staining with 
propidium iodide (PI) to show cell death within the MB49 tumour (Fig. 3.12).  
Lymphocytes show a very high proportion of dying or dead cells within the tumour 
compared to the local draining lymph node (0.46:1 vs 0.04:1) (Fig. 3.12a,b and d).  
Tumour cells themselves also show a high proportion of dead or dying cells (0.36:1) 
(Fig. 3.12b and d).  MB49 tumours are therefore active sites of immunological 
relevance with a high proportion of cell turnover of both lymphocytes and tumour 
cells.   
 To fully elucidate the phenotype of a tumour in vivo, it is necessary to 
understand the tumour microenvironment and its effects on modulating the immune 
system.  MB49 is clearly immunogenic (Fig. 3.1-4) and recognisable in vivo where 
potent T cell responses can be induced to its HY antigens (Fig. 3.5-12).  However, at 
higher does (>2 x 10
4
) MB49 cells can escape immune control and develop into a 
progressively growing solid tumour (Fig. 3.6d, 3.12c).  One likely contributing factor 
is the modulation of the T cell anti-tumour response by secretion of factors into the 
local microenvironment.  This can be seen by gene expression studies (Fig. 3.4) that 
indicate expression of genes that encode TGF-, IL-10, IL-4, IL-17 amongst others.  
TGF-, IL-10 and IL-17 have potent effects on the induction of Tregs, the 
suppression of Th1 responses and the induction of Th17 responses respectively.  
Excised ex vivo MB49 tumours were again subjected to RNA extraction and cDNA 
conversion in order to analyse the production of these factors (Fig. 3.13).  As 
indicated by previous genotyping (Fig. 3.4), TGF- is highly expressed in both the 
MB49 cell line and tumour (Fig. 3.13a) and seems to be a constitutively expressed 
factor involved in immune modulation by the induction of Tregs.  Subsequent studies 
by colleagues have shown blocking TGF- signalling on Tregs, through over 
expression of dominant negative form of TGF- receptor type II, can abrogate Treg 
functionality and induce an improved tumour prognosis (Coe, Addey et al. 2010).  
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Expression of IL-10 and IL-17 is induced in vivo by MB49 tumours (Fig. 3.13b and 
c).  However IL-10 and IL-17 expression is increased further in tumours from mice 
lacking exogenous cytokine (IL-10 KO and IL-17 KO mice).  This demonstrates 
MB49 has the capacity to compensate for modifications to the local tumour 
microenvironment such as reduced cytokine availability.  IL-10 is important for 
suppression of NF-B induced Th1 responses by monocytes and tends to lead to poor 
tumour prognosis (de Waal Malefyt, Haanen et al. 1991).  The function of IL-17 in 
tumour systems is controversial, with some groups reporting IL-17 as anti-tumour 
(Nakae, Komiyama et al. 2002) and others with pro-tumour effects (Wang, Yi et al. 
2009) in the MB49 system.  MB49 upregulates IL-10 and IL-17 expression in vivo 
and maintains expression of TGF- into the local tumour microenvironment.   
Another well documented mechanism for tumour evasion from immune 
responses is through the depletion of essential amino acids (EAAs), depriving T cells 
of these EAAs can prevent proliferation and activation in response to antigen (Munn, 
Sharma et al. 2004).  This is well documented for enzymes such as IDO which has a 
potent role in controlling foetal immune responses in the placenta.  MB49 was 
therefore tested as described previously for the production of enzymes involved in 
EAA depletion, namely IDO, Hdc and Bcat1 (Fig. 3.14).  IDO, which catabolises 
tryptophan, was shown to be significantly upregulated both in the draining lymph 
node and tumour compared to non-draining lymph node and cell line respectively 
(Fig. 3.14a).  Hdc an enzyme that metabolises histidine was shown to be significantly 
increased and Bcat1 was also expressed by tumours (Fig. 3.14b and c).  MB49 
therefore actively modifies the local microenvironment by the secretion of several 
immune-modulating factors that can have a significant impact on the local immune 
response. 
 MB49 can now be characterised as an aggressive, immunogenic solid tumour 
that can induce potent antigen-specific local T cell responses.  MB49 is an actively 
growing tumour that is capable of overcoming the T cell response at higher doses.  
This is achieved through specific interactions with lymphocytes (e.g PD-L1-PD-1) 
and through the induction of local tolerance driven by the local milieu of the tumour 
microenvironment.  By understanding the endogenous anti-tumour response I am 
now able to evaluate antigen-specific T cell responses in an adoptive transfer system. 
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Chapter 4: Distinct in vivo antigen-specific CD8 and CD4 T 
cell responses against normal and malignant tissue 
 
4.1:  Introduction 
 In the previous chapter endogenous T cell mediated responses against MB49 
were evaluated.  This elucidated a definitive disparity in anti-tumour responses 
between female and male mice, conferred by reactivity to HY in female mice (see 
Fig. 3.5 and 3.6).  Previous data also shows endogenous responses in female mice are 
insufficient to mediate the rejection of MB49 at moderate to high doses (Fig. 3.6).  
Further to this MB49, despite being immunogenic, is also highly aggressive and 
displays several immunoevasive and immunosuppressive markers and factors (Fig. 
3.1-4) which would potentiate direct killing of tumour infiltrating lymphocytes (Fig. 
3.12).  This coupled with the ability of MB49 to modulate the tumour 
microenvironment in vivo (Fig. 3.13-14), prevents tumour rejection in WT mice.  In 
this chapter the antigen-specific CD4, CD8 T and Treg cells are evaluated for their 
anti-tumour responses.  In addition, these anti-MB49 specific T cell responses will be 
compared to those to non-malignant tissues, to attempt to define the 
immunosuppressive effect induced in the tumour microenvironment. 
 
4.1.1:  HY-specific T cells 
 As discussed in chapter 3, the availability of CD4 (Marilyn) and CD8 
(Matahari) transgenic mice allows for the generation of TCR transgenic monoclonal 
T cells on a C57BL/6 H2
b+
  Rag
-/-
 background that can be utilised for adoptive 
transfer (Lantz, Grandjean et al. 2000; Valujskikh, Lantz et al. 2002).  The studies of 
T cell responses to HY minor antigens were initially developed in the context of 
transplant rejection (Scott, Ehrmann et al. 1995; Simpson, Scott et al. 1997; Simpson, 
Scott et al. 2001).  Consequently HY antigens are one of the best characterised 
transplantation antigens (Simpson, Scott et al. 2001).  Subsequent development of 
tetramers (Millrain, Chandler et al. 2001) and TCR transgenic mice (Valujskikh, 
Matesic et al. 1999; Lantz, Grandjean et al. 2000) has allowed for the detailed 
dissection of HY-specific T cell responses in the context of tolerance and 
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transplantation.  More recently our lab, and others, has explored the role of HY as a 
surrogate tumour-associated antigen (Perez-Diez, Joncker et al. 2007).  This 
approach takes advantage of HY-expressing tumour cell lines that can form 
transplantable solid progressive tumours (see chapter 3).  As T cell mediated 
immunity is highly dependent on the environment in which they are primed, the 
study of HY-specific T cell responses in normal and malignant tissues provides an 
insight into the immunoevasive environments tumours can employ. 
 
4.1.2:  HY-expressing malignant and normal tissues 
 T cell mediated responses to allografts of normal tissues generally produce a 
strong productive response leading to tissue rejection (Auchincloss and Sultan 1996).  
Conversely T cell mediated responses to transplantable tumours are generally 
defective, leading to a failure to eliminate the tumour (Kim, Emi et al. 2006).  The 
HY male antigen allows for studies to be conducted in situations where normal and 
tumour allografts share the same alloantigens.  The distinct outcomes to these tissues 
can be at least in part attributed to the T cell response, giving two distinct ways of 
comparing antigen-driven responses.  Comparison of antigen-specific T cell 
immunity to normal and tumour allografts can provide insights into the molecular 
and cellular mechanisms that underlie the failure to induce tumour rejection. 
 
4.1.3:  Antigen-specific allograft responses to minor H antigens  
 T cell responses against minor histocompatibility (H) antigens are responsible 
for the rejection of MHC matched transplants.  These responses can elicit major 
clinical complications by inducing host versus graft (HvG) responses and graft 
versus host disease (GvHD) (Zheng, Matte-Martone et al. 2009).  Therefore 
understanding the cellular and molecular mechanisms that underpin T cell responses 
to allografts has become crucial in clinical applications such as bone marrow 
transplantation in treating leukaemia patients.   
 Initial skin grafting experiments revealed a large number of minor H antigens 
at multiple loci scattered across the genome (Graff and Bailey 1973).  The antigens  
are encoded by mitochondrial DNA, the Y chromosome and autosomal 
chromosomes (Rotzschke, Falk et al. 1990).  Despite many minor H antigens having 
been characterised in humans and mice, relatively little is known about natural 
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regulation of immunity to minor H antigens (Simpson, Scott et al. 2001).  CD8 T 
cells alone have been shown to be capable of rejecting allografts expressing multiple 
minor H antigens (Youssef, Otley et al. 2004), however, the identification of both 
MHC I and MHC II restricted epitopes indicates the requirement for both CD4 and 
CD8 responses to generate effective responses (Roopenian 1992).  Indeed the 
depletion of either CD4 or CD8 T cell subsets can lead to a state of unresponsiveness 
to allografts (VanderVegt and Johnson 1993).  Subsequent experiments have shown 
that while CD8 priming can occur in the absence of CD4 help, this results in a 
diminished capacity to differentiate into memory cells (Janssen, Lemmens et al. 
2003).  Most strategies used for the induction of tolerance have therefore focused on 
the CD4 T cell subset, mainly by the induction of Tregs from conventional CD4 T 
cells (Karim, Feng et al. 2005).  It has also been demonstrated that nTregs can 
modulate immunity to minor H antigens in TCR transgenic mice (Benghiat, Graca et 
al. 2005).  The specific role of antigen-specific Tregs in regulating allograft 
responses has not been fully explored but this population is clearly a powerful factor 
in the suppression of allograft responses (Chai, Coe et al. 2008; Verginis, 
McLaughlin et al. 2008).   
HY antigen-specific CD4, CD8 and Treg responses to male allografts are 
evaluated in this chapter.  Male skin graft can induce potent T cell responses in 
female mice when antigens are presented in the context of H2
b
 but not other 
haplotypes (Robertson, Chai et al. 2007).  Previous published data has shown both 
Matahari CD8 and Marilyn CD4 transgenic females are capable of rejecting male 
skin grafts through direct antigen presentation by target cells (Valujskikh, Lantz et al. 
2002) and also indirectly through host APC interaction  (Braun, Grandjean et al. 
2001).  These transgenic mice have therefore been used to evaluate the potency of 
the allograft response in comparison with that to a HY
+
 tumour.  HY-specific CD4 T 
cell responses in male lymphopenic mice can also induce GvHD when radiation pre-
conditioned, this is dissected in Chapter 7. 
 
4.1.4:  Antigen-specific responses to minor H antigen in the context of tumour 
 The expression of minor H antigens in tumours is becoming increasingly 
recognised as a way to induce potent anti-tumour T cells responses in adoptive 
immunotherapy (Overwijk 2005).  Directional approaches targeting T cells against 
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one specific minor H antigen is a promising new approach designed to elicit effective 
local anti-tumour responses.  This has an obvious role in the eradication of 
hematopoietic malignancy using donor minor H antigen-specific lymphocytes 
(Hambach and Goulmy 2005).  Mismatches in minor H antigens are currently 
exploited to induce rejection of malignant cells for a graft versus leukaemia (GvL) 
effect (Feng, Hui et al. 2008).  These responses are also responsible for the induction 
of GvHD, depending on the distribution and expression level of the minor H antigens 
(Kaplan, Anderson et al. 2004).  In chapter 7 I will also explore the role of Marilyn 
antigen-specific T cells in the induction of GvHD in male lymphopenic mice where 
the relevant minor H antigen is expressed ubiquitously.   
Minor H antigen-specific therapies against solid state tumours are now 
becoming clinically relevant (Meunier, Delisle et al. 2005).  The identification of T 
cell populations able to target malignant tissue without inducing GvHD is the key 
objective to this therapeutic approach.  Some antigens are restricted to tumour tissue 
and often result from onco-related genes, however, like HY, most self antigens are 
universally expressed (den Haan, Meadows et al. 1998).  In spite of ubiquitous 
expression, immunity to a single minor H antigen can induce regression of solid 
tumours without causing GvHD (Meunier, Delisle et al. 2005) (see chapter 7). 
 Many anti cancer vaccine approaches and adoptive transfer therapies have 
previously focused on methods to elicit primarily tumour-specific CD8 CTLs.  CTLs 
have historically been shown to be capable of rapid allograft rejection and tumour 
killing in vitro (Lee, Wang et al. 1999), therefore it is reasonable to assume they 
should be potent anti-tumour effectors in vivo.  T cell transgenic mouse models have 
generated similar results for CD8 anti-tumour responses, with some able to clear 
small tumours (Hanson, Donermeyer et al. 2000), but most do not do so without 
additional treatment (Blank, Brown et al. 2004; Antony, Piccirillo et al. 2005; 
Gattinoni, Klebanoff et al. 2005).  CD4 anti-tumour responses have been generally 
less studied or if they have it is usually in the context of providing help to CD8 CTLs 
(Antony, Piccirillo et al. 2005).  However reports have revealed that CD4 cells are 
capable of eradicating tumours completely independently of CD8 T cells (Corthay, 
Skovseth et al. 2005), It is therefore crucial to the understand the nature of CD4 and 
CD8 responses to antigen in the context of tumour in order to design new vaccines 
and therapeutic approaches that focus on both CD4 and CD8 responses in vivo. 
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As discussed previously, MB49 is an H2
b+
 bladder carcinoma that expresses 
both MHC I and II restricted HY antigens as a model for TAA (see chapter 3).  
MB49 is immunogenic and recognised in vivo where these responses are mainly HY-
specific (Fig. 3.11).  However MB49 is able to overcome endogenous T cell 
responses to HY at moderate to high doses due to immunosuppressive mechanisms 
employed such as the production of IL-10, TGF- and IDO in the local tumour 
microenvironment (Fig. 3.13-14).  Previous studies by Perez-Diez et al have shown 
both Matahari and Marilyn Rag
-/-
 transgenic T cells are capable of recognising and 
killing MB49 cells in vitro, however only Marilyn Rag
-/-
 but not Matahari Rag
-/-
 mice 
are able to reject MB49 in vivo.  Furthermore, Marilyn CD4 but not Matahari CD8 
are capable of causing tumour rejection following adoptive cell transfer to female 
Rag
-/-
 MB49-bearing (10
5
) mice (Perez-Diez, Joncker et al. 2007).  In addition, HY-
specific Marilyn Tregs have also been shown to cause a worse prognosis for tumours 
and a positive outcome for normal tissue allograft survival by our lab (Chai, Coe et 
al. 2008; Coe, Begom et al. 2010).  This section attempts to understand the kinetics 
of these T cell responses and characterise the cellular and molecular mechanisms that 
underlie the different outcomes.   
  
4.1.5:  Allograft and tumour responses, opposite side of the same coin 
 In a clinical setting most transplants between MHC matched individuals have 
multiple mismatched minor H antigens and therefore powerful immunosuppressive 
treatments are often used to prevent T cell mediated rejection of donor tissue 
(Grinyo, Bestard et al. 2010).  In order to prevent rejection in the long term without 
these drugs, T cell tolerance must be induced to the minor H antigens on donor 
tissue.  Many techniques use the induction of Tregs to achieve this tolerance 
(Sakaguchi, Ono et al. 2006).  In contrast, the primary approach to tumour 
immunotherapy is to overcome immune tolerance to minor H antigens in the tumour 
environment, and therefore approaches for cancer immunotherapy tend to be 
opposite to therapies designed to mediate transplant tolerance.   Here, I have applied 
adoptive transfer of defined populations of HY-specific effector and regulatory T 
cells to compare responses in mice bearing tumours, male skin grafts or both.  These 
experiments provide insight into the cellular and molecular mechanisms that 
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determine why T cell mediated immune responses can lead to the rejection of 
allografts but acceptance of tumours.   
 
 
 
4.2:  Results 
 
4.2.1:  Matahari mice are capable of rejecting skin graft but not tumour 
 Syngeneic B6 male skin (from tail skin) was grafted to either WT B6 or 
Rag1
+/- 
Matahari females (Fig. 4.1a).  100% of Matahari mice are able to efficiently 
reject the skin graft with a mean survival time (MST) of 15 days while only 50% of 
B6 female mice had rejected the graft by day 70 with an MST of 60 days.  This 
demonstrates that Matahari have an enhanced primary anti-HY response mediated by 
HY-specific CD8 T cells.  In spite of this response, when Matahari females are 
challenged with MB49 cells at an optimal dose (5 x 10
5
) (see chapter 3), tumours 
develop over a similar period to WT mice (Fig. 4.1b and c).  Matahari CD8 T cells 
but not CD4 are capable of responding to cognate antigen in vitro (Fig. 4.1d).  
Matahari spleen and lymph node cells and sorted Matahari CD8 T cells respond 
similarly to antigen, while Matahari CD4 T cells are non-functional (Matahari mice 
are capable of producing a small fraction of non-functional CD4 T cells that are 
MHC I restricted V8.3+ TCR transgenic).  Taken together, these results show that 
while the presence of high frequency functional HY-specific CD8 T cells alone is 
sufficient to mediate rejection of non-malignant transplants, they cannot mediate 
rejection of malignant tissues. 
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Figure 4.1. Rag1
+/-
 Matahari mice can reject male skin grafts but not MB49 
tumours 
a. Kinetics of rejection of syngeneic B6 male skin grafts by Rag1
+/-
 Matahari and 
WT B6 females.  Tail skin from syngeneic B6 male mice was transplanted onto B6 
WT (n=6, WT+graft) or Rag1
+/-
 Matahari females (n=5, Matahari+graft). Grafts were 
assessed every other day and <10% healthy graft tissue was recorded as rejection. 
b and c. MB49 tumour growth in Rag1
+/- 
Matahari and WT B6 females.  Rag1
+/-
 
Matahari females (n=6, B) and WT B6 (n=8, C) were inoculated s.c with 5x10
5
 
MB49 cells on day 0. MB49 tumour growth was monitored by measuring tumour 
size every other day. 
118 
 
d. CD4-expressing transgenic V8.3 do not recognise cognate peptide - tritiated 
thymidine proliferation assay.  Matahari Rag
+/-
 SP+LN (2 x 10
5
), FACS sorted 
CD8
+
V8.3+ T cells (2 x 104) and CD4+V8.3+  T cells (2 x 104) were plated out 
with cognate antigen D
b
-UTY in tenfold dilution and cultured for 64 hours in the 
presence of APC (irradiated B6 female spleen cells, 5x10
5
 cells/well).  1l thymidine 
(containing 1 Ci activity) was added/well.  8 hours later the plate was harvested and 
counted using a microbeta counter (Wallac).  Assays were conducted in triplicate 
error is displayed as ± standard deviation. 
   
 
4.2.2:  Distinct Matahari CD8 responses to skin graft and tumour   
 To attempt to elucidate the cellular basis for the distinct outcomes to tumour 
and skin grafts, a series of CD8 adoptive transfer experiments were performed (Fig. 
4.2).  Purified Matahari CD8 T cells were CFSE labelled prior to infusion (i.v.) to 
groups of WT B6 female mice that were untreated (group 1, G1) or one day later 
were given either a male skin graft (G2) or MB49 tumour cells (G3) (Fig. 4.2a).  On 
day 12 mice were culled and pLN of G1 or graft/tumour dLN of G2 and G3 were 
analysed for the presence of donor CD8 T cells.  The absolute donor cell number 
recovered from the graft dLN was significantly higher than those recovered from the 
tumour dLN (Fig. 4.2b), indicating that the graft environment is more potent than 
tumour at the local priming of CD8 T cells.  Similarly, the frequency of donor cells 
was higher in the graft ndLN compared to tumour and control pLN (Fig. 2a and b) 
suggesting that the graft environment is also more efficient for inducing systemic T 
cell activation. 
 Prior labelling with CFSE allows for T cell proliferation to be measured in 
vivo (Fig. 4.2c).  Over 90% of donor T cells recovered from control pLN failed to 
divide, due to lack of antigen, while donor cells in the skin graft and tumour dLN did 
show proliferation.  T cells in the tumour dLN underwent ~6 divisions with ~20% 
undivided while T cells in the graft dLN divided over 6 times with only 7% 
undivided (Fig. 4.2c).  This increased division of donor T cells in graft dLN was also 
correlated with increased CD44 expression compared to those in tumour dLN (Fig. 
4.2c (top)).  
 The expression level of TCR on donor T cells in pLN and dLN was also 
evaluated (Fig. 4.2d).  Donor cells from control pLN maintained a high expression of 
V8.3, while TCR downregulation was seen particularly in the tumour dLN and also 
in graft dLN to a lesser extent.  Finally, CFSE dilution and CD44 expression was 
119 
 
measured for donor T cells within the tumour or skin grafts (Fig. 4.2e).  Although 
donor cells were present in both tumours and grafts with a similar frequency (Fig. 
4.2e left), they display distinct CD44 expression, with 96% of T cells in graft being 
CD44
high
 compared to only 11% in MB49 tumours (Fig. 4.2e right).  Matahari CD8 T 
cells are therefore able to recognise and respond to both graft and tumour in vivo. 
However, this response is only sufficient to mediate skin graft not tumour rejection 
(Fig. 4.1).  
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Figure 4.2. Distinct responses of Matahari CD8 T cells to tumours and male skin 
grafts 
a. 5x10
6
 CFSE labelled Matahari CD8 cells (Thy1.1) were injected (i.v.) into 3 
groups of Thy1.2 WT B6 females at day -1. On day 0, the mice in G1 were left 
untreated, those in G2 were inoculated with 5x10
5
 MB49 cells (s.c.) and those in G3 
were transplanted with syngenic B6 male skin grafts. All mice were culled on day 12 
and the pLN cells of G1 and dLN and ndLN cells of G2 and G3 were stained with 
anti-Vβ8.3PE and anti-Thy1.1PerCP. Panels show the percentage of donor CD8 T cells 
identified by co-expression of Thy1.1 and Vβ8.3. One representative experiment of 
three is shown.  
b. Comparison of absolute number and frequency of donor CD8 cells in pLN, dLN 
and ndLN. Absolute cell numbers (top) and frequency of donor CD8 cells (bottom) 
recovered from pLN of G1, dLN and ndLN of G2 and G3 are represented.  For G2 
and G3, black and white bars represent dLN and ndLN, respectively, for G1 bars 
represent inguinal and axillary LN. * p <0.05, ** p< 0.01. 
c. Top panel: Comparison of CFSE and CD44 expression by donor CD8 cells. pLN 
of G1, dLN cells of G2 and G3 were stained with anti-Vβ8.3PE, anti-Thy1.1PerCP and 
anti-CD44
APC
. Gated Thy1.1
+Vβ8.3+ cells were further analysed for CFSE and CD44 
expression. Bottom panel: Comparison of Mean Fluorescence Intensities (MFI) of 
CFSE by donor CD8 cells.  
d. Donor CD8 cells in tumour dLN show greater downregulation of Vβ8.3 compared 
to those in graft-dLN. Top panel: pLN of G1, dLN cells of G2 and G3 were stained 
with anti-Vβ8.3PE and anti-Thy1.1PerCP. MFI of Vβ8.3 by gated Thy1.1+Vβ8.3+ cells 
in each group is showed in histogram. Bottom panel: MFI of Vβ8.3 MFI of donor 
CD8 cells in each group are represented.  * p <0.05, ** p< 0.01. 
e. Graft-infiltrating but not tumour-infiltrating donor CD8 cells express high levels of 
CD44. The cells from either MB49 tumour mass or male skin grafts were stained 
with anti-Vβ8.3PE, anti-Thy1.1PerCP and anti-CD44APC. Both frequency (left hand) 
and CD44 expression (right hand) of donor CD8 cells in tumour and skin graft were 
shown.   
Error is represented as ± standard deviation and all data is representative of three 
independent experiments.  
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4.2.3:  CD8 responses are inversely correlated with tumour progression 
 To dissect the kinetics of the Matahari T cell response to MB49, CFSE 
labelled T cells were infused into WT B6 female MB49-bearing mice inoculated 
with MB49 cells 1, 3 or 7 days prior to T cell adoptive transfer.  Responses were then 
measured on days 4, 7 and 14 following transfer (Fig. 4.3) with analysis being 
conducted as in the previous section.   The proportion of tumour infiltrating donor T 
cells was significantly higher in the most recently established tumours, with the 
maximum accumulation seen by day 14 (Fig. 4.3a).  Donor T cells in the tumour 
dLN display a similar profile of CFSE dilution at each time point for all groups (Fig. 
4.3b).  It therefore seems to be a narrow window in which activated CD8 T cells are 
able to enter the tumour despite a similar level of proliferation and activation in the 
dLN.  This limitation does not apply to male skin grafts where Matahari T cells are 
able to migrate into grafts that have already healed (not shown).   
 The efficiency of priming of Matahari CD8 T cells by MB49 challenge plus 
HY-Uty peptide and CFA vaccination was compared with that in an untreated 
control group (Fig. 4.3c).  Donor Matahari CD8 T cells show a vigorous expansion 
(at least 4 fold increase in terms of donor CD8 frequency) and a complete CFSE 
(99%, and up to 9 divisions) dilution 4 days after vaccination, but they displayed no 
responses to MB49 challenge in the absence of peptide vaccination.  Moreover, poor 
responses by donor CD8 T cells in MB49-bearing mice was not due to „ignorance‟, 
because both transgenic V8.3 on donor CD8 T cells and endogenous V8.3 on host 
T cells in MB49 dLN showed a significantly reduced expression, revealed by 
decreased MFI (reduced from 124 to 90 for donor CD8, and from 513 to 382 for host 
T cells).  In contrast, peptide vaccination induced upregulation of transgenic V8.3 
expression by donor CD8 T cells (from 124 to 178) while this had no influence on 
endogenous V8.3 expression (from 513 to 494) (Fig. 4.3c). 
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Figure 4.3. Kinetics of CD8 responses to MB49 tumours at different stages of 
progression 
a and b. MB49 inoculation was performed on day -7, -3 or 1 and CD8 transfer was 
conducted at day 0, as illustrated in Figure 4.3. Analysis was carried out at day 4, 7 
and 14 as described in Figure 4.2 except anti-CD8
APC
 rather than anti-CD44
APC
 was 
used. One representative experiment of three is shown. 
c. Three groups of Thy1.2 B6 females (n=3) were adoptively transferred with CFSE-
labelled Thy1.1 Matahari CD8 T cells (4x10
6
 cells/mouse) by i.v. injection. On the 
next day mice were inoculated (s.c) with 5x10
5
 MB49 cells (G2), or inoculated with 
HY-Uty peptide (100g) plus CFA (s.c.) (G3). Four days later, all mice were culled 
and pLN (G1) or dLN (G2 and G3) cells were analysed for the presence of donor 
CD8 T cells (R2, left hand panels), the MFI of V8.3 by donor CD8 (R3, middle 
panels) and by endogenous T cells (R4, middle panels) and CFSE dilution profiles 
(right hand panels). In each panel, data is representative of two independent 
experiments.  
 
 
4.2.4:  Impact of concurrent male skin grafts on CD8 responses against tumours 
 Matahari CD8 T cells can mediate HY
+
 skin graft rejection (Fig. 4.1) but 
cannot cause regression of HY
+
 MB49 solid tumours (Fig. 4.1-3).  In an attempt to 
investigate these different outcomes, a dual tumour and skin grafting experiment was 
conducted (Fig. 4.4).  The potential for cross talk between MB49 tumours and male 
allografts was assessed by comparing CD8 T cell responses between mice either 
bearing MB49 tumour alone, allograft alone (Fig. 4.4a) or both (Fig. 4.4b).  Skin 
allografts and MB49 tumour cell injections were conducted as described previously.  
The mice that received MB49 alone or allograft alone recapitulated the data shown in 
previous figures, causing rejection of the skin graft while being unable to mediate 
tumour rejection (Fig. 4.4a).  Importantly, in the group that received both graft and 
tumour, the CD8 T cell response was significantly enhanced to both the graft and the 
tumour as evidenced by the significantly increased frequency of tumour and graft 
infiltrating donor CD8 T cells (Fig. 4.4b).  This ability to cross talk suggests that a 
synergistic positive effect between graft and tumour may be able to overcome the 
suppressive factors induced in the tumour environment. 
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Figure 4.4. CD8 T cell responses to MB49 tumours in the absence or presence of 
male skin grafts   
a and b. MB49 inoculation, skin grafting, CD8 transfer and analysis were conducted 
as described in Figure 4.2. One representative experiment of two is shown. 
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4.2.5:  CD4 help in restoring of the diminished anti-MB49 CD8 responses  
 Matahari CD8 T cell responses are unable to control MB49 tumours even if 
inoculated on the same day as the tumour (Fig. 4.1b).  To assess the requirement for 
CD4 help in the Matahari anti-tumour response, a co-adoptive transfer experiment 
was set up (Fig. 4.5).  Four groups of WT Thy1.2 B6 females were either inoculated 
with MB49 (5 x 10
5
) on day -7 (G2 and G4), or received no tumour (G1 and G3).  
All groups received CFSE labelled CD8 T cells purified from Thy1.1 Rag
+/-
 Matahari 
mice (4x10
6
 cells/mouse).  Two groups of mice (G3 and G4) also received CFSE 
labelled CD4 T cells purified from Thy1.1 Rag
+/-
 Marilyn mice (1x10
6
 cells/mouse) 
(i.v.).  On day 8, mice were analysed for the accumulation and CFSE dilution of 
donor Matahari CD8 T cells (Fig. 4.5). 
 Mice that received CD8 T cells alone failed to control the established tumour 
and showed reduced accumulation of donor CD8 T cells in ndLN and tumour 
compared to those that received both CD4 and CD8 T cells.  Mice that received both 
CD4 and CD8 controlled the tumour and showed greater CFSE dilution in the donor 
CD8 compartment in dLN and ndLN (Fig. 4.5).  Control mice that received CD8 T 
cells alone were similar in the levels of CD8 expansion and proliferation to control 
mice that received CD4 and CD8; demonstrating CD8 cells do not undergo 
additional expansion in response to CD4 alone.  CD4 help is therefore capable of 
inducing an enhanced anti-tumour response in adoptively transferred Matahari CD8 
T cells. 
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Figure 4.5. CD4 help enhances CD8 anti-tumour responses  
Two groups of Thy1.2 B6 females (n=3/group) were inoculated with 5x10
5
 MB49 
cells (s.c) on day -7 (G2 and G4) an additional two groups received no inoculation 
(G1 and G3).  On day 0, all mice were adoptively transferred with CFSE labelled 
Thy1.1 Matahari CD8 T cells (4x10
6
 cells/mouse) alone (G1 and G2) or co-
transferred with Thy1.1 Marilyn CD4 T cells (1x10
6
 cells/mouse, G3 and G4).  On 
day 8 all mice were culled and pLN of G1 and G3, dLN, ndLN and MB49 tissue 
cells were analysed for the presence of donor CD8 (R3) and their CFSE profiles as 
described in Fig. 4.2. Data is representative of two independent experiments.  
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4.2.6:  Matahari T cells appear to be self reactive and have a low TCR 
expression 
 To investigate the effects of this phenotype, Rag
-/-
 Matahari and WT B6 mice 
were tail bled at various ages and tested for CD44 vs CD62L expression by V8.3+ 
CD8 T cells (Fig. 4.6a) (CD62L
high
 CD44
low
 = naive, CD62L
high
 CD44
high
 = central 
memory, CD62
low
 CD44
high
 = effector).  Matahari mice have a high proportion of 
CD44
high
 cells in the CD8 V8.3 compartment while WT mice maintain a CD44low 
phenotype, this effect is also compounded with age (Fig. 4.6a).  Rag
-/-
 Matahari mice 
also have defective thymic development compared to WT and Rag
-/-
 Marilyn mice, 
with only 1 x10
6
 thymocytes (Fig. 4.6b).  The phenotype of the T cells in these mice 
may be due to homeostatic expansion of Matahari CD8 transgenic T cells to fill the 
peripheral „space‟ due to the low numbers of cells that enter the periphery from the 
thymus.  Alternatively it may be caused by Matahari T cells reacting to other self 
antigens due to a self reactive TCR.  Nevertheless Matahari T cells have a very good 
avidity and generate CTLs in vivo and in vitro and the rejection of skin grafts is 
efficient, as shown in Fig. 4.1. 
 Matahari Rag
+/-
 mice have a more obvious self reactive phenotype, with 
young adult mice (>8 weeks) displaying splenomegaly and ongoing proliferation of 
transgenic T cells shown through Ki67 expression in the spleen of Matahari mice 
compared to WT B6 (Fig. 4.6c).  To evaluate the effect of self reactivity on TCR 
expression, Matahari or Marilyn transgenic T cells were CFSE labelled and 
adoptively transferred to WT B6 females.  5 days later, pLN harvested and tested for 
proliferation of donor cells (Fig. 4.6d and e).  Matahari CD8 transgenic T cells have 
a much lower expression of V8.3 (MFI 124) compared to the host endogenous CD8 
compartment (513) while Marilyn CD4 transgenic T cells have similar expression 
level of V6 as the endogenous compartment of the host (Fig. 4.6d).  In addition, 
Rag1
+/- 
Matahari CD8 T cells gradually diluted CFSE after adoptive transfer in WT 
B6 females, whereas adoptively Rag2
+/- 
Marilyn CD4 T cells did not undergo 
proliferation (Fig. 4.6e). Taken together, Rag1
+/- 
Matahari CD8 T cells exhibit self-
reactivity and express reduced level of transgenic V8.3. 
128 
 
 
Figure 4.6. Perpetual reactivity and proliferation by Matahari CD8 T cells 
a. PBL from Rag1
-/-
 Matahari or WT B6 mice with indicated age were stained with 
anti-CD44
FITC
, anti-V8.3PE, anti-CD8PerCP and anti-CD62LAPC. V8.3+CD8+ cells 
were gated and analysed for the expression of CD44 vs. CD62L.  
b. Image comparing the size of thymus from a WT, Rag2
-/-
 Marilyn female and 
Rag1
-/-
 Matahari female or male (all 12 weeks old). Thymocytes cells from Rag1
-/-
 
Matahari females were stained with anti-CD8
PerCP
 and anti-CD4
APC
. In each panel, 
data are representative of ten independent experiments.  
c. Image comparing the size of spleen and LN isolated from a Rag1
+/-
 Matahari 
female with a WT B6 female mouse (20 weeks old). Spleen cells from Rag1
+/-
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Matahari or WT B6 mice were surfaced stained with anti-V8.3FITC, anti-CD8PerCP 
and then stained intracellulary for anti-Ki67
PE
, V8.3+CD8+ cells were gated and 
analysed for the expression of Ki-67. 
d and e. Two groups of Thy1.2 B6 females (n=3) were adoptively transferred with 
CFSE labelled Thy1.1 Matahari CD8 T cells (4x10
6
 cells/mouse, G1) or CFSE 
labelled Thy1.1 Marilyn CD4 T cells (1x10
6
 cells/mouse, G2) (i.v.). 5 days later, all 
mice were culled and pLN cells were analysed for the presence of donor CD8 or 
CD4 T cells (R2).  The MFI of V8.3 between donor CD8 (R3) and host T cells 
(R4), and the MFI of V6 between donor CD4 (R3) and host T cells (R4) was 
compared. In each panel, data are representative of two independent experiments.  
At different time points, pLN cells from the three individual mice in each group were 
stained with PE-conjugated anti-V8.3 or anti-V6, anti-Thy1.1PerCP and APC-
conjugated anti-CD8
 
or anti-CD4 and analysed for the presence CFSE dilution 
amongst transgenic populations (e) data representative of two experiments. 
 
 
4.2.7:  Comparison of CD4 responses against MB49 tumours and male skin 
grafts 
Matahari CD8 T cells are capable of rejecting syngeneic skin grafts but not 
HY
+
 tumours; these mice have defective thymic T cell development and display a 
self reactive phenotype in the periphery.  Previous work had shown HY-specific 
Marilyn CD4 T cells are capable of controlling both skin graft rejection (Braun, 
Grandjean et al. 2001) and tumour growth following adoptive cell transfer (Perez-
Diez, Joncker et al. 2007).  The different responses to skin grafts and tumour tissue 
by Marilyn T cells were assessed using the same strategy as previously used to 
evaluate Matahari responses.  Three groups of WT Thy1.2 B6 females received no 
treatment or were inoculated with MB49 cells or transplanted with syngeneic male 
skin grafts on day -7.  All groups then received CFSE labelled Thy1.1
+
 Marilyn CD4 
T cells on day 0, and analysis was conducted on day 5 (Fig. 4.7). 
 Donor Marilyn CD4 T cells accumulated in the graft dLN and ndLN to a 
significantly greater degree than in tumour dLN and ndLN (Fig. 4.7a and b) in a 
similar manner to Matahari T cells.  Marilyn T cells also showed an accelerated 
progression of cell division in the graft dLN compared with tumour dLN (Fig. 4.7c) 
indicating Marilyn cells proliferated in the local dLN in response to antigen rather 
than just accumulating there.  Activated donor cells were also present in the skin 
graft but were excluded from the tumour mass (Fig. 4.7d).  These data indicate that 
Marilyn T cells are capable of responding to antigen with a more pronounced effect 
to skin grafts compared to tumours, as is seen with Matahari T cells. 
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Figure 4.7. Differential response of Marilyn CD4 T cells to MB49 and skin 
grafts 
a. On day -7, Thy1.2
+
 WT B6 females were split into 3 groups.  G1 did not receive a 
HY challenge, those in G2 were inoculated with 5x10
5
 MB49 cells (s.c) and those in 
G3 were transplanted with male B6 skin grafts. On day 0, 1x10
6
 Thy1.1
+
 CFSE-
labelled Marilyn CD4 T cells were injected (i.v.) into all recipient mice. On day 5 
pLN cells of G1, dLN and ndLN cells of G2 and G3 were stained with anti-Vβ6PE 
and anti-Thy1.1
PerCP
. Panels show the frequency of donor CD4 cells identified by co-
expression of Thy1.1 and Vβ6.  
b. Comparison of the frequency of donor CD4 cells in pLN, dLN and ndLN.  
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c. Donor CD4 cells (Thy1.1
+Vβ6+) present in pLN of G1, dLN of G2 and G3 mice 
were analysed for CFSE and CD44 expression. Data is representative of two 
independent experiments. Comparison CFSE MFI by donor CD4 cells detected in 
pLN of G1 and dLN of G2 and G3 (middle and bottom panels). 
d. Donor cells in MB49 and grafts were identified by co-expression of Thy1.1 and 
Vβ6 (top). The frequency of donor CD4 cells is represented.  Error is expressed as 
mean ± SD (bottom). Data is representative of two independent experiments. * p 
<0.05, ** p< 0.01. 
 
 
 
4.2.8:  CD4 responses are inversely correlated to tumour progression 
 The previous figure shows Marilyn CD4 responses against an established 
tumour (day -7) at an early time point (day 5).  The kinetics of the Marilyn T cell 
response to tumours established at different times was also evaluated, as with 
Matahari mice in Figure 4.3, and assessed at different time points (day 4, 8 and 15) 
(Fig. 4.8).  Marilyn CD4 T cell infiltration into tumour tissue was significantly lower 
the longer the tumour has been established (Fig. 4.8a) demonstrating that the 
progression of tumours are inversely correlated with the level of tumour infiltration 
by donor CD4 T cells, as with Matahari CD8.  CFSE profiles show that donor cell 
proliferation in the dLN of the most established tumours (day -7) were already in a 
state of arrest at the first time point (day 4) which is maintained throughout the other 
two time points (day 8 and 15) (Fig. 4.8b).  As is the case for CD8 T cells there is a 
restricted window in which CD4 cells can enter and proliferate in the tumour mass.  
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Figure 4.8. Kinetics of CD4 responses to MB49 tumours at different stages of 
progression 
a and b. MB49 inoculation was performed at -7, -3 or 1 day and CD4 transfer was 
conducted at day 0, using the same dose as described in Figure 4.7. Analysis was 
carried out at day 4, 8 and 15 as described in Figure 4.7 except anti-CD4
APC
 rather 
than anti-CD44
APC
 was used. One representative experiment of two is shown. 
 
4.2.9:  The impact of male skin grafts on CD4 responses against tumours 
 The anti-tumour responses of Matahari T cells are increased in mice that 
receive both tumour and skin graft, demonstrating immune cross talk (Fig. 4.4).  The 
ability of Marilyn CD4 T cells to cross talk was also assessed using the same 
procedure, with CFSE labelled Marilyn CD4 being infused in place of Matahari CD8 
(Fig. 4.9).  Mice that received MB49 alone or skin allograft alone recapitulated the 
data in previous figures (Fig. 4.7), mediating rejection of the graft and tumour.  
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Donor CD4 T cell infiltration was seen in both graft and tumour with a higher 
frequency of donor T cells in the local dLN compared to ndLN (Fig. 4.9a).  Marilyn 
T cell responses against tumour were significantly enhanced in mice that received 
both graft and tumour as evidenced by an increased frequency of donor CD4 T cells 
in the tumour dLN, ndLN and to a lesser extent in the tumour itself (Fig. 4.9b).  Anti-
graft responses appeared to be inhibited in mice that received both graft and tumour, 
shown by a significantly decreased frequency of donor T cells in the graft dLN, 
ndLN and to a lesser extent the graft itself (Fig. 4.9b).  Marilyn responses to tumour 
are therefore enhanced by the presence of an allograft but the allograft response itself 
is inhibited.  
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Figure 4.9. CD4 T cell response to MB49 tumours in the absence or presence of 
male skin grafts   
a and b. MB49 inoculation, skin grafting, CD4 transfer and analysis were conducted 
as described in Figure 4.7. One representative experiment of two is shown. 
 
 
4.2.10:  HY antigens in the context of allograft but not tumour direct Marilyn 
CD4 T cells to differentiate towards a Th1-like effector state  
 Earlier in this section Marilyn CD4 T cell responses to skin allograft and 
established tumour were evaluated at an early stage (day 5) (Fig. 4.7).  This 
comparison was extended to include functional analysis for later stage responses (day 
16) (Fig. 4.10).  Three groups of Thy1.2 B6 females received no treatment, 
inoculation with MB49 cells or transplant with syngeneic male skin grafts on day-1, 
on the following day all mice received Thy1.1 Marilyn CD4 T cells depleted of 
CD25 cells to minimise the impact of Tregs on subsequent ex vivo assays.  On day 
16, mice were analysed for the accumulation and phenotype of donor T cells by 
CD44 and CD62L expression in various tissues (Fig. 4.10a).  In addition, donor T 
cells from pLN (G1) or dLN (G2 and 3) were assayed for in vitro proliferation 
against cognate antigen (A
b
-Dby) (Fig. 4.10b) and for intracellular cytokine 
production (Fig. 4.10c). 
 Donor cells in the graft dLN showed a greater accumulation compared to 
tumour dLN and control pLN, in fact tumour dLN had a 60% and 85% reduction in 
frequency compared to control pLN (Fig. 4.10a).  This suggests that anti-tumour 
CD4 responses are initiated but not sustained as demonstrated by previous data (Fig. 
4.7 and 4.8).  Donor cells in both tumour and graft dLN became CD44
high
 while those 
in control pLN maintained a primarily naive phenotype in the absence of antigen 
(Fig. 4.10a).  Ex vivo functional responses to antigen were measured by plating out 
pLN (G1) and dLN cells (G2 and G3) with A
b
-Dby cognate antigen to measure total 
proliferation (Fig. 4.10b (left panels)) with responses also presented as CPM per 
donor CD4 cell (Fig. 4.10b (right panels).  dLN cells from skin grafted mice (G3) 
showed 3 fold greater proliferation than pLN (G1) while dLN cells from tumour 
mice (G2) did not show a dose-dependent response to peptide but a high background 
proliferation in the absence of peptide.  Similar results were seen when comparing 
proliferation per donor cell (Fig. 4.10b).  IFN production by pLN or dLN cells was 
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evaluated following a 5 day ex vivo culture with male spleen cells (Fig. 4.10c).  
Donor cell frequency in dLN of G3 increased from 0.7 to 4% of which 92% 
produced IFN.  Donor cells from tumour dLN (G2) failed to expand further and 
produced limited IFN upon re-stimulation (Fig. 4.10c).  This demonstrates that 
donor cells from dLN of male skin graft can differentiate to a Th1-like phenotype 
while donor cells in tumour dLN largely fail to respond to re-stimulation suggesting 
these cells are in a state of anergy. 
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Figure 4.10. Anti-tumour and graft responses by Marilyn CD4 T cells 
a. MB49 inoculation, skin grafting and CD4 transfer were performed as described in 
Figure 4.7. Analysis was conducted at day 16 by staining pLN, dLN, ndLN, MB49 or 
graft tissue cells with anti-CD62L
FITC
, anti-Vb6
PE
, anti-Thy1.1
PerCP
 and anti-
CD44
APC
.  Donor CD4 cells identified by Thy1.1
+
Vb6
+
 were further analysed for 
CM (central memory, CD62L
+
CD44
+
), EM (effector memory, CD62L
-
CD44
+
) or 
naïve (CD62L
+
CD44
-
) phenotypes.  
b. pLN, MB49-dLN and graft-dLN cells (10
5
/well) were cultured without or with 
HY/Dby peptide for 3 days. 1l thymidine (equivalent to 1Ci) was added/well.  8 
hours later the plate was harvested and counted using a microbeta counter (Wallac).  
Assays were conducted in triplicate. 
c. Measurement of IFN and IL-10 production by intracellular staining. pLN, MB49-
dLN, and graft-dLN cells (1x10
6
/well) cultured with irradiated male B6 spleen cells 
(4x10
6
/well) in 24 well plates for 5 days.  Cells were then restimulated with PMA 
(50ng/ml) and ionomycin (250ng/ml) in the presence of Brefeldin A (1μg/ml) before 
staining for surface CD4 and Thy1.1 expression. Cells were fixed and stained for 
intracellular IL10 and IFN. Donor T cells identified by Thy1.1+CD4+ (R2) were 
further analysed for IFNvs. IL10.  One representative experiment of two is shown. 
 
 
4.2.11:  Distinct levels of antigen presentation and immunomodulatory factors 
in graft vs tumour dLN 
 Donor CD4 cells from the MB49 dLN can proliferate in the absence of 
exogenous antigen (Fig. 4.10b).  This effect may be explained due to a higher level 
of antigen presentation in MB49 dLN compared to the dLN of male skin graft.  
CD11c
+ 
DCs from graft and tumour dLN were compared for their ability to stimulate 
resting Marilyn T cells in vitro (Fig. 4.11a).  CD11c
+ 
cells from MB49 dLN but not 
graft dLN were able to induce a suboptimal proliferative response suggesting that 
they display an elevated level of cross presentation for tumour.   
 In the previous chapter MB49 tumours were evaluated for their ability to 
express immunomodulatory factors IL-10, IDO and TGF (Fig. 3.13 and 3.14).  
MB49 tumours express TGF both in vivo and in vitro, IL-10 in vivo (confirmed in 
IL-10KO mice) and also express IDO mRNA in vivo.  These results were compared 
to the ability of 4 individual male skin grafts to express the same modulatory factors 
(Fig, 4.11b-d).  Male skin grafts expressed some TGF although not as much as in 
vivo tumour (Fig. 4.11b) and virtually no expression of IDO (Fig. 4.11c).  Male skin 
grafts did however express relatively high levels of IL-10 mRNA (Fig. 4.11d).  Male 
skin grafts are therefore less immunomodulatory than tumours but conversely have a 
lower level of antigen presentation by CD11c+ DCs. 
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Figure 4.11. Distinct microenvironments in tumour vs skin graft 
a. B6 females were transplanted with syngeneic male skin grafts or inoculated with 
MB49 tumour cells as described in Fig. 4.7. Two weeks later, CD11c
+
 cells, purified 
from pooled dLN by MACS and cultured (from 1.5 ×10
4
/well to 12 x10
4
/well ) with 
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purified Marilyn CD4 T cells (2.5 ×10
5
/well) in 96-well round-bottomed plates for 
3 days. 1l thymidine (equivalent to 1Ci) was added to each well.  8 hours later the 
plate was harvested and counted using a microbeta counter (Wallac).  Assays were 
conducted in triplicate. 
b-d. Ex vivo MB49 cells and male skin graft cells were harvested from a B6 mice 
inoculated as described above. Samples were subjected to RNA extraction and 
cDNA conversion before running RT-PCR Taqman® assay in triplicate for the 
expression of TGF (b), IDO (c), and IL-10 (d).  All data is expressed as relative 
quantification (RQ) to 18sRNA.  An MB49 cell line was also harvested as well as 
male tail skin as a control.  Error is expressed as ± standard deviation. 
b. TGF- gene expression changes between cell line and tumour and graft. 
c. IDO gene expression changes between cell line, tumour and graft. 
d. IL-10 gene expression changes between cell line, tumour and graft. 
 
 
4.2.12:  HY-specific Tregs in MB49-bearing versus male skin graft bearing mice 
 Tumours are known to promote the maintenance and expansion of Tregs in 
vivo (Curiel 2007).  Marilyn Rag
+/- 
mice produce CD4
+
 CD25
+
 FoxP3
+
 regulatory T 
cells as ~5% of the CD4 T cell compartment, these Tregs are HY-specific (Coe, 
Addey et al. 2010).  To evaluate the effect HY-specific Tregs would have in response 
to skin grafts and tumour, an adoptive transfer experiment was performed.  As 
described previously, Thy1.2 WT B6 female mice were inoculated with MB49 cells 
or given syngeneic male skin graft or a matched female skin graft.  The following 
day all mice received Thy1.1 Marilyn Tregs, on day 12 dLN, ndLN and the 
graft/tumour were harvested and assessed for the level of Treg expansion in these 
tissues (Fig. 4.12). 
 The proportion of Tregs recovered from male skin graft dLN was 4 fold 
higher than Tregs recovered from female grafts, demonstrating that Treg expansion 
in vivo is antigen dependent.  No significant difference was seen in Treg frequencies 
between male skin graft dLN and tumour, indicating that both types of tissue are able 
to expand HY-specific Tregs.  Interestingly MB49 dLN contained proportionally 
fewer host CD4 T cells (15±0.3%) than the MB49 ndLN (29±2%) whereas graft dLN 
and ndLN had similar proportions (30±2% and 31±2% respectively); this may 
indicate that growing MB49 tumours can inhibit local CD4 help.  In support of these 
data, male skin grafts themselves accumulated over 3 fold more host CD4 T cells 
(37±4%) compared to tumours (10±2%).  Conversely however the proportion of 
donor antigen-specific Tregs in the tumour was 4 fold higher (12%) in the tumour 
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compared to the male skin graft (3%).  These distinct cell distributions are likely to 
contribute to the poor immunity to MB49 compared to skin graft.  Finally Tregs that 
infiltrate into male skin grafts maintain FoxP3 expression while a significant fraction 
of tumour infiltrating Tregs became FoxP3 negative.  This property is investigated in 
detail in Chapter 5 (Bluestone, Mackay et al. 2009; Addey, White et al. 2011). 
 
Figure 4.12. Distinct fates of adoptively transferred Marilyn Treg cells in MB49-
bearing and male skin graft bearing mice  
Three groups of Thy1.2 B6 females (n=3/group) were used.  On day 0, mice in G2 
were inoculated (s.c.) with 5x10
5
 MB49 cells (b), those in G1 and G3 were 
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transplanted with male and female skin grafts respectively (a and c). On the next day 
all mice were transferred with 10
5
 FACS sorted Thy1.1 Marilyn Tregs. Analysis was 
performed at day 12 by surface staining of dLN, ndLN, MB49 or graft tissue cells 
with anti-V6PE, anti-Thy1.1PerCP before intracellular staining with anti-FoxP3FITC. 
Data is representative of four independent experiments.  Error is represented as +/-
standard deviation. 
 
 
 
4.3:  Discussion 
 Classically, anti-tumour responses in vivo are believed to be mediated directly 
by CD8 CTL due to the potency of in vivo killing and also by response to minor H 
antigens in the context of allograft and to tumour cells in vitro (Lee, Wang et al. 
1999).  In the MB49 model system Matahari transgenic CD8 T cells are capable of 
rejecting syngeneic male skin grafts (Fig. 4.1a) and recognising and responding to 
cognate antigen in vitro (Fig. 4.1d) but are incapable of mediating effective anti-
MB49 responses in vivo (Fig. 4.2b).   CD4 anti-tumour responses can mediate 
tumour and graft rejection independently of CD8 T cells (Corthay, Skovseth et al. 
2005) and Marilyn CD4 transgenic T cells have been shown to be capable of 
rejecting both male syngeneic skin grafts (Valujskikh, Lantz et al. 2002) and MB49 
tumours in the absence of CD8 T cells (Perez-Diez, Joncker et al. 2007). 
 Matahari CD8 T cells can respond to MB49 tumours upon adoptive cell 
transfer in vivo demonstrated by the expansion in local dLN and tumour (Fig. 4.2), 
however the functional state is poor within the tumour with most infiltrating cells 
remaining CD44
low
 (Fig. 4.2e).  Matahari CD8 T cells in the male skin graft and graft 
dLN however expand to a significantly greater degree (Fig. 4.2) and graft infiltrating 
T cells remain in a functional state with a CD44
high
 phenotype (Fig. 4.2e).  At this 
stage it was noted that Matahari CD8 T cells in the tumour dLN significantly down 
regulate TCR, and to a lesser extent in the graft dLN (Fig. 4.2d).  Marilyn CD4 T 
cells respond to graft and tumour in a phenotypically similar manner (Fig. 4.7).  
Marilyn cells expand in response to both tumour and graft with significantly higher 
proliferation seen in the graft dLN compared to tumour dLN (Fig. 4.7b and c) and in 
the graft compared to tumour (Fig. 4.7d).  Marilyn cells did not however demonstrate 
any significant downregulation of TCR.  
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 Despite a similar T cell phenotype upon adoptive cell transfer, only Marilyn 
CD4 cells are sufficient to mediate tumour rejection.  To attempt to elucidate this 
disparity, the kinetics of the tumour response was measured for Matahari (Fig. 4.3) 
and Marilyn (Fig. 4.8) adoptively transferred CFSE labelled T cells.  Matahari and 
Marilyn T cell responses are inversely correlated to tumour progression.  Matahari T 
cells show the highest infiltration into tumour mass by day 14 for all tumours with 
the highest infiltration for the most recently established tumours (day 1 post T cell 
transfer) (Fig. 4.3a), with Marilyn CD4 T cells peaking at day 8 again with highest 
infiltration for 1 day old tumours (Fig. 4.8a).   Adoptively transferred Marilyn cells 
proliferated in the tumour dLN with over 96% CFSE dilution by day 8 in all groups 
(Fig. 4.7b).  Matahari CD8 T cells did not proliferate to the same degree with on 
average 40% CFSE dilution in the local dLN by day 14 (Fig. 4.3b).  This is not a 
failure of Matahari CD8 T cells to proliferate in vivo in response to cognate antigen, 
as shown through parallel vaccination experiment (Fig. 4.3c).  Matahari and Marilyn 
T cells are both therefore capable of expanding and infiltrating the tumour mass in 
response to antigen, however Marilyn cells are capable of responding more robustly 
in the local dLN and are able to enter the tumour mass at an earlier time point.  It is 
also of interest to note that unlike Matahari cells, Marilyn cells undergo less 
proliferation in homeostatic conditions (G1) where antigen is not present, which is 
consistent with the notion that Matahari TCR is self-reactive whereas Marilyn TCR 
is not. 
 It is generally unclear whether MB49 induces systemic or local immune 
suppression of T cell responses.  To test this, an approach was used to measure the 
effect of cross talk between graft and tumour, by inoculation of tumour cells, skin 
grafting or both to mice that received adoptively transferred Matahari (Fig. 4.4) or 
Marilyn (Fig. 4.9) T cells at the same time.  Data with skin graft or tumour alone 
recapitulates results described above for both Matahari and Marilyn (Fig. 4.4a and 
4.9a).  Mice that received Matahari T cells along with both a skin graft and tumour 
cells were able to mount a significantly enhanced response to both graft and tumour.  
In contrast, graft and tumour-bearing recipients of Marilyn CD4 T cells showed an 
increased response to tumour but a reduced response to graft.  This is shown by an 
increased representation of both donor CD8 (Fig. 4.4b) and donor CD4 (Fig. 4.9b) 
cells in tumour dLN and ndLN.   
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Matahari responses to tumour were noticeably greater than Marilyn in the 
presence of the skin graft, thus, immunisation by male skin graft principally benefits 
the donor CD8 T cell mediated anti-MB49 response.  On the other hand, when the 
reciprocal impact of MB49 tumours on the anti-graft T cell response was compared, 
it was found that Matahari CD8 cells and Marilyn CD4 T cells have distinctive 
susceptibility to MB49-derived suppression.  Anti-graft CD8 responses were 
significantly enhanced by a contemporaneous MB49 tumour (Fig. 4.4) whereas anti-
graft CD4 responses were reduced by at least 50% (Fig. 4.9).  This effect is 
potentially due to the distinct mechanisms used by CD8 and CD4 cells in tumour 
rejection (Antony, Piccirillo et al. 2005).   
CD8 T cells tend to kill tumours directly through cytotoxic mechanisms and 
therefore enhanced activation in response to antigen on the graft may be sufficient to 
induce tumour killing.  CD4 on the other hand tend to kill tumours indirectly, usually 
by priming other cytotoxic mediators such as NK cells by IFN (Cohen, Peng et al. 
2000; Perez-Diez, Joncker et al. 2007).  It is likely tumour derived suppression could 
have a more potent effect on direct CD8 responses rather than modulating CD4 help.  
To further assess this hypothesis, a CFSE labelled Matahari and Marilyn T cells were 
co-transferred to mice bearing established tumours (day 7) (Fig. 4.5).  The presence 
of Marilyn T cells significantly increases the Matahari response both in terms of 
accumulation in the dLN and tumour as well as increased proliferation in both (Fig. 
4.5). 
Matahari mice have a self reactive phenotype that may account for their 
impaired anti-MB49 abilities (Fig. 4.1 and 4.3).  This is potentially due to several 
intrinsic factors pertaining to the development of the T cells.  Firstly this is possibly 
due to self reactivity related to endogenous TCR rearrangement in Rag+/- mice that 
could potentiate self reactive T cells into the periphery.  These T cells in the 
periphery are in a constant state of division, this is also associated with splenomegaly 
in these mice (Fig. 4.6c).  Rag
-/- 
Matahari mice, that do not undergo 
TCRrearrangement, however also display a self reactive phenotype with T cells 
progressively becoming CD44
high
 with age (Fig. 4.6a).  These mice also display 
visibly smaller thymus compared to female B6 and Marilyn Rag
-/-
 with dramatically 
reduced CD8
+
 thymocytes in the thymus (Fig. 4.6b).  This phenotype may be due to 
increased clonal deletion to eliminate those cells with reactivity to self antigens 
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expressed in the thymus, but leaving others to populate the periphery where, as an 
oligoclonal population, they expand homeostatically.  Overall this suggests Matahari 
mice have an altered TCR transgenic T cell development in both Rag
-/-
 and Rag
+/-
 
mice.  
In an adoptive therapy setting Matahari T cells reduce TCR (V8.3) 
expression in response to antigen (Fig. 4.2d).  TCR is further reduced in the tumour 
due to the inhibitory environment associated with MB49.  This environment caused 
both donor and host CD8 V8.3 to be downregulated (Fig. 4.3c).  This effect is not 
seen with adoptively transferred Marilyn T cells (Fig. 4.7 and 4.8).  Matahari Rag
+/-
 
low TCR expression is also seen in naive B6 female mice that receive T cells (Fig. 
4.6d) and therefore is not solely a response to TCR/HY engagement.  In this antigen 
free environment Matahari cells also show spontaneous proliferation (Fig. 4.6e) 
while Marilyn T cells do not.  While it remains to be determined if this 
downregulation of TCR is also associated with reduced TCR signalling, there are 
significantly more CD44 expressing cells detected in grafts than in MB49 tumours 
(Fig. 4.2e). 
Marilyn T cells have been found to be more effective than Matahari T cells at 
tumour rejection in five different HY-expressing tumour models (Perez-Diez, 
Joncker et al. 2007).  Marilyn T cells are directed to a Th1-like phenotype in 
adoptive transfer to mice bearing male skin grafts but not in the tumour (Fig. 4.10).  
This effect is correlated with greater expansion and infiltration into the graft (Fig. 
4.7, 4.9 and 4.10a), along with high levels of IFN production (Fig. 4.10c).  When 
cultured ex vivo Marilyn cells from control pLN or graft dLN but not from tumour 
dLN respond to cognate antigen in a dose-dependent manner (Fig. 4.10b).  However 
donor cells in the dLN of tumour showed a uniform proliferation at all doses of 
antigen and even in the absence of exogenous antigen.  This effect was further 
highlighted when CD11c
+
 DCs sorted from graft, tumour dLN and control pLN were 
plated out with Marilyn CD4 T cells in the absence of exogenous antigen (Fig. 
4.11a).  Proliferation was seen in response to CD11c cells from tumour dLN was far 
higher than the background while very little was seen in response to graft CD11c 
cells.  DCs from tumour dLN may therefore have elevated levels of cross 
presentation of HY/Dby antigen to T cells that may mediate increased anti-MB49 
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responses.  Although CD11c cells from graft dLN expressed lower levels of antigen 
complexes they are able to induce strong Th1 responses (Fig. 4.10). 
Despite naturally occurring self reactivity, Matahari T cells can still mediate 
skin graft rejection but not rejection of MB49.  This may be due to the 
immunosuppressive microenvironment in tumours but not accepted grafts that are 
known to upregulate immuno-regulatory factors such as IDO and TGF-.  Indeed 
knockout of IDO or TGF- results in an enhanced tumour clearance in a number of 
murine models (Munn and Mellor 2007; Coe, Addey et al. 2010).  As seen here and 
in the previous chapter, the MB49 tumour cell line constitutively express TGF- 
genes and upregulate IDO and IL-10 expression following in vivo tumour formation 
(Fig. 3.14 and 4.11b-d) demonstrating that a highly modulatory environment by 
MB49 tumour.  Expression of IDO and TGF- was significantly lower in male skin 
grafts (Fig. 4.11b and c), although IL-10 expression was higher in ¾ grafts compared 
to that of the tumour (Fig. 4.11d).  One major prospect for this effect is an increased 
induction and maintenance of Tregs in tumours mediated by IDO and TGF- 
previously shown to facilitate tumour growth (Coe, Addey et al. 2010; Coe, Begom 
et al. 2010).   
Tregs have been shown to be powerful mediators in the induction of tolerance 
(Karim, Feng et al. 2005).  Previous work in our group have shown that intranasal 
inhalation of HY-Dby peptide and injection (s.c) of DCs pulsed with HY-Uty 
(James, Scott et al. 2002) can cause transplantation tolerance through induction of 
Tregs.  Marilyn HY-specific Tregs were therefore evaluated in tumour and, male and 
female, graft environments (Fig. 4.12).  The frequency of Tregs in the MB49 tumour 
mass and dLN is significantly increased while the proportion of host CD4 T cells 
was reduced by up to 50% (Fig. 4.12b).  While Treg infiltration into male grafts and 
dLN was significantly higher than female graft, this did not lead to a reduction of 
host CD4 frequency (Fig. 4.12c).  Growing tumours are generally associated with 
increased Treg proportions compared to rejecting tumours (Curiel 2007).  Therefore 
HY-specific Tregs are preferentially promoted in the MB49 tumour 
microenvironment, supported by previous published results from our lab (Chai, Coe 
et al. 2008).  At this point it is of note that HY-specific Tregs lose FoxP3 upon 
antigen exposure (55% loss in tumour, 24% loss in male graft) and can even lose 
FoxP3 expression under non-antigenic inflammatory conditions (14% loss in female 
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graft dLN), this is supported by several other labs (Bluestone, Mackay et al. 2009).  
This effect and further HY-specific Treg responses are investigated in detail in 
chapter 5 (Addey, White et al. 2011). 
A final consideration must be given to the distinct process of antigen 
presentation between graft and tumour.  Skin contains three major populations of 
DC: Langerhans cells in the epidermis; and Langerin
+
 and Langerin- CD11c
+
 
conventional DC populations in the dermis (Shortman and Liu 2002), which can 
mature and migrate to the dLN in response to inflammation caused by surgery. 
Consequently, these graft-derived professional APCs can participate in direct antigen 
presentation resulting in rapid T cell activation.  In contrast, as MB49 cells are non-
migrating, non-professional APCs, antigen presentation will be indirect and delayed 
until host DCs have infiltrated the developing tumour.  In addition, the local 
inflammation associated with skin transplantation but not inoculation (s.c.) of 
cultured MB49 cells.  Indeed vaccination using CFA and peptide is sufficient to 
mediate potent responses by Matahari T cells potentially due to increased 
inflammatory factors that may increase DC maturation, migration and antigen 
presentation (Fig. 4.3c). 
This study provides an insight into antigen-specific CD4, CD8 and Treg 
responses to antigen presented in two dramatically different in vivo environments.  
Marilyn CD4 T cells are seen to be more efficient in mounting anti-MB49 responses 
compared to Matahari CD8 T cells.  This effect is due to several factors including 
different mechanisms of tumour rejection, antigen presentation by APCs and the 
nature of Matahari TCR being self reactive.  MB49 generates a local immuno-
regulatory environment that prevents full T cell activation, accumulation and 
proliferation particularly for CD8 T cells.  This effect can be abrogated when graft 
and tumour are given simultaneously creating cross talk sufficient to induce more 
robust anti-tumour responses for CD4 and CD8 T cells.  Finally HY-specific Tregs 
are preferentially induced and maintained in tumour environments further 
modulating T cell responses.  The role that antigen-specific T cells and Tregs play in 
both allografts and tumour environments in critical to the prognosis of transplant and 
tumour.  By characterising and manipulating these responses it is possible to 
understand the factors that lead to graft tolerance and conversely tumour rejection.   
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Chapter 5: Tumour antigen-specific regulatory T cells lose 
FoxP3 expression following antigen recognition in vivo 
 
5.1:  Introduction 
 
5.1.1:  Regulatory T cells and tumours 
Regulatory T cells (Tregs) are a subset of CD4 T cells with high avidity T 
cell receptors against a self antigen and they are characterised by their ablity to 
suppress immune responses against that antigen (see section 1.3.3) (Kim, Rasmussen 
et al. 2007).  Tregs suppress self reactive peripheral T cells that escape thymic 
deletion, this was shown by studies using neonatal thymectomy, or by depletion 
experiments using anti-CD25 antibodies (Sakaguchi, Sakaguchi et al. 1995; Kohm, 
McMahon et al. 2006).  Tregs are crucial components of the immune regulatory 
network and can potently inhibit immune responses to a wide range of cancers 
(Curiel 2007).  Most tumour antigens are self antigens which are either over 
expressed for their cell type or altered in sequence or structure (see chapter 3) 
(Dranoff 2009).  Tregs are primarily specific for self antigens and functionally 
suppress immune responses to these antigens, thus interaction between Tregs and 
tumours constitute a major evasive mechanism in cancer (see section 1.6.3) (Kim, 
Emi et al. 2006).  
Despite recognition of the effect of suppressive CD4
+ 
cells on tumour 
immunity in the 1980s (Bursuker and North 1984) it was largely forgotten until the 
turn of this century.  In vivo depletion of CD25
+
CD4
+
 cells led to increased 
endogenous tumour immunity (Shimizu, Yamazaki et al. 1999), which was also 
tumour antigen-specific (Tanaka, Tanaka et al. 2002).  With interest in Tregs and 
cancer re-established, it was further noted that Tregs can inhibit both tumour-specific 
CD4 (Nishikawa, Jager et al. 2005) and CD8 effector responses (Chen, Pittet et al. 
2005).  Understanding of the mechanisms of Treg action on anti-tumour effector T 
cells is incomplete, although it is known to occur through cell-cell contact and the 
production of soluble cytokines such as IL-10 and TGF-(Levings, Sangregorio et 
al. 2002) (Wang 2006).   
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Tregs are composed of two distinct subsets called natural (nTreg) and 
adaptive/induced Tregs (iTregs) (Thornton, Korty et al. 2010).  nTregs arise in the 
thymus in a setting in which T cells with high affinity against thymically expressed 
self antigens are removed, in order to protect against autoimmunity (see section 
1.3.3).  Peripheral Tregs in lymph nodes and spleen contain both nTregs and iTregs 
(Thornton, Korty et al. 2010).  iTregs arise in Proinflammatory situations in the 
periphery, such as in cancer, and suppress immunity by heterogeneous mechanisms 
(Bluestone and Abbas 2003) (see section 1.3.3).  nTegs can be sorted directly from 
the CD8 depleted thymus while iTregs can be selected from conventional CD4 T 
cells by their capacity to express FoxP3.  nTregs are believed to be the main 
regulatory cell type that infiltrates the tumour microenvironment, although the 
relative contribution of nTreg and iTreg is yet to be fully understood (Zhou and 
Levitsky 2007). 
Tumours that secrete TGF- have been shown to expand tumour-specific 
nTregs in an antigen dependent way (Ghiringhelli, Puig et al. 2005).  MB49 and 
B16/HY tumours can induce expansion and migration of HY-specific nTregs, but 
HY-specific nTregs are inhibited in dN
+
TGF- mice (Ghiringhelli, Puig et al. 2005; 
Coe, Addey et al. 2010).  Furthermore, in vivo depletion of nTreg improves tumour 
immune surveillance and enhances the efficacy of cancer vaccines (Shimizu, 
Yamazaki et al. 1999; Turk, Guevara-Patino et al. 2004), shown by using DTA-1 
(GITR) mAb depletion and adoptive transfer in models of B16 melanoma.  
Understanding and characterising the fate of tumour-specific Tregs in vivo is 
increasingly important when using tumour-specific immune-therapies.   
 
5.1.2:  FoxP3 transcription factor 
The Forkhead box P3 (FoxP3) transcription factor is crucial in controlling 
development and maintaining the suppressive phenotype and function of Tregs 
(Fontenot, Gavin et al. ; Hori, Nomura et al. 2003; Khattri, Cox et al.).  FoxP3 
expression is regulated by a positive autocrine feedback loop (Gavin, Rasmussen et 
al. 2007; Williams and Rudensky 2007)  and by epigenetic modification of the 
FoxP3 locus (Floess, Freyer et al. 2007); nTregs display several features of a stable 
CD4 subset, for example nTregs retain high FoxP3 expression after adoptive transfer 
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to lymphoreplete hosts (Floess, Freyer et al. 2007; Gavin, Rasmussen et al. 2007; 
Williams and Rudensky 2007). 
With a recent explosion in research involving Treg adoptive therapy in 
animal models (Fontenot, Gavin et al. 2003; Hori, Nomura et al. 2003; Fontenot, 
Rasmussen et al. 2005); T cells that express FoxP3 have become critical in the 
transference of self-tolerance.  Induction or transfer of FoxP3
+
 Tregs has led to 
significant improvements in disease severity in diabetes, asthma, inflammatory 
bowel disease, multiple sclerosis and renal disease models (Suri-Payer and 
Fritzsching 2006).  Recent investigations however also noticed that the Treg lineage 
is more plastic than first thought, possibly inducing Th1 or Th17-like T effector cells 
under proinflammatory conditions (Zhou, Bailey-Bucktrout et al. 2009).  This effect, 
unwelcome in autoimmune models, may be beneficial in the context of tumours.  
 Auto aggressive T cells arising from Tregs could be a serious consequence in 
adoptive immunotherapy, as use of Treg therapy is becoming a progressively 
favoured approach in autoimmune diseases such as diabetes.  Recent results have 
shown that attenuation of the FoxP3 locus expression can lead to multi-organ 
autoimmunity but has no effect on thymic development, homeostatic expansion, or 
TGF-production in vivo (Wan and Flavell 2007).  Zhou et al. have also shown 
polyclonal Tregs that lose FoxP3 expression under proinflammatory conditions in 
autoimmune pancreatic tissue can cause autoimmune pathology and rapid onset of 
diabetes upon adoptive cell transfer (Zhou, Bailey-Bucktrout et al. 2009).  
Conversely inducing auto aggressive T cells from tumour-specific Tregs has the 
potential for future cancer immunotherapy strategies. 
 
5.1.3:  Functional plasticity of Tregs 
Initially FoxP3 loss was noted in polyclonal Tregs from FoxP3
GFP
 B6 mice 
following transfer into lymphopenic hosts.  For example, green tagged Tregs, 
CD4
+
CD25
+
GFP
+
 cells isolated from FoxP3
GFP
 reporter mice (Fontenot, Rasmussen 
et al. 2005), eventually decrease GFP expression upon adoptive transfer into Rag2
-/- 
B6 mice, indicating that Tregs can lose FoxP3 following homeostatic stimulation in 
vivo.  Our lab also noticed that loss of FoxP3 could also occur in vitro (Chai, Coe et 
al. 2008).  FACS sorted "green" Tregs (with >99% purity) from FoxP3
GFP
 mice were 
expanded in vitro by CD3/CD28 beads plus IL-2, 7 days after the first round of 
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stimulation, expanded green Tregs were largely GFP-positive, suggesting that FoxP3 
expression in expanded Tregs is well maintained.  In contrast by day 14, 7 days after 
the second round of culture, the majority of expanded Tregs became GFP negative, 
indicating that repeated stimulation leads to the loss of FoxP3 in Tregs (Chai, Coe et 
al. 2008).  Others have also shown that in vitro TCR stimulation in the presence of 
IL-6 led to down-regulation of FoxP3 in polyclonal green Tregs (Xu, Kitani et al. 
2007; Yang, Nurieva et al. 2008).  
The functional plasticity of peripheral Tregs has also been observed in vivo. 
Our lab has recently demonstrated that a significant fraction of tumour antigen-
specific green Tregs lost FoxP3 expression after adoptive transfer to tumour-bearing 
WT B6 mice (see chapter 4, Fig. 4.12) (Coe, Addey et al. 2010).  Other studies have 
also shown that a large proportion of polyclonal green Tregs became GFP-negative 
and differentiated to Th1-like effector cells or follicular helper T cells in Rag
-/-
 
(Duarte, Zelenay et al. 2009; Komatsu, Mariotti-Ferrandiz et al. 2009) and CD3
-/-
 
recipients (Tsuji, Komatsu et al. 2009), respectively.  In addition, mice with 
attenuated expression of endogenous FoxP3 develop lympho-proliferative syndromes 
which are correlated with impaired suppressive function of Tregs and their 
conversion to effector cells (Wan and Flavell 2007).  Bluestone and colleagues have 
used a well designed dual reporter mouse model to distinguish T cells that 
constitutively express or have ceased expressing FoxP3 at any time point in vivo 
(Zhou, Bailey-Bucktrout et al. 2009).  They have found that a substantial fraction of 
peripheral Tregs can lose FoxP3 even under steady state conditions in un-
manipulated healthy mice, and these “ex-Tregs” also had an activated memory 
phenotype.  It is important to note that ex-Tregs are present at a significantly higher 
frequency in an autoimmune diabetic settings and these auto aggressive 
proinflammatory effector cells capable of transferring diabetes (Zhou, Bailey-
Bucktrout et al. 2009).  
The reprogramming of Tregs was also noted in an in vivo tumour model by 
Mellor et al.  Previous studies by this group have demonstrated Tregs can be 
activated and maintained in tumour tissues through the expression of IDO by pDCs; 
many immunosuppressive tumours express IDO (see chapters 3 and 4).  When IDO 
is blocked, Tregs in tumour-bearing hosts can differentiate towards a Th17-like 
linage (Sharma, Hou et al. 2009), however it is unclear whether these converted 
Tregs are functional.  Mellor showed polyclonal Tregs reprogrammed in a standard 
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CPG-OVA vaccine model are functional in priming of tumour antigen-specific OT-1 
(CD8 OVA transgenic) T cells.  Treg reprogramming is driven by proinflammatory 
signals, and can provide helper function almost immediately without prior priming.  
This effect is believed to be IL-6 driven; IL-6 is expressed by pDCs in a negative 
feedback loop with IDO.  Proinflammatory signals through pathogen recognition 
receptors are sufficient to inhibit IDO and induce IL-6 in this model (Sharma, Hou et 
al. 2010).  Results here suggest Tregs could be acting as first responders providing 
help or rapid suppression, depending on the context of the immune response. 
Conversely Rubtsov et al. suggest Tregs are a stable in vivo linage.  This 
group use the same dual reporter system as Bluestone, whereby FoxP3
+
 Tregs 
express GFP and YFP and ex-Tregs express YFP alone, providing an elegant system 
to track differentiation of Tregs.  Results showed Tregs maintained FoxP3 expression 
over a period of 5 months under conditions including lymphopenia (6Gy treatment) 
and IL-2 blocking using an anti-IL-2 mAb (Rubtsov, Niec et al. 2010).  It is 
important to note however that these results are generated in a non-antigenic 
homeostatic system not in a proinflammatory environment, where Treg conversion is 
seen in other studies. 
Despite the development of ex-Tregs being studied in homeostatic (Duarte, 
Zelenay et al. 2009; Komatsu, Mariotti-Ferrandiz et al. 2009; Tsuji, Komatsu et al. 
2009) and autoimmune models (Wan and Flavell 2007; Zhou, Bailey-Bucktrout et al. 
2009), very little information is available in terms of their differentiation in the 
context of tumours (Sharma, Hou et al. 2009; Sharma, Hou et al. 2010).  Adoptive 
transfer experiments have so far utilised polyclonal Tregs that have limited value in 
studying the role of antigen-driven responses, therefore not much is known in terms 
of the cellular and molecular mechanisms of ex-Treg generation and regulation 
(Zhou, Bailey-Bucktrout et al. 2009).  A current controversial question asks whether 
the development of ex-Tregs is restricted to the CD25 negative subset of Tregs 
(Komatsu, Mariotti-Ferrandiz et al. 2009; Zhou, Bailey-Bucktrout et al. 2009) and 
whether thymic nTregs, like iTregs, could also be converted to ex-Tregs; neither 
been directly assessed.  
Due to the preferential development of ex-Tregs in the lymphopenic 
environment (Duarte, Zelenay et al. 2009; Komatsu, Mariotti-Ferrandiz et al. 2009; 
Tsuji, Komatsu et al. 2009) a recently described in vivo model has been modified 
(Coe, Addey et al. 2010) to generate and characterise antigen-specific ex-Tregs, by 
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adoptively transferring HY-specific green Tregs (thymic or peripheral) to MB49 
tumour-bearing Rag
-/-
 B6 female recipients.  To explore the cellular and molecular 
events that affect ex-Treg development, a second in vivo model has been developed 
in which green HY-specific peripheral Tregs were adoptively transferred to Rag
-/- 
B6 
male mice in which the HY antigen is expressed endogenously and systemically. 
 
 
 
 
5.2:  Results 
 
5.2.1:  Impact of HY-specific Treg cells on co-transferred HY-specific 
conventional CD4 T cells in response to MB49 tumours in vivo 
To assess the role of HY-specific nTregs in regulation of anti-MB49 
responses by conventional CD4 T cells with matched antigen-specificity in vivo, 
CD4
+
 Vβ6+ Thy1.1+ T cells from HY-specific TCR Marilyn Rag2+/-  female mice 
were either depleted of CD25
+
 cells (Fig. 5.1a and b) or not (Fig. 5.1c and d).  These 
cells were CFSE labelled and adoptively transferred to WT B6 females inoculated 
with MB49 on the following day, and 5 days later mice were analysed for donor cell 
expansion.  MB49-bearing mice that received CD25 depleted Marilyn T cells 
showed a significant expansion (8 fold) in the dLN (Fig. 5.1a) compared to MB49 
free recipients (Fig. 5.1b) (0.545 vs 0.065%, p-value <0.01) with a high 
accumulation of donor cells in the tumour (3.55%), this expansion was also 
correlated with an increased CD44 expression compared to the MB49 free control 
(86.7 vs 5.98%, p-value < 0.01).  Mice that received donor cells without CD25 
depletion showed a comparatively poor response to MB49 (Fig. 5.1c) in the dLN 
(0.01 vs 0.055%, p-value >0.05) and tumour itself (0.06%).   
This effect is likely due to a failure of conventional CD4
 
T cells to respond to 
antigen in the presence of Tregs, either by not activating or through activation 
induced cell death.  Marilyn nTregs therefore have a significant impact on the 
success of the conventional CD4 response even when transferred as a minority 
population (5-10%). 
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Figure 5.1. Anti-MB49 responses by CD25-depleted and CD25-intact Marilyn 
CD4 T cells  
Four groups of Thy-1.2
+
 B6 females (n=3 or 4/group) were adoptively transferred 
with (1.5 x 10
6
) CFSE labelled CD25-depleted (a, b) or CD25-intact Thy-1.1
+
 
Marilyn CD4 T cells (c, d) (i.v.).  On the next day two groups of mice were 
inoculated with MB49 cells (5 x 10
5
) (s.c.) (a, c). Five days after MB49 inoculation, 
all groups were analysed by staining of dLN and MB49 (a, c) or pLN (b, d) with 
anti-V6PE, anti-Thy-1.1PerCP and anti-CD4APC. The donor cells LN and MB49 tissue 
were identified by co-expression of Thy-1.1 and CD4.  In addition, LN samples were 
also stained with anti-V6PE, anti-Thy-1.1PerCP and anti-CD44APC. The donor cells 
were identified by co-expression of Thy-1.1 and V6 and their CFSE profiles were 
presented as CFSE versus CD44.  A total of 2 million events (no gate) were acquired 
for each sample. For MB49 samples, tumour size is also indicated. One 
representative experiment of three is shown. 
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5.2.2:  Marilyn and B6 nTreg responses to MB49 
 To evaluate how HY-specific Marilyn nTregs inhibit the anti-tumour 
response by conventional CD4 T cells, an adoptive transfer experiment was set up to 
compare Marilyn Thy1.1
+
 nTregs with polyclonal Thy1.2
+
 nTregs from a B6 mouse.  
These Treg cells were transferred to MB49-bearing (inoculated on the next day) or 
MB49 free B6 female hosts (Thy1.2
+
).   
 In the presence of MB49 tumours, Marilyn nTregs underwent an 8 fold 
expansion in the dLN (Fig. 5.2b) compared to MB49 free recipients (Fig. 5.2a) 
(0.0207 vs 0.0026, p-vlaue <0.05), this was profoundly reflected in the increase of 
absolute cell number (Fig. 5.2c).  In recipients that received polyclonal nTregs, no 
expansion of the nTreg was seen in response to tumour (Fig. 5.2e) in the dLN or the 
tumour itself.  This effect was true in terms of frequency (Fig. 5.2d and e) and 
absolute cell number (Fig. 5.2f).  Therefore MB49 tumours cannot expand nTreg 
non-specifically, a crucial observation for the use of this model. 
 Importantly at this stage it was noticed that expanded donor Marilyn nTregs 
showed a significant loss of FoxP3 expression in the dLN of MB49-bearing (Fig. 
5.2.b) compared with MB49 free mice (Fig. 5.2a) (84.83 vs 96.55%, p-value <0.01).  
This effect was not seen to the same degree in MB49-bearing (Fig. 5.2d) and MB49 
free (Fig. 5.2e) mice that received polyclonal nTreg (91.74 vs 90.88%, p-value 
>0.05).  Strikingly, in the tumour itself only 33.93% of transferred Marilyn nTregs 
maintained FoxP3 expression (Fig. 5.2b) whereas 89.12% polyclonal nTregs 
maintained FoxP3 expression in the tumour (Fig. 5.2e).  MB49 clearly induced 
antigen-specific nTreg expansion and induction of FoxP3 loss.  However the lack of 
a HY-negative MB49 variant does not allow for the role of HY to be assessed in 
terms of nTreg expansion.  From here on Tregs that have lost FoxP3 will be referred 
to as “ex-Tregs”. 
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Figure 5.2. MB49 tumour expands Marilyn but not B6 nTreg cells in vivo  
nTregs are derived from CD8 depleted thymocytes of a Marilyn-FoxP3
GFP
 Rag2
-/-
 or 
B6-FoxP3
GFP
 donor and FACS sorted for CD4
+
 GFP
+
 CD25
+
 CD8
-
 cells.  Four 
groups of Thy-1.2 B6 females (n=3/group) were transferred with 10
5
 Thy-1.1
+
 
Marilyn nTreg (a, b) or Thy-1.1
+
 B6 nTreg cells (d, e), of which two groups of mice 
were given MB49 cells the on next day (b, e) the other two groups were MB49 free 
(a, d).  11 days after MB49 inoculation, analysis was performed by staining cells 
(dLN, ndLN and MB49) with anti-V6PE or anti-TCR-PE, anti-Thy-1.1PerCP and 
anti-CD4
APC
, before intracellular staining with anti-FoxP3
FITC
. The donor cells were 
identified by co-expression of Thy-1.1 and CD4 (R2), and their FoxP3 expression 
was presented as CD4 versus FoxP3.  The absolute numbers of donor cells in various 
tissues, peripheral lymph nodes (pLN), dLN and ndLN, were calculated by total cell 
number, % of gated lymphocytes (R1) then by % of donor cells (R2) (c, f). One 
representative experiment of four is shown. A total of 2 million events were acquired 
for each sample. For the MB49 samples, tumour size is also indicated.  All error is 
represented as ± standard error mean. 
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5.2.3:  Marilyn HY-specific FoxP3-GFP
+
 nTreg responses to B16 and B16/HY 
tumours 
 To evaluate the effect of the HY antigen for the expansion and loss of FoxP3 
in Marilyn nTregs, a second B16 tumour model was used.  Although B16 is a 
relatively non-immunogenic tumour, it is known to expand polyclonal nTregs in a 
TGF- dependent manner (Ghiringhelli, Puig et al. 2005).  B16 cells do not express 
HY antigens but this tumour cell line has been previously transduced with the HY 
gene Dby encoding CD4 T cell epitope (B16/HY).  This system provides a model in 
which antigen-driven expansion of Tregs, by tumour, can be evaluated in vivo.  To 
expose the property of antigen induced FoxP3 loss, green Marilyn Tregs 
(CD4
+Vβ6+CD25+GFP+ cells) were FACS sorted from (FoxP3GFP B6 × Marilyn) F1 
females; these antigen-specific green nTreg cells (Thy1.1
+
) were adoptively 
transferred into three groups of Thy1.2
+
 B6 females, of which two groups were 
injected (s.c.) with either B16 or B16/HY cells on the next day.  Donor Treg 
expansion and FoxP3 expression was measured 11 days after tumour inoculation.   
As with MB49, HY-specific Tregs do not expand effectively without antigen 
(Fig. 5.3a and b) but are more capable of expanding in mice bearing B16/HY 
tumours (Fig. 5.3c).  Following antigen recognition, expanded Tregs can also lose 
FoxP3 (Fig. 5.3c).  In addition, it seems that loss of FoxP3 by tumour-infiltrating 
Treg cells is greater (77·68 ± 0·02%, Fig. 5.2c) than that by those in dLN 
(91·37 ± 0·08%, Fig. 5.2c). 
To confirm the HY Dby expression by the B16/HY cell line, RT-PCR was 
performed (Fig. 5.3d), this showed that while Dby B16/HY is lower than the MB49 
cell line, it was significantly higher than the B16 line (p <0.05).  Furthermore, 
B16/HY tumour cells ex vivo were analysed for Dby expression, which showed that 
it was maintained in vivo (Fig. 5.3e), and that the HY transgene is stable in vivo.  
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Figure 5.3. Antigen-specific downregulation of FoxP3 expression by expanded 
adoptively transferred Marilyn Tregs  
Three groups of Thy1.2
+
 B6 females (n=3/group) were adoptively transferred with 
10
5
 Thy1.1
+
 Marilyn nTreg cells co-expressing FoxP3
GFP
 (Mar-nTreg
GFP
) (i.v.) (a-c), 
of which two groups of mice were inoculated (s.c.) with B16 cells (b) or B16/HY 
cells (c) (5 × 10
5
) on the next day.  Eleven days after tumour inoculation, analysis 
was performed by staining the cells from various tissues with anti-Vβ6PE, anti-Thy-
1.1
PerCP
 and anti-CD4
APC
. The donor cells were identified by co-expression of Thy-
1.1 and Vβ6 and their FoxP3 expression was presented as Vβ6 versus GFP. One 
representative experiment of two is shown. A total of 2 million events were acquired 
for each sample. For the B16 and B16/HY samples, tumour size is also indicated. 
a. Treg cells alone. 
b. Treg cells with B16 inoculation. 
c. Treg cells with B16-HY inoculation. 
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d. B16, B16/HY and MB49 cell lines were compared for Dby expression by RT-PCR 
with male or female B6 spleen cells were used as internal controls. One 
representative experiment of three is shown.  
e. Two groups of B6 females (n=3 /group) were inoculated (s.c.) with 5 x 10
5
 B16 or 
B16/HY cells, respectively. Two weeks later, B16 and B16/HY tumours from 
individual mice were compared for Dby expression by RT-PCR with B16 and MB49 
cell lines were used as internal controls. One representative experiment of two is 
shown.  All error is represented as ± standard error mean. 
 
 
 
5.2.4:  Ex-Treg development in MB49-bearing WT B6 female hosts 
 To confirm that the generation of HY-specific ex-Tregs is antigen-driven and 
not a product of other stimuli from the tumour environment, green Tregs (containing 
both nTreg and iTreg cells) were adoptively transferred to WT B6 female hosts (Fig. 
5.4a and b) and MB49-bearing B6 female hosts (Fig. 5.4c-f).  HY-specific Tregs 
maintained GFP expression (Fig. 5.4b) and failed to expand (Fig. 5.4a) in naive 
female mice, similar to the effect seen in female mice given nTreg (Fig. 5.2a), further 
confirming that HY-specific Tregs do not expand in a homeostatic manner in 
lymphoreplete hosts.  In the presence of MB49 tumour, a significant expansion of 
green Tregs was observed (Fig. 5.4c and e) and a proportion of these became ex-
Tregs (Fig. 5.4d and f) (14% dLN, 20% MB49).  
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Figure 5.4. Development of ex-Tregs in MB49-bearing WT B6 female mice 
Two groups of Thy1.1
+
 B6 females (n=3/group) were adoptively transferred with 10
5
 
Thy1.2
+
 Marilyn Treg cells co-expressing FoxP3
GFP
 (Mar-Treg
GFP
) (i.v.) (a,c), of 
which one group of mice were inoculated (s.c.) with MB49 cells (c) (5 × 10
5
) on the 
next day.  Seven days after tumour inoculation, analysis was performed by staining 
the cells from iLN/dLN (a,c) and MB49 (e) with anti-Vβ6PE, anti-CD4PerCP and anti-
Thy1.2
APC
. The donor cells were identified by co-expression of Thy-1.2 and Vβ6 and 
their FoxP3 expression was presented as CD4 versus GFP.  One representative 
experiment of two is shown. iLN, inguinal LN. 
 
 
 
5.2.5:  Generation of HY-specific ex-Tregs in lymphopenic hosts 
In order to develop an in vivo model in which ex-Tregs can be generated in 
sufficient quantities, highly purified HY-specific peripheral green Treg (Fig. 5.5a) 
were transferred into MB49 free (Fig. 5.5b) or MB49-bearing Rag2
-/-
 (lymphopenic) 
B6 females (Fig. 5.5c).  A significant accumulation of donor Tregs progeny were 
found in tumour dLN (27%), spleen (0.6%) and tumour tissue (27%) on day 12 (Fig. 
5.5c).  The representation of donor Tregs accumulation in inguinal LN (iLN) and 
spleen in control mice was low due to lack of antigens (Fig. 5.5b) (0.3 and 0.05%).  
The difference in frequency (Fig. 5.5d) and absolute cell number (Fig. 5.5f) of donor 
Tregs between iLN and dLN was statistically significant. 
In tumour-bearing mice A fraction of the donor Tregs in the dLN (23%), 
spleen (35%) and MB49 (8%) become GFP-negative (Fig. 5.5c), whereas the donor 
Tregs in the iLN and spleen of control mice remained 100% GFP-positive (Fig. 
5.5b).  Ex-Tregs in dLN have statistically significant increased frequency (Fig. 5.5e) 
and absolute cell number (Fig. 5.4g), in comparison to those in iLN.   
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Figure 5.5. Development of HY-specific ex-Tregs in vivo  
a. The purity of HY-specific peripheral green Tregs, following FACS sorting, prior 
to injection.  
b and c. Analysis of representation of ex-Tregs in vivo.  HY-specific green Tregs 
(2x10
4
/mouse) were adoptively transferred to MB49-free (b) or MB49-bearing Rag2
-
/-
 B6 females (c) (n=4/group).  FACS analysis was conducted on day 12.  dLN, 
spleen (SP) and MB49 tissue cells were stained with anti-Vβ6PE, anti-Thy1.1PerCP and 
anti-CD4
APC
. The donor cells were identified by co-expression of Thy-1.1 CD4 and 
Vβ6 and their FoxP3 expression was presented as CD4 versus GFP.  Dot-plots of one 
representative mouse of each group are shown. One representative experiment of 
three is shown. 
d to g. The percentage (d and e) and absolute cell number (f and g) of donor Tregs (d 
and f) and donor ex-Tregs (e and g) in iLN of control (black bars) and dLN of 
MB49-bearing mice (white bars) are shown.  All error is represented as ± standard 
error mean. 
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5.2.6:  Generation of HY-specific ex-Tregs in MB49-bearing Rag
-/-
 B6 female 
recipients of Marilyn nTregs 
Peripheral Tregs isolated from the lymph node and spleen are composed of 
both nTregs and iTregs, whereas those from thymus are largely, if not exclusively, 
nTregs (Thornton, Korty et al. 2010).  FACS sorted HY-specific thymic green Tregs 
(Fig. 5.6a) were transferred to MB49-bearing Rag2
-/-
 B6 females.  Ex-Treg cells 
were clearly present in dLN (41%), spleen (67%) and MB49 (23%) on day 12 (Fig. 
5.6b), therefore nTregs can be converted into ex-Tregs following in vivo activation, 
recapitulating the behaviour of peripheral Tregs. 
 
Figure 5.6. Development of HY-specific ex-Tregs from nTregs in MB49-bearing 
Rag
-/- 
B6 females 
a. The purity of HY-specific thymic green nTregs (developed as in Fig. 5.2), 
following FACS sorting, prior to injection. 
b. Analysis of the representation of ex-Treg cells in vivo. HY-specific green nTregs 
(1x10
4
/mouse) were transferred to MB49-bearing Rag2
-/-
 B6 females (n=4). Analysis 
was conducted on day 12 dLN, spleen (SP) and MB49 tissue cells were stained with 
anti-Vβ6PE, anti-CD4PerCP and anti-Thy1.2APC. The donor cells were identified by co-
expression of Thy-1.2 CD4 and Vβ6 and their FoxP3 expression was presented as 
CD4 versus GFP.  FACS dot-plots of one representative mouse of four are shown. 
One representative experiment of three is shown. 
 
 
5.2.7:  GFP negative Ex-Tregs are FoxP3 negative cells 
Lymphoreplete Marilyn female mice are used to generate sufficient quantities 
of green Tregs (Fig. 5.7a), since they have many more of this population compared to 
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lymphopenic Marilyn female mice.  To confirm ex-Tregs are Tregs that have lost 
FoxP3 expression, both GFP
+
 and GFP
-
 cells, as shown in Fig. 5.5c, were re-isolated 
by FACS sorting before staining with anti-FoxP3
FITC
 (Fig. 5.7b).  Ex-Treg cells are 
FoxP3 negative in cells from both types of donor.   
 
Figure 5.7. Anti-FoxP3 mAb does not produce positive staining for Ex-Tregs   
a. PBL from Marilyn females co-expressing FoxP3
GFP
 as a fusion protein on Rag 
sufficient (Rag
+/- 
Marilyn, n=>40) or Rag deficient background (Rag
-/- 
Marilyn, n=8) 
were stained with anti-Vβ6PE, anti-CD4PerCP and anti-B220APC. The frequency of 
Treg cells is represented by the percentage of GFP
+
 cells within gated CD4
+
Vβ6+ 
population. Absence of both B220
+
 and CD4
+
 cells indicates the Rag-deficiency and 
presence of a large fraction of CD4
+
Vβ6+ suggesting the phenotype is TCR 
transgenic. **, p<0.01. All error is represented as ± standard error mean. 
b. The development and identification HY-specific ex-Treg and unconverted Treg 
cells were described in Fig. 5.5. After re-isolation by FACS sorting, ex-Treg 
(CD4+GFP-) (left hand panel) and unconverted green Treg cells (right hand panel) 
were subsequently subjected to intracellular FoxP3 staining using anti-FoxP3
FITC
 
mAb (e-Biosciences) (e-Biosciences fixation buffer causes an abolition of GFP 
expression).   
 
 
 
5.2.8:  Development of ex-Tregs is not due to over-expansion of GFP
-ve
 
contaminants in the input donor cell population 
A contamination experiment was designed to rule out the possibility that the 
generation of ex-Tregs is caused by selective expansion by contaminating GFP 
negative conventional CD4 T cells.  1,000 Thy1.1
+
 HY-specific naïve CD4 T cells 
were transferred alone or co-transferred with 19,000 Thy1.2
+
 HY-specific green 
Tregs to two groups of MB49-bearing Rag2
-/-
 B6 females.  
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In the group that received conventional CD4 alone, a significant 
accumulation of donor naïve CD4 T cell progeny was found in the dLN (11%), 
spleen (2.6%) and MB49 (5.4%) after 12 days, despite the limited number of input 
cells (Fig. 5.8a).  In the presence of co-transferred Tregs however expansion of donor 
naive CD4 T cells was dramatically impaired, with a 93-99% reduced accumulation 
in the dLN (0.8%), spleen (0.08%) and MB49 (0.01%) (Fig. 5.8b).  A significant 
reduction was also revealed by quantitative analysis of frequency (Fig. 5.8c) and 
absolute number (Fig. 5.8d) of donor naïve cells in the dLN of mice that received 
both naive and Tregs.  Naïve CD4 T cells completely failed to expand when co-
transferred with excess Tregs, from this evidence it is clear that the emergence of ex-
Tregs represents differentiation from donor Treg cells rather than over-expansion of 
FoxP3 negative contaminants. 
 
Figure 5.8. Development of ex-Tregs is not due to over-expansion of GFP 
negative contaminants 
a and b. Analysis of donor naïve CD4 T cells in vivo. Thy1.1
+
 HY-specific naive 
CD4 T cells alone (1x10
3
/mouse), or mixed with Thy1.2
+
 HY-specific green Tregs 
(19x10
3
/mouse) were transferred to two groups of MB49-bearing Rag2
-/-
 B6 females 
(n=4/group).  Analysis was conducted on day 12 as described in Figure 5.5.  FACS 
dot-plots of one representative mouse of four are shown. One representative 
experiment of two is shown. 
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c and d. The percentage (c) and absolute number (d) of donor naive CD4 T cells in 
the dLN were compared for both groups. N, naïve alone; N+Treg, co-transfer.  All 
error is represented as ± standard error mean. 
 
 
 
5.2.9:  Ex-Tregs expand more potently than Tregs in Rag2
-/- 
B6 male mice 
A secondary adoptive transfer was performed to compare the function of ex-
Tregs and Tregs which retained FoxP3.  Tregs and ex-Tregs, generated as described 
in Fig. 5.5, were re-isolated from MB49-bearing Rag
-/-
 B6 females by FACS sorting 
with >99% purity (Fig. 5.9a and 5.9b) and separately transferred to two groups of 
Rag2
-/- 
B6 males.  The frequency of donor cells in recipients of ex-Tregs (Fig. 5.9d) 
was much greater than that in recipients of Tregs on day 28 (Fig. 5.9c). These 
differences were statistically significant in dLN, mesenteric LN (mLN) and spleen 
(Fig. 5.9e to 5.9g).  In addition, the progeny of donor ex-Tregs showed a higher 
frequency in mLN but lower in pLN (Fig. 5.9d).  Interestingly, a significant fraction 
of donor ex-Tregs in spleen but not in mLN or pLN re-expressed GFP following the 
secondary transfer (Fig. 5.9h). These differences were also statistically significant 
(Fig. 5.9i) elucidating the functional plasticity of these ex-Tregs. 
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Figure 5.9. Ex-Tregs are functional effector cells in vivo  
a and b. Purity of input donor cell populations. Tregs (a) and ex-Tregs (b) were 
FACS sorted from spleen and pooled dLN of MB49-bearing Rag2
-/-
 B6 female 
recipients of HY-specific Tregs at day 12 as described in Fig. 5.5. 
c and d. ex-Tregs but not Tregs are responsive to endogenous HY antigens.  Tregs 
and ex-Tregs (2x10
3
/mouse) were transferred into two groups of Rag2
-/-
 B6 males (3 
mice/group).  Analysis was conducted at day 28. FACS dot-plots of one 
representative mouse of three are shown. One representative experiment of two is 
shown. 
e to g. Comparison of the frequency of donor Tregs and donor ex-Tregs in pLN (e), 
mLN (f) and spleen (g). 
h. Re-expression of GFP by ex-Tregs in vivo. FACS dot-plots of one representative 
mouse of three are shown. One representative experiment of two is shown. 
i. Comparison of the frequency of donor ex-Tregs which re-gained GFP expression 
in pLN, mLN and SP.  Error is represented as ± Standard error mean. 
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5.2.10:  Ex-Tregs downregulate Treg specific genes and upregulate Th1-like 
genes 
To further characterise the phenotype and function of ex-Tregs, gene 
expression profiles between ex-Tregs and Tregs were compared.  Tregs and ex-Tregs 
generated as described in Fig. 5.5, from MB49-bearing Rag
-/-
 B6 females, were re-
isolated by FACS sorting before analysing gene expression profiles.  As expected, 
FoxP3 expression was reduced by 10 fold in ex-Tregs which also showed a 116 fold 
decrease of Gpr83 (G protein-coupled receptor 83), a Treg-specific surface marker 
(Sugimoto, Oida et al. 2006; Lu, Gavin et al. 2007).  Other Treg-associated genes 
including Ctla4 (CTLA4) (Wing, Onishi et al. 2008), Folr4 (FR4) (Yamaguchi, 
Hirota et al. 2007), Nt5e (CD73) (Deaglio, Dwyer et al. 2007), and Ccr7 (CCR7) 
(Menning, Hopken et al. 2007) were also downregulated (Fig. 5.10a).  Conversely, 
ex-Treg cells displayed a significant increase of Ifn (IFN), Cd80 (CD80), Gzmb 
(Granzyme B) and Gzma (Granzyme A) (Fig. 5.10b).  To a lesser extent, Th1 
cytokine genes including Csf2 (GM-CSF), Tnf (TNF) and IL-2 (IL-2) were also 
moderately but significantly upregulated in ex-Treg cells.  Several Treg-related genes 
including Runx1 (Kitoh, Ono et al. 2009; Klunker, Chong et al. 2009) and Gal1 
(Galectin 1) (Garin, Chu et al. 2007) were maintained in ex-Treg cells, indicating 
that re-differentiation was incomplete and possibly reversible.  
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Figure 5.10. Comparison of gene expression profiles between Tregs and ex-
Tregs 
a and b. Tregs and ex-Treg cells, sorted from pooled dLN and SP cells of MB49-
bearing Rag2
-/- 
B6 female recipients of HY-specific green Tregs at day 12, were 
subjected to RNA extraction and cDNA conversion before running qPCR array assay 
using mouse Treg Phenotyping 383 StellARray
TM
 plates. 8 genes were 
downregulated (b) and 15 genes up-regulated (a) in ex-Tregs compared with Tregs.  
 
 
 
5.2.11:  Validation of qPCR data by FACs analysis 
To confirm if ex-Tregs express more IFN than Tregs with sustained FoxP3 
at protein level, an intracellular staining approach was used.  MB49-bearing Rag2
-/-
 
B6 female recipients of HY-specific green Treg cells were prepared as described in 
Fig. 5.5.  On day12, dLN cells were subjected to a standard intracellular 
IFNstaining procedure following a brief in vitro re-stimulation (Fig. 5.11a).  The 
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frequency of IFN-producing cells in ex-Tregs was significantly higher than that in 
Tregs.  The mean fluorescence intensity (MFI) of IFN in ex-Tregs (304) was also 
higher than that in Tregs (173), thus overall, ex-Tregs produced more IFN than 
Tregs.  Neither IL-4 nor IL-17 was detectable in this experiment (Fig. 5.11b), 
indicating that Tregs differentiated into Th1-like but not Th2 or Th17-like cells.  
Using FACS analysis, it was also confirmed that expression of both FR4 and CCR7 
was significantly reduced on ex-Tregs (Fig. 5.11b), compared with Tregs.  
 
Figure 5.11. Comparison of IFN, FR4 and CCR7 expression between Tregs and 
ex-Tregs by FACS analysis 
a. HY-specific green Tregs were transferred to MB49-bearing Rag2
-/-
 B6 females 
(n=4).  12 days later, dLN cells were briefly stimulated with PMA (50ng/ml) and 
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Ionomycin (250ng/ml) in the presence of Brefeldin A (1g/ml) before surface 
staining for CD4
 
and Thy1.2. After fixation and permeabilisation, the cells were 
stained for FoxP3
 
and IFN. Donor cells were further divided into Tregs (R4) and ex-
Tregs (R3). Both the frequency and MFI of IFN-positive cells in Tregs (black bars) 
and ex-Tregs (white bars) were measured. FACS dot-plots of one representative 
mouse of four are shown. One representative experiment of two is shown.  
b. Staining conducted as described in „a‟, except that two additional anti-IL4PE and 
anti-IL17
PE
 were also utilized for intracellular staining. 
c. HY-specific green Tregs (Thy1.2) were transferred to MB49-bearing Rag2
-/-
 B6 
females (n=3). 12 days later, dLN cells were stained with anti-FR4
PE
 (or anti-
CCR7
PE
), anti-CD4
PercP
 and Thy1.2
APC
.  Donor Treg cells identified by CD4
+
Thy1.2
+
 
were distinguished as Treg (R5) or ex-Tregs (R6) based on GFP expression. 
Expression of FR4 and CCR7 by Tregs (open area) and ex-Tregs (closed area) are 
shown as histograms. FACS profiles of one representative mouse of three are shown. 
One representative experiment of three is shown. MFI of FR4 and CCR7 by Tregs 
(black bars) and ex-Tregs (white bars) were measured.  Error is represented as ± 
Standard error mean. 
 
 
 
5.2.12:  HY-specific green Tregs preferentially differentiate into ex-Tregs in the 
mesenteric lymph nodes of Rag
-/- 
B6 male mice 
The mechanisms of the differentiation of ex-Tregs were examined in the 
second model in which HY-specific green Tregs were adoptively transferred into 
Rag2
-/-
 B6 males, i.e. hosts expressing the cognate antigen endogenously on all 
somatic tissues.  Surprisingly, a complete ex-Treg conversion was seen in mLN 
(98%) but not in pLN (24%) or spleen (25%) on day 14 (Fig. 5.12a and 5.12b).  
When mLN cells were compared with pLN for cytokine/chemokine/receptor gene 
expression, 7 genes showed significant up-regulation (Fig. 5.12c), of which IL6 
mRNA displayed an over 300 fold increase.  A moderate increase of IL-1 receptor 
antagonist, CXCL10, IL-10, CXCR4 and IL-21 was also observed.  
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Figure 5.12. Microenvironment of mLN in Rag2
-/-
 B6 male mice favours ex-Treg 
development  
a. HY-specific green Tregs (Thy1.1) (1 × 10
4
/mouse) were transferred to Rag2
-/-
 B6 
male mice (n = 4). Analysis was conducted on day 14 by staining of pLN, mLN, or 
spleen cells with anti-Vβ6PE, anti-Thy1.1PerCP, and anti-CD4APC.  Donor Tregs 
identified as Vβ6+ Thy1.1+ and analysed for FoxP3 expression.  FACS profiles of 
one representative mouse of four are shown. One representative experiment of three 
is shown.  
b. Comparison of the frequency of ex-Tregs in various tissues. Error is represented as 
± Standard error mean. 
c. Comparison of gene expression profiles between pLN and mLN. pLN and mLN 
cells from a Rag2
-/-
 B6 male mouse were subjected to RNA extraction and cDNA 
conversion before running qPCR array assay using mouse cytokine/ chemokine/ 
receptor 383 StellARray plates. One representative experiment of two is shown. 
 
 
 
5.2.13:  Regulation of ex-Treg differentiation by naive CD4 T cells 
To investigate whether HY-specific naïve CD4 T cells could influence HY-
specific ex-Treg development in Rag2
-/- 
B6 male recipients, a co-transfer experiment 
was performed.  As shown in Fig. 5.13a and 5.13b, the co-transfer of naive CD4 T 
cells led to a striking reduction (~80%) of ex-Treg frequency in the mLN.  A modest 
but significant decrease (~40%) of ex-Treg frequency was also seen in pLN but not 
in the spleen.   Feedback from naïve CD4 T cells seems to prevent the loss of FoxP3 
by Tregs.  The presence of co-transferred HY-specific naïve CD4 T cells did not 
increase the frequency of donor Tregs, indicating that the promotion of Treg 
expansion does not represent the major feedback pathway.  
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Figure 5.13. Co-transfer of naive CD4 inhibits FoxP3 loss and ex-Treg 
generation 
a. Inhibition of ex-Treg differentiation by co-transferred naive CD4 cells. HY-
specific green Tregs (Thy1.1) (1 × 10
4
/mouse) mixed with an equal number of HY-
specific naive CD4 T cells (Thy1.2) were transferred to Rag2
-/-
 B6 male mice (n = 4). 
Analysis was conducted on day 14, as described in Fig. 5.9a. FACS profiles of one 
representative mouse of four are shown. One representative experiment of three is 
shown.  
b. Comparison of the frequency of ex-Tregs in the absence (black bars) or presence 
of co-transferred naive CD4 T cells (white bars). Error is represented as ± Standard 
error mean. 
 
 
5.2.14:  Tregs regulate HY-specific naive CD4 expansion 
 To evaluate the suppressive function of HY-specific Tregs in this second 
model of ubiquitous somatic cell antigen expression, a co-transfer experiment was 
set up to measure naive CD4 cell expansion in the presence of Tregs in a 1:1 ratio 
(Fig. 5.14).   In the absence of HY-specific Tregs, naive CD4 T cells expanded in a 
typical manner until day 15 before contracting (Fig. 5.14a).  However in the presence 
of Tregs, this response was suppressed, with reduced expansion of naive CD4 cells 
(Fig. 5.14a).  In parallel experiment, pLN, mLN and spleen were analysed for the 
representation of conventional donor CD4 T cells on day 14.  In all peripheral 
lymphoid organs tested, the expansion of naive CD4 T cells was reduced when Tregs 
were co-transferred (Fig. 5.14b), although in the mLN this impaired expansion was 
not significant, possibly due to reduced suppression induced by the increased 
generation of ex-Tregs (Fig. 5.12).  This result suggest that while the presence of 
naïve CD4 T cells prevents loss of FoxP3 by Tregs, and co-presence of Tregs also 
reduces the ability of naive CD4 T cells to expand in respond to antigen.  
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Figure 5.14. Co-transferred Tregs inhibit antigen-specific naive CD4 T cell 
responses in vivo   
Comparison of the frequency of naïve CD4 T cells in the absence or presence of co-
transferred Tregs.   
a. HY-specific green Treg cells (Thy1.1) (1x10
4
/mouse) alone or co-transfer with 
HY-specific naive CD4 T cells were transferred to Rag2
-/- 
B6 males (n=3/group) 
(naive alone white bars, co-transfer black bars).  Analysis was conducted by PBL day 
9, 15 and 22.  Cells were lysed and stained using anti-CD4
PE
, anti-Thy1.1
PerCP
 and 
anti-Thy1.2
APC
. Naive cells were identified as GFP- CD4+ Thy1.2+, Tregs as GFP+ 
CD4+ Thy1.2-.  Error is represented as ± Standard error mean. 
b. In a parallel experiment pLN, mLN, or SP were analysed on day 14 (n=3/group).  
 
 
5.2.15:  Modulation of ex-Treg development by co-transferred naïve CD4 T cells 
in MB49-bearing Rag2
-/-
 female hosts 
To explore whether the conclusions obtained from experiments using Rag2
-/-
 
B6 male recipients would also be applicable to other HY models, HY-specific green 
Tregs (Thy1.2) were transferred with or without HY-specific naive CD4 T cells 
(Thy1.1) to MB49-bearing Rag2
-/-
 B6 females.  In the absence of naïve CD4 T cells, 
Tregs expanded and some of them became ex-Tregs during the course of antigen 
recognition (Fig. 5.15a), thus confirming previous data as shown in Fig. 5.5c.  In the 
presence of naive CD4 T cells, the accumulation of Tregs in the dLN and tumour 
mass was reduced (Fig. 5.15b), indicating that naive CD4 T cells do not modulate 
Tregs by promoting their expansion.  Conversely, the development of ex-Tregs in 
MB49 tissues was significantly impaired when naive CD4 T cells co-existed, 
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suggesting that naive CD4 T cells can regulate Tregs by preventing the loss of 
FoxP3.  Taken together, data from two different models demonstrate that naive CD4 
T cells can protect Tregs with the same antigen-specificity from losing FoxP3 in 
vivo, defining a previously unrecognised feedback pathway which acts to maintain a 
functional Treg population.      
 
Figure 5.15. Development of ex-Tregs in MB49-bearing female Rag2
-/-
 mice was 
impaired by co-transferred naïve CD4 T cells 
a and b. HY-specific green Treg (Thy1.2) (1x10
4
/mouse) alone (a) or mixed with an 
equal number of HY-specific naive CD4 T cells (Thy1.1) (b) were transferred to two 
groups of MB49-bearing Rag2
-/-
 B6 females (n=4). Analysis was conducted on day 
12 by staining of dLN, MB49, or SP cells with anti-CD4
PE
, anti-Thy1.1
PerCP
 and anti- 
Thy1.2
APC
. Donor Treg cells identified as CD4
+
Thy1.2
+
 and were analysed for 
FoxP3. FACS profiles of one representative mouse of four are shown. One 
representative experiment of three is shown. 
c. Comparison of the frequency of ex-Treg cells in the absence (black bars) or 
presence of naive CD4 T cells (white bars). Error is represented as ± Standard error 
mean. 
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5.3:  Discussion 
This chapter describes the establishment of an in vivo model in which the fate 
of tumour antigen-specific adoptively transferred Tregs in tumour-bearing mice can 
be studied.  CD25
+
 Tregs from HY-specific TCR transgenic Marilyn females were 
found to prevent expansion of conventional Marilyn CD4 T cells in response to 
MB49 tumours (Fig. 5.1).  How could this minor population of Treg cells (5%) have 
such a huge impact on a large population of conventional CD4 T cells (95%)?  One 
possible explanation is that Treg cells undergo a rapid expansion in response to 
cognate antigen released from tumour.  Indeed, polyclonal Tregs from a WT B6 
female did not expand in response to MB49 (Fig. 5.2e) while Marilyn Tregs showed 
a significant expansion in MB49-bearing females, both in terms of frequency (Fig. 
5.2b) and absolute cell number (Fig. 5.2b).  Unlike other reports that rely on viral 
vaccination to detect Treg in tumour (Zhou, Drake et al. 2006; Zhou and Levitsky 
2007; Sharma, Hou et al. 2010), in this model, Tregs were readily detected without 
any boost in dLN and tumour (Fig. 5.2).  The use of endogenous (MB49) and 
transfected (B16/HY) HY antigen expressing tumour lines has demonstrated that  
HY-specific Tregs can be induced to proliferate in dLN and subsequently migrate 
into tumours in vivo (Fig. 5.3).   
In the course of characterising the Treg cellular response to tumour, it was 
noticed that a proportion of proliferating Treg cells lost FoxP3 (Fig. 4.12, 5.2 and 
5.3).  To expand this model, Marilyn Treg cells were sorted and used for an adoptive 
transfer experiment to MB49-bearing B6 female recipients (Fig. 5.4).  This showed 
significant loss of FoxP3
GFP
 expression in tumour-bearing mice.  However weak 
expansion of Treg in WT hosts (0.024% of dLN) is not particularly sensitive.  
Therefore in order to derive sufficient quantities of ex-Tregs lymphopenic hosts were 
used for the remainder of the study. 
The downregulation of FoxP3 in polyclonal Treg subsets in vivo has been 
observed previously (Zhou, Bailey-Bucktrout et al. 2009; Sharma, Hou et al. 2010) 
and was also noted by our group in an in vitro culture system in which FoxP3
GFP
 
polyclonal Tregs lost GFP expression upon repeated in vitro expansion (Chai, Coe et 
al. 2008).  For the purposes of this study, Rag
-/-
 B6 mice were used as recipients of 
HY-specific green Tregs, which were purified from F1 (B6 FoxP3
GFP
 x Marilyn) 
female mice.  This is in contrast with a study by Rubtsov et al. (Rubtsov, Niec et al. 
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2010), in which FoxP3
GFP-Cre-ERP2
 x ROSA26
YFP
 mice were used as a model of Treg 
differentiation, this group demonstrated FoxP3 stability over 5 months.  The different 
conclusions with regard to FoxP3 stability are likely to be due to the use of a non-
inflammatory homeostatic system. 
FoxP3 expression by ex-Tregs was examined by intracellular staining (FACS 
sorted from MB49-bearing mice, based on the loss of GFP expression), before the 
secondary transfer (as shown in Fig. 5.9) and qRT-PCR analysis (as shown in Fig. 
5.10).  These GFP negative ex-Tregs had lost mRNA FoxP3 expression and staining 
with an anti-FoxP3 mAb was also negative, whereas positive FoxP3 staining was 
seen in the sorted GFP
+
 population (Fig. 5.7b).  Therefore, it can be confirmed that 
Tregs which lose GFP are indeed FoxP3 negative, consistent with RT-PCR analysis 
showing a significant downregulation (10-fold) of FoxP3 mRNA expression in ex-
Tregs compared with that in unconverted green Tregs (Fig. 5.10a). 
In the first part of this investigation HY-specific ex-Tregs (Fig. 5.5-5.7) that 
have developed in an in vivo tumour model (Fig. 5.5) were characterised.  The 
possibility that these represent over-expansion of contaminating conventional CD4 
cells (Fig. 5.8) was excluded.  This work has several novel features: This is the first 
study to explore the plasticity of antigen-specific Tregs in the context of tumour (Fig. 
5.5), extending previous studies using polyclonal Tregs in either homeostatic (Chai, 
Coe et al. 2008; Yang, Nurieva et al. 2008; Coe, Begom et al. 2010) or autoimmune 
settings (Chai, Coe et al. 2008; Tsuji, Komatsu et al. 2009).  Secondly, analysis of 
gene expression is more comprehensive than in previous studies in which only a very 
limited number of genes were considered (Fig. 5.10) (Chai, Coe et al. 2008; Coe, 
Addey et al. 2010).  Thirdly, this is the first report showing that HY-specific green 
Tregs sorted from thymus (Fig. 5.2, 5.3, 5.6) are also cable of differentiating into ex-
Tregs in response to HY-expressing MB49 tumours, thus providing direct evidence 
that nTregs can be the precursors of ex-Tregs.  Finally, novel mechanisms were 
found that are involved in the regulation of ex-Treg development in vivo. 
HY-specific green Tregs (CD4
+
V6+CD25+GFP+) are capable of 
differentiating into ex-Tregs in both MB49-bearing Rag
-/-
 B6 females (Fig. 5.5c and 
Fig. 5.15a) and Rag
-/- 
B6 males (Fig. 5.12a), demonstrating that FoxP3 expression in 
CD25
+
 Treg subset is unstable after in vivo activation.  These results are consistent 
with another report showing that a fraction of islet auto antigen-specific 
CD4
+
GITR
hi
GFP
+
 cells (of which a vast majority are CD25
+
) lose FoxP3 after 
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transfer to TCR-/- NOD mice (Zhou, Bailey-Bucktrout et al. 2009), but appears to 
conflict with another study suggesting that the plasticity of Tregs is exclusive to the 
CD25 negative Treg subset (Komatsu, Mariotti-Ferrandiz et al. 2009).  Failure to 
detect ex-Tregs in Rag
-/-
 B6 recipients of CD25
+ 
Treg cells by Komatsu et al 
(Komatsu, Mariotti-Ferrandiz et al. 2009) could be because the test was carried out 
only at an early time point (day 5), and presumably only pLN (whose environment is 
less inflammatory than that in mLN) was analysed.  At the later time point on day 28, 
90% of donor CD4
+
FoxP3
+ 
Tregs (of which a vast majority are CD25
+
) became 
FoxP3 negative when recovered from epithelial lymphocytes (Duarte, Zelenay et al. 
2009) and Peyer‟s patches (Tsuji, Komatsu et al. 2009).  The cytokine milieu in a 
Proinflammatory environment can promote ex-Treg development.  Given IL-2 is 
critical to maintain stable expression of FoxP3 in Tregs (Fontenot, Rasmussen et al. 
2005), it is understandable why the CD25 negative Treg subset is more susceptible to 
FoxP3 loss (Komatsu, Mariotti-Ferrandiz et al. 2009), however, it does not 
necessarily indicate that CD25 negative Treg subset is the sole population from 
which ex-Tregs are generated.  Upon homeostatic expansion in lymphopenic mice, 
CD25
+
 Tregs lose CD25 expression (Gavin, Clarke et al. 2002) and conversely 
CD25
-
 Tregs regain CD25 expression in vivo (Zelenay, Lopes-Carvalho et al. 2005).  
Here nTregs are shown to be able to differentiate to ex-Tregs (Fig. 5.2, 5.3 
and 5.6).  Previous studies have exclusively used peripheral Tregs (Yang, Nurieva et 
al. 2008; Duarte, Zelenay et al. 2009; Komatsu, Mariotti-Ferrandiz et al. 2009; Tsuji, 
Komatsu et al. 2009; Zhou, Bailey-Bucktrout et al. 2009), containing both nTregs 
and iTregs, which have differential Helios expression (Thornton, Korty et al. 2010). 
As a transcription factor, Helios has limited value in separating the two subsets of 
peripheral Tregs.  The use of thymic green Tregs as an alternative strategy provides 
direct evidence that in vivo, nTregs can be the precursors of ex-Tregs.  
In this model, ex-Tregs have characteristics of Th1 rather than Th17 or Th2 
cells (Fig. 5.11a and c).  This result is supported in a study by Zhou et al. (Zhou, 
Bailey-Bucktrout et al. 2009) showing that polyclonal ex-Tregs in the lymph node 
produced IFN-γ but not IL-17, whereas those in Peyer‟s patches made both 
cytokines.  The cytokine profile of ex-Tregs therefore depends on the location and 
environment in which they were generated.  The ex-Treg population appears to be 
heterogeneous.  qPCR analysis has shown that expression of some Treg related 
genes, including Runx1 (Kitoh, Ono et al. 2009; Klunker, Chong et al. 2009) and 
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galectin 1 (Garin, Chu et al. 2007), are maintained in ex-Tregs (Fig. 5.10).  Upon 
secondary transfer to Rag2
-/-
 B6 male mice, some ex-Tregs in spleen but not lymph 
node became FoxP3
+
 (Fig. 5.9h), suggesting that re-expression of FoxP3 also 
depends on the local tissue environment.  FoxP3 re-expression by polyclonal ex-
Tregs has been reported (Komatsu, Mariotti-Ferrandiz et al. 2009), although it is 
unclear whether ex-Tregs in the spleen are more likely than those in lymph node to 
regain FoxP3 expression.  
Treg conversion in lymphoreplete hosts appears to be less efficient than that 
in lymphopenic hosts (Fig. 5.2 and 5.4) (Duarte, Zelenay et al. 2009; Komatsu, 
Mariotti-Ferrandiz et al. 2009; Zhou, Bailey-Bucktrout et al. 2009).  This raises 
concerns over the biological significance of the conversion of Tregs in vivo; 
nevertheless, Tregs can be converted to ex-Tregs under non-lymphopenic conditions. 
Interestingly, this conversion takes place mainly in inflamed tissues expressing 
antigen, including the MB49 tumour (Fig. 5.2 and 5.4) (Coe, Addey et al. 2010) and 
the pancreas of prediabetic NOD mice (Zhou, Bailey-Bucktrout et al. 2009).  
Conversion of Tregs takes place in the MB49 microenvironment despite 
immunosuppressive gene expression (Fig. 3.4, 3.13) with production of IDO and 
TGF-into the local microenvironment (Fig. 4.11).  From such studies, it has been 
proposed that the conversion of Tregs under physiological conditions could 
contribute to the development of autoimmune diseases and cancer surveillance.  In 
addition, the generation of effector like ex-Tregs at sites of infected tissue might help 
initiate viral clearance (Zhou, Bailey-Bucktrout et al. 2009).  Exploration of the 
biological relevance of Treg conversion in WT mice requires robust model systems 
and novel approaches.  A commonly used strategy is to perform a secondary 
adoptive transfer of ex-Tregs to lymphopenic hosts, which has been used by us in the 
current study and by others (Komatsu, Mariotti-Ferrandiz et al. 2009; Tsuji, Komatsu 
et al. 2009; Zhou, Bailey-Bucktrout et al. 2009).  
The second part of this study explores the cellular events controlling the 
development of ex-Tregs.  There are three key observations. The first is that the 
microenvironment of the mesenteric but not peripheral lymph node favours the 
generation of ex-Tregs (Fig. 5.12a and b).  A subsequent comparison of gene 
expression profiles revealed that IL6 mRNA shows a significant increase (>300-fold) 
in the mesenteric lymph node compared with peripheral lymph node (Fig. 5.12c).  
IL-6 alone can induce downregulation of FoxP3 expression by TCR-stimulated 
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Tregs, which can be further promoted by the presence of IL-1 and IL-21 (Xu, Kitani 
et al. 2007; Yang, Nurieva et al. 2008; Sharma, Hou et al. 2009; Tsuji, Komatsu et al. 
2009).  IL-6 induces re-methylation of the FoxP3 nonintronic upstream CpG-rich 
island, closing the chromatin structure of the FoxP3 locus (Lal, Zhang et al. 2009).  
Higher IL-6 expression in the mesenteric lymph node provides a mechanistic basis 
for increased development of ex-Tregs in this tissue, which extends previous studies 
showing that inflammatory environments such as gut-associated tissues (Duarte, 
Zelenay et al. 2009; Tsuji, Komatsu et al. 2009) and islets of NOD mice (Zhou, 
Bailey-Bucktrout et al. 2009; Zhou, Bailey-Bucktrout et al. 2009) can facilitate the 
development of ex-Tregs.  
It is of interest to test whether ex-Tregs that resulted from in vivo conversion 
would have pathological consequences, such as the development of colitis.  
However, there is a concern that the activities of ex-Tregs would be limited by the 
coexistence of non-converted Tregs, especially in the peripheral lymph node where 
the Treg conversion was incomplete.  Another concern is that the use of HY-specific 
Tregs is the main focus in the current investigation, whereas the development of 
colitis in B6 mice appears to require a polyclonal CD4 T cell response.  To explore 
whether ex-Tregs can induce a pathological response in vivo, unconverted Tregs 
would need to be removed as described earlier.  The effector potential of ex-Tregs 
can be assessed by their anti-MB49 immunity or the development of graft-versus-
host disease (GvHD) after transfer to irradiated male recipients, which has been seen 
after adoptive transfer of conventional Marilyn CD4 T cells (See chapter 7).  It is 
also of interest to use Rag
-/-
 IL6 KO mice to examine whether these hosts fail to 
convert the Tregs.  
The second novel observation is that HY-specific naive CD4 T cells can 
partially prevent ex-Treg development in vivo (Fig. 5.13 and 5.15).  Similar results 
have been reported by others using polyclonal Tregs (Almeida, Zaragoza et al. 2006; 
Duarte, Zelenay et al. 2009).  Although the precise molecular mechanisms for 
regulating FoxP3 expression in Tregs by co-transferred naive CD4 cells are still 
elusive, involvement of cytokines including IL-2 and TGF-β have been suggested.  
Duarte et al. showed that lymphopenia induced loss of FoxP3 by polyclonal Tregs 
was accelerated by anti–IL-2 treatment but prevented by IL-2 administration (Duarte, 
Zelenay et al. 2009).  Similarly, IL-2 treatment can restore CD25 expression and 
Treg function in inflamed islet of NOD mice (Tang, Adams et al. 2008).  TGF-β 
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produced by Tregs is required for maintaining FoxP3 expression and protection from 
apoptosis (Li, Sanjabi et al. 2006).  
Finally, in a converse situation, HY-specific Treg cells can partially inhibit 
HY-specific naive CD4 expansion upon co-transfer to Rag
-/-
 B6 male mice (Fig. 
5.14).  This result indicates a cyclical feedback pathway between antigen-specific 
Tregs and conventional CD4 cells preventing outgrowth of CD4 cells.  These results 
are mirrored in the development of GvHD in irradiated FoxP3-DTR (diphtheria toxin 
receptor) male mice that receive 5Gy, conventional CD4 cells and diphtheria toxin to 
remove Tregs.  Without Treg removal GvHD is inhibited, however, removal of Tregs 
can induce lethal GvHD (see chapter 7 Figure 7.11) 
What are the implications of this study?  Firstly, some features of Tregs 
revealed by previous studies might warrant alternative interpretations due to the 
instability of FoxP3 expression.  For example, in a vaccination model, Tregs act as 
effector cells in lymphopenic hosts (Vendetti, Davidson et al. 2010); Tregs secrete 
granzyme B and/or perforin to kill DC, CD8, and NK cells in tumour dLN 
(Boissonnas, Scholer-Dahirel et al. 2010) or in tumour tissues (Cao, Cai et al. 2007); 
and Tregs preferentially expand in response to cancer vaccines (Zhou, Drake et al. 
2006).  Secondly, there is concern over the use of Treg adoptive therapy in 
autoimmune diseases (Zhou, Bailey-Bucktrout et al. 2009; Zhou, Bailey-Bucktrout et 
al. 2009).  Because IL-6 plays a key role in converting Tregs to ex-Tregs (Xu, Kitani 
et al. 2007; Yang, Nurieva et al. 2008; Sharma, Hou et al. 2009), the efficiency of 
adoptive Treg therapy may be enhanced by blockade of IL-6 signalling pathways. 
Finally, the promotion of ex-Treg development in the context of tumours can be of 
therapeutic benefit.  
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Chapter 6: Genetic modification of MB49 with recombinant 
human IL-2 as a novel in vivo vaccine approach 
 
6.1:  Introduction 
 
6.1.1:  IL-2 and T cells  
 Interleukin-2 as a soluble factor was known to immunology many years 
before its use for tumour therapy: IL-2 was one of the first endogenous mitogenic 
factors for lymphocytes described.  In 1965 two reports described a „blastogenic 
factor‟ in the culture supernatant of stimulated lymphocytes that induced their 
proliferation (Gordon and MacLean 1965; Kasakura and Lowenstein 1965).  Over 
the next 15 years many reports described mitogenic factors in lymphocyte 
conditioned media.  A quantitative assay was developed based on the ability for this 
T cell Growth factor to promote the long-term survival and proliferation of T cells in 
culture (Gillis, Ferm et al. 1978; Robb, Munck et al. 1981; Robb and Smith 1981).  
In 1981, Kendall Smith and colleagues used immunoaffinity chromatography to 
attribute this to one molecule, IL-2 (Robb and Smith 1981; Smith, Favata et al. 
1983).  IL-2 was the first cytokine discovered to mediate its effects through a 
receptor (IL-2R, later named CD25/CD122) (Robb, Munck et al. 1981) and the first 
to be cloned from a cDNA library (Taniguchi, Matsui et al. 1983).  Despite being 
discovered earlier, IL-2 was called number two as IL-1 released by macrophages was 
initially believed to induce IL-2 in T cells (Smith, Gilbride et al. 1980; Smith, 
Lachman et al. 1980). 
IL-2 is now known to be released as part of an adaptive immune response 
(Cantrell and Smith 1984; Smith 1988). Antigen binding to the TCR induces the 
secretion of IL-2, and stimulates the expression of IL-2 receptors. The IL-2/IL-2R 
interaction can then induce the proliferation and survival of antigen-specific 
cytotoxic lymphocytes (CTLs) causing the upregulation of genes characteristic of 
activation such as Granzyme B (Stern and Smith 1986; Beadling, Johnson et al. 
1993; Beadling and Smith 2002).  IL-2 is also necessary for the development of T 
cell memory and is required both for the development of Tregs in the thymus and 
their maintenance in the periphery (Sakaguchi, Sakaguchi et al. 1995).  Tregs can 
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prevent Th1 cells producing IL-2 and therefore act as regulators of CTLs; this is 
believed to be a cause of suppression of anti-tumour responses (Khattar, Chen et al. 
2009). 
IL-2 is a 15 kDa helical cytokine produced mainly by activated T cells and 
to some extent by activated DCs, NK and NKT cells (Granucci, Vizzardelli et al. 
2001; Yui, Sharp et al. 2004).  IL-2 mRNA production is induced transiently by TCR 
engagement to peptide-MHC-II with subsequent formation of a DNA binding protein 
(NF-AT/AP-1).  The mRNA is then stabilised through a second DNA binding protein 
induced by the additional engagement of co-stimulatory molecules such as CD28 on 
the cell surface.  IL-2 then undergoes transcriptional silencing in activated T cells 
through a poorly understood mechanism believed to be influenced by binding of T-
bet to the IL-2 promoter (Jain, Loh et al. 1995; Hwang, Hong et al. 2005).  IL-2 
works in an autocrine fashion, upregulating its receptor and downregulating its own 
production in T cells by induction of the Stat5 transcription factor (Villarino, Tato et 
al. 2007).  IL-2 also sensitises activated T cells to undergo apoptosis upon TCR re-
stimulation (Su, Cousens et al. 1998) and conversely induces effector T cell 
development in vitro (Leung, Morefield et al. 2000).  Therefore IL-2 has roles in the 
contraction of the immune response and the promotion of effector cell development. 
IL-2 is also crucial in the maintenance and expansion of Tregs in vivo, 
signalling through the highly expressed CD25 (IL-2R) (Fontenot, Rasmussen et al. 
2005) this can result in much of the IL-2 in a local environment being used by Tregs.  
Therefore IL-2 is now suspected to have a dual role in vivo being necessary for the 
induction of Th1 immune responses but also inducing tolerance through Treg 
activation in the local environment.  Indeed IL-2 knockout mice have a lympho-
proliferative disorder and autoimmunity rather than immunodeficiency (Sadlack, 
Lohler et al. 1995; Klebb, Autenrieth et al. 1996), since many functions of IL-2 are 
redundant.  This has influenced the use of IL-2 therapy in cancer due to the 
tolerogenic effects produced in certain tumour models.  It is therefore important to 
understand how IL-2 is used and made available to different T cell populations in 
order to induce therapeutic anti-tumour responses.  
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6.1.2:  IL-2 and immunotherapy 
Immunotherapy was initially discovered when William Coley noticed that, 
rarely, tumours can spontaneously regress and these patients had commonly suffered 
from recent bacterial infections.  He took this further by injecting live Streptococcus 
pyogenes directly into inoperable tumours, causing some tumour regression (Hoption 
Cann, van Netten et al. 2003).  In the 1970s, Thomas and Burnet had developed the 
“cancer immunosurveillance” hypothesis suggesting that tumours only develop when 
circulating lymphocytes fail to either survey or destroy tumourigenic cells (Burnet 
1970).  Subsequent experiments using knockout mice showed that Rag2
-/-
 mice had 
an increase in spontaneously arising and chemically induced tumours (Shinkai, 
Rathbun et al. 1992).  Spurred by these results, investigators began to modulate the 
immune system searching for target molecules to boost tumour regression.  
Combined with the timely discovery of IL-2 in 1976 (Morgan, Ruscetti et al. 1976) 
this signals the beginning of cytokine based immunotherapy. 
Recombinant human IL-2 has been used for many years in the treatment of 
cancers and chronic viral infections (Gratama, Bruin et al. 1993; Simpson, Heys et al. 
1995).  The primary aim of these treatments is to overcome immune suppression 
caused by chronic antigen exposure or immunoevasive mechanisms which often lead 
to CTL death or anergy.  Initially the belief that IL-2 had a central role in promoting 
T cell growth and differentiation drove its use as a systemic infusion, following 
reports of significant anti-tumour effects in mice (Rosenberg, Mule et al. 1985).  IL-2 
is now clinically used as a treatment of renal cell carcinoma (Fyfe, Fisher et al. 1995) 
and several forms of malignant melanoma (Parkinson, Abrams et al. 1990).  Despite 
this initial enthusiasm, optimal clinical responses to IL-2 therapy are only seen for a 
limited number of patients demonstrating a clear lack of efficacy.  Combined with 
this, IL-2 was found to have significant toxicity when administered systemically in 
humans (White, Schwartzentruber et al. 1994) 
The positive therapeutic results of using IL-2 for viral infections has not been 
mirrored in treatment of cancer as the mechanisms by which IL-2 induces cancer 
regression are not fully understood.  Indeed, as discussed above, IL-2 can support 
tumour growth by inducing immune suppression.  New approaches are beginning to 
reveal that IL-2 may have differing physiological effects at different doses.  At a high 
dose IL-2 is believed to stimulate Treg development and homeostasis (Thornton, 
Donovan et al. 2004) while at lower doses IL-2 may preferentially stimulate effector 
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T cell expansion/contraction and function.  Such findings have led to the use of low 
dose IL-2 in cancer treatment (Dudley and Rosenberg 2003; Dudley and Rosenberg 
2007).  
 
6.1.3:  IL-2 and gene therapy 
 Despite the mixed results of IL-2 administration, research into the use of 
cytokine gene therapy has continued unabated.  This has many advantages since the 
gene of interest can be delivered locally at high concentrations, mirroring a natural 
immune response while also providing sustained paracrine effects supporting 
immune activation.  For established tumours in vivo this can be achieved through 
local injection of viral carriers containing the gene targeted to tumour cells and/or 
specific immune cells (Dummer, Hassel et al. 2004; Dummer, Rochlitz et al. 2008).  
A wide range of vectors are also now available for in vivo or ex vivo modification of 
the immune system, including lentivirus (Poeschla, Wong-Staal et al. 1998), 
adenovirus (Bramson, Hitt et al. 1996), retrovirus (Miller, Miller et al. 1993), herpes 
simplex virus (Rees, McArdle et al. 2002), vaccinia (Carroll, Overwijk et al. 1998), 
fowlpox (Kim, Cormier et al. 1998) etc.  For example, this method has been used, 
with therapeutic effect, to transduce several cytokine genes into prostate cancers 
using canarypox viral carriers (Griffith, Kawakita et al. 2001).  Some studies are 
even using inert vectors as carriers of DNA to avoid safety concerns with 
recombinant viruses.  A recent study has demonstrated experimental treatment of 
murine melanoma using IL-2 cDNA loaded onto inert nanoparticles (Yao, Ng et al. 
2011). 
The first IL-2 experimentally expressing tumours were developed over 20 
years ago by Fearon et al. (Fearon, Pardoll et al. 1990).  This group transduced a 
poorly immunogenic murine colon cell line (CT26) and the B16/F10 melanoma cell 
line with a murine IL-2 gene under a CMV promoter.  A strong CTL response was 
induced to these tumours even in the absence of CD4 T cells, however, anti-tumour 
responses were abrogated when CD8 T cells were depleted.  These data, along with 
other studies, suggest intra-tumoural IL-2 may act in a paracine fashion bypassing 
the requirement for T cell help (Fearon, Pardoll et al. 1990; Guarini, Riera et al. 
1997).  Indeed, a study by Alosco et al. using an IL-2 transduced murine 
fibrosarcoma cell line (CMS-5) showed that this tumour could be rejected in SCID 
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mice in an NK dependent manner without the need for T cells (Alosco, Croy et al. 
1993).  Other groups have reported that endogenous IL-2-producing renal 
carcinomas can be rejected in lymphopenic mice depleted of NK cells, suggesting 
rejection by non-specific inflammatory responses alone (Hara, Hotta et al. 1996). 
IL-2 transduced tumours have also been used in vaccination experiments due 
to the potent CTL induction seen in these early experiments.  The use of whole cell 
vaccines provides a major advantage to single target vaccines due to the potential for 
induction of polyvalent responses to multiple factors associated with the immunising 
tumour.  In a model relevant to this study, a vaccine of murine bladder transitional 
carcinoma cells (MBT-2) modified to express IL-2 and irradiated, was able to cure 
mice bearing MBT-2 tumours and also protect against second challenge with a high 
dose of unmodified MBT-2 tumour cells inoculated to the bladder wall (Connor, 
Bannerji et al. 1993).  Similar effects were also shown in a model of retrovirally 
modified human bladder carcinoma vaccine (Milella, Jacobelli et al. 1999).  The 
protective effect of IL-2 retroviral modification introduced directly into tumours as a 
vaccine has also been noted in human cancers of multiple origin, such as melanoma 
(Gansbacher, Zier et al. 1992), renal cell carcinoma (Gastl, Finstad et al. 1992), 
myeloid and lymphoid leukaemic cells (Cignetti, Guarini et al. 1994), colon 
carcinoma (Stein, Walther et al. 1996) and lung carcinoma (Guarini, Riera et al. 
1996).  T cells from tumour-bearing hosts are often defective in signalling molecules 
required for their complete activation (Mizoguchi, O'Shea et al. 1992).  The 
transduction of IL-2 into tumour cells as a vaccine is principally designed to 
compensate for defective cytokine signalling from Th cells (Fearon, Pardoll et al. 
1990; Gansbacher, Zier et al. 1990).   
 Many groups, including our own, are now using lymphocytes genetically 
modified to express cytokines to increase the efficacy of adoptive cell transfer in 
cancer immunotherapy (Murphy, Westwood et al. 2005).  These studies have had 
varied results, perhaps attributable to factors such as too few of the transferred 
lymphocytes being able to infiltrate the tumour to produce a significant local effect 
of the cytokine.  Modification of tumour cells with immunomodulatory cytokines is 
an effective way of enhancing their immunogenicity in vivo without the need for 
complex vaccination protocols (Gansbacher, Zier et al. 1990).  This is a feature 
afforded to the MB49 system since cell lines maintained in vitro can be modified 
before standard administration in vivo in this tumour model.  In this study, MB49 is 
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modified by retroviral transduction with a retroviral rhIL-2 construct (provided by Dr 
Istvan Bartok) to model tumour development with local production of IL-2 by 
compared with wild type MB49.  This is a study of direct ex vivo tumour 
modification, designed to elucidate the in vivo effects of local IL-2 production on 
tumour growth and anti-tumour immune responses aimed at providing insights into 
the cellular mechanisms of tumour rejection.   
 
 
 
 
6.2:  Results 
 
6.2.1:  Genetic modification of the MB49 cell line with rhIL-2 gene 
 To develop an in vivo model in which IL-2 could be produced in the local 
tumour microenvironment, an IL-2 expressing MB49 cell line was made.  The 
Phoenix packaging cell line was transfected with a MIGR1 retroviral vector 
containing a recombinant human IL-2 (rhIL-2) cDNA gene (Fig. 6.1b) or with the 
empty MIGR1 vector containing a GFP reporter gene alone (Fig. 6.1a).  Viral 
supernatant was harvested on day 3 and Phoenix cells tested for transfection 
efficiency (GFP expression) by FACS (Fig. 6.1a and b).  MB49 cells were then 
transduced using a spin infection method.  MB49 cells transduced with MIGR1 
containing IL-2 (MB/IL-2) (Fig. 6.1c) and with an empty MIGR1 (MB/GFP) were 
tested for transduction efficiency by FACS.  GFP
+
 cells were then FACS sorted and 
placed into culture, cells were then tested for GFP expression two weeks later (Fig. 
6.1b).   
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Figure 6.1. Retroviral transduction of the MB49 cell line with MIGR1/rhIL-2 
Phoenix cells were transfected using the lipofectamine
TM
 2000 method with either 
MIGR1 alone (a) or MIGR1 containing a rhIL-2 cDNA (b).  MB49 cells were plated 
out at 10
5
 cells/well for 48 hours and transduced using spin infection (2500 rpm, 
120mins) with 1ml of viral supernatant from the transfected Phoenix culture. 
a and b. Phoenix transfection efficiency for MIGR1 (a) and MIGR1/rhIL-2 (b). 
FACS profiles of phoenix cells were analysed for GFP expression by transfected 
cells (green histogram) and untransfected control (red histogram). 
c and d. MB49-MIGR1/rhIL-2 transduction efficiency.  GFP expression by 
transduced MB49 cells before (c) and 2 weeks after FACS sorting (d).  
e and f. Deconvolution microscopy of MB49-MIGR1/rhIL-2 unsorted cells (e) and 2 
weeks after sorting (f). Images display FITC channel overlaid onto standard visible 
light image. 
 
 
6.2.2:  Development of monoclonal MB/IL-2 and MB/GFP populations 
 To obtain uniform MB/IL-2 and MB/GFP cell lines, a single cell cloning 
approach was used.  MB49 cells were plated out individually in culture and selected 
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using deconvolution microscopy and FACS for proliferation and GFP reporter gene 
expression.  GFP positive single cell clones were selected (Fig. 6.2a and b) for the 
highest fluorescence of GFP (Fig. 6.2a) and best proliferation (Fig. 6.2b).  Selected 
GFP expressing MB49 clones were found to proliferate in vitro with similar kinetics 
to untransduced MB49.  Selected clones were maintained under the same conditions 
as un-transduced MB49 cell line in vitro. 
 The progeny of single cell cloned populations can lose transgene expression 
over time (Fig. 6.2c), as reported by others (Krueger, Jorgensen et al. 1999).  This is 
important when considering long-term experiments using an in vitro cell line.  The 
MB/IL-2 cell line was maintained in culture for 6 months and retested for GFP 
expression by FACS (Fig. 6.2c) and imaged using deconvolution microscopy (Fig. 
6.2d).  Despite the clone losing GFP expression over this time (~30%) it was 
considered to be sufficiently stable for in vitro and in vivo use (~5% GFP loss each 
month).  Frozen stocks of both MB/IL-2 and MB/GFP clones were made at ~60% 
GFP
+
 expression.  All experiments from this point forward use MB/IL-2 or MB/GFP 
from these frozen stocks at between 50-60% GFP
+
 expression.  The in vitro cell line 
was refreshed every 4-6 weeks from frozen stocks. 
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Figure 6.2. Single cell cloning and GFP loss by MB/GFP and MB/IL-2 
After FACS sorting MB/GFP and MB/IL-2 were plated in 96 flat bottom plate at ~1 
cell/3 wells and cultured for 14 days.  Colonies were then selected by deconvolution 
microscopy based on GFP expression and proliferation.  
a. FACS profile of MB/IL-2 single cell clone.  GFP expression by transduced (green 
histogram) and untransduced control (red histogram) was analysed.   
b. Deconvolution microscopy image of GFP
+
 single cell clone of MB/IL-2.  
c. FACS profile of an MB/IL-2 clone after 6 months continuous culture.  GFP 
expression by transduced clone which has been maintained for 6 months (green 
histogram) and untransduced control (red histogram) was analysed.  
d. Deconvolution microscopy image of GFP
+
 single cell clone of MB/IL-2 after 6 
months culture. 
 
 
6.2.3:  Confirmation of the rhIL-2 transgene activity 
 CTLL-2 CD8
+ 
T cells were derived from C57BL/6 mice as an IL-2 dependent 
T cell line that constitutively expresses the IL-2R on their surface.  Following long-
term culture, CTLL2 cells have lost their original antigen-specificity and CTL 
activity, but retain IL-2 dependency, and thus the activity of IL-2 in biological 
samples can be determined by measuring their proliferation using tritiated thymidine 
incorporation assays.  Both human and murine IL-2 can support the in vitro 
proliferation of CTLL-2 cells.  In order to confirm the rhIL-2 transgene was active in 
transduced cells, a second transduction into CTLL-2 cells was conducted and 
expression of IL-2 assessed by comparison with an unmodified CTLL-2 T cell clone.   
Phoenix cells were transfected with a MIGR1/rhIL-2 construct as described 
previously, and transfection efficiency determined by FACS (Fig. 6.3a).  CTLL-2 
cells were then transduced and tested for transduction efficiency by FACS (Fig. 
6.3b).  The transduction efficiency was 11% and this CTLL-2/IL-2 cell line was 
maintained as bulk culture for 7 days in vitro with 20IU exogenous IL-2.  CTLL-2 
cells were starved of exogenous IL-2 for 24 hours before being plated out for a 
tritiated thymidine assay (Fig. 6.3c).  Untransduced CTLL-2 cells failed to proliferate 
in the absence of exogenous IL-2 whereas those transduced with the rhIL-2 transgene 
were able to proliferate in media alone (without exogenous IL-2), suggesting that the 
rhIL-2 produced endogenously as a transgene is sufficient to maintain the growth of 
CTLL-2 cells in this bioassay, showing that product of transgene is biologically 
functional.  
 To confirm the production of rhIL-2 by the MB/IL-2 cell line and to evaluate 
whether MB49 produces IL-2, a second CTLL2 proliferation assay was performed 
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(Fig. 6.3d).  MB49 or MB/IL-2 cells were plated out in serial dilutions and left to 
grow for 24 hours then irradiated (50Gy) to prevent further proliferation.  
Supernatants were filtered and plated out with the addition of CTLL-2 cells in a 
proliferation assay (Fig. 6.3d).  CTLL-2 cells were also plated out with exogenous 
IL-2 to provide a reference (black line).  As expected, CTLL-2 cells proliferated in a 
standard dose response curve to exogenous IL-2 (black line).  CTLL-2 cells plated 
out with supernatant of MB/IL-2 also proliferated in a dose-dependent manner 
suggesting MB/IL-2 produces IL-2 in culture at approximately 20IU/ml/0.5M 
cells/day (red line).  CTLL-2 cells plated out with MB49 supernatant, however, 
displayed no significant proliferation, indicating MB49 does not produce IL-2. 
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Figure 6.3. Functional verification of rhIL-2 transgene 
a. Transfection efficiency of Phoenix by MIGR1/rhIL-2 vector.  Phoenix cells were 
transfected as in Fig. 6.1. CTLL-2 cells were plated out for 48 hours at 10
5
 cells/well 
and transduced as in Fig. 6.1.  FACS profile shows GFP expression by transfected 
Phoenix cells (green histogram) and untransfected control (red histogram). 
b. CTLL-2 transduction efficiency with MIGR1/rhIL-2.  FACS profile shows GFP 
expression by transduced CTLL2 (green histogram) untransduced control (red 
histogram). 
c. Thymidine proliferation assay. Transduced (red) or untransduced (blue) CTLL-2 
cells plated out at 10
4
 cells/well in a 96U bottom plate (BD Falcon) with or without 
exogenous rhIL-2.  48 hours later 1l thymidine (containing 1 Ci activity) was 
added/well.  8 hours later the plate was harvested and counted using a microbeta 
counter (Wallac).  Assays were conducted in triplicate and data is represented as 
mean ± standard deviation. 
d. Thymidine proliferation assay.  MB49 or MB/IL-2 cells were plated out in 200l 
media on a 96U bottom plate in serial dilution from 5 x 10
5
 to 15.125 x 10
4
 
cells/well.  24 hours later the plate was irradiated (50Gy) and 100l supernatant was 
taken from each well and added to a new 96U plate.  CTLL-2 cells which had been 
starved of IL-2 for 24 hours, were plated out at 10
4
 cells /well in 96 U bottom plate 
containing with 100l supernatant from either MB49 (blue line) or MB/IL-2 cells 
(red line).  As a positive control, CTLL2 cells were also cultured with serially diluted 
exogenous rhIL-2 (black line) (IU/ml top row X axis).  48 hours later 1l thymidine 
(containing 1 Ci activity) was added/well.  8 hours later the plate was harvested and 
counted using a microbeta counter (Wallac).  Assays were conducted in triplicate and 
data is represented as mean ± standard deviation. 
 
 
 
6.2.4:  MB/IL-2 tumours fail to grow out in lymphoreplete hosts 
 At an innoculum of 5 x 10
5
, MB49 establish tumours which are not rejected 
by lymphoreplete B6 mice (see chapter 3).  To compare growth profiles of the 
transduced MB/IL-2 cell line with MB49, MB/IL-2 cells were injected into WT B6 
female (Fig. 6.4a) and male (Fig. 6.4b) mice at a dose of 5 x10
5
 cells (s.c.).  In both 
female and male mice the MB/IL-2 tumour grew into a visible mass and then 
regressed.  100% of female B6 mice became tumour free (Fig. 6.4a) by 17 days and 
100% of male B6 mice became tumour free after 19 days (Fig. 6.4b).   To determine 
if the rejection of MB/IL-2 was mediated by an immune response to the tumour the 
same mice were re-challenged with a high dose of 1 x 10
6
 MB49 cells to the same 
site on day 21.  All mice, both male and female, failed to develop tumour upon re-
challenge, suggesting that MB/IL-2 is immunogenic, inducing an immunological 
memory recall response to MB49.   
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Retrovirally transduced genes can be lost readily in vivo (Krueger, Jorgensen 
et al. 1999).  To confirm the MB/IL-2 tumour maintained transgene expression in 
vivo one female B6 mouse challenged with MB/IL-2 was culled on day 10 and its 
tumour analysed by FACS for GFP expression (Fig. 6.4c).  >50% of the cells 
displayed GFP expression indicating the MB/IL-2 tumour is stable in vivo for the 
course of tumour growth experiments. 
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Figure 6.4. Spontaneous regression of MB/IL-2 in lymphoreplete recipients 
a. MB/IL-2 was injected at 5 x 10
5
 cells (s.c.) to the right flank of B6 female mice 
(n=14) tumour growth was measured on consecutive days using digital callipers and 
tumour area calculated (length x width (mm
2
)).  On day 21, mice were re-challenged 
with 10
6
 MB49 cells (s.c.).  
b. MB/IL-2 was injected at 5 x 10
5
 cells (s.c.) to the right flank of B6 male mice 
(n=40) tumour growth was measured as above.  On day 21 mice were re-challenged 
with10
6
 MB49 cells (s.c.). 
c. MB/IL-2 or MB49 were injected at 5 x 10
5
 cells (s.c.) to the right flank of B6 
female mice, tumour growth was measured as above. On day 10 tumours were 
excised and tested for GFP expression ex vivo. FACS profile shows GFP expression 
by MB/IL-2 (blue) or MB49 control (red). 
 
 
 
6.2.5:  MB/IL-2 tumours have a distinct appearance in lymphoreplete hosts 
 MB/IL-2 tumours regress in lymphoreplete hosts, therefore these mice cannot 
be killed at the humane endpoint used for MB49 for tumour analysis.  Therefore two 
groups of female B6 mice were injected with 5x10
5
 of either MB49 or MB/IL-2 cells 
and culled on day 21 and day 10 respectively (Fig. 6.5).  MB49 tumours grew in a 
typical fashion with a large tumour mass reaching the humane endpoint at day 21 (at 
least one dimension being 14mm): the mouse shown was culled and photographed 
(Fig. 6.5a, c and e).  MB/IL-2 tumour-bearing mice (one shown in Fig. 6.5b, d and f) 
were culled on day 10, as previous data suggested this was the point of maximal 
tumour growth in WT B6 female mice (Fig. 6.5b).  MB/IL-2 showed a small solid 
tumour mass.   
The outer layer of skin was removed and tumour was photographed again.  
MB49 displays a clear tumour mass with angiogenesis and enlarged dLN (Fig. 6.5c) 
whereas MB/IL-2 tumours have limited angiogenesis and smaller dLN (Fig. 6.5d).  
Tumours were cut using a scalpel to examine the internal structure.  MB49 tumours 
form an internal cavity with a high blood volume that creates a metastatic pressure 
leading to bleeding when the tumour is cut (Fig. 6.5e).  MB/IL-2 tumours did not 
show an internal cavity or significant blood pooling (Fig. 6.5c); this resembles the 
features of rejected tumours.    
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Figure 6.5. MB/IL-2 and MB49 have distinct tumour structure in lymphoreplete 
recipients 
MB49 or MB/IL-2 cells were injected at 5 x 10
5
 cells (s.c.) to the right flank of B6 
female mice (n=2).  Tumours were imaged on day 21 (MB49) (a,c,e) and day 10 
(MB/IL-2) (b,d,f).  Tumours were also cut using a 22 grade scalpel (e and f). 
 
 
 
6.2.6:  MB/GFP cells grow into tumours normally in lymphoreplete hosts 
 It is possible that retroviral modification of the MB49 tumour cell line leads 
to expression of additional antigens deriving from the MIGR1 retroviral vector, 
including the GFP reporter.  This might lead to a more robust immune response 
contributing to elimination of the tumour in lymphoreplete hosts.   
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To minimise this possibility, the MB/GFP cells (Fig. 6.1, 6.2) were injected 
in both the right and left lateral flanks of B6 male mice (Fig. 6.6).  The MB/GFP cell 
line had >50% GFP expression at the time of injection (Fig. 6.6b).  100% of mice 
developed tumours and reached the humane endpoint (Fig. 6.6a) indicating that the 
retrogenic MB/GFP tumour is viable and not rejected through antigenic contributions 
from MIGR1 or GFP.  Tumour-bearing mice were also photographed on day 14 (Fig. 
6.6b) (this mouse was culled as the humane endpoint had been reached due to 
ulceration).  MB/GFP displays similar structure to MB49 in vivo developing 
angiogenesis and blood pooling (Fig. 6.6c). 
 
Figure 6.6. MB/GFP displays normal growth in lymphoreplete recipients 
a. MB/GFP was injected at 5 x 10
5
 cells (s.c.) to the right flank of B6 male mice 
(n=8) tumour growth was measured as in Fig. 6.4. 
b. Expression of GFP by MB/GFP cells at time of injection.  FACS profile shows 
GFP expression by transduced MB/GFP (green histogram) and untransduced control 
(red histogram). 
c. MB/GFP was injected at 5 x 10
5
 cells (s.c.) to the right flank of B6 female mice.  
Tumours were imaged on day 14. 
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6.2.7:  MB/IL-2 cells can develop into tumours in lymphopenic recipients 
 There is a possibility that MB/IL-2 may be non-viable or the rhIL-2 produced 
by the tumour may cause non-specific toxicity to the tumour itself.  To explore this 
further, lymphopenic recipients were injected with MB/IL-2 or MB49 cells at a 
standard dose of 1 x 10
5
 cells, as suggested by others (Perez-Diez, Joncker et al. 
2007).  In male B6 Rag2
-/-
 mice given MB/IL-2 cells 100% (33/33) developed 
tumour reaching the humane end point (Fig. 6.7a).  100% of female B6 Rag2
-/-
 mice 
(8/8) developed MB49 tumours to the same end point at a similar rate (Fig. 6.7b), 
indicating that the MB/IL-2 is viable in vivo and has similar growth characteristics to 
MB49. 
 
Figure 6.7. MB/IL-2 cells develop into tumours in lymphopenic recipients  
a. MB/IL-2 was injected at 1 x 10
5
 cells (s.c.) to the right flank of Rag
-/-
 B6 male 
mice (n=33) tumour growth was measured as in Fig. 6.4.  
b. MB49 was injected at 1 x 10
5
 cells (s.c.) to the right flank of Rag
-/-
 B6 female 
mice (n=8) tumour growth was measured as in Fig. 6.4.  
 
 
6.2.8:  MB/IL-2 has a similar appearance to MB49 in lymphopenic recipients 
 MB/IL-2 and MB49 tumours from lymphopenic hosts (From Fig. 6.7) were 
compared with respect to appearance and structure.  Mice were culled at the relevant 
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humane end points and tumour structure was photographed for MB49 (Fig. 6.8a) and 
MB/IL-2 (Fig. 6.8b) tumours.  In lymphopenic recipients both tumour types showed 
significant tumour mass (Fig. 6.8a and b), angiogenesis (Fig. 6.8c and d) and blood 
pooling (Fig. 6.8e and f), indicating that the MB/IL-2 tumour can grow with the same 
characteristics as MB49 in the absence of an adaptive immune system. 
 
Figure 6.8. MB/IL-2 and MB49 have similar tumour structure in lymphopenic 
recipients 
MB49 or MB/IL-2 was injected at 1 x 10
5
 cells (s.c.) to the right and left flank of B6 
Rag2
-/-
 male mice.  Tumours were imaged at the humane end point for MB49 (a,c,e) 
and MB/IL-2 (b,d,f).  Tumours were also cut using a scalpel (e and f). 
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6.2.9:  MB/IL-2 primarily induces a local immune response 
 MB/IL-2 is rejected in WT recipients and can induce a potent secondary 
response to MB49 re-challenge (Fig. 6.1).  To explore whether MB/IL-2 induces a 
systemic or local primary response, a dual inoculation experiment was conducted 
using two groups of mice.  MB49 was injected subcutaneously with a high dose of 5 
x 10
5
 cells into each of the left and right flanks of B6 female mice (n=4) (G1). 
Another group of 4 recipient B6 females received 5 x 10
5
 MB49 cells in the left flank 
and 5 x 10
5
 MB/IL-2 cells in the right flank (G2).  All MB49 inoculations grew at a 
similar rate whether injected alongside MB/IL-2 or not (Fig. 6.9).  Only MB/IL-2 
tumours regressed, as described previously (Fig. 6.3) with no effect on growth of 
MB49 on the left flank of the mouse (Fig. 6.9 MB49 G2 left).  These data indicate 
the MB/IL-2 induces a sufficient local immune response to cause primary rejection 
but insufficient systemic immunity to prevent MB49 tumour growth when injected at 
the same time point. 
 
Figure 6.9. MB/IL-2 does not provide systemic protection to MB49 when 
injected at the same time 
G1 - MB49 were injected at 5 x 10
5
 cells (s.c.) to the left and right flank of B6 
female mice (n=4).  
G2 - MB49 were injected at 5 x 10
5
 cells (s.c.) to the left flank and MB/IL-2 were 
injected at 5 x 10
5
 cells (s.c.) to the right flank of B6 female mice (n=4), tumour 
growth was measured was in Fig. 6.4.  Error is displayed as ± standard error mean. 
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6.2.10:  MB/IL-2 is rejected even when mixed with MB49 
 The most likely cause of MB/IL-2 rejection is through a local immune 
response that is sufficient to induce systemic immunological memory (Fig. 6.1) but 
insufficient to cause simultaneous systemic immunity when co-inoculated with 
MB49 (Fig. 6.9).  To examine the potency of the local immune response induced by 
MB/IL-2, a mixing experiment was set up.  MB/IL-2 cells were mixed with MB49 
cells in various ratios (50:50, 25:75, 10:90, 5:95, 1:99), and a total number of 5 x 10
5 
tumour cells injected (s.c.) (Fig. 6.10).  Mice that received tumours at ratios of 
MB/IL-2:MB49 at 50:50, 25:75 and 10:90 all failed to develop as large tumours; 
tumours in these mice were less than 20mm
2
 and regressed by day 20 with 100% of 
mice becoming tumour free (not shown).  Mice that received mixed tumour cells 
with a 5:95 MB/IL-2:MB49 ratio also showed tumour regression with 100% mice 
becoming tumour free, whereas those that received tumours at the ratio of 1:99 were 
75% tumour free (Fig. 6.10).  These data sets indicate that even a small number of 
MB/IL-2 cells (equal to or less than 5%) is sufficient to cause rejection of tumours 
incorporating those cells along with WT or homologous non-IL-2 expressing tumour 
cells. 
 
Figure 6.10. The presence of a small fraction of MB/IL-2 cells in mixture with 
MB49 cells can induce regression  
MB49 cells mixed with MB/IL-2 cells at a ratio of 95:5 (n=5) and 99:1 (n=4). The 
MB49 mixtures were injected at 5 x 10
5
 cells (s.c.) to the right flank of B6 female 
mice and tumour growth was measured as in Fig. 6.4. 
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6.2.11:  MB/IL-2 rejection requires CD8 T cells 
 In the second part of this study an attempt was made to understand the 
cellular and molecular mechanisms underlying MB/IL-2 tumour rejection.  MB49 is 
primarily recognised and killed by T cells (Perez-Diez, Joncker et al. 2007).  To 
determine the relative contribution of different T cell subpopulations to protection, 
depleting monoclonal antibodies for CD4 and CD8 were used to remove either or 
both compartments, in B6 female mice before MB/IL-2 inoculation.  Mice were 
injected with depleting antibody (i.p.) 1 day before MB/IL-2 cells and PBL tested on 
the day of inoculation to confirm depletion of the relevant T cells.  Mice were 
injected with MB/IL-2 s.c. as described previously.  All mice from the untreated 
control group and the CD4 depleted group showed typical MB/IL-2 growth with a 
small tumour that quickly regressed by day 20, with 100% of mice tumour free.  
Mice that received CD8 antibody alone or in conjunction with theCD4 antibody all 
developed tumours (0% tumour free), and no significant difference was seen between 
the CD8 alone and CD4/8 double depleted group (Fig. 6.11).  These experiments 
strongly indicate the need for a CD8 T cell compartment in order to mediate rejection 
of MB/IL-2 in WT B6 recipients. 
 
Figure 6.11. MB/IL-2 tumours can be controlled by CD8 but not CD4 T cells 
MB/IL-2 cells were injected at 5 x 10
5
 cells (s.c.) to the right flank of B6 female 
mice (n=42) and tumour growth was measured as in Fig. 6.4.  Data displayed as 
average tumour growth for each group, Error is displayed as ± standard error mean. 
G1 – mice received anti-CD4 depleting antibody (YTS191) 0.2ml (i.p.) 1 day prior to 
tumour injection (n=12). 
G2 - mice received anti-CD8 depleting antibody (YTS169.4) 0.2ml (i.p.) 1 day prior 
to tumour injection (n=10). 
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G3 - mice received anti-CD4 and anti-CD8 depleting antibody (i.p.) 1 day prior to 
tumour injection (n=14). 
G4 – mice received no treatment (n=6). 
 
 
 
6.2.12:  MB/IL-2 is rejected in Matahari Rag
-/-
 mice  
 Based on the requirement for an intact CD8 T cell compartment to mediate 
rejection of MB/IL-2 in WT mice, an experiment was set up to explore if anti-HY 
CD8 TCR transgenic Matahari Rag deficient mice were capable of rejecting MB/IL-
2.  In Matahari Rag
+/-
 female mice ~50% CD8 T cells are HY-specific while in 
Matahari Rag
-/-
 females all CD8 T cells are HY-specific (Fig. 6.12a).  Female 
Matahari Rag
-/-
 mice were inoculated with MB49 or MB/IL-2.  79% of mice that 
received MB/IL-2 were tumour free by day 35 while all mice that received MB49 
developed tumour by day 15 (Fig. 6.12b).  All mice that received MB/IL-2 failed to 
reach the humane end point and survived to day 35 while all mice that received 
MB49 reached humane endpoint by day 30 and were culled (Fig. 6.12c).  Based on 
the Matahari Rag
-/-
 T cell phenotype (Fig. 6.12a) rejection of MB/IL-2 is most likely 
mediated solely by the TCR transgenic HY restricted monoclonal CD8 population.   
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Figure 6.12. Matahari Rag deficient mice can reject MB/IL-2 tumours 
a. Matahari Rag
-/- 
and Matahari Rag
+/-
 PBL, cells stained for anti-V8.3PE and anti-
CD8
PerCP
.  FACS plots of lymphocytes gate then CD8 vs V8.3. 
b. MB/IL-2 (n=28) or MB49 (n=10) was injected (s.c.) to the right lateral flank of 
Matahari Rag
-/-
 females at 1 x 10
5
 cells.  Tumour growth was measured as described 
previously.  Data displays % tumour free mice at various time points. 
c. % Survival for each group as described above. 
 
6.2.13:  Adoptively transferred Matahari and WT CD8 T cells can control 
MB/IL-2 but not WT MB49 in lymphopenic recipients  
 To further explore the role of CD8 T cells in tumour rejection, adoptive cell 
transfers (ACT) of naïve WT CD8 T cells and monoclonal Matahari T cells were 
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made to MB49 or MB/IL-2 bearing lymphopenic B6 female recipients.  WT CD8 T 
cells were purified from a B6 female donor and Matahari CD8 T cells from a 
Matahari Rag
+/-
 donor using MACS and FACS sorting.  All recipients of both types 
of donor cells (WT CD8 T cells (grey line n= 2) or Matahari T cells (red line n=9) 
(Fig. 6.13a)), developed tumours following MB49 injection, reaching the humane 
end point by day 17 for the WT CD8 T cell group and day 25 for the Matahari group 
(Fig. 6.13b).  On the other hand, mice that received MB/IL-2 were able to control the 
tumour in the presence of either WT CD8 (green line n=5) or Matahari CD8 T cells 
(blue line n=9) (Fig. 6.13a).  All mice in both MB/IL-2 groups survived to day 25 
(Fig. 6.13b).  These data further demonstrate that CD8 T cells are both necessary and 
sufficient to induce rejection of MB/IL-2 but not MB49.  
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Figure 6.13. Matahari and WT CD8 can control MB/IL-2 but not MB49 tumour 
upon adoptive transfer to lymphopenic mice 
a. Matahari T cells were purified from a Matahari Rag
+/- 
donor by MACS enrichment 
of V8.3 cells by anti-V8.3PE staining and PE microbeads and further FACS sorting 
of CD8, V8.3, Thy1.1 triple positive population (V8.3-enriched cells were stained 
with anti-CD8
PE/Cy5 
and anti-Thy1.1
PerCP 
 before sorting).  WT CD8 T cells were 
purified using anti-CD8 MACS beads followed by further FACS sorting by staining 
for anti-CD8
PE/Cy5 
and anti-CD4
APC
 and sorted for CD8, single positive population.  
B6 female Rag
-/-
 mice were challenged with either MB49 (n=6) or MB/IL-2 cells 
(n=14) at 1x10
5
 (s.c.).  MB49-bearing (n=4 red line) and MB/IL-2 bearing mice (n=9 
blue line) were given 1 x 10
6
 Matahari T cells (i.v.). MB49-bearing (n=2 grey line) 
and MB/IL-2 bearing mice (n=5 green line) were given 1 x 10
6
 WT CD8 T cells 
(i.v.).  Tumour growth was measured as described previously.  Error is displayed as 
± standard deviation.  P-value <0.01). 
b. % Survival for each group as described above.  
 
 
 
6.2.14:  Matahari CD8 T cells proliferate more in dLN in response to MB/IL-2 
compared with MB49  
 To elucidate the mechanism underlying CD8 T cell mediated rejection 
stimulated by MB/IL-2 in adoptive transfer, Matahari cells were labelled with CFSE 
for an in vivo proliferation assay.  Labelled Matahari CD8 T cells (Thy1.2) were 
injected into control (G1), MB49-bearing (G2) or MB/IL-2 bearing (G3) B6 female 
(Thy1.1) recipients.  Mice were culled on day 9 and donor T cell populations were 
analysed in the dLN and ndLN (Fig. 6.14).  In mice that received MB/IL-2 tumour, 
donor T cells showed the highest expansion in the tumour dLN (0.096% of 
lymphocyte gate) compared to MB49 (0.026%) and T cell alone control (0.014%) 
(Fig. 6.14a).  Donor cells in dLN of the MB/IL-2 bearing group also showed the 
highest CFSE dilution with 88.8% cells dividing compared to 38.3% for the MB49-
bearing group (10.2% for control) (Fig. 6.14b).  This was also reflected in the mean 
MFI of CFSE (Fig. 6.14c and d) which was statistically significant.   These data 
show Matahari CD8 T cells proliferate to a greater extent in response to the IL-2 
replete MB/IL-2 environment compared to MB49. 
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Figure 6.14. Adoptively transferred Matahari T cells are capable of 
proliferating in response to MB/IL-2 
Matahari T cells were purified form Thy1.2 Matahari Rag
+/- 
female mice by MACS 
sorting using anti-V8.3PE staining and PE microbeads.  T cells were then FACS 
sorted (as in Fig. 6.13 with anti-Thy1.2
APC
 in place of anti-Thy1.1
PerCP
) and then 
labelled with CFSE and injected at 4 x 10
6
 /mouse (n= 10).  Mice were then also 
challenged with a high dose (5 x 10
5
 cells) with MB49 (G2) (n= 4) or MB/IL-2 (G3) 
(n=4) or no tumour challenge (G1) (n= 2).  Mice were culled on day 9 and peripheral 
lymphoid organs analysed for donor cells. 
a. pLN of G1 or dLN of G2 and G3 were harvested and stained using anti-V8.3PE, 
anti-CD8
PerCP
, anti-Thy1.2
APC
.  Cells were analysed by FACS and gated using 
lymphocyte gate, then CD8
+
 V8.3+ before final donor population FACS plot 
displayed as Thy1.2 vs V8.3.  One representative FACS plot of 3 is shown. 
b. Cells were gated as in (a) FACS plot for Thy1.2
APC
 vs CFSE . 
c. Histogram plot for MFI of CFSE for cells from gate described in (a). 
d. Graph of mean MFI of CFSE for G1-3.  Error displayed as ± standard error mean. 
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6.2.15:  Matahari CD8 T cells accumulate in the dLN but not ndLN in response 
MB/IL-2 tumour  
 From the same experiment in Fig. 6.14, dLN and ndLN were compared to 
evaluate the systemic versus local responses of adoptively transferred Matahari CD8 
T cells (Fig. 6.15).  For both tumours the highest levels of donor cell expansion was 
seen in the local dLN compared to the ndLN (Fig. 6.15a).  The level of donor cell 
expansion in the dLN of MB/IL-2 bearing mice was statistically higher than that of 
MB49-bearing mice and control mice both in terms of frequency and absolute cell 
number (Fig. 6.15b).  MB49 tumours induced a poor donor cell expansion in dLN, 
with no statistically significant difference between MB49 tumour-bearing mice and 
control mice.  Finally, donor cells in all mice showed similar levels of expansion in 
ndLN in terms of frequency and absolute cell number (Fig. 6.15c), indicating that 
adoptively transferred Matahari T cells expand in response to MB/IL-2 in the local 
dLN but not systemically in ndLNs.   
 
Figure 6.15. Adoptively transferred Matahari T cells are proliferate more 
extensively in the dLN in response to MB/IL-2 tumour 
Experimental set up as in Fig. 6.14. 
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a. pLN of G1 or dLN of G2 and G3 were harvested and stained using anti-V8.3PE, 
anti-CD8
PerCP
, anti-Thy1.2
APC
.  Cells were analysed by FACS and gated using 
lymphocyte gate, then CD8
+
 V8.3+ before final donor population FACS plot 
displayed as Thy1.2 vs V8.3.  One representative FACS plot of 3 is shown. 
b. Mean donor cell frequency in local dLN/pLN (top) and absolute donor cell 
number (bottom). 
c. Mean donor cell frequency in local ndLN/pLN (left) and absolute donor cell 
number (right) Error displayed as ± standard error mean. 
 
 
 
6.2.16:  Matahari T cells infiltrate MB/IL-2 more effectively than MB49 
tumours 
 In a parallel experiment (without CFSE staining) the representation of 
Matahari CD8 T cells infiltrating the MB49 and MB/IL-2 tumours were examined.  
Matahari CD8
+
 T cells (Thy1.2) were injected to MB49-bearing or MB/IL-2 bearing 
B6 female (Thy1.1) recipients.  Mice were culled on day 9 and donor T cell 
populations were analysed in the dLN and ndLN.  Tumours were harvested and 
stained for the presence of Matahari donor T cells as described in section 6.14.  
Tumour infiltrating donor Matahari T cells were gated and analysed for their 
activation status according to expression of CD62L and CD44 (Fig. 6.16a).  Matahari 
CD8 T cells accumulated to a higher level in MB/IL-2 compared to MB49 tumours 
(Fig. 6.16b).  This was also reflected in average CD44 MFI which was significantly 
higher in Matahari T cells from MB/IL-2 compared with those in MB49 tumours 
(Fig. 6.16c) consistent with an effector phenotype.  Donor cells in the local dLN 
were also stained for CD44 and CD62L to give a readout of their activation status.  
Donor CD8s in the MB/IL-2 dLN showed a greater skew towards an effector 
memory phenotype (CD44
high
, CD62L
low
) compared to those in MB49 tumours (Fig. 
6.16d).  Together, these data suggest Matahari CD8 T cells are more capable of 
expanding in response to MB/IL-2, express a stronger effector phenotype and are 
more effective at entering the tumour itself compared to MB49. 
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Figure 6.16. Adoptively transferred Matahari T cells infiltrate MB/IL-2 more 
effectively than MB49 
Experimental set up as in Fig. 6.14, except CFSE staining was not performed. 
a. Tumours were harvested and stained using anti-CD62L
FITC
, anti-V8.3PE, anti-
CD8
PerCP
 and anti-CD44
APC
.  Cells were analysed by FACS and gated using 
lymphocyte gate, then CD8
+
 Vb8.3
+
 before final donor population FACS plot 
displayed as CD44 vs CD62L.  Four representative FACS plot is shown of four 
independent tumours. 
b. Mean donor cell frequency in tumours (n=4/group).  
c. Mean MFI of CD44 for donor cells tumours (n=4/group).  
d. dLNs were harvested and stained using anti-CD62L
FITC
, anti-V8.3PE, anti-
CD8
PerCP
, anti-CD44
APC
.  Cells were analysed by FACS and gated using lymphocyte 
gate, then CD8
+
 V8.3+ before final donor populations were analysed for CD44 vs 
CD62L expression.  Average donor populations of CM vs EM donor cells are shown 
(n=4/group).  Error is displayed as ± standard error mean. 
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6.2.17:  MB/IL-2 tumours induce a stronger systemic activation of donor 
Matahari and WT CD8 T cells compared to MB49 
 In the experiment described in Fig. 6.13, Rag
-/- 
female B6 mice received 
either FACS sorted Matahari or WT CD8 T cells and were challenged with either 
MB49 or MB/IL-2.  Both groups of mice controlled or cleared MB/IL-2 tumours but 
not MB49 tumours (see Fig. 6.13).   On day 20, 2 mice from each group were 
sacrificed and analysed for the ability of donor T cells to produce the 
proinflammatory Th1 cytokines TNF and IFN (Fig. 6.17).   Spleen and tumour 
tissue cells were harvested and plated out with PMA and Ionomyin in the presence of 
Brefeldin A for 4 hours and stained for intracellular TNF (Fig. 6.17a and b) and 
IFN (Fig. 6.17c and d).  Both Matahari and WT CD8 T cells produced more TNF 
and IFN in the spleen and tumour samples of mice injected with MB/IL-2 compared 
to those bearing MB49 tumours.  This also was true in terms of MFI (Fig. 6.17e) and 
the proportion of cells expressing each cytokine (Fig. 6.17f).  All comparisons of 
cytokine production by T cells from MB/IL-2 tumour-bearing mice show statistically 
greater expression than those from their MB49 counterparts.  Therefore donor T cells 
from mice that were injected with MB/IL-2 are able to induce a stronger systemic 
Tc1 cytokine response than those given MB49.  This is reflected by the ability for 
both types of CD8 T cells to control MB/IL-2 but not MB49 (Fig. 6.13).   
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Figure 6.17. Matahari and WT CD8 from MB/IL-2 bearing mice produce a 
stronger Tc1 response ex vivo 
Experimental set up as in Fig. 6.13.  On day 20, 2 mice from each group were culled 
(1 mouse for Mata + MB49 group) and SP and tumour were harvested and cell 
suspension plated out in vitro with PMA (50ng/ml) + Ionomycin (250ng/ml) + 
Brefeldin A (1g/ml) for 4 hours.  Cells were harvested and stained for anti-
TCRFITC (WT CD8) or V8.3FITC (Matahari) and anti-CD8PerCP and then 
intracellular for anti-TNFPE and anti-IFNAPC.  Cells were analysed by FACS and 
gated on lymphocytes and then CD8
+
 TCR+/V8.3+ cells. (* P-value <0.01).   
a and b. FACS plots of CD8 vs TNF for Matahari ACT mice (a) and WT CD8 
ACT mice (b).  One representative FACS plot/sample shown. 
c and d. FACS plots of CD8 vs IFN for Matahari ACT mice (c) and WT CD8 ACT 
mice (d).  One representative FACS plot/sample is shown.  
e. Average MFI of TNFPE (blue) and IFNAPC (red) for each condition as described 
above. 
f. Average proportion of TNF (blue) and IFN (red) producing cells for each 
condition as described above.  Error is displayed as ± standard error mean. 
 
 
6.2.18:  Ex vivo adoptively transferred Matahari CD8 T cells from MB/IL-2 
tumour dLN maintain a stronger Tc1 response after in vitro HY re-stimulation 
compared to those from MB49 dLN 
 Donor Matahari T cells from the dLN of experimental mice in Fig. 6.16 were 
isolated ex vivo and plated out in an in vitro assay to explore how donor T cells from 
MB/IL-2 and MB49-bearing mice respond to secondary antigen re-stimulation.  dLN 
cells from MB49-bearing and MBIL-2 bearing mice, as well as control mice (CD8 
cell transfer into non-tumour-bearing mice) were harvested and plated out with 
irradiated male spleen for 5 days in vitro.  On day 5, cells were harvested and 
analysed for expression of Tc1 cytokines IFN and TNF (Fig. 6.18a and b).  
Matahari donor cells from the dLN of MB/IL-2 and MB49-bearing mice showed a 
higher level of INF- (Fig. 6.18a) and TNF (Fig. 6.18b) expression compared to the 
T cell alone control.  However donor cells from the dLN of mice injected with 
MB/IL-2 showed higher expression levels of INF- (Fig. 6.18a) and TNF (Fig. 
6.18b) compared to those from MB49 tumour-bearing mice.  These data indicate that 
donor T cells from mice injected with MB/IL-2 cells are more capable of maintaining 
a Tc1 phenotype ex vivo in response to male spleen compared to those from MB49-
bearing hosts. 
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Figure 6.18. Adoptively transferred ex vivo Matahari in vitro Th1 responses to 
male spleen 
Experimental set up as in Fig. 6.16.  Mice were culled on day 9 and peripheral 
lymphoid organs were harvested and plated out with irradiated (30Gy) Male SP cells 
at 5 x 10
6
/well in a 24 well plate and cultured for 5 days in vitro (G1 n=1, G2 n=1, 
G3 n=2).  Cells were harvested and stained using anti-V8.3FITC, anti-CD8PerCP and 
anti-Thy1.2
APC
.  Cells were then fixed and stained intracellular.    
a. Cells were stained using anti-IFN-PE and analysed by FACS, cells were gated as 
V8.3, CD8 and Thy1.2 triple positive and then expressed as CD8 vs IFN-
b. Cells were stained using anti-TNF PE and analysed by FACS, cells were gated as 
V8.3, CD8 and Thy1.2 triple positive and then expressed as CD8 vs TNF 
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6.2.19:  MB/IL-2 displays a very similar surface phenotype to MB49 
 To assess the impact of genetic modification on the surface expression profile 
of the tumour cell lines, MB49 or MB/IL-2 cells were plated out for 4 days in the 
presence of IFN-.  This method is used in the study to characterise natural MB49 
responses (see chapter 3).  MB49 cells are gated as a single population while MB/IL-
2 cells are gated on MB49 then GFP
+
 cells to ensure a transgenic population is 
assessed (Fig. 6.19a), surface expression on the cells were then measured for a range 
of molecules.  MB49 typically upregulates MHC class I (D
b
 and K
b
), Class II (A
b
) as 
well as immunoevasive molecules such as PD-L1 and CTLA-4 upon exposure to 
IFN-(Fig. 6.19b).  This is also shown by the MB/IL-2 cell line (Fig. 6.19c).  MB49 
and MB/IL-2 upregulate immunogenic molecules such as GITR/GITRL which might 
induce T cell co-stimulation and block suppression (Fig. 6.19b and c), while also 
expressing adhesion molecules such as CD49b and CD44.  Both cell lines also 
upregulate stem cell marker Sca-1, as well as the CCR9 gut homing receptor (Fig. 
6.19 b and c).  These data indicate that IL-2 gene transfer to MB49 cell line by a 
retroviral approach does not have a significant influence on phenotype of the tumour 
cell, at least for the molecules analysed.  In response to IFN, MB/IL-2 modulates 
gene expression with a similar phenotype to MB49 cells, adding further evidence for 
the direct role of rhIL-2 in stimulating CD8 T cells to induce rejection of this tumour 
line. 
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Figure 6.19. MBIL-2 and MB49 cells are phenotypically similar 
MB49 and MBIL-2 cells were plated out at 5 x 10
5
 cells for 4 days in the presence of 
IFN (10ng/ml).  Cells were harvested and aliquoted in equal amounts for surface 
staining using a range of PE-conjugated mAbs and analysed using FACS. 
a. MB49 cells were gated as a single population; MB/IL-2 cells were further gated 
using GFP
+ 
fraction.  
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b. MB49 surface expression of D
b
, K
b
, A
b
, PD-1, PD-L1, GITR, GITRL, CTLA-4, 
CD44, CD49b, Sca-1, CCR9 (blue line) and isotype
PE
 control (red line). 
c. MB/IL-2 surface expression of D
b
, K
b
, A
b
, PD-1, PD-L1, GITR, GITRL, CTLA-4, 
CD44, CD49b, Sca-1, CCR9 (blue line) and isotype
PE
 control (red line). 
 
  
 
 
6.3: Discussion  
 In this section, a model of IL-2 mediated tumour rejection is established.  
Previous studies using systemic IL-2 therapy in cancer therapy have yielded mixed 
results especially in patients showing non-specific IL-2 toxicity (Rosenberg, Packard 
et al. 1988; Siegel and Puri 1991).  Despite this limitation, several types of cancer are 
currently treated using variable IL-2 dose regiments, including renal cancer (Fisher, 
Rosenberg et al. 2000), colorectal cancers (Simpson, Heys et al. 1995) and 
melanoma (Guminski and Thompson 2009; Powell and Dudek 2009).  However the 
efficacy of these treatments remains an issue with some patients experiencing 
complete regression and others having no protective response following systemic IL-
2 treatment (Guirguis, Yang et al. 2002).   
To overcome some of these problems, IL-2 gene therapy using recombinant 
viral vectors has been employed in treatment of a number of cancer types to deliver 
IL-2 locally.  This has yielded some therapeutic responses particularly in prostate 
cancers (Pantuck and Belldegrun 2001) and other solid tumours such as melanomas 
(Bubenik 1993; Tan, Xu et al. 1996; Lichtor, Glick et al. 2002).  Despite the reduced 
toxicity and increased efficacy, there remain many questions for a full understanding 
of the effects or IL-2 in contributing to cancer regression.  For most tumours, IL-2 
genes cannot be effectively delivered in vivo, resulting in poor IL-2 production.   
Several groups have transduced tumours with cytokine genes such as IL-2 ex vivo to 
act as a whole cell vaccine in murine (Connor, Bannerji et al. 1993) and human 
cancers (Milella, Jacobelli et al. 1999).  While these approaches can be effective in 
inducing protective immunity, they have not provided insight into mechanisms of 
rejection. 
The use of IL-2 transduced tumours to induce a potent anti-tumour immune 
response is not new (Fearon, Pardoll et al. 1990).  Studies by Fearon et al. and others 
have demonstrated that a paracine effect of intra-tumoural IL-2 capable of inducing 
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strong CTL responses and protective immunity (Gansbacher, Zier et al. 1990; 
Cignetti, Guarini et al. 1994).  Despite these initial findings, little is known regarding 
the cellular and molecular mechanisms that allow recognition and rejection of these 
tumours while overcoming immunosuppressive factors.  Our current study allows the 
effects of local IL-2 to be studied in a murine solid carcinoma model which is not 
spontaneously rejected in WT hosts.  The design of this system is an attempt to 
understand the cellular and molecular effects of IL-2 in overcoming tolerogenic 
mechanisms employed by MB49 tumours to prevent killing by the adaptive immune 
system. 
 In order to generate a model by which IL-2 would be released into the local 
tumour microenvironment, the MB49 cell line was directly transduced with MIGR1 
retrovirus containing a rhIL-2 gene (Fig. 6.1).  The tumour line was FACS sorted 
(Fig. 6.1c) and selected by single cell cloning (Fig. 6.2a) to generate a monoclonal 
cell line (called MB/IL-2).  MB49 was also transduced with MIGR1 empty vector to 
generate a „green‟ tumour cell line with no additional transgene, which acts as a 
control (called MB/GFP) to evaluate the effects of rhIL-2 (Fig. 6.1).  MB/IL-2 and 
MB/GFP cells were maintained as an in vitro cell line, and it was noted that the 
retrovirally transduced transgene was subject to loss over time (Fig. 6.2b), as has 
been reported in several situations in which transgenes can „jump out‟ of the genome 
(Krueger, Jorgensen et al. 1999).  In order to ensure consistency in the level of rhIL-
2 production, MB/IL-2 frozen stocks were used for all subsequent experiments 
between with a transduction efficiency of between 50-60% (as measured by GFP
 
expression). 
 To confirm functional activity of the rhIL-2 construct, MIGR1/rhIL-2 
retrovirus was generated (Fig. 6.3a) and used to transduce a CTLL-2 murine 
cytotoxic T cell line (Fig. 6.3b).  As CTLL-2 is strictly dependent on exogenous IL-2 
for survival and maintenance in vitro, this is an appropriate system to test the 
bioactivity of IL-2 and is often used as the industry standard IL-2 activity assay 
(Weston, Geczy et al. 1998).  CTLL-2 cells transduced with rhIL-2 (11% GFP
+
) 
were able to proliferate in the absence of exogenous IL-2 with the same level at all 
IL-2 doses tested, indicating that the functional rhIL-2 proteins are secreted by 
transduced cells (Fig. 6.3c).  To confirm the transduced MB/IL-2 tumour secreted 
functional rhIL-2, supernatant from MB/IL-2 cells were examined for the presence of 
IL-2 by a standard CTLL2 bioassay.  Supernatant from MB/IL-2 cells can support 
215 
 
CTLL2 to grow in vitro whereas those from MB49 cells cannot.  In addition, based 
on this standard bioassay, it was estimated that rhIL-2 production by MB/IL-2 cells 
is approximate 20IU/0.5M cells/day in vitro (Weston, Geczy et al. 1998) (Fig. 6.3d) 
characterising MB/IL-2 as a low IL-2 producer (Yang, Topalian et al. 1994).  
The MB49 bladder carcinoma is an aggressive immunogenic tumour (Perez-
Diez, Joncker et al. 2007) which can induce rapidly growing tumours in WT B6 
female mice (see chapter 3).  MB/IL-2 tumours fail to grow in lymphoreplete hosts 
but are able to induce a protective immunity to MB49 re-challenge in both males and 
females (Fig. 6.4).  This suggests that MB/IL-2 is immunogenic and capable of 
inducing a polyclonal immunological effector memory response directed against 
additional tumour-specific transplantation antigens, as male B6 mice do not generate 
T cells or B cells reactive to HY genes expressed by MB49 (Scott, Ehrmann et al. 
1995) (Fig. 6.4b).  This result is concordant with those of several studies showing 
protective immunity against IL-2 transduced tumours in lymphoreplete mice (Fearon, 
Pardoll et al. 1990; Cignetti, Guarini et al. 1994) capable of inducing long standing 
immunological memory.  These data indicate that rejection of MB/IL-2 is at least not 
wholly dependent on HY-specific responses but more likely induces polyclonal 
immune response to additional antigens.  Tumours from male mice were harvested 
on day 10 and analysed for GFP expression (Fig. 6.4c), and showed >50% GFP
+ 
expression demonstrating that the transgene is stable in vivo for the duration of 
tumour growth.  MB/IL-2 tumours also display a distinct appearance in 
lymphoreplete hosts prior to complete rejection, with small tumours (~3mm 
maximum size), compact internal structure with no angiogenesis or blood pooling 
(Fig. 6.5).   
To exclude the possibility that tumour rejection is mediated by additional 
antigenic components from the MIGR1 vector itself provides (such as GFP), 
tumourigenicity of transduced tumours was tested using the MB/GFP cell line 
(MIGR1 transduced alone (Fig. 6.6b)) inoculated to WT male recipients (Fig. 6.6).  
All mice developed tumours (Fig. 6.6a) which grew with similar kinetics to 
untransduced MB49 cells.  MB/GFP tumours also showed significant mass, 
angiogenesis and blood pooling (Fig. 6.6c).  This result indicates that retroviral 
modification itself does not induce tumour regression and any antigenic contribution 
of additional proteins is minimal. 
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 Spontaneous rejection of MB/IL-2 tumours could also be attributed to non-
specific toxicity of the transgene to tumour cells.  If this was the case, one might 
anticipate that MB/IL-2 cells would not grow as progressive tumours in lymphopenic 
recipients in which T and B cells are absent.  To test this possibility, lymphopenic 
recipients were inoculated with MBIL-2 (Fig. 6.7a) or MB49 cells (Fig. 6.7b): all 
tumours grew to reach the humane end point at very similar rates.  In lymphopenic 
recipients MB/IL-2 showed significant tumour mass (Fig. 6.8b), angiogenesis (Fig. 
6.8d) and blood pooling (Fig. 6.8c) similar to MB49 (Fig. 6.8a,c,e).  The ability of 
MB/IL-2 to grow into tumours in lymphopenic hosts illustrates that the presence of 
an intact adaptive immune system is required for protection; IL-2 is therefore likely 
to be acting on specific adaptive immune responses to induce tumour killing rather 
than on innate responses alone.  This result is consistent with several other examples 
of IL-2 transduced tumours (Fearon, Pardoll et al. 1990; Gansbacher, Zier et al. 
1990; Cignetti, Guarini et al. 1994).  In contrast, Alosco et al. have reported that the 
IL-2 transduced murine fibrosarcoma cell line (CMS-5) is rejected in SCID mice in 
an innate NK dependent manner (Alosco, Croy et al. 1993).  And Hara et al. have 
even shown an IL-2 producing renal carcinoma is rejected in NK depleted athymic 
Balb/c mice by a non-specific inflammatory mechanism.  These two models however 
used IL-2-high producing tumours, and high levels of IL-2 have been shown to 
independently activate NK, neutrophils and granulocytes that may mediate rejection.  
In addition, high levels of IL-2 from a therapeutic standpoint would be most likely 
toxic in humans (Assier, Jullien et al. 2004), while mice seem to be tolerant to high 
doses of IL-2. 
Mice that have rejected MB/IL-2 are capable of rejecting large doses of 
MB49 (Fig. 6.4) indicating a potent memory immune response has been induced.  
Mice injected with MB/IL-2 and MB49 cells in the separate sites were investigated 
to determine if they could reject both tumours (Fig. 6.9).  This experimental 
approach gives each tumour its own microenvironment and local dLN.  Under these 
conditions MB/IL-2 was rejected as shown previously while MB49 on the opposite 
flank grew normally, with no difference in MB49 growth between those receiving 
two site injections of MB49 and those receiving MB49 and MB/IL-2.  MB/IL-2 
therefore is capable of inducing a potent primary local response but this is 
insufficient to provide systemic protection to MB49 on the same hosts when 
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challenged at the same time.   To use MB/IL-2 as a therapeutic vaccine for 
established tumours it is likely that inoculation must therefore be applied locally. 
In a parallel experiment to assess the local response, MB49 and MB/IL-2 
cells were mixed in a range of ratios and inoculated to WT B6 female mice (Fig. 
6.10).   Mixtures of tumour cells were rejected in 100% of mice in ratios of 
MB49:MB/IL-2 as low as 95:5 and 75% rejection in 99:1 ratio (Fig. 6.10).  This 
indicates that the level of IL-2 production required to induce rejection is relatively 
low, with less than 5% of cells needed to produce rhIL-2 to cause rejection of the 
whole tumour.  This effect is even more pronounced when it is considered that 
MB/IL-2 is only ~60% GFP
+
 at the time of injection.  This result is consistent with 
those of Gansbacher et al. who showed that co-injection of IL-2 producing CMS-5 
cells with unmodified tumour cells inhibited tumour formation even when highly 
tumourigenic doses of CMS-5 cells were used (Gansbacher, Zier et al. 1990). 
Having elucidated the growth characteristics of MB/IL-2 cells, the second 
part of this study focused on the exploration of the mechanisms of rejection.  From 
previous studies injecting MB49 cells in vivo, it is clear that T cells are required in 
order to induce rejection, although CD8 T cells alone are insufficient (see chapters 3 
and 4) (Perez-Diez, Joncker et al. 2007).  Previous evidence however has shown the 
role of CD8 effectors is crucial in the rejection of IL-2 producing tumours (Fearon, 
Pardoll et al. 1990; Gansbacher, Zier et al. 1990).  Also, IL-2 is a potent regulator of 
CD4 and CD8 effector T cells and memory development, as well as Treg 
maintenance and expansion, (Fontenot, Rasmussen et al. 2005) and intratumoural 
cytokine vaccination has been shown to increase recruitment of CD4 and CD8 
effectors to certain tumours (Kianmanesh, Hackett et al. 2001).  To evaluate the 
effects of T cells in this model a series of experiments were performed. 
B6 male mice were depleted of CD4 T cells, CD8 T cells or both using in 
vivo depleting antibodies before tumour inoculation (Fig. 6.11).  Only mice that 
received anti-CD8 treatment, either alone or with anti-CD4, had their protection 
abrogated, leading to tumour outgrowth in all mice.  This result indicates that CD8 T 
cells play a potent role in the rejection of MB/IL-2.  No significant difference was 
seen in tumour growth between CD8 depleted and CD4/8 double depleted groups 
suggesting that CD4 T cells are not required for rejection.  This conclusion was also 
in line with the observation that CD4 depleted mice are able to clear MB/IL-2 
tumours as efficiently as mice in the untreated group.  Fearon et al. performed 
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similar depleting experiments of CD8 and CD4 T cell with similar results (Fearon, 
Pardoll et al. 1990).  
Several studies have highlighted the idea that intra-tumoural IL-2 may act in 
a non-specific or polyvalent manner, bypassing direct responses to TAAs (Alosco, 
Croy et al. 1993; Hara, Hotta et al. 1996).  So far other studies have only evaluated 
polyclonal CTLs in the rejection of IL-2 producing tumours.  Therefore CD8 
mediated MB/IL-2 rejection was assessed further using HY-specific Matahari CD8 T 
cells (Fig. 6.12-19).  Initially Rag
-/-
 Matahari mice were challenged with MB/IL-2 
tumour (Fig. 6.12) as these mice produce only TCR transgenic monoclonal CD8 T 
cells reactive to HY-Uty/D
b
 complexes expressed by MB49 (and MB/IL-2) (Fig. 
6.12a).  79% of Matahari mice rejected MB/IL-2 with 100% survival to day 35 
compared to complete tumour development and 0% survival in the MB49 group.  
This result suggests that antigen-specific CD8 T cells alone can be sufficient to 
control MB/IL-2 without any other components of the adaptive immune system. 
Following the results using female Matahari Rag
-/-
 mice themselves as, 
adoptive transfer experiments were designed to assess the role of Matahari CD8 T 
cells and WT CD8 T cells in MB/IL-2 and MB49-bearing Rag
-/-
 B6 hosts (Fig. 6.13).  
Lymphopenic mice that received adoptive transfer of either WT CD8 or HY-specific 
Matahari CD8 T cells were able to control MB/IL-2 tumours but not those arising 
from MB49 cells (Fig. 6.13b).  Importantly in this experiment, although the 
lymphopenic recipients were able to limit outgrowth of MB/IL-2 tumours, adoptive 
transfer did not induce a durable cure; this is most likely due insufficient 
reconstitution of CD8 T cells in the periphery, compared to the use of lymphoreplete 
WT (Fig. 6.9) or Matahari mice as recipients (Fig. 6.12).  Collectively, these data 
indicate both WT and antigen-specific CD8 T cells can provide protection against an 
MB/IL-2 tumour in WT and transgenic mice as well as upon adoptive transfer to 
lymphopenic tumour-bearing recipients.  CD8 T cells are therefore both necessary 
and sufficient to induce MB/IL-2 rejection in vivo. 
In a separate experiment, Matahari CD8 T cells were purified, CFSE labelled 
and injected alone (G1) to MB49-bearing mice (G2) or to MB/IL-2 bearing (G3) WT 
B6 mice (Fig. 6.14, 6.15).  Donor T cells expanded significantly more in MB/IL-2 
bearing mice both in terms of frequency and absolute cell number (Fig. 6.14a and 
Fig. 6.15a and b).  This was also reflected in the dilution of CFSE showing almost all 
donor cells in dLN of G3 underwent an extensive division while those in mice from 
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G1 and G2 did not (Fig. 6.14b,c and d).  Interestingly, there was no significant 
difference in levels of expansion for each of the three groups with respect to the 
ndLN (Fig. 6.15c), again indicating that the primary CD8 response against MB/IL-2 
is restricted locally. 
In a parallel experiment (as in Fig. 6.14, except no CFSE staining of donor T 
cells) tumours and dLN were harvested and analysed for donor Matahari T cell 
tumour infiltration and their activation status (Fig. 6.16).  Donor Matahari CD8 T 
cells again accumulated more efficiently in MB/IL-2 compared to MB49 tumours 
(Fig. 6.16b) and showed a significantly higher level of activation in terms of CD44 
expression (Fig. 6.16a and c).  The dLN of MB/IL-2 bearing mice was shown to have 
a significantly higher level of effector memory CD8 T cells and a significantly lower 
level of central memory CD8 T cells (Fig. 6.16d), effector memory CD8 T cells have 
been shown to be more effective than central memory T cells at tumour killing in 
vivo (Klebanoff, Gattinoni et al. 2005).  A higher state of activation may partially 
explain the enhanced CTL response seen against IL-2 transduced tumours (Fearon, 
Pardoll et al. 1990; Gansbacher, Zier et al. 1992). 
Due to the enhanced CD8 activation seen in MB/IL-2 bearing mice, HY-
specific donor cells were also evaluated for their Tc1 cytokine response following 
HY re-stimulation (Fig. 6.18).  Donor cells from MB/IL-2 bearing recipient mice 
showed the highest levels of IFN- and TNF- production.  These data suggest the 
donor CD8 T cells have been induced to differentiate to Tc1-like cells by the MB/IL-
2 tumour.  Taken together, these data clearly show a requirement for CD8 T cells for 
rejection of MB/IL-2.  MB/IL-2 is capable of expanding and activating antigen-
specific CD8 T cells, while MB49 does not.  This suggests a role for rhIL-2 in the 
local tumour microenvironment that prevents the induction of tolerance in tumour-
specific CD8 T cells. 
HY-specific and WT CD8 responses to MB49 and MB/IL-2 were also 
directly compared ex vivo by measuring the ability of donor cells from mice depicted 
in Fig. 6.13 to produce Tc1 cytokine upon in vitro stimulation (Fig. 6.17).  Both 
Matahari and WT CD8 T cells produced more IFNand TNF from mice bearing 
MB/IL-2 tumours compared to those bearing MB49 tumours, with similar levels of 
cytokine production (by percentage and MFI) for both WT and antigen-specific CD8 
T cells.  This was true both systemically in the spleen and locally in the tumour itself.  
This shows MB/IL-2 tumours are able to induce a strong Tc1 proinflammatory 
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phenotype in CD8 T cells even in lymphopenic mice where no additional adaptive 
responses are present.  This also shows little discernable difference in the potency of 
the WT and Matahari HY-specific CD8 response.  This result is also profound when 
considering the naturally self-reactive phenotype usually seen in Matahari CD8 T 
cells (See chapter 4, Fig. 4.6).  
A final consideration of this model is the phenotype of the tumour itself, as 
rhIL-2 may induce changes in surface marker expression that may indirectly increase 
the immunogenicity of the tumour (Fig. 6.19).  MB/IL-2 shows a very similar pattern 
of surface molecule expression in vitro to MB49, crucially upregulating MHC Class 
I, Class II and PD-L1 in response to IFN exposure.  rhIL-2 is therefore most likely 
to have a direct effect on T cells rather than changing the immunogenicity of the 
tumour itself.  A model of MB/IL-2 based on these data is shown in the table below. 
Table 8: Model of MB/IL-2 rejection 
 
This study adds to and supports current knowledge regarding the role of intra-
tumoural IL-2 in anti-tumour immunity (Fearon, Pardoll et al. 1990; Gansbacher, 
Zier et al. 1990; Gansbacher, Zier et al. 1992; Gastl, Finstad et al. 1992; Cignetti, 
Guarini et al. 1994; Milella, Jacobelli et al. 1999).   Here it is shown that low level 
intra-tumoural IL-2 secretion is capable of inducing MB49 rejection in a CD8 
dependent manner and that this response can be mediated by both WT and antigen-
specific monoclonal CD8 T cell compartments.  I also show that low IL-2 producing 
MB/IL-2 is not rejected by innate immune responses in lymphopenic hosts, as has 
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been reported with IL-2 high tumours (Alosco, Croy et al. 1993; Hara, Hotta et al. 
1996).  rhIL-2 production is sufficient to overcome tumour-induced tolerance (See 
chapter 3) providing a mechanism to break CD8 T cell adaptation seen with MB49 
tumours (see chapters 4) and other antigenic environments (see chapter 7).   MB/IL-2 
rejection is also mediated locally, potentially avoiding the toxic systemic effects of 
IL-2 observed in humans.   
The principal aim of this study was to investigate the kinetics of MB/IL-2 
rejection, using these data to attempt to model mechanisms of primary rejection.  The 
potential of IL-2 to provoke therapeutic responses in recipients bearing established 
tumours has not been addressed in this study.  The capability of IL-2 transduced 
tumours to act as an in vivo vaccine boost for established tumours has been 
confirmed with several reports in mice (Fearon, Pardoll et al. 1990; Gansbacher, Zier 
et al. 1990; Alosco, Croy et al. 1993) and humans (Gansbacher, Zier et al. 1992; 
Cignetti, Guarini et al. 1994; Milella, Jacobelli et al. 1999).  Having elucidated the 
potential mechanisms of rejection further investigation can now take place into the 
ability of this modified tumour to act as a therapeutic vaccine of established MB49 
tumours.  
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Chapter 7: Acute Graft vs Host Disease (GvHD) can be 
induced in male mice by adoptive transfer of HY-specific 
CD4 but not CD8 T cells 
 
7.1:  Introduction 
 
7.1.1:  GvHD  
 Graft versus host disease (GvHD) is characterised by hematopoietic stem cell 
(HSC) transplantation and is produced by donor T cells attacking host tissues though 
recognition of either mis-matched MHC or minor H antigens.  GvHD was originally 
observed when irradiated mice were infused with allogenic spleen cells and bone 
marrow cells.  Mice recovered from the acute affects of irradiation and 
haematopoietic aplasia but died of a subsequent disease which caused weight loss, 
skin rash, diarrhoea and appetite loss (Barnes, Loutit et al. 1962), later described by 
Simonsen as GvHD (Simonsen 1965).  The three requirements for the development 
of GvHD were formulated soon after by Billingham (Billingham 1966) who 
demonstrated that firstly, immunologically competent cells are required and that the 
level of GvHD severity is directly associated with donor mature T cells (Kernan, 
Collins et al. 1986; Korngold and Sprent 1987).  Secondly, recipients must be 
immuno-compromised and therefore incapable of rejecting the donor cells, a 
conditioning induced by chemo/radio therapy (Welniak, Blazar et al. 2007).  Thirdly, 
the recipient must express antigens not present in the original donor, this observation 
was a major step in the discovery of the mouse and human MHC loci (Petersdorf and 
Malkki 2006) (Krensky, Weiss et al. 1990).   
 
7.1.2:  Acute GvHD and T cells 
 GvHD has two major classifications, chronic and acute GvHD.  Chronic 
GvHD occurs typically from 3 months post-transplant and is induced by T cells 
resulting from engrafted bone marrow.  It is associated with T cells that escape 
negative thymic selection (Whedon and Wujcik 1997) and it is analogous to systemic 
Lupus Erythematosis in terms of symptoms.  In contrast, acute GvHD represents a 
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normal but exaggerated inflammatory response, shortly after transplantation, in an 
environment where the effect is undesirable.  Donor lymphocytes, usually infused to 
treat leukaemia, encounter tissues that have been damaged by conditioning radiation.  
Donor cells not only respond to a foreign environment but to one that has been 
altered to a proinflammatory phenotype promoting activation and proliferation.  
Therefore acute GvHD is an exaggerated version of a normal inflammatory immune 
response (Reddy and Ferrara 2003) and is characterised by three phases.   
 The first stage of acute GvHD is the activation of APCs.  This can be 
triggered by total body irradiation therapy prior to the infusion of allogenic donor 
bone marrow (Clift, Buckner et al. 1990) leading to changes in the local 
inflammatory environment whereby damaged tissues release factors such as IL-1 and 
TNF, in what is known as a cytokine storm (Hill and Ferrara 2000).  This leads to 
increased expression of adhesion molecules, co-stimulatory molecules, MHC and 
chemokines that can recruit infused donor lymphocytes (Hill and Ferrara 2000).  
Furthermore, damage to certain tissues such as the gastrointestinal tract can lead to 
systemic translocation of microbial compounds such as LPS inducing a Th1 pattern 
APC activation in the local environment, which may be the source of donor T cell 
priming of activated APCs (Paris, Fuks et al. 2001; Murai, Yoneyama et al. 2003).  
The relationship between the initial radiation intensity and the resultant GvHD is 
strongly correlated with higher levels leading to increased cytokine production, tissue 
damage and APC activation, as shown by elegant murine studies (Hill, Crawford et 
al. 1997; Paris, Fuks et al. 2001).  Amongst APCs, DCs are the most important in 
inducing GvHD which can be regulated by qualitatively or quantitatively modulating 
DC subsets (Duffner, Maeda et al. 2004; Chorny, Gonzalez-Rey et al. 2006), with 
DC ablation prior to irradiation resulting in reduced GvHD severity (Auffermann-
Gretzinger, Lossos et al. 2002).   
The second phase of acute GvHD is caused by infused donor T cells that 
interact with primed APCs in secondary lymphoid organs where they are primed and 
activated for subsequent proliferation and migration (Beilhack, Schulz et al. 2005).  
T cells can interact with either host (direct presentation) or donor APCs (indirect 
presentation) (Shlomchik 2003).  For direct presentation T cells will bind either 
directly to MHC (in the case of a MHC mismatch) or to peptide bound to MHC 
(minor H mismatch) while indirect presentation results from the degradation of 
antigens for presentation by donor APCs in the context of self-MHC (Lechler, Ng et 
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al. 2001).  It is direct rather than indirect presentation that is critical in inducing 
GvHD to minor H antigens (Shlomchik 2003).  T cell activation is further induced by 
binding co-stimulation molecules on host APCs that have been upregulated in 
response to the cytokine storm induced by irradiation.  The B7 and TNF family 
receptors play a crucial role in GvHD (Greenwald, Freeman et al. 2005), and their 
blockade can reduce murine GvHD (Blazar, Sharpe et al. 2003).  On the other hand, 
blockade of co-inhibitory receptors such as PD-1 and CTLA-4 on T cells can 
increase the severity of GvHD (Perez, Van Parijs et al. 1997; Blazar, Carreno et al. 
2003).   
Following co-stimulation and TCR engagement, T cells are induced to 
transcribe Th1 cytokines such as IFN-, IL-2 and TNF all of which have been 
implicated in GvHD (Liu, Siegel et al. 2007).  Anti-IL-2 therapy has been used to 
treat GvHD in many studies (e.g., cyclosporine therapy) although the role of IL-2 in 
inducing and maintaining Tregs seems to have a reverse role requiring IL-2 for the 
development of long-term tolerance (Gavin, Rasmussen et al. 2007).  IFN and other 
Th1 cytokines play a role dependent on the level of mismatch and the initial radiation 
dose while regulatory cytokines such as IL-10 and TGF-  have a crucial role in 
suppressing experimental GvHD (Lin, Storer et al. 2003) (Banovic, MacDonald et al. 
2005).  Following activation in lymphoid organs, donor T cells traffic to target 
organs directed by chemokine gradients induced by the initial cytokine storm where 
they induce tissue damage (Wysocki, Panoskaltsis-Mortari et al. 2005).  T cells can 
then cause further recruitment of leukocytes for example by the release of 
macrophage inflammatory protein 1 alpha (MIP-1) which has been shown to 
increase CD8 T cell migration to liver, lung and spleen (Serody, Burkett et al. 2000).  
The final and most damaging phase of acute GvHD is the effector phase.  
This can be grouped into cellular effectors such as CTLs and NK cells and 
inflammatory effectors such as cytokines and chemokines, a combination of which is 
a likely determinant of the severity of GvHD (Sallusto, Mackay et al. 2000).   CTLs 
and NK cells are the main effectors of GvHD, mediating their effect through Fas-
FasL, perforin and TNFR apoptosis-inducing ligands such as TRAIL (van den Brink 
and Burakoff 2002).  Infusion of perforin deficient T cells can significantly delay the 
onset of GvHD against minor H antigens but does not abrogate the disease (van den 
Brink and Burakoff 2002).  The perforin pathway seems to be the main mechanism 
225 
 
of CD8 T cell-induced GvHD, while CD4 effectors preferentially use the Fas-FasL 
pathway (Jaksch and Mattsson 2005).  FasL deficient CD4 T cells effect significantly 
reduced GvHD in the liver, skin and lymphoid organs (van den Brink and Burakoff 
2002), while treatment with anti-FasL can significantly reduce liver damage in 
GvHD (Hattori, Hirano et al. 1998).  GvHD is not completely prevented where donor 
T cells are deficient for both perforin and Fas suggesting a role for other effector 
molecules and/or cells such as NK cells (Jiang, Podack et al. 2001). 
The production of inflammatory mediators often synergises with CTL 
recruitment in GvHD.  Macrophages primed with IFN- released by the donor T cells 
can produce TNF and IL-1 upon secondary stimulation through Toll-like receptors.  
This can be caused by microbial compounds such as LPS which can be increased due 
to gastrointestinal tract damage during radiation conditioning (Hill and Ferrara 2000; 
Iwasaki and Medzhitov 2004).  The severity of GvHD appears directly related to 
immune cell priming which is conversely related to the level of TNF, IL-1 and 
nitric oxide produced (Teshima, Ordemann et al. 2002).  A role for TNF in GvHD 
was identified over 20 years ago when mice that developed GvHD following 
infusion of donor T cells showed high levels of TNF mRNA in damaged tissues 
(Piguet, Grau et al. 1987).  Anti-TNF therapy can also inhibit organ damage (Hill, 
Crawford et al. 1997).  TNF can induce maturation of DCs enhancing antigen 
presentation, recruitment of T cells, recruitment of monocytes and neutrophilis to 
target tissues through the induction of chemokines, thus causing direct tissue damage 
by inducing apoptosis in target tissues.  Phase II clinical trials using TNF 
antagonists have demonstrated reduced GvHD severity (Uberti, Ayash et al. 2005).  
IL-1 has also shown similar increases in mRNA levels correlating with GvHD 
severity and therapy using soluble IL-1R reduces GvHD severity (Abhyankar, 
Gilliland et al. 1993; Antin, Weisdorf et al. 2002) although this is not as profound as 
for TNF
 
7.1.3:  T cell response to persistent systemic minor H antigen in cancer models 
 T cells respond to minor H antigens on grafts or tumours in order to induce 
rejection of these tissues (see chapters 3 and 4) (Feng, Hui et al. 2008).  However, 
expression patterns of minor H antigens are not generally different between normal 
and tumour cells.  This broad expression of antigen can have the effect of inducing 
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chronic stimulation that can affect the activation threshold for T cells (Singh and 
Schwartz 2003).  However, over exposure to antigen can lead to an unresponsiveness 
of T cells, characterised by reduced cytokine production and poor proliferation in 
response to subsequent exposure to cognate antigen.  This is often characterised as T 
cell anergy; in some responses to minor H antigens this is actually T cell adaptive 
tolerance (Chiodetti, Choi et al. 2006).  The major feature of such T cell adaptation is 
their requirement for constant exposure to cognate antigen to remain unresponsive: 
this is reversible if T cells are removed from the antigen bearing host (Tanchot, 
Barber et al. 2001).  Adaptation therefore allows self antigen reactive T cells to 
persist which have obvious potential use against malignancies. 
 Several reports have recently demonstrated an ability to revive the function of 
antigen-specific CD4 T cells adapted to persistent systemic antigen stimulation 
(Rivas, Weatherly et al. 2009).  In this study, Marilyn CD4 T cells are unable to fully 
respond to chronic antigen exposure in lymphopenic male mice.  Marilyn T cells 
become quickly adapted, expressing high levels of negative co-stimulatory 
molecules.  Following negative co-stimulation blockade (PD-L1), a dramatic 
expansion of Marilyn cells was seen and a severe T cell mediated wasting disease 
was caused.  If combined with a sub-lethal dose of LPS, this could cause acute 
GvHD.  From these results it is clear that adapted T cells can be revived to function 
in proinflammatory environments where negative co-stimulation is blocked.  Other 
studies have found blockade of CTLA-4 can have a similar effect (Tivol, Borriello et 
al. 1995; Perez, Van Parijs et al. 1997).   
Kitamura et al (Kitamura, Sedlik et al. 2010) used adoptively transferred 
Marilyn CD4 T cells to treat methylcholanthrene induced HY positive (MCA-HY) 
transplantable tumour-bearing WT or Rag
-/- 
female B6 mice.  In these experiments 
vaccination using long chain peptides (containing HY-Dby (class II) and HY-Uty 
(class I) sequences) induced activation and proliferation of the adoptively transferred 
CD4 cells to an extent that caused death of recipients within hours of vaccination.  
This was associated with a dramatic increase in IFN-, IL-2 and TNF causing a 
cytokine storm that correlated with increased APC activation and priming.  This 
study implicates a role for both Th1 and Th17 responses in the induction of GvHD.  
Improvements in the specificity of T cells and priming strategies in anti-tumour 
treatments means caution must be taken when pre-conditioning or boosting as this 
can result in an acute, potentially lethal GvHD like syndrome. 
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7.1.4:  GvHD models 
 The availability of well characterised inbred mouse strains has led to the 
development of several mouse models of GvH responses.  GvHD caused by MHC 
disparity is well understood, CD4 and CD8 T cells mediate an additive pathology 
leading to a „cytokine storm‟ capable of inducing GvHD in organs and tissues by 
direct recognition of non-self MHC (Teshima, Ordemann et al. 2002; Reddy, Negrin 
et al. 2008).  Many mouse models are available for the study of minor H antigens in 
GvHD with CD4 or CD8 T cells having variable roles depending on genetic disparity 
and the experimental system. 
In the case of HY disparity T cells are activated by recognition of HY 
peptides expressed in the context of MHC.  These peptides are produced 
endogenously by male tissues, including the MB49 tumour (Scott, Ehrmann et al. 
1995) (see chapters 3 and 4).  In a series of experiments performed to assess MB49 
tumour growth profile in lymphopenic male mice, it was noted that adoptively 
transferred HY-specific Marilyn T cells became „adapted‟ in response to this chronic 
antigen exposure.  However if mice were pre-conditioned with sub-lethal irradiation 
(5Gy) the same T cells induced acute GvHD leading to death.  Based on these results 
it was decided to perform a study to evaluate the functional differences in T cell 
responses in lymphopenic male mice either pre-conditioned or not with radiation.  
This novel model allows dissection of the roles of minor H antigen-specific 
monoclonal HY-specific T cells in inducing GvHD  
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7.2:  Results 
 
7.2.1:  Impact of adoptive transferred Marilyn T CD4 cells on the growth of 
MB49 tumours in lymphopenicB6 mice with or without pre-conditioning (5Gy)  
 Marilyn CD4 T cells are capable of rejecting MB49 tumours upon adoptive 
transfer to lymphopenic B6 female mice whereas Matahari CD8 T cells cannot do so 
(Perez-Diez, Joncker et al. 2007) (see chapter 4).  Following adoptive Marilyn cell 
transfer to MB49-bearing Rag
-/-
 B6 mice, all female recipients showed regression of 
MB49 tumours and survived as tumour free by day 30, whereas males developed 
tumours reaching humane end points by day 26 (Fig. 7.1a).  Additional groups of 
females (Fig. 7.1b) and males (Fig. 7.1c) were sub-lethally irradiated (5Gy).  Female 
mice developed tumours at the same rate whether irradiated or not, with no statistical 
difference between the groups (Fig. 7.1b).  3 out of 5 female mice were culled due to 
ulceration, most likely caused by irradiation damage, however, the 2 mice that did 
not ulcerate showed tumour regression by day 30, similar to the non-irradiated group 
given Marilyn cells (Fig. 7.1.b).  Male mice that received irradiation and Marilyn 
cells developed tumours at the same rate as the non-irradiated male recipients of 
Marilyn cells, with no statistical difference in growth rate.  However, these irradiated 
male recipients became very sick with weight loss, skin problems, hunched posture 
and low body temperature, requiring them to be culled by day 12.  These 
observations suggested that the donor Marilyn cells were inducing an acute GvHD in 
male mice when infused with T cells after pre-conditioning with radiation.  
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Figure 7.1. Marilyn cells can induce GvHD in B6 Rag
-/-
 male mice following 
irradiation (5Gy)  
MB49 cells (1 x10
5
 cells/mouse) were injected (s.c) to the right lateral flank of 
female (n=10) and male (n=9) B6 Rag
-/-
 mice on day 0.  On day 7, 4 male and 5 
female mice were irradiated with 5Gy.  Also on day 7, SP+LN were harvested from a 
Marilyn Rag1
-/-
 donor female mouse and injected at 1 x 10
7
 (i.v.).    
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a. Average tumour growth profile of male (red line) and female (blue line) B6 Rag
-/-
 
mice that received Marilyn cells alone.  Tumour growth was measured on 
consecutive days using digital callipers and tumour area calculated (length x width 
(mm
2
)). 
b. Average tumour growth profile of female mice that received either Marilyn cells 
alone (blue line) or with 5Gy irradiation (red line). 
c. Average tumour growth profile of male mice that received either Marilyn cells 
alone (blue line) or with 5Gy irradiation (red line). 
Results are an average of each group.  Error is expressed as ± standard error mean. 
 
 
7.2.2:  Marilyn cell transfer induces weight loss in male mice but pre-
conditioning (5Gy) is required to cause acute GvHD 
 Marilyn CD4 T cell transfer alone does not induce lethal GvHD upon 
adoptive transfer to male lymphopenic hosts, although this can cause a transient 
weight loss with recovery (Rivas, Weatherly et al. 2009).  In an initial experiment, 
male Rag
-/-
 B6 mice were either irradiated (5Gy) alone, subjected to Marilyn cell 
transfer alone or both, while female Rag
-/-
 B6 mice were subjected to both irradiation 
and cell transfer (Fig. 7.2).  Weight was measured at regular intervals up to day 6 
when mice were sacrificed for analysis of donor populations (See Fig. 7.4).  Weight 
change is plotted as percentage of weight at day 0, prior to irradiation or T cell 
transfer.   
Non-irradiated male mice (open squares) showed very little weight change, 
similar to irradiated female recipients that received Marilyn cells (open triangles) 
(Fig. 7.2) suggesting that irradiation with adoptive transfer of Marilyn cells does not 
directly induce weight loss in the absence of HY antigens.  Male mice that received 
5Gy alone displayed some weight loss (closed circles) although this was not 
significant compared to the untreated group (open squares).  Non-irradiated male 
mice that received Marilyn cells lost weight from day 3 following T cell transfer 
(open circles) and this weight loss was significant compared to male mice given 
irradiation alone group and female mice that received irradiation and Marilyn cells.  
These data indicate that Marilyn cell transfer alone in male lymphopenic mice does 
not cuase GvHD as these recipients remain healthy in appearance.  Male mice that 
received Marilyn cell transfer and irradiation (closed triangles) showed the most 
dramatic weight loss from day 1, which was more profound than Marilyn cell 
transfer alone.  Irradiated male mice given Marilyn cells also displayed signs of 
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clinical acute GvHD with hunched posture, reduced activity, piloerection, skin 
problems and low body temperature to the point where mice they either died or 
reached the humane end point by day 6.  
 
Figure 7.2. Marilyn cells can induce GvHD in male mice following radiation 
pre-conditioning  
SP and pLNs were harvested from Marilyn Rag2
-/-
 female mice and injected (i.v.) 
into 9 Rag
-/-
 B6 mice at 1 x 10
7
/mouse (6 male and 3 female). One group (n=3) of 
each sex was sub-lethally irradiated (5Gy) prior to Marilyn cell transfer.  Weight was 
measured at regular intervals and plotted as % weight change.  G1 - male with 5Gy 
alone (closed circles), G2 - male with Marilyn cells alone (open circles), G3 - male 
with 5Gy and Marilyn cells (closed triangles), G4 - female with 5Gy and Marilyn 
cells (open triangles), G5 - untreated male mice. n=3 for all groups. Error is 
expressed as ± standard error mean. 
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7.2.3:  Marilyn CD4 T cell transfer together with radiation pre-conditioning 
(5Gy) induces lethal GvHD 
 Lymphopenic male mice that receive Marilyn cells lose a significant amount 
of weight without developing GvHD.  To confirm weight loss is dependent on 
Marilyn T cells and not other cells present in the donor suspension of spleen and 
lymph node cells (SP+LN), the experiments were repeated using four groups of Rag
-
/- 
B6 male recipients.   Male mice were given 5Gy alone (G1) with purified Marilyn 
T cells (G2) or Marilyn spleen and lymph node cell suspension (G3).  In addition, 
one group of male mice were given purified Marilyn T cells alone (G4).   
As shown in Fig. 7.3a, mice that received 5Gy alone (G1) lost some weight 
but this was fully recovered.  All mice in G2 and G3 lost weight rapidly reaching the 
humane end point by day 8.  Weight loss was accompanied by acute GvHD with 
hunched posture, low body temperature, piloerection, skin problems and low activity 
(Fig. 7.3b).  Interestingly, the use of purified CD4 T cells (G2) did not accelerate the 
onset of GvHD compared to that of spleen and lymph node cell suspension (G3), 
with no significant difference in weight loss between the two groups.  Importantly 
non-irradiated males that received enriched T cells alone (G4) did show a significant 
amount of weight loss compared to the 5Gy alone group (G1), and showed no signs 
of clinical GvHD, with 100% survival (Fig. 7.3b).  These mice however also showed 
significantly reduced weight loss compared to G2 and G3 but recovered to within 5% 
of their starting weight by day 12.  These data confirm that it is Marilyn CD4 cells 
that induce GvHD, as purified Marilyn CD4 T cells and Marilyn spleen and lymph 
node cells (containing both T cells and APC) have similar capacity to trigger GvHD 
in male mice after 5Gy. 
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Figure 7.3. GvHD in irradiated male mice is induced by Marilyn CD4 T cells  
Spleen and pLNs were harvested from two Marilyn Rag2
-/-
 female mice and were 
injected at 1 x 10
7 
(i.v.) to sub-lethally irradiated (5Gy) Rag
-/-
 B6 male mice (n=10, 
G3 open squares).  One group of Rag
-/-
 male mice (n=7) received sub-lethal 
irradiation (5Gy) alone (G1 closed circles).  SP+LNs from two Marilyn Rag2
-/-
 
female mice were used to purify CD4 T cells by MACS which were injected (4 x 10
6
 
cells; i.v.) into sub-lethally irradiated (5Gy) Rag
-/-
 B6 male mice (n=6) (G2 closed 
squares) or to non-irradiated Rag
-/-
 mice (n=6) (G4 open circles).   
a. Weight was measured at regular intervals and plotted as % weight change.  Error 
is expressed as ± standard error mean. 
b. Percentage survival for each group as described above. 
 
 
234 
 
7.2.4:  Irradiation does not influence Marilyn T cell expansion in Rag
-/-
 B6 male 
recipients  
 Marilyn CD4 T cells may be able to proliferate more robustly after irradiation 
in lymphopenic hosts which may lead to increased pathological T cell responses.  To 
evaluate the expansion of adoptively transferred T cells, male and female Rag
-/-
 B6 
mice were adoptively transferred with Marilyn spleen and lymph node cells, with or 
without 5Gy pre-conditioning (Fig. 7.2 and Fig. 7.4a).  On day 6, mice were analysed 
for the frequency of donor cells in peripheral lymphoid organs.  As expected, donor 
cells transferred to males expanded significantly more than those in female mice, due 
to the combination of HY driven and non-specific homeostatic proliferation. 
Surprisingly, there was no indication that donor T cells underwent greater expansion 
in male mice given 5Gy compared with non-irradiated male mice, with no difference 
in donor T cell frequency in various lymph nodes between the groups (Fig. 7.4a).  
However, at day 6 when the mice were culled for the analysis, male mice that 
received 5Gy and T cells showed signs of weight loss, skin problems, low body 
temperature and a hunched appearance whereas male mice that received T cells alone 
showed some weight loss but appeared to be generally healthy.  As shown 
previously, female mice that received both T cells and irradiation were also healthy 
and showed no signs of weight loss.   
In a separate experiment, male and female Rag
-/-
 B6 mice received enriched 
(MACS purified) Marilyn CD4 T cells with or without irradiation (5Gy); all mice 
were culled at day 8 for analysis.  Absolute donor cell numbers were calculated in 
the organs specified in Fig. 7.4b.  Donor T cells underwent significant expansion 
only in the male 0Gy and 5Gy groups.  In addition, male mice showed donor T cell 
infiltration into non-lymphoid organs while females did not (Fig. 7.4b).  However, 
there was no significant difference between absolute donor cell numbers recovered 
from various tissues between irradiated and non-irradiated male recipients (Fig. 
7.4b).  Tissues were also weighed, allowing absolute cell number per mg of tissue to 
be calculated (Fig. 7.4c).  Again no significant difference was seen in absolute cell 
number between irradiated and non-irradiated male recipients (Fig. 7.4c).  These data 
show that enhanced expansion of the donor T cell population is not the sole 
mechanism responsible for the development of GvHD in this model.  
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Figure 7.4. Comparison of Marilyn CD4 T cell expansion in Rag
-/-
 B6 male mice 
with or without 5Gy pre-conditioning  
a. SP and pLNs were harvested from Marilyn Rag2
-/-
 female mice and injected (i.v.) 
into 9 Rag
-/-
 B6 mice at 1 x 10
7
/mouse (6 male and 3 female). One group (n=3) of 
each sex was sub-lethally irradiated (5Gy) prior to Marilyn cell transfer.  On day 6, 
all mice were sacrificed and pLN including iLN (inguinal) cLN (cerviacal) and mLN 
(mesenteric) were harvested and stained using anti-V6FITC, anti-CD4PE and anti-
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Thy1.1
PerCP
 and analysed by FACS.  Donor cells are represented as % of total 
lymphocytes.  N=3 for each group.  
b. Marilyn CD4 T cells were purified from SP +LN cells by MACS and injected 
(i.v.) at 4 x 10
6
 cells/mouse to irradiated (5Gy) male (n=4) and female (n=2) Rag
-/-
 
B6 mice and one group of non-irradiated male Rag
-/-
 B6 mice (n=4).  On day 8 mice 
were sacrificed and peripheral lymphoid (pLN, mLN, SP) and non-lymphoid organs 
(heart, kidney, liver, and lung) were harvested and cells were counted.  Cells were 
stained as above and analysed by FACs and absolute donor cells numbers in each 
organ was calculated using proportion of donor cells x total cells.   
c. Tissues were weighed and data presented as absolute cell donor cell number per 
mg tissue.  All Error is expressed as ± standard error mean. 
 
 
7.2.5:  Marilyn T cells transferred to male lymphopenic mice become activated 
 Donor T cells in the same experiment as shown in Fig. 7.4b were also 
examined for their phenotype.  Donor T cells in lymphoid and non-lymphoid organs 
were gated for a further analysis of T cell activation markers CD44 and CD62L (Fig. 
7.5).  In addition, Rag2
-/-
 Marilyn female mice whose T cells display a resting 
phenotype and „double‟ transgenic Marilyn TCR+/dominant negative TGF receptor 
type II
+
 (dnTGFRII+) [F1(dnTGFRII+ x Rag2-/- Marilyn+) female)], whose CD4 T 
cells are expected to display a chronic activation phenotype were included for 
comparison (Gorelik and Flavell 2001) (Fig. 7.5c). 
 All donor T cells recovered from lymphoid tissues in male mice with (Fig. 
7.5b) or without (Fig. 7.5a) irradiation, were predominantly CD44 high, indicating an 
activated phenotype.  Similarly, non-lymphoid organs from both groups of male mice 
were also significantly infiltrated (Fig. 7.5a and b) with donor CD4 T cells, which 
expressed of CD44.  As expected, CD4 T cells from the naïve Rag2
-/-
 Marilyn female 
mouse showed no signs of activation, with most cells being predominantly CD44 low 
and CD62L high, a naive phenotype, in both lymphoid and non-lymphoid organs 
(Fig. 7.5d).  On the other hand, CD4 T cells from the Marilyn double transgenic 
mouse (Fig. 7.5c) showed a higher state of activation, with many CD4
+
 T cells 
becoming CD44 high, particularly in non-lymphoid organs.  Finally, female Rag
-/-
 
B6 mice that received irradiation and T cell transfer showed little T cell expansion 
(Fig. 7.4b) and displayed a naive phenotype (Fig. 7.5e), similar to those from 
Marilyn Rag
-/-
 female mice (Fig. 7.5d).  Only cells isolated from peripheral lymph 
nodes, spleen and liver are represented for female recipients as other organs did not 
have sufficient cells for analysis.  These data indicate that Marilyn CD4
+
 T cells 
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become activated upon transfer to lymphopenic male mice infiltrate into non-
lymphoid organs.  Donor CD4 T cells in female recipient mice show poor expansion, 
activation and organ infiltration, indicating that the induction of GvHD requires 
antigen dependent organ infiltration along with sub-lethal irradiation.  This is 
supported by the phenotype of Marilyn double transgenic mice which have activated 
organ infiltrating T cells and a spontaneous autoimmune phenotype with wasting 
disease syndromes (loss of weight).  
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Figure 7.5. Marilyn CD4 T cells become activated in lymphopenic male mice  
Donor Marilyn spleen and pLNs were harvested, purified by MACS and injected 
(i.v.) at 4 x 10
6
 cells/mouse to irradiated (5Gy) male (n=4) and female (n=2) Rag
-/-
 
B6 mice and one group of non-irradiated male Rag
-/-
 B6 mice (n=4), as described in 
Fig. 7.4  On day 8, two mice from each group were sacrificed along with a naive 
Marilyn Rag2
-/-
 female mouse and a naïve double transgenic mouse.  Lymphoid 
tissues (pLN, mLN, SP) and non-lymphoid organs (heart, kidney, liver and lung) 
were harvested and cells were stained with anti-CD62L
FITC
, anti-V6PE, anti-
CD4
PerCP
 and anti-CD44
APC
.  Donor CD4 T cells were gated on lymphocytes and 
then V6+ CD4+ cells, FACS plots represent CD44 and CD62L expression by gated 
donor T cells. 
a. Male Rag
-/-
 B6 mice received T cell alone (n=4) (one representative FACS plot 
shown). 
b. Male Rag
-/-
 B6 mice received T cells and 5Gy radiation pre-conditioning (n=4) 
(one representative FACS plot shown). 
c. Double transgenic female mouse.  
d. Marilyn Rag2
-/-
 female mouse. 
e. Female Rag
-/-
 B6 mice received T cells and 5Gy radiation pre-conditioning (n=2) 
(one representative FACS plot shown). 
 
 
 
7.2.6:  Donor CD4 T cells in irradiated male mice harbour more effector 
memory and less central memory T cells 
 The data acquired from the peripheral lymph node suspensions in Fig. 7.5 
was quantitatively analysed to reveal any differences in memory T cell subsets 
between lymphopenic male mice that receive T cells alone and those that received T 
cells and 5Gy (Fig. 7.6).  Naive T cells are defined as CD44
low
CD62L
high
, effector 
memory (EM) cells are defined as CD44
high 
CD62L
low
 and central memory (CM) 
cells are defined as CD44
high
CD62L
high
.  EM T cells are associated with cytotoxic 
activity and mediate killing through Granzyme B and IFN CM cells act as a stem 
cell like memory pool that primarily home to lymphoid organs and produce IL-2 but 
not IFN- or Granzyme B (Okada, Kondo et al. 2008). 
As expected, T cells in peripheral lymph nodes of naïve Rag
-/- 
Marilyn female 
mice have a primarily naive phenotype while those from double transgenic mice 
have significantly higher levels of EM and CM T cells (Fig. 7.6), reflecting their 
spontaneous autoimmune phenotype.  Donor CD4 T cells isolated from female Rag
-/-
 
B6 recipients that received 5Gy and Marilyn T cells maintained a mainly naïve T cell 
phenotype with ~20% becoming CM cells and ~1% EM cells.  Male Rag
-/-
 B6 mice 
that received T cells with or without 5Gy had converted >99% of donor T cells to an 
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EM or CM activated phenotype.  There was a clear difference between the phenotype 
of donor cells recovered from male and female recipient mice and also between male 
mice and two the strains of control mice (i.e., single transgenic and double transgenic 
mice).  Male mice that received 5Gy and T cells have significantly more EM cells 
and significantly fewer CM cells compared to the 0Gy and T cell group (Fig. 7.6).  
These mice have similar absolute donor cell numbers in lymphoid and non-lymphoid 
organs (Fig. 7.5b and c).  Collectively, these results demonstrate that donor Marilyn 
T cells expand in male but not female mice (Fig. 7.4).  In addition, activated T cells 
in males migrate into non-lymphoid organs, displaying a CD44
high
 phenotype (Fig. 
7.5).  Male mice have a higher level of donor cell activation compared to female 
mice and control mice (Fig. 7.6) but similar absolute numbers of donor cells (Fig. 
7.5b and c), male mice receiving 5Gy in addition to T cells preferentially expand EM 
T cells compared to 0Gy mice (Fig. 7.6). 
Figure 7.6. Adoptive transfer to male mice induces donor T cells to become EM 
Donor Marilyn cells were harvested, purified by MACS and injected (i.v.) at 4 x 10
6
 
cells/mouse to irradiated (5Gy) male (n=4) and female (n=2) Rag
-/-
 B6 mice and one 
group of non-irradiated male Rag
-/-
 B6 mice (n=4), as described in Fig. 7.4.  On day 
8, 2 mice from each group were sacrificed along with a naive Marilyn Rag2
-/-
 female 
mouse and a naïve double-transgenic mouse.  Peripheral LNs were harvested and 
cells were stained using anti-CD62L
FITC
, anti-V6PE, anti-CD4PerCP and anti-
CD44
APC
.  Cells were gated on lymphocytes and then V6+ CD4+ cells and analysed 
by FACS for CD62L and CD44 expression (Fig. 7.5).  Mean % of naive (CD62L
+
 
CD44
-
) (green), effector memory (CD62L
- 
CD44
+
) (blue) and central memory 
(CD62L
+
 CD44
+
) (red) T cells were calculated.  Error is expressed as ± standard 
error mean. 
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7.2.7:  Donor cells recovered from male recipient mice with or without 5Gy have 
similar cytokine production profiles 
 The cytokine production profiles of donor Marilyn cells in each group were 
analysed as for the experiment described in Fig. 7.5.  Cells were stained ex vivo for 
T-bet and were also stimulated in vitro and stained for INF, TNF, IL-17 and IL-10 
expression.  The Th1 transcription factor T-bet is induced upon activation of T cells, 
particularity CD4 T cells, and its expression is required for expression of 
IFN(Szabo, Kim et al. 2000).  Marilyn donor T cells isolated from male mice that 
received T cells showed a very high proportion of cells expressing T-bet and IFN- 
(Fig. 7.7a and b), indicative of the strong activation phenotype (Fig. 7.5 and 7.6), 
although no significant difference was seen between recipients of 0Gy and 5Gy.  
This phenotype is also reflected in the mean fluorescence intensities (MFI) of T-bet 
and IFN- (Fig. 7.7c).  Conversely, donor cells recovered from female mice that 
received 5Gy and T cells from Marilyn Rag
-/-
 mice showed little expression of T-bet 
or IFN- (Fig. 7.7a) either by proportion or MFI (Fig. 7.7c).  Donor CD4 T cells 
isolated from double transgenic mice displayed an intermediate phenotype in the 
lymphoid organs with a moderate upregulation of both T-bet and IFN- (Fig. 7.7 b 
and c) 
Unlike IFN, TNF production by donor T cells from male mice was low 
with no significant difference between male and control groups (Fig. 7.7a) either by 
proportion (Fig. 7.7b) or MFI (Fig. 7.7c).  Female mice receiving 5Gy showed high 
expression of TNF both as a proportion (Fig. 7.7b) and MFI (Fig. 7.7c) although 
this result is not conclusive due to the very low cell recovery (Fig. 7.7a).  
Importantly, neither expression of IL-17 nor IL-10 by donor CD4 T cells was seen in 
male recipient mice that received T cells, suggesting that donor T cells are driven 
towards a Th1 rather than a Th17 phenotype (Fig. 7.7a). 
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Figure 7.7. Marilyn CD4 cytokine expression profile in GvHD mice  
Donor Marilyn cells were harvested, purified by MACS and injected (i.v.) at 4 x 10
6 
cells/mouse into irradiated (5Gy) male (n=4) and female (n=2) Rag
-/-
 B6 mice and 
one group of non-irradiated male Rag
-/-
 B6 mice (n=4), as described in Fig. 7.4. On 
day 8, 2 mice from each group were sacrificed along with a naive Marilyn Rag2
-/-
 
female mouse and a naïve double-transgenic mouse.  Lymphoid (pLN, mLN, SP) and 
non-lymphoid organs (heart, kidney, liver, and lung) were harvested and half of the 
cells were surface stained using anti-V6FITC and anti-CD4PerCP, cells were fixed and 
intracellular stained with anti-T-bet
PE
.  The other half was stimulated for 4 hours 
with PMA (50ng/ml) + Ionomycin (250ng/ml) in the presence of Brefeldin A 
(1g/ml), cells were harvested, and after removal of dead cells, the cells were surface 
stained for anti-V6FITC and anti-CD4PerCP.  Cells were then fixed and stained for 
TNFPE, IFNAPC or IL-17PE, IL-10APC and analysed by FACs gating on lymphocytes 
and then V6+CD4+ cells. 
a. Intracellular production of T-bet, INF and TNF by donor T cells in pLN from 
5Gy male mice, 0Gy male mice, 5Gy female mice and Marilyn Rag
-/-
 mice is 
represented by plots of CD4 (Y axis) vs cytokine expression.  Expression of IL-17 (Y 
axis) and IL-10 (X axis) is shown for the 5Gy male and 0Gy male groups only.  One 
representative FACs plot for each group is shown. 
b. Average proportions of cells in CD4
+
 V6+ gate expressing T-bet (blue), IFN 
(red) and TNF (Green) for lymphoid tissues (pLN, mLN, SP) and non-lymphoid 
organs (heart, kidney, liver, and lung).  Error is expressed as ± standard error mean. 
c. Average mean fluorescence intensity of cells in CD4
+
V6+ gate expressing T-bet 
(blue), IFN (red) and TNF (Green).  Error is expressed as ± standard error mean. 
 
 
 
7.2.8:  Delayed Pre-conditioning (5Gy) of Rag
-/-
 B6 male abrogates lethal GvHD 
 To determine whether timing of irradiation would be critical to the induction 
of lethal GvHD, one group of male Rag
-/-
 B6 mice were given 5Gy irradiation ten 
days prior to T cell transfer (Fig. 7.8).  Mice initially lost weight following 5Gy 
treatment at day -10 but recovered to within 5% of their original weight by day 0.  
On day 0, mice were injected (i.v.) with purified Marilyn CD4 T cells.  From day 3 
onwards mice showed a rapid loss of weight, as was seen in the control group of 
mice receiving 5Gy and T cells on the same day (day 0) (Fig .7.3-7 and Fig. 7.8a).  
By day 7, all mice showed clear signs of acute GvHD with hunched posture, reduced 
body temperature, skin problems and piloerection.  All were expected to reach 
humane end point by day 8 as did control mice receiving T cells and 5Gy at day 0 
(Fig. 7.8a).  However mice in the group irradiated ten days before being given 
Marilyn cells began to recover and gain weight over the next 12 days and by day 20 
none of them showed signs of acute GvHD (Fig. 7.8a and b),  all recovering to their 
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original weight by day 30.  This result indicates that T cell transfer following 
irradiation 10 days previously induces a weaker, transient form of acute GvHD 
which does not reach the humane end points.  Therefore the initial in vivo 
environment (cytokine storm) created following radiation precondition is important 
in determining the level of acute GvHD induced. 
 
Figure 7.8. Timing of radiation pre-conditioning is critical to the development of 
lethal GvHD  
SP and pLNs were harvested from a Marilyn Rag2
-/-
 donor mouse and subjected to 
MACS purification of CD4 cells.  T cells were injected (i.v.) at 4 x 10
6
 cells/mouse 
at day -10 to sub-lethally irradiated (5Gy) Rag
-/-
 mice (n=7).  5Gy and enriched T 
cells were also given to male mice on day 0 in a separate experiment (from Fig. 7.3-
7) and is included as a reference (n=10). 
a. Weight was measured at regular intervals and plotted as % weight change.  Error 
is expressed as ± standard error mean. 
b. Percentage survival for each group as described above. 
244 
 
7.2.9:  T cells from male mice irradiated on day -10 exhibit adaptive tolerance 
 Male mice receiving 5Gy on day-10 prior to Marilyn CD4 T cell transfer 
became sick but did not die from acute GvHD (Fig. 7.8).  Once they had recovered to 
their original starting weight by day 30, 2 mice were sacrificed and donor cells 
analysed for expression of surface markers CD44 and CD62L (as in Fig. 7.5.) and 
intracellular cytokines (as in Fig. 7.7.).  Donor cells from male mice given 5Gy on 
day -10 become CD44
+
 as seen with those isolated from mice given 5Gy on day 0 
(Fig. 7.9a) however, these T cells display an intermediate CD44 expression, 
characteristic of chronically activated adapted T cells (Chiodetti, Choi et al. 2006).  
Donor cells isolated on day 8 from mice given Marilyn cells and 5Gy on day 0 were 
used as a reference.  This is not a direct comparison, due to the different stage of T 
cell activation, as this group does not survive to day 30.   
Donor cells isolated from lymphoid and non-lymphoid tissues were also 
stained for T-bet or cultured with PMA and Ionomycin in the presence of Brefeldin 
A for 4 hours.  As shown in Fig. 7.7, the cells were then harvested, stained for IFN- 
and analysed by FACS to  determine the proportions (Fig. 7.9c) and MFI (Fig. 7.9d) 
of T-bet and IFN expressing T cells.  Donor cells from mice receiving 5Gy on day-
10 show low production of the transcription factor T-bet and the Th1 cytokine IFN- 
(Fig. 7.9c and d) in donor cells isolated from lymphoid and non-lymphoid organs.  
This is reflected in both the MFI of T-bet and IFN- (Fig. 7.9b and c) and also the 
proportion of cells producing these molecules (Fig. 7.9b and c).  5Gy on day -10 
before injection of Marilyn T cells prevents the severe acute GvHD seen in mice that 
receive 5Gy on day 0.  Marilyn donor T cells from 5Gy day -10 male mice exhibit a 
CD44 intermediate phenotype with poor cytokine production.  
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Figure 7.9. Donor CD4 T cells from 5Gy day-10 mice are not fully activated 
SP and peripheral LNs were harvested from a Marilyn Rag2
-/-
 donor mouse and 
subjected to MACS purification of CD4 cells.  T cells were injected (i.v.) at 4 x 10
6
 
cells/mouse to sub-lethally irradiated (5Gy) Rag
-/-
 mice (n=7).  5Gy and enriched T 
cells were also given to male mice on day 0 and included as a reference (n=10).  On 
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day 30, two mice from the 5Gy day-10 group were sacrificed and analysed for T cell 
activation status.  
a. Lymphoid (pLN, mLN, SP) and non-lymphoid organs (kidney, liver, lung) were 
harvested and cells were stained using anti-CD62L
FITC
, anti-V6PE, anti-CD4PerCP 
and anti-CD44
APC
.  Cells were gated on Vb6
+
 CD4
+
 lymphocytes; FACS plots 
represent CD44 and CD62L expression from this gate.  One, representative set of 
plots is shown. 
b. Donor T cells were stained ex vivo for T-bet by intracellular staining (left) or 
cultured for 4 hours with PMA and Ionomycin in the presence of Brefeldin A (as in 
Fig. 7.7) and stained for intracellular INF-APC, one representative FACS plot is 
shown. 
c. Average mean fluorescence intensity of cells in the CD4
+
 V6+ gate expressing T-
bet (blue) and IFN (red). Error is expressed as ± standard error mean. 
d. Average proportion of cells in CD4
+
 V6+ gate expressing T-bet (blue) and IFN 
(red).  Error is expressed as ± standard error mean. (* P value <0.01, ** <0.05). 
 
 
 
 
7.2.10:  T cells from mice that have recovered from acute GvHD fail to induce 
disease upon secondary adoptive transfer 
 Two mice that recovered from acute GvHD in the previous experiment (Fig. 
7.8 and 7.9) were sacrificed on day 30 and donor Marilyn T cells were re-isolated 
using MACs purification.  These T cells were then adoptively transferred into 3 sub-
lethally irradiated (5Gy) B6 Rag
-/-
 male recipients and weight loss measured at 
regular intervals (open circles) (Fig. 7.10).  These mice did not develop any signs of 
acute GvHD or weight loss, compared with male recipients given 5Gy and T cells in 
the previous experiments (Fig. 7.3-7).  These data indicate Marilyn CD4+ T cells 
have adapted so that on secondary adoptive cell transfer they are unable to induce 
acute GvHD following radiation pre-conditioning on day 0. 
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Figure 7.10. T cells from mice that have recovered from acute GvHD failed to 
induce disease upon secondary adoptive transfer 
SP and pLNs were harvested from two male mice recovered from GVHD in the 
experiment depicted in Fig. 7.8.  On day 30 and CD4 cells MACs purified.  These re-
isolated CD4 T cells were injected (i.v.) at 4 x 10
6
 cells/mouse to 3 sub-lethally 
irradiated (5Gy) Rag
-/-
 B6 male mice (open circles).  Mice that receiving 5Gy (day 0) 
and SP+LN from a Marilyn Rag2
-/-
 donor mouse in Fig. 7.3 were included for 
reference (closed circles).  Weight was measured at regular intervals and plotted as 
% weight change.  Error is expressed as ± standard error mean. 
 
 
 
 
7.2.11:  Marilyn CD4 T cells can induce acute GvHD in FoxP3-DTR male mice 
following Treg depletion 
Mice with a novel diphtheria toxin receptor (DTR) knock-in strain were used 
as recipients for this set of experiments.  These mice are on a WT B6 background 
with genes encoding GFP and DTR inserted into the endogenous FoxP3 locus, 
leading to co-expression at the cell surface of DTR on green Tregs cells (Kim, 
Rasmussen et al. 2007).  This allows for efficient selective depletion of DTR-
expressing Tregs by administration of a sub-lethal dose of diphtheria toxin (DT) 
(both DT and FoxP3-DTR mice kindly provided by the group of Prof Daniel Altman 
at the Hammersmith Hosp).  Resting Marilyn T cells were purified as described 
previously and injected to sub-lethally irradiated (5Gy) male FoxP3-DTR mice.  One 
group of mice received a single dose of DT (i.p.) (12.5g) one day before T cell 
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transfer (closed squares) and the efficiency of DT-mediated Treg depletion 
confirmed by FACS.  
 Both DT treated and untreated mice lost weight rapidly following 5Gy 
radiation pre-conditioning and adoptive cell transfer (Fig. 7.11a) in a similar manner 
to lymphopenic recipients receiving Marilyn T cells alone (Fig. 7.3).  Mice that 
received the additional DT treatment one day before CD4 T cell transfer however 
showed signs of acute GvHD as described previously and all reached the humane end 
points by day 7 (Fig. 7.11b).  Mice that received no DT showed a similar degree of 
weight loss up to day 5 but did not display additional signs of acute GvHD, and these 
mice recovered to within 5% of their original weight by day 20 (2 mice were culled 
on day 7 for cytokine analysis, see next figure).  These data indicate that the GvHD 
can be induced in WT male B6 mice by adoptive transfer of HY-specific CD4 T cells 
if the polyclonal Treg compartment is removed, highlighting a role for Treg cells in 
controlling the activation of Marilyn T cells in vivo. 
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Figure 7.11. Tregs are crucial in preventing lethal GvHD induced by Marilyn 
CD4 T cells in male FoxP3-DTR mice 
SP and pLNs were harvested from a Rag2
-/-
 Marilyn female mouse and CD4 cells 
purified by MACS.  Purified Marilyn CD4 T cells were injected (i.v.) at 4 x 10
6
 
cells/mouse to sub-lethally irradiated (5Gy) male FoxP3-DTR mice (n=12).  A group 
of these mice (n=8) received a single dose of DT treatment (12.5g) 1 day prior to 
CD4 transfer by (i.p.) injection.   
a. Weight was measured at regular intervals and plotted as % weight change.  Error 
is expressed as ± standard error mean. 
b. Percentage survival for each group as described above. 
 
 
 
 
7.2.12:  Donor T cell cytokine analysis from FoxP3-DTR male mice is consistent 
with male lymphopenic mice 
  On day 7, when all DT treated mice had reached the humane end point, 2 
mice each from the DT treated and untreated group shown in Fig. 7.11 were culled.  
Lymphoid and non-lymphoid organs were harvested and the cells were plated out 
with PMA and Ionomycin in the presence of Brefeldin A, and analysed for the for 
Th1 cytokine profiles amongst adoptively transferred donor Marilyn CD4
 
T cells, as 
described previously (see Fig. 7.7).  Again little discernable difference was seen in 
proportion (Fig. 7.12a) or MFI (Fig. 7.12b) of donor cells producing TNF and 
IFN.  These data in combination with donor cell analyses from lymphopenic acute 
GvHD mice (Fig. 7.7 and 7.9) suggests that Marilyn CD4 T cells are able to induce 
acute GvHD with radiation pre-conditioning in lymphopenic mice or in conjunction 
with Treg depletion in WT mice.  However little functional or phenotypic differences 
were seen in the markers tested for donor Marilyn T cells from both groups, 
suggesting that the mechanisms for induction of lethal acute GvHD are complex and 
may directly or indirectly involve host cells. 
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Figure 7.12. Comparison of IFN and TNF production by donor CD4 T cells in 
DT treated and untreated mice 
On day 7, 2 mice from the DT-treated and untreated group were culled and 
peripheral lymphoid (pLN, mLN, SP) and non-lymphoid organs (heart, kidney, liver, 
lung) were harvested and stimulated for 4 hours with PMA + Ionomycin in the 
presence of Brefeldin A.  After removal of dead cells, cells were stained for anti-
V6FITC and anti-CD4PerCP.  Cells were then fixed and stained with anti-TNFPE and 
anti-IFNAPC.  Samples were analysed by FACS and were gated on lymphocytes and 
then V6+ CD4+ cells. 
a. Average proportion of cells in CD4
+
 V6+ gate expressing TNF (blue) and IFN 
(red).  Error is expressed as ± standard error mean. 
b. Average mean fluorescence intensity of cells in CD4
+
V6+ gate expressing TNF 
(blue) and IFN (red).  Error is expressed as ± standard error mean. 
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7.2.13:  TNF production is essential to induce GvHD 
TNF production has been shown to be strongly implicated in the severity of 
GvHD (Teshima, Ordemann et al. 2002), and higher serum levels of this cytokine 
increase Marilyn induced GvHD (Rivas, Weatherly et al. 2009; Kitamura, Sedlik et 
al. 2010).  Anti-TNF therapy has also been inhibit organ damage (Hill, Crawford et 
al. 1997) and reduce disease severity in humans (Uberti, Ayash et al. 2005).  To 
explore this further, four groups of Rag
-/-
 male mice were either untreated (G1) 
treated with T cells alone (G2), 5Gy alone (G3) or both (G4) and blood collected on 
days 1, 4 and 7, serum TNF levels were determined using a mouse ELISA kit 
(Biolegend™) (Fig. 7.13a).   Mice that received T cells (G2 and G4) produced 
significantly more TNF than untreated mice and those given 5Gy alone (G1 and 
G3), while 5Gy alone did not induce more TNF than untreated mice.  Mice that 
received 5Gy and T cells (G4) however produced more TNF at each time point than 
the T cell alone group (G2) with significantly higher levels on day 4.  An increased 
TNF level on day 4 correlates with peak GvHD severity and weight loss.    
In another experiment Rag
-/-
 male mice were given T cells alone (G1), 5Gy 
and Marilyn T cells (G2) or 5Gy, Marilyn T cells anti-TNF drug Embrel® (i.p.) 
(G3), (Embrel
®
 was developed by Immunex and kindly provided by Dr Richard 
Wilson, Kennedy Institute – Imperial college London).   A clear protective effect was 
seen in the anti-TNF treated group with significantly prolonged survival in this 
group (Fig. 7.13b and c) although this was not sufficient to prevent weight loss and 
eventual acute GvHD induced death in 6/7 mice.  TNFlevels in serum were 
positively associated with onset of acute GvHD. 
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Figure 7.13. TNF serum levels correlate to GvHD and anti-TNF reduces 
GvHD disease severity 
a. 4 groups of Rag
-/-
 male mice were either untreated (G1, n=3), given 5Gy alone 
(G3, n=2) injected with 1 x 10
7
 Marilyn SP+LN suspension alone (i.v.) (G2, n=2), 
injected with Marilyn cells with 5Gy (G4, n=2).  Blood was collected on days 1, 4 
and 7 and serum used for mouse TNFELISA (Biolegend™).  Plates were read at 
450nM absorbance (SpectramaxM2, Molecular Devices – SoftMax Pro) and protein 
concentrations calculated from the standard curve.  Error is expressed as ± standard 
error mean. (* P value 0.0329). 
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b. A separate group of Rag
-/-
 male mice were given 1 x 10
6
 Marilyn SP+LN 
suspension alone (i.v.) (n=3), Marilyn cells with 5Gy (n=5) or with additional anti-
TNF mAb (Embrel®) treatment, 400g in 200l (i.p.) in 4 doses (day 0, 3, 7 and 9) 
(n=7).  Weight was measured at regular intervals and plotted as % weight change.  
Error is expressed as ± standard error mean. 
c. Percentage survival for each group as described above. 
 
 
 
7.2.14:  Neither HY-specific nor polyclonal CD8 T cells are able to induce GvHD 
in male lymphopenic mice 
  Matahari CD8
+
 T cells express a transgenic, HY-specific TCR recognising 
the HY/UTY peptide in the context of H2D
b
 (see chapters 3 and 4).  In the next part 
of this study CD8 T cells were evaluated for their ability to induce GvHD in 
lymphopenic male mice given 5Gy irradiation (Fig. 7.14).  Due to the numbers of 
CD8 T cells in Matahari Rag
-/-
 mice, Matahari Rag
+/-
 female mice were used as tissue 
donors to provide HY-specific CD8 T cells.  As shown in Fig. 7.14, adoptive transfer 
of resting Matahari CD8 T cells to Rag
-/-
 B6 male mice receiving 5Gy did not induce 
significant weight loss (open circles) in comparison to those given 5Gy alone (closed 
circles).  In vitro activated Matahari CD8 T cells were then used as donor cells to test 
for inducing GVHD.  To prepare activated CD8 T cells, spleen and pooled lymph 
node cells from Rag
+/-
 Matahari mice were cultured with HY-D
b
UTY peptide and 
further expanded with rhIL-2.  These in vitro activated CD8 cells were injected to 
Rag
-/-
 B6 male mice that received 5Gy on day 0, but again no significant weight loss 
was seen compared to the 5Gy alone group (closed squares). 
 Matahari CD8 T cells represent a particular HY-specific CD8 T cell clone.  
These cells have also been identified as having a chronically activated self-reactive 
phenotype (chapter 4, Fig. 4.6).  To evaluate whether polyclonal HY-specific CD8 T 
cells can induce GvHD in this GVHD model, we have taken advantage of the 
availability of the HY-D
b
UTY tetramers.  Polyclonal T cells were sourced from WT 
B6 females that had previously rejected an MB49 tumour and then boosted with male 
bone marrow derived dendritic cells (BMDCs) by i.p. injection.  HY-D
b
UTY 
tetramer and CD8-double positive cells were FACS purified from spleen and pooled 
lymph node cells of these mice (see FACS panel inset in Fig. 7.14).  HY-specific 
CD8 T cells were injected (i.v.) into Rag
-/-
 B6 male mice given 5Gy; none of these 
recipients lost a significant amount of weight, nor did they show any signs of acute 
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GvHD (closed squares).  These data indicate that CD8 T cell responses to male 
antigen are insufficient to induce acute GvHD with radiation pre-conditioning. 
Figure 7.14. HY-specific CD8 T cells do not induce GvHD in lymphopenic male 
mice 
SP and peripheral LNs were harvested from two Matahari Rag
+/-
 donor mice.  Cells 
were MACS purified for CD8 and FACS sorted for V8.3PE+ CD8PerCP+ cells and 
injected (i.v.) at 4 x 10
6
 cells/mouse to sub-lethally irradiated (5Gy) Rag
-/-
 B6 male 
mice (n=10) (open circles).  One group of Rag
-/-
 B6 male mice (n=7) received sub-
lethal irradiation (5Gy) alone (closed circles).  SP and LN cells of Matahari Rag
+/-
 
donor mice were stimulated with 1nM D
b
UTY peptide for 2 days, and activated CD8 
T cells were further expanded for a further 2 days with 40IU/ml rhIL-2.  On day 4, 
cells were harvested and FACS purified as above and injected (i.v.) at 1 x 10
7
 
cells/mouse to sub-lethally irradiated (5Gy) Rag
-/-
 B6 male mice (n=4) (closed 
squares).  Finally tetramer
+
 CD8
+
 cells were MACS purified for CD8 and FACS 
sorted from a B6 female mice that had cleared an MB49 tumour and received a male 
BMDC vaccine boost (inset FACS plot). 2 x 10
5
 cells tetramer positive CD8 T cells 
were injected i.v. (open squares) (n=2).  Weight was measured at regular intervals 
and plotted as % weight change.  Error is expressed as ± standard error mean. 
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7.2.15:  Matahari and WT tetramer positive CD8 T cells maintain activation 
markers but are poor Th1 cytokine producers 
  Two mice each from the two groups that received in vitro activated Matahari 
or freshly isolated HY-specific tetramer positive polyclonal CD8 T cells in the above 
experiment, shown in Fig. 7.14, were culled on day 20.  Donor cells were analysed 
for the activation phenotype in comparison with T cells from a B6 female mouse as a 
control.  Both types of donor cells mostly express CD44, indicative of a memory 
population, with few naive (CD62L
high
 CD44
low
) cells in each group (Fig. 7.15a).  As 
CD44 is expressed at an intermediate level, these cells may have undergone adaptive 
tolerance resulting from chronic antigen exposure (Chiodetti, Choi et al. 2006) as 
seen with Marilyn cells in Fig. 7.9. 
As shown in Fig. 7.7, cells were stained for intracellular T-bet or cultured for 
4 hours with PMA and Ionomycin in the presence of Brefeldin A and stained for 
intracellular IFN and TNF.  Both Matahari and WT tetramer positive CD8 cells 
were poor producers of IFN and TNF determined by MFI (Fig. 7.15b) and the 
proportion of expressing cells (Fig. 7.15c).  Although Matahari cells expressed 
significantly more T-bet than B6 pLN and WT CD8 T cells, this was still low 
compared to Marilyn cells that induce GvHD (Fig. 7.7).  In conclusion, Matahari and 
tetramer positive CD8 T cells maintain activation markers in vivo but may undergo 
adaptive tolerance and consequently are poor producers of Proinflammatory Th1 
cytokines necessary for the induction of acute GvHD in male lymphopenic mice. 
256 
 
 
Figure 7.15. Matahari and WT CD8 are poor Th1 cytokine producers 
pLN, mLN, SP, kidney, liver and lung were harvested from mice that received 
activated Matahari or tetramer positive CD8 T cells on day 20 (see Fig. 7.14) a WT 
B6 female pLN was used as a control.   
a. Lymphoid (pLN, mLN, SP) and non-lymphoid organs (kidney, liver, lung) were 
harvested and cells were stained with anti-CD62L
FITC
, anti-V8.3PE, anti-CD8PerCP 
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and anti-CD44
APC
.  Cells were gated on lymphocytes and then V8.3+ CD8+ cells, 
FACS plots represent CD44 and CD62L expression from this gate.  One set of 
representative FACS plots shown. 
b. Cells were stained for anti-T-bet
PE
 by intracellular staining (left) or cultured for 4 
hours with PMA and ionomycin in the presence of Brefeldin A (as in Fig. 7.7), cells 
were stained for intracellular anti-TNFPE and anti-INF-APC.  A representative 
FACS plot is shown. 
c. Average mean fluorescence intensity of cells in the CD8
+
 V8.3+ gate expressing 
T-bet (blue), IFN (red) and TNF (green). Error is expressed as ± standard error 
mean. 
d. Average proportion of cells in CD8+ V8.3+ gate expressing T-bet (blue), IFN 
(red) and TNF (green).  Error is expressed as ± standard error mean. 
 
 
 
 
 
7.3: Discussion 
 It has generally not been possible to identify T cell epitopes exclusively 
expressed by human tumours.  Tumour-associated antigens (TAA), expressed at 
higher levels in tumour cells but also expressed on non-malignant tissue have been 
more readily identified (see chapters 3 and 4).  In addition, the increasing use of 
combination therapies such as lympho-depletion in conjunction with T cell adoptive 
transfer has the potential to cause adverse effects (Dudley and Rosenberg 2003).  The 
HY system is an informative model for understanding anti-tumour T cell responses 
investigating such potential adverse effects.   Evidence by several groups has 
demonstrated that when HY-specific T cell adoptive transfer is combined with 
additional therapies, this has the potential to induce potent anti-self responses (Rivas, 
Weatherly et al. 2009; Kitamura, Sedlik et al. 2010).   
Two other groups have studied the role of Marilyn CD4 transgenic T cells in 
mouse models that have given GvHD or GvHD-like symptoms.  Marilyn CD4 T 
cells infused into lymphopenic male mice expanded and displayed markers of 
activation but ultimately became „adapted‟, a functionally unresponsive state (Rivas, 
Weatherly et al. 2009).  Following systemic treatment with blockading antibody 
PD-L1 with or without CTLA-4 specific to co-inhibitory molecules, male 
lymphopenic mice infused with Marilyn CD4 T cells developed a multi organ 
wasting disease ultimately leading to pathology and mortality.  A study by Kitamura 
258 
 
et al. has also reported a similar effect when WT and Rag2
-/-
 B6 female mice are 
infused with Marilyn CD4 T cells and vaccinated with long chain peptides 
containing the cognate HY-Dby (Class II) and HY-Uty (Class I) sequence with 
adjuvant (IFA and CpG).   Ten days later the mice boosted with long chain peptide 
developed shock like symptoms, rapid weight loss and acute GvHD, with death 
within 72 hours.  However this did not happen if HY-Dby short chain peptide was 
used alone (Kitamura, Sedlik et al. 2010).  Both of these studies showed that the 
acute GvHD effect was associated with a cytokine storm, demonstrating increased 
levels of Proinflammatory cytokines such as TNF, IFN and IL-1 in mice with 
multiple organ wasting.  
The novel approach used in this study is the induction of acute GvHD by 
adoptive transfer of Marilyn CD4 T cells into lymphopenic male mice following 
radiation conditioning, and into WT B6 male mice after in vivo depletion of Treg 
cells.  This has implications for cancer therapy as most current treatment regimens 
use either radio- or chemo-therapy in conjunction with any novel therapy such as T 
cell adoptive transfer.  The acute GvHD effect was initially noted during a tumour 
challenge experiment in which resting Marilyn T cells were transferred to tumour-
bearing (for 7 days) Rag
-/- 
B6 male and female hosts with or without sub-lethal 
radiation pre-conditioning with 5Gy (Fig. 7.1).  The original aim of this experiment 
was to evaluate whether Marilyn CD4 T cells would control MB49 tumour in male 
recipients where cognate antigens were systemically expressed.  However, the effect 
of acute GvHD in the male group was noted, with these mice reaching the humane 
end point by day 6.  While the combined cell transfer/irradiation had little impact on 
tumour growth rate, it did induce a multiple organ wasting like disease analogous to 
GvHD.  Mice receiving only radiation lost significantly more weight than those 
receiving T cells alone or female mice that received both.  T cells expanded 
significantly in male mice but not female mice, indicating that this GvHD occurs in 
an antigen dependent manner (Fig. 7.4a).  Surprisingly, T cells were no better at 
proliferating or infiltrating organs in the radiation pre-conditioned group compared to 
those receiving only T cells, suggesting that the distinct outcomes cannot be 
explained only by the presence of donor T cells (Fig. 7.4-6). 
Clearly, the induction of acute GvHD is dependent on the direct effect of 
Marilyn CD4 cells.  For triggering GvHD in lymphopenic male mice given 5Gy, 
highly purified Marilyn CD4 T cells were as efficient as un-fractioned spleen plus 
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lymph node cell suspensions from Marilyn mice (containing other cell types such as 
donor APC) (Fig. 7.2).  This experiment did show however that transfer of large 
doses of purified Marilyn CD4 T cells alone were sufficient to induce an initial 
weight loss more that that shown by the group given 5Gy alone (Fig. 7.3), although 
this is insufficient to cause acute GvHD or death.  Subsequent analysis of these mice 
showed that T cells are able to infiltrate non-lymphoid organs in both 5Gy treated 
and untreated mice (Fig. 7.4b and c) suggesting that induction of acute GvHD in 
these mice is not caused by quantitatively different T cell infiltration.  Further 
analysis of the phenotype of these donor T cells (Fig. 7.5) showed that cells in both 
the 5Gy and non-irradiated group became activated (CD44
high
) and maintained this 
status in the non-lymphoid organs (Fig. 7.5).  The only noticeable difference in T cell 
activation was a significant skew towards effector memory T cells in 5Gy group 
(Fig. 7.6).  This effect is likely to contribute towards the pathology of acute GvHD 
due to the ability of effector memory T cells to mediate killing through Granzyme B 
and Perforin (Okada, Kondo et al. 2008).  Our results with the non-irradiated 
recipient group are consistent with those by Rivas et al. who showed Marilyn T cells 
can expand and activate in lymphopenic male mice but they become adapted and can 
only induce GvHD in their model upon additional negative co-stimulation blockade 
(PD-L1) (Rivas, Weatherly et al. 2009).  Kitamura et al. also demonstrate Marilyn 
T cells can induce GvHD in vaccinated B6 female mice following boosting with the 
long peptide, although they failed do so when short peptides were used for 
vaccination and boost (Kitamura, Sedlik et al. 2010).  Together with our data this 
indicates that Marilyn T cells can induce GvHD only with additional stimulation (by 
PD-L1 blockade, vaccination or irradiation). 
In order to elucidate the molecular mechanisms that prevent T cell adaptation 
in irradiated lymphopenic male mice, donor T cells were analysed for their ability to 
produce Th1 proinflammatory cytokines (Fig. 7.7) implicated in the induction of 
GvHD (Reddy and Ferrara 2003; Kitamura, Sedlik et al. 2010).  T cells infused into 
male lymphopenic mice were able to produce significant amounts of T-bet, IFN and 
TNF however, no significant difference was seen between non-irradiated and 5Gy 
recipients.   It is important to note that Marilyn CD4 T cells infused into 
lymphopenic male mice adopt a strong Th1 but not Th17 phenotype (Fig. 7.7 a).  
This again is in line with observation by Kitamura et al. who showed ex vivo Marilyn 
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T cells produce similar levels of IFN in both short peptide vaccinated and long 
peptide vaccinated B6 females and even higher levels of TNF in the short peptide 
group.  Rivas et al. however showed poor cytokine production from adapted Marilyn 
T cells from untreated lymphopenic male mice, although these T cells were evaluated 
at a much later stage (28 days). The cytokine production by Marilyn T cells is 
therefore not the major mechanism for the induction of GvHD. 
Although the exact functional requirements for Marilyn T cells to escape 
adaptation remain elusive, it is clear radiation pre-conditioning is needed in this 
model.  Male mice receiving 5Gy 10 days prior to T cell transfer showed an initial 
shock-like syndrome and rapid weight loss, a phenotype similar to mice receiving 
both 5Gy and T cells on day 0.  The 5Gy -10 day mice however began to recover 
weight with 100% survival (Fig. 7.8) and donor T cells displayed a CD44 
intermediate phenotype consistent with an adapted phenotype (Fig. 7.9a) (Choi and 
Schwartz 2007).  Assessment of the cytokine profiles of the donor T cells of these 
mice from both lymphoid and non-lymphoid organs revealed low levels of T-bet and 
IFN expression (Fig. 7.9b,c and d).  The phenotype of these T cells on day 30 
displayed some similarity with the adapted Marilyn T cells described by Rivas et al. 
in untreated male mice, in that they were also poor cytokine producers and expressed 
markers of an adapted phenotype (Rivas, Weatherly et al. 2009).  More importantly, 
the adapted T cells from male mice receiving 5Gy on day -10 were unable to induce 
GvHD or significant weight loss upon secondary transfer (Fig. 7.10).  This is 
consistent with another report showing minor H antigen mismatched (B10.D2 (H-2
d
) 
→ BALB/c (H-2d)) memory CD4+ T cells do not induce GvHD while naive CD4 T 
cells do (Anderson, McNiff et al. 2003).  This may suggest that reconstitution of the 
immune system with memory or adapted T cells may abrogate these harmful effects.   
Marilyn T cells can also induce acute GvHD in WT B6 male mice following 
Treg depletion (Fig. 7.11).  This effect was also noticed by Kitamura et al. when B6 
female mice boosted with HY-long peptide alone and Treg depleted (with no 
Marilyn T cell transfer) could develop GvHD like symptoms with some lethality 
(Kitamura, Sedlik et al. 2010).  In the studies reported in this chapter, FoxP3-DTR 
male mice that received 5Gy, DT toxin and T cells lost weight at the same rate as 
mice that didn‟t receive DT toxin, but these mice also displayed signs of clinical 
acute GvHD reaching the humane end point by day 7 (Fig. 7.11b).  No difference 
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was seen in the Th1 cytokine profiles of donor T cells (Fig. 7.12), indicating that 
GvHD inducing signals may not be provided directly by T cells but more likely by 
professional APCs.  These data indicate the requirement for Tregs in preventing 
GvHD in WT mice that receive radiation pre-conditioning and Marilyn adoptive 
transfer.  Shevach et al. have shown polyclonal Treg cells are able to modulate 
antigen-specific CD4 T cells effectors by various mechanisms, including bystander 
suppression and limiting their migration into peripheral tissues (Davidson and 
Shevach 2011).  This is an important finding to consider when designing adoptive 
transfer systems that require Treg abrogation or depletion. 
Cytokine storms are a major factor in the induction of clinical acute GvHD 
(Hill and Ferrara 2000).  Coupled with tissue damage and the release of factors such 
as LPS from the gut, this is believed to recuit, activate and mature APCs (Murai, 
Yoneyama et al. 2003) that are then able present antigen to and costimulate T cells in 
an immunogenic fashion (Beilhack, Schulz et al. 2005).  IFN released from 
activated T cells activates macrophages which has been shown to lead to the 
production of TNF by macrophages and DCs, the level of which has been shown to 
correlate to the severity of GvHD (Teshima, Ordemann et al. 2002).  In our model, 
serum levels of TNF were shown to increase in male lymphopenic mice receiving 
Marilyn T cells, with a significant increase of TNF in mice that received both T 
cells and 5Gy (Fig. 7.13a).  This suggests a synergistic effect of combining 
irradiation and T cells in the induction of GvHD.  The highest levels of TNF were 
also seen on day 4 in both T cell groups correlating with peak weight loss and onset 
of GvHD.  Detectable TNF was not produced in the 5Gy group indicating radiation 
treatment alone is not sufficient to induce TNF production.  This is consistent with 
an early study of the role TNF in GvHD which showed high levels of TNF 
mRNA in damaged tissues (Piguet, Grau et al. 1987). 
Anti-TNF therapy has been shown to inhibit organ damage (Hill, Crawford 
et al. 1997) and reduce GvHD severity in humans (Uberti, Ayash et al. 2005).  
Blocking TNF in vivo using the commercially available drug Embrel® gave a 
significant protective effect and delayed death (Fig. 7.13b).  This result confirms that 
of Kitamura et al. who showed TNF production by APCs was essential for long 
peptide mediated death, with highest serum levels in this group, in addition, anti-
TNF mAb treatment could abrogate Marilyn CD4 T cell induced GvHD in long 
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peptide vaccinated mice.  Indeed Rivas et al. have also shown LPS induced toxic 
shock occurs only with adapted Marilyn T cells not naive T cells in lymphopenic 
male mice, and this is correlated with a dramatic increase in TNF blood serum 
levels.  A model for GvHD induction following irradiation and T cell transfer is 
shown in the table below. 
Table 9: Model of GvHD induction 
 
In the second part of the study, Matahari CD8 T cells were evaluated for their 
ability to induce GvHD in radiation pre-conditioned lymphopenic male hosts.  
Resting and in vitro activated Matahari CD8 T cells infused into irradiated (5Gy) 
lymphopenic male recipients were unable to induce GvHD, nor were tetramer 
positive HY-specific polyclonal WT CD8s T cells able to do so (Fig. 7.14).  Despite 
some expansion and infiltration of both types of T cell (Fig. 7.15), significant weight 
loss or GvHD symptoms were not seen following transfer of HY-specific CD8 T 
cells.  Both WT CD8 and Matahari CD8 T cells displayed some Tc1 cytokine 
production (Fig. 7.15b) although this was low in comparison with Marilyn CD4 T 
cells (Fig. 7.7).  HY-specific CD8 T cells are therefore unable to induce acute GvHD 
in lymphopenic male mice when combined with sub-lethal radiation pre-
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conditioning.  Consistent with these results Kitamua et al. also found Matahari T 
cells could not induce GvHD like symptoms or death in long peptide, short peptide 
and male splenocyte vaccinated mice 
Acute GvHD in the model shown here with adoptive transfer of HY-specific 
Marilyn TCR CD4 T cells is likely caused by a runaway CD4 T cell response in the 
presence of a radiation-induced cytokine storm.  Cytokines such as IL-1 released by 
the endothelium increases APC Th1 activation status (particularly DC) and therefore 
also increases positive co-stimulatory signalling to CD4 T cells while decreasing 
negative signals (Abhyankar, Gilliland et al. 1993) (Rivas, Weatherly et al. 2009).  
This results in a higher serum level production of the Th1 proinflammatory cytokine 
TNF by APCs that likely acts to maintain activation signals and enhance antigen 
presentation preventing antigen-driven T cell adaptation as is seen in the non-
irradiated groups (Rivas, Weatherly et al. 2009).  In lymphopenic hosts this effect 
becomes „runaway‟ due to the lack of regulation.  This effect can be reproduced in 
WT DTR male mice by the depletion of Tregs prior to radiation pre-conditioning and 
donor T cell infusion.  However, neither Matahari or polyclonal tetramer positive 
CD8 T cells are able to cause GvHD or weight loss in this model possibly due to 
their inability to provide help to mediators of killing such as NK cells and 
macrophages (van den Brink and Burakoff 2002). 
In light of this and similar studies using negative co-stimulation blockade 
(Rivas, Weatherly et al. 2009) and long peptide vaccination (Kitamura, Sedlik et al. 
2010), it is clear great care must be taken when using combinational T cell therapy.  
This highlights the need to understand the cross-talk between the innate and adaptive 
immune components when designing immuno-therapies.  Attention must always be 
given to potential secondary effects of therapeutic immunotherapy.  Conversely 
however, the study reported in this thesis does show that T cell adaptation can be 
reversed when combined with radiation pre-conditioning, which if targeted correctly, 
could be applied to boost therapeutic immunity against cancer. 
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Summary 
This study has established MB49 as a relevant murine model for the study of 
tumour antigen-specific immune responses in cancer immunotherapy.  MB49 is a 
HY
+
 immunogenic tumour in vivo that is rejected at low doses by female C57BL/6 
mice due to HY-specific cellular responses.  MB49 utilises co-inhibitory ligands 
(PD-L1, FAS-L) and secretes local immunosuppressive factors (IDO, IL-10, TGF-) 
to abrogate anti-tumour T cell responses and promote Treg development, both 
hallmarks of cancer (Zitvogel, Tesniere et al. 2006).   
Using TCR transgenic T cells, HY-specific responses to malignant and non-
malignant tissues were compared.  These results confirm CTL responses are 
inhibited in tumour tissues, mediated by immunoevasive factors, but can be enhanced 
by the co-presence of a male skin graft.  This mechanism of cross talk is assessed as 
a novel route to enhance antigen-specific T cell responses to tumour.   
Conversely, tumours are shown to expand HY-specific Tregs, although this is 
associated with some cells losing FoxP3 expression.  Using a FoxP3-GFP reporter 
system this work shows for the first time that antigen-specific Tregs (both thymic 
and peripheral) can become Th1-like effector T cells in tumour-bearing hosts.  These 
cells have distinct gene expression profiles and are able to maintain this phenotype 
upon secondary adoptive cell transfer.  This observation has profound implications 
for Treg therapy in autoimmune settings (Zhou, Bailey-Bucktrout et al. 2009) and 
potential protective effects if induced against tumours.   I am indebted to Dr C. 
Addey, Dr D. Coe and Dr J-G. Chai for their assistance in preparing chapter 5 of this 
thesis for publication (submission and print) in the Journal of Immunology (Addey, 
White et al. 2011).  
Utilising our ability to perform retroviral genetic modification, an 
MB49/rhIL-2 retrogenic tumour was produced.  As with previous studies using 
tumours modified to produce IL-2, the MB/IL-2 tumour was shown to induce 
effective CTL responses, with long standing immunity (Fearon, Pardoll et al. 1990).  
Unlike previous studies however we also demonstrate that IL-2 in the local 
microenvironment can act to enhance tumour antigen-specific CD8 responses to a 
similar degree as polyclonal responses.  It is also shown that rejection of IL-2 low 
producing tumours is mediated by CD8 T cells and these tumours are viable in 
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lymphopenic recipients.  This work exposes the need for multiple approaches in 
inducing effective antigen-specific T cell mediated in vivo responses to tumour. 
The principles of adoptive immunotherapy in the context of radiotherapy are 
considered using a model of T cell induced GvHD.   Administration of Marilyn CD4 
but not Matahari CD8 has the effect of inducing weight loss in lymphopenic male 
mice, and if combined with sublethal radiation preconditioning this is sufficient to 
induce death by GvHD.  This mirrors systems using Marilyn T cells with negative 
co-stimulation blockade and long peptide vaccination (Rivas, Weatherly et al. 2009; 
Kitamura, Sedlik et al. 2010).  GvHD could also be induced in lymphoreplete DTR 
males following the depletion of Tregs, consistent with studies by others (Tawara, 
Shlomchik et al. 2010).  It is therefore important to assess the synergistic effect of 
combining multiple treatments in future adoptive immunotherapy strategies to minor 
H antigens. 
Studies using adoptive cell transfer of antigen-specific T cell subsets in 
murine models are essential to the development of effective and safe treatments in 
human cancers.  This work shows both polyclonal and antigen-specific T cell subsets 
can rarely be manipulated without consideration to other T cells, immune cells and 
treatments.  Despite being over 20 years old, the field of adoptive immunotherapy in 
cancer has yet to yield widespread safe and effective treatments in a clinical setting.  
Using lessons from studies such as this it may be possible to refine current 
approaches to provide high efficacy treatments while minimising unwanted side 
effects. 
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